"6.1 Ocular Surgery    Ocular adverse reactions occurring in 5-15% of subjects in clinical studies with DUREZOL included corneal edema, ciliary and conjunctival hyperemia, eye pain, photophobia, posterior capsule opacification, anterior chamber cells, anterior chamber flare, conjunctival edema, and blepharitis.",Ocular adverse reactions is an adverse reaction entity
"6.1 Ocular Surgery    Ocular adverse reactions occurring in 5-15% of subjects in clinical studies with DUREZOL included corneal edema, ciliary and conjunctival hyperemia, eye pain, photophobia, posterior capsule opacification, anterior chamber cells, anterior chamber flare, conjunctival edema, and blepharitis.",corneal edema is an adverse reaction entity
"6.1 Ocular Surgery    Ocular adverse reactions occurring in 5-15% of subjects in clinical studies with DUREZOL included corneal edema, ciliary and conjunctival hyperemia, eye pain, photophobia, posterior capsule opacification, anterior chamber cells, anterior chamber flare, conjunctival edema, and blepharitis.",ciliary hyperemia is an adverse reaction entity
"6.1 Ocular Surgery    Ocular adverse reactions occurring in 5-15% of subjects in clinical studies with DUREZOL included corneal edema, ciliary and conjunctival hyperemia, eye pain, photophobia, posterior capsule opacification, anterior chamber cells, anterior chamber flare, conjunctival edema, and blepharitis.",conjunctival hyperemia is an adverse reaction entity
"6.1 Ocular Surgery    Ocular adverse reactions occurring in 5-15% of subjects in clinical studies with DUREZOL included corneal edema, ciliary and conjunctival hyperemia, eye pain, photophobia, posterior capsule opacification, anterior chamber cells, anterior chamber flare, conjunctival edema, and blepharitis.",eye pain is an adverse reaction entity
"6.1 Ocular Surgery    Ocular adverse reactions occurring in 5-15% of subjects in clinical studies with DUREZOL included corneal edema, ciliary and conjunctival hyperemia, eye pain, photophobia, posterior capsule opacification, anterior chamber cells, anterior chamber flare, conjunctival edema, and blepharitis.",photophobia is an adverse reaction entity
"6.1 Ocular Surgery    Ocular adverse reactions occurring in 5-15% of subjects in clinical studies with DUREZOL included corneal edema, ciliary and conjunctival hyperemia, eye pain, photophobia, posterior capsule opacification, anterior chamber cells, anterior chamber flare, conjunctival edema, and blepharitis.",posterior capsule opacification is an adverse reaction entity
"6.1 Ocular Surgery    Ocular adverse reactions occurring in 5-15% of subjects in clinical studies with DUREZOL included corneal edema, ciliary and conjunctival hyperemia, eye pain, photophobia, posterior capsule opacification, anterior chamber cells, anterior chamber flare, conjunctival edema, and blepharitis.",anterior chamber cells is an adverse reaction entity
"6.1 Ocular Surgery    Ocular adverse reactions occurring in 5-15% of subjects in clinical studies with DUREZOL included corneal edema, ciliary and conjunctival hyperemia, eye pain, photophobia, posterior capsule opacification, anterior chamber cells, anterior chamber flare, conjunctival edema, and blepharitis.",anterior chamber flare is an adverse reaction entity
"6.1 Ocular Surgery    Ocular adverse reactions occurring in 5-15% of subjects in clinical studies with DUREZOL included corneal edema, ciliary and conjunctival hyperemia, eye pain, photophobia, posterior capsule opacification, anterior chamber cells, anterior chamber flare, conjunctival edema, and blepharitis.",conjunctival edema is an adverse reaction entity
"6.1 Ocular Surgery    Ocular adverse reactions occurring in 5-15% of subjects in clinical studies with DUREZOL included corneal edema, ciliary and conjunctival hyperemia, eye pain, photophobia, posterior capsule opacification, anterior chamber cells, anterior chamber flare, conjunctival edema, and blepharitis.",blepharitis is an adverse reaction entity
Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex).,exacerbate viral infections of the eye is an adverse reaction entity
Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex).,exacerbate herpes simplex is an adverse reaction entity
(  5.1  )          item{ Cataracts- Use of corticosteroids may result in posterior subcapsular cataract formation.,posterior subcapsular cataract is an adverse reaction entity
Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex).,exacerbate viral infections of the eye is an adverse reaction entity
Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex).,exacerbate herpes simplex is an adverse reaction entity
"Documented symptomatic hypoglycemia occurred in 39% and 40% of patients when TRULICITY 0.75 mg and 1.5 mg, respectively, was co-administered with a sulfonylurea.",symptomatic hypoglycemia is an adverse reaction entity
EXCERPT:     WARNING: RISK OF THYROID C-CELL TUMORS         See full prescribing information for complete boxed warning.,THYROID C-CELL TUMORS is an adverse reaction entity
TRULICITY 0.75 mg and 1.5 mg resulted in a mean increase in heart rate (HR) of 2-4 beats per minute (bpm).,increase in heart rate is an adverse reaction entity
TRULICITY 0.75 mg and 1.5 mg resulted in a mean increase in heart rate (HR) of 2-4 beats per minute (bpm).,increase in HR is an adverse reaction entity
"Injection-site Reactions       In the placebo-controlled studies, injection-site reactions (e.g., injection-site rash, erythema) were reported in 0.5% of TRULICITY-treated patients and in 0.0% of placebo-treated patients.",injection-site reactions is an adverse reaction entity
"Injection-site Reactions       In the placebo-controlled studies, injection-site reactions (e.g., injection-site rash, erythema) were reported in 0.5% of TRULICITY-treated patients and in 0.0% of placebo-treated patients.",injection-site erythema is an adverse reaction entity
"Injection-site Reactions       In the placebo-controlled studies, injection-site reactions (e.g., injection-site rash, erythema) were reported in 0.5% of TRULICITY-treated patients and in 0.0% of placebo-treated patients.",injection-site rash is an adverse reaction entity
"Cases of MTC in patients treated with liraglutide, another GLP-1 receptor agonist, have been reported in the postmarketing period; the data in these reports are insufficient to establish or exclude a causal relationship between MTC and GLP-1 receptor agonist use in humans.",MTC is an adverse reaction entity
"Cases of MTC in patients treated with liraglutide, another GLP-1 receptor agonist, have been reported in the postmarketing period; the data in these reports are insufficient to establish or exclude a causal relationship between MTC and GLP-1 receptor agonist use in humans.",MTC is an adverse reaction entity
"It is unknown whether TRULICITY causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of dulaglutide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions (5.1), and Nonclinical Toxicology (13.1)].",thyroid C-cell tumors is an adverse reaction entity
"It is unknown whether TRULICITY causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of dulaglutide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions (5.1), and Nonclinical Toxicology (13.1)].",medullary thyroid carcinoma is an adverse reaction entity
"It is unknown whether TRULICITY causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of dulaglutide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions (5.1), and Nonclinical Toxicology (13.1)].",MTC is an adverse reaction entity
"It is unknown whether TRULICITY causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of dulaglutide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions (5.1), and Nonclinical Toxicology (13.1)].",thyroid C-cell tumors is an adverse reaction entity
"Table 1 shows common adverse reactions, excluding hypoglycemia, associated with the use of TRULICITY in the pool of placebo-controlled trials.",hypoglycemia is an adverse reaction entity
*   Renal Impairment: Monitor renal function in patients with renal impairment reporting severe adverse gastrointestinal reactions (  5.5  ).,Renal Impairment is an adverse reaction entity
"It is unknown whether TRULICITY will cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of dulaglutide-induced rodent thyroid C-cell tumors has not been determined.",thyroid C-cell tumors is an adverse reaction entity
"It is unknown whether TRULICITY will cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of dulaglutide-induced rodent thyroid C-cell tumors has not been determined.",medullary thyroid carcinoma is an adverse reaction entity
"It is unknown whether TRULICITY will cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of dulaglutide-induced rodent thyroid C-cell tumors has not been determined.",MTC is an adverse reaction entity
"It is unknown whether TRULICITY will cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of dulaglutide-induced rodent thyroid C-cell tumors has not been determined.",thyroid C-cell tumors is an adverse reaction entity
"*   Hypoglycemia: When TRULICITY is used with an insulin secretagogue (e.g., a sulfonylurea) or insulin, consider lowering the dose of the sulfonylurea or insulin to reduce the risk of hypoglycemia (  5.3  ).",Hypoglycemia is an adverse reaction entity
"5.2 Hypersensitivity Reactions      Anaphylactic and other hypersensitivity reactions with cardiovascular, respiratory and cutaneous manifestations, ranging from mild to severe, including shock have uncommonly occurred following EOVIST administration [see Adverse Reactions (  6  )]  .",Anaphylactic reactions is an adverse reaction entity
"5.2 Hypersensitivity Reactions      Anaphylactic and other hypersensitivity reactions with cardiovascular, respiratory and cutaneous manifestations, ranging from mild to severe, including shock have uncommonly occurred following EOVIST administration [see Adverse Reactions (  6  )]  .",hypersensitivity reactions is an adverse reaction entity
"5.2 Hypersensitivity Reactions      Anaphylactic and other hypersensitivity reactions with cardiovascular, respiratory and cutaneous manifestations, ranging from mild to severe, including shock have uncommonly occurred following EOVIST administration [see Adverse Reactions (  6  )]  .",cardiovascular manifestations is an adverse reaction entity
"5.2 Hypersensitivity Reactions      Anaphylactic and other hypersensitivity reactions with cardiovascular, respiratory and cutaneous manifestations, ranging from mild to severe, including shock have uncommonly occurred following EOVIST administration [see Adverse Reactions (  6  )]  .",respiratory manifestations is an adverse reaction entity
"5.2 Hypersensitivity Reactions      Anaphylactic and other hypersensitivity reactions with cardiovascular, respiratory and cutaneous manifestations, ranging from mild to severe, including shock have uncommonly occurred following EOVIST administration [see Adverse Reactions (  6  )]  .",cutaneous manifestations is an adverse reaction entity
"5.2 Hypersensitivity Reactions      Anaphylactic and other hypersensitivity reactions with cardiovascular, respiratory and cutaneous manifestations, ranging from mild to severe, including shock have uncommonly occurred following EOVIST administration [see Adverse Reactions (  6  )]  .",shock is an adverse reaction entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *    Nephrogenic Systemic Fibrosis has occurred in patients with impaired elimination of GBCAs.,Nephrogenic Systemic Fibrosis is an adverse reaction entity
"The GBCA-associated NSF risk appears highest for patients with chronic, severe kidney disease (GFR < 30 mL/min/1.73m  2  ) as well as patients with acute kidney injury.",NSF is an adverse reaction entity
"*  The risk for NSF appears highest among patients with:oChronic, severe kidney disease (GFR < 30 mL/min/1.73m2), oroAcute kidney injury.",NSF is an adverse reaction entity
"5.6 Neurologic Reactions      Use of TNF blockers, of which CIMZIA is a member, has been associated with rare cases of new onset or exacerbation of clinical symptoms and/or radiographic evidence of central nervous system demyelinating disease, including multiple sclerosis, and with peripheral demyelinating disease, including Guillain-Barre syndrome .",central nervous system demyelinating disease is an adverse reaction entity
"5.6 Neurologic Reactions      Use of TNF blockers, of which CIMZIA is a member, has been associated with rare cases of new onset or exacerbation of clinical symptoms and/or radiographic evidence of central nervous system demyelinating disease, including multiple sclerosis, and with peripheral demyelinating disease, including Guillain-Barre syndrome .",multiple sclerosis is an adverse reaction entity
"5.6 Neurologic Reactions      Use of TNF blockers, of which CIMZIA is a member, has been associated with rare cases of new onset or exacerbation of clinical symptoms and/or radiographic evidence of central nervous system demyelinating disease, including multiple sclerosis, and with peripheral demyelinating disease, including Guillain-Barre syndrome .",peripheral demyelinating disease is an adverse reaction entity
"5.6 Neurologic Reactions      Use of TNF blockers, of which CIMZIA is a member, has been associated with rare cases of new onset or exacerbation of clinical symptoms and/or radiographic evidence of central nervous system demyelinating disease, including multiple sclerosis, and with peripheral demyelinating disease, including Guillain-Barre syndrome .",Guillain-Barre syndrome is an adverse reaction entity
"If reactivation occurs, stop CIMZIA and begin anti-viral therapy (  5.5  )   *  Demyelinating disease, exacerbation or new onset, may occur (  5.6  )   *  Cytopenias, pancytopenia - advise patients to seek immediate medical attention if symptoms develop, and consider stopping CIMZIA (  5.7  )   *  Lupus-like syndrome - stop CIMZIA if syndrome develops (  5.9  )             5.1 Risk of Serious Infections       [see  Boxed Warning  ]       Patients treated with CIMZIA are at an increased risk for developing serious infections involving various organ systems and sites that may lead to hospitalization or death.",Demyelinating disease is an adverse reaction entity
"If reactivation occurs, stop CIMZIA and begin anti-viral therapy (  5.5  )   *  Demyelinating disease, exacerbation or new onset, may occur (  5.6  )   *  Cytopenias, pancytopenia - advise patients to seek immediate medical attention if symptoms develop, and consider stopping CIMZIA (  5.7  )   *  Lupus-like syndrome - stop CIMZIA if syndrome develops (  5.9  )             5.1 Risk of Serious Infections       [see  Boxed Warning  ]       Patients treated with CIMZIA are at an increased risk for developing serious infections involving various organ systems and sites that may lead to hospitalization or death.",Cytopenias is an adverse reaction entity
"If reactivation occurs, stop CIMZIA and begin anti-viral therapy (  5.5  )   *  Demyelinating disease, exacerbation or new onset, may occur (  5.6  )   *  Cytopenias, pancytopenia - advise patients to seek immediate medical attention if symptoms develop, and consider stopping CIMZIA (  5.7  )   *  Lupus-like syndrome - stop CIMZIA if syndrome develops (  5.9  )             5.1 Risk of Serious Infections       [see  Boxed Warning  ]       Patients treated with CIMZIA are at an increased risk for developing serious infections involving various organ systems and sites that may lead to hospitalization or death.",pancytopenia is an adverse reaction entity
"If reactivation occurs, stop CIMZIA and begin anti-viral therapy (  5.5  )   *  Demyelinating disease, exacerbation or new onset, may occur (  5.6  )   *  Cytopenias, pancytopenia - advise patients to seek immediate medical attention if symptoms develop, and consider stopping CIMZIA (  5.7  )   *  Lupus-like syndrome - stop CIMZIA if syndrome develops (  5.9  )             5.1 Risk of Serious Infections       [see  Boxed Warning  ]       Patients treated with CIMZIA are at an increased risk for developing serious infections involving various organ systems and sites that may lead to hospitalization or death.",Lupus-like syndrome is an adverse reaction entity
"If reactivation occurs, stop CIMZIA and begin anti-viral therapy (  5.5  )   *  Demyelinating disease, exacerbation or new onset, may occur (  5.6  )   *  Cytopenias, pancytopenia - advise patients to seek immediate medical attention if symptoms develop, and consider stopping CIMZIA (  5.7  )   *  Lupus-like syndrome - stop CIMZIA if syndrome develops (  5.9  )             5.1 Risk of Serious Infections       [see  Boxed Warning  ]       Patients treated with CIMZIA are at an increased risk for developing serious infections involving various organ systems and sites that may lead to hospitalization or death.",infections is an adverse reaction entity
"If reactivation occurs, stop CIMZIA and begin anti-viral therapy (  5.5  )   *  Demyelinating disease, exacerbation or new onset, may occur (  5.6  )   *  Cytopenias, pancytopenia - advise patients to seek immediate medical attention if symptoms develop, and consider stopping CIMZIA (  5.7  )   *  Lupus-like syndrome - stop CIMZIA if syndrome develops (  5.9  )             5.1 Risk of Serious Infections       [see  Boxed Warning  ]       Patients treated with CIMZIA are at an increased risk for developing serious infections involving various organ systems and sites that may lead to hospitalization or death.",death is an adverse reaction entity
"*  Monitor all patients for active TB during treatment, even if initial latent TB test is negative (5.1)   *  Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which CIMZIA is a member (5.2).",Lymphoma is an adverse reaction entity
"*  Monitor all patients for active TB during treatment, even if initial latent TB test is negative (5.1)   *  Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which CIMZIA is a member (5.2).",malignancies is an adverse reaction entity
"*  Monitor all patients for active TB during treatment, even if initial latent TB test is negative (5.1)   *  Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which CIMZIA is a member (5.2).",fatal is an adverse reaction entity
"Hypersensitivity Reactions         The following symptoms that could be compatible with hypersensitivity reactions have been reported rarely following CIMZIA administration to patients: angioedema, dermatitis allergic, dizziness (postural), dyspnea, hot flush, hypotension, injection site reactions, malaise, pyrexia, rash, serum sickness, and (vasovagal) syncope  [see  Warnings and Precautions (5.4)  ]  .",hypersensitivity reactions is an adverse reaction entity
"Hypersensitivity Reactions         The following symptoms that could be compatible with hypersensitivity reactions have been reported rarely following CIMZIA administration to patients: angioedema, dermatitis allergic, dizziness (postural), dyspnea, hot flush, hypotension, injection site reactions, malaise, pyrexia, rash, serum sickness, and (vasovagal) syncope  [see  Warnings and Precautions (5.4)  ]  .",angioedema is an adverse reaction entity
"Hypersensitivity Reactions         The following symptoms that could be compatible with hypersensitivity reactions have been reported rarely following CIMZIA administration to patients: angioedema, dermatitis allergic, dizziness (postural), dyspnea, hot flush, hypotension, injection site reactions, malaise, pyrexia, rash, serum sickness, and (vasovagal) syncope  [see  Warnings and Precautions (5.4)  ]  .",dermatitis allergic is an adverse reaction entity
"Hypersensitivity Reactions         The following symptoms that could be compatible with hypersensitivity reactions have been reported rarely following CIMZIA administration to patients: angioedema, dermatitis allergic, dizziness (postural), dyspnea, hot flush, hypotension, injection site reactions, malaise, pyrexia, rash, serum sickness, and (vasovagal) syncope  [see  Warnings and Precautions (5.4)  ]  .",dizziness postural is an adverse reaction entity
"Hypersensitivity Reactions         The following symptoms that could be compatible with hypersensitivity reactions have been reported rarely following CIMZIA administration to patients: angioedema, dermatitis allergic, dizziness (postural), dyspnea, hot flush, hypotension, injection site reactions, malaise, pyrexia, rash, serum sickness, and (vasovagal) syncope  [see  Warnings and Precautions (5.4)  ]  .",dyspnea is an adverse reaction entity
"Hypersensitivity Reactions         The following symptoms that could be compatible with hypersensitivity reactions have been reported rarely following CIMZIA administration to patients: angioedema, dermatitis allergic, dizziness (postural), dyspnea, hot flush, hypotension, injection site reactions, malaise, pyrexia, rash, serum sickness, and (vasovagal) syncope  [see  Warnings and Precautions (5.4)  ]  .",hot flush is an adverse reaction entity
"Hypersensitivity Reactions         The following symptoms that could be compatible with hypersensitivity reactions have been reported rarely following CIMZIA administration to patients: angioedema, dermatitis allergic, dizziness (postural), dyspnea, hot flush, hypotension, injection site reactions, malaise, pyrexia, rash, serum sickness, and (vasovagal) syncope  [see  Warnings and Precautions (5.4)  ]  .",hypotension is an adverse reaction entity
"Hypersensitivity Reactions         The following symptoms that could be compatible with hypersensitivity reactions have been reported rarely following CIMZIA administration to patients: angioedema, dermatitis allergic, dizziness (postural), dyspnea, hot flush, hypotension, injection site reactions, malaise, pyrexia, rash, serum sickness, and (vasovagal) syncope  [see  Warnings and Precautions (5.4)  ]  .",injection site reactions is an adverse reaction entity
"Hypersensitivity Reactions         The following symptoms that could be compatible with hypersensitivity reactions have been reported rarely following CIMZIA administration to patients: angioedema, dermatitis allergic, dizziness (postural), dyspnea, hot flush, hypotension, injection site reactions, malaise, pyrexia, rash, serum sickness, and (vasovagal) syncope  [see  Warnings and Precautions (5.4)  ]  .",malaise is an adverse reaction entity
"Hypersensitivity Reactions         The following symptoms that could be compatible with hypersensitivity reactions have been reported rarely following CIMZIA administration to patients: angioedema, dermatitis allergic, dizziness (postural), dyspnea, hot flush, hypotension, injection site reactions, malaise, pyrexia, rash, serum sickness, and (vasovagal) syncope  [see  Warnings and Precautions (5.4)  ]  .",pyrexia is an adverse reaction entity
"Hypersensitivity Reactions         The following symptoms that could be compatible with hypersensitivity reactions have been reported rarely following CIMZIA administration to patients: angioedema, dermatitis allergic, dizziness (postural), dyspnea, hot flush, hypotension, injection site reactions, malaise, pyrexia, rash, serum sickness, and (vasovagal) syncope  [see  Warnings and Precautions (5.4)  ]  .",rash is an adverse reaction entity
"Hypersensitivity Reactions         The following symptoms that could be compatible with hypersensitivity reactions have been reported rarely following CIMZIA administration to patients: angioedema, dermatitis allergic, dizziness (postural), dyspnea, hot flush, hypotension, injection site reactions, malaise, pyrexia, rash, serum sickness, and (vasovagal) syncope  [see  Warnings and Precautions (5.4)  ]  .",serum sickness is an adverse reaction entity
"Hypersensitivity Reactions         The following symptoms that could be compatible with hypersensitivity reactions have been reported rarely following CIMZIA administration to patients: angioedema, dermatitis allergic, dizziness (postural), dyspnea, hot flush, hypotension, injection site reactions, malaise, pyrexia, rash, serum sickness, and (vasovagal) syncope  [see  Warnings and Precautions (5.4)  ]  .",vasovagal syncope is an adverse reaction entity
The median time to onset of TB for all patients exposed to CIMZIA across all indications was 345 days.,TB is an adverse reaction entity
"Malignancies, some fatal, have been reported among children, adolescents, and young adults who received treatment with TNF-blocking agents (initiation of therapy <= 18 years of age), of which CIMZIA is a member.",Malignancies is an adverse reaction entity
"Malignancies, some fatal, have been reported among children, adolescents, and young adults who received treatment with TNF-blocking agents (initiation of therapy <= 18 years of age), of which CIMZIA is a member.",fatal is an adverse reaction entity
"During controlled and open-labeled portions of CIMZIA studies of Crohn's disease and other diseases, malignancies (excluding non-melanoma skin cancer) were observed at a rate (95% confidence interval) of 0.5 (0.4, 0.7) per 100 patient-years among 4,650 CIMZIA-treated patients versus a rate of 0.6 (0.1, 1.7) per 100 patient-years among 1,319 placebo-treated patients.",malignancies is an adverse reaction entity
"During controlled and open-labeled portions of CIMZIA studies of Crohn's disease and other diseases, malignancies (excluding non-melanoma skin cancer) were observed at a rate (95% confidence interval) of 0.5 (0.4, 0.7) per 100 patient-years among 4,650 CIMZIA-treated patients versus a rate of 0.6 (0.1, 1.7) per 100 patient-years among 1,319 placebo-treated patients.",non-melanoma skin cancer is an adverse reaction entity
"5.9 Autoimmunity      Treatment with CIMZIA may result in the formation of autoantibodies and rarely, in the development of a lupus-like syndrome.",formation of autoantibodies is an adverse reaction entity
"5.9 Autoimmunity      Treatment with CIMZIA may result in the formation of autoantibodies and rarely, in the development of a lupus-like syndrome.",lupus-like syndrome is an adverse reaction entity
EXCERPT:     WARNING: SERIOUS INFECTIONS AND MALIGNANCY         See full prescribing information for complete boxed warning.,INFECTIONS is an adverse reaction entity
EXCERPT:     WARNING: SERIOUS INFECTIONS AND MALIGNANCY         See full prescribing information for complete boxed warning.,MALIGNANCY is an adverse reaction entity
"Reports include cases of miliary, lymphatic, peritoneal, as well as pulmonary TB.",miliary TB is an adverse reaction entity
"Reports include cases of miliary, lymphatic, peritoneal, as well as pulmonary TB.",lymphatic TB is an adverse reaction entity
"Reports include cases of miliary, lymphatic, peritoneal, as well as pulmonary TB.",peritoneal TB is an adverse reaction entity
"Reports include cases of miliary, lymphatic, peritoneal, as well as pulmonary TB.",pulmonary TB is an adverse reaction entity
General disorders and administration site conditions:  Bleeding and injection site reactions.,Bleeding is an adverse reaction entity
General disorders and administration site conditions:  Bleeding and injection site reactions.,injection site reactions is an adverse reaction entity
"Patients with Crohn's disease that require chronic exposure to immunosuppressant therapies may be at higher risk than the general population for the development of lymphoma, even in the absence of TNF blocker therapy [see  Adverse Reactions (6.1)  ]  .",lymphoma is an adverse reaction entity
"Tuberculosis and Opportunistic Infections         In completed and ongoing global clinical studies in all indications including 5,118 CIMZIA-treated patients, the overall rate of tuberculosis is approximately 0.61 per 100 patient-years across all indications.",tuberculosis is an adverse reaction entity
"5.7 Hematological Reactions      Rare reports of pancytopenia, including aplastic anemia, have been reported with TNF blockers.",pancytopenia is an adverse reaction entity
"5.7 Hematological Reactions      Rare reports of pancytopenia, including aplastic anemia, have been reported with TNF blockers.",aplastic anemia is an adverse reaction entity
"Reported infections include:       *  Active tuberculosis, including reactivation of latent tuberculosis.",Active tuberculosis is an adverse reaction entity
"Reported infections include:       *  Active tuberculosis, including reactivation of latent tuberculosis.",reactivation of latent tuberculosis is an adverse reaction entity
"One of the 1,564 Crohn's disease patients treated with CIMZIA developed symptoms of a lupus-like syndrome.",lupus-like syndrome is an adverse reaction entity
"*  Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis.",Invasive fungal infections is an adverse reaction entity
"*  Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis.",histoplasmosis is an adverse reaction entity
"*  Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis.",coccidioidomycosis is an adverse reaction entity
"*  Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis.",candidiasis is an adverse reaction entity
"*  Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis.",aspergillosis is an adverse reaction entity
"*  Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis.",blastomycosis is an adverse reaction entity
"*  Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis.",pneumocystosis is an adverse reaction entity
BOXED WARNING: WARNING: SERIOUS INFECTIONS AND MALIGNANCY      WARNING: SERIOUS INFECTIONS AND MALIGNANCY        SERIOUS INFECTIONS         Patients treated with CIMZIA are at increased risk for developing serious infections that may lead to hospitalization or death   [see   Warnings and Precautions (5.1)   and   Adverse Reactions (6.1)  ]  .,INFECTIONS is an adverse reaction entity
BOXED WARNING: WARNING: SERIOUS INFECTIONS AND MALIGNANCY      WARNING: SERIOUS INFECTIONS AND MALIGNANCY        SERIOUS INFECTIONS         Patients treated with CIMZIA are at increased risk for developing serious infections that may lead to hospitalization or death   [see   Warnings and Precautions (5.1)   and   Adverse Reactions (6.1)  ]  .,MALIGNANCY is an adverse reaction entity
BOXED WARNING: WARNING: SERIOUS INFECTIONS AND MALIGNANCY      WARNING: SERIOUS INFECTIONS AND MALIGNANCY        SERIOUS INFECTIONS         Patients treated with CIMZIA are at increased risk for developing serious infections that may lead to hospitalization or death   [see   Warnings and Precautions (5.1)   and   Adverse Reactions (6.1)  ]  .,INFECTIONS is an adverse reaction entity
BOXED WARNING: WARNING: SERIOUS INFECTIONS AND MALIGNANCY      WARNING: SERIOUS INFECTIONS AND MALIGNANCY        SERIOUS INFECTIONS         Patients treated with CIMZIA are at increased risk for developing serious infections that may lead to hospitalization or death   [see   Warnings and Precautions (5.1)   and   Adverse Reactions (6.1)  ]  .,MALIGNANCY is an adverse reaction entity
BOXED WARNING: WARNING: SERIOUS INFECTIONS AND MALIGNANCY      WARNING: SERIOUS INFECTIONS AND MALIGNANCY        SERIOUS INFECTIONS         Patients treated with CIMZIA are at increased risk for developing serious infections that may lead to hospitalization or death   [see   Warnings and Precautions (5.1)   and   Adverse Reactions (6.1)  ]  .,infections is an adverse reaction entity
BOXED WARNING: WARNING: SERIOUS INFECTIONS AND MALIGNANCY      WARNING: SERIOUS INFECTIONS AND MALIGNANCY        SERIOUS INFECTIONS         Patients treated with CIMZIA are at increased risk for developing serious infections that may lead to hospitalization or death   [see   Warnings and Precautions (5.1)   and   Adverse Reactions (6.1)  ]  .,death is an adverse reaction entity
5.3 Malignancy      The impact of treatment with BENLYSTA on the development of malignancies is not known.,malignancies is an adverse reaction entity
"Three patients with anti-belimumab antibodies experienced mild infusion reactions of nausea, erythematous rash, pruritus, eyelid edema, headache, and dyspnea; none of the reactions was life-threatening.",infusion reactions is an adverse reaction entity
"Three patients with anti-belimumab antibodies experienced mild infusion reactions of nausea, erythematous rash, pruritus, eyelid edema, headache, and dyspnea; none of the reactions was life-threatening.",nausea is an adverse reaction entity
"Three patients with anti-belimumab antibodies experienced mild infusion reactions of nausea, erythematous rash, pruritus, eyelid edema, headache, and dyspnea; none of the reactions was life-threatening.",erythematous rash is an adverse reaction entity
"Three patients with anti-belimumab antibodies experienced mild infusion reactions of nausea, erythematous rash, pruritus, eyelid edema, headache, and dyspnea; none of the reactions was life-threatening.",pruritus is an adverse reaction entity
"Three patients with anti-belimumab antibodies experienced mild infusion reactions of nausea, erythematous rash, pruritus, eyelid edema, headache, and dyspnea; none of the reactions was life-threatening.",eyelid edema is an adverse reaction entity
"Three patients with anti-belimumab antibodies experienced mild infusion reactions of nausea, erythematous rash, pruritus, eyelid edema, headache, and dyspnea; none of the reactions was life-threatening.",headache is an adverse reaction entity
"Three patients with anti-belimumab antibodies experienced mild infusion reactions of nausea, erythematous rash, pruritus, eyelid edema, headache, and dyspnea; none of the reactions was life-threatening.",dyspnea is an adverse reaction entity
"The following have been observed with BENLYSTA and are discussed in detail in the Warnings and Precautions section:     *     Mortality  [ see   Warnings and Precautions (5.1)  ]    *     Serious Infections  [ see   Warnings and Precautions (5.2)  ]    *     Malignancy  [ see   Warnings and Precautions (5.3)  ]    *     Hypersensitivity Reactions, including Anaphylaxis  [ see   Warnings and Precautions (5.4)  ]    *     Infusion Reactions  [ see   Warnings and Precautions (5.5)  ]    *     Depression  [ see   Warnings and Precautions (5.6)  ]         EXCERPT:   Common adverse reactions (>=5%) in clinical trials were: nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, and pharyngitis.",Mortality is an adverse reaction entity
"The following have been observed with BENLYSTA and are discussed in detail in the Warnings and Precautions section:     *     Mortality  [ see   Warnings and Precautions (5.1)  ]    *     Serious Infections  [ see   Warnings and Precautions (5.2)  ]    *     Malignancy  [ see   Warnings and Precautions (5.3)  ]    *     Hypersensitivity Reactions, including Anaphylaxis  [ see   Warnings and Precautions (5.4)  ]    *     Infusion Reactions  [ see   Warnings and Precautions (5.5)  ]    *     Depression  [ see   Warnings and Precautions (5.6)  ]         EXCERPT:   Common adverse reactions (>=5%) in clinical trials were: nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, and pharyngitis.",Infections is an adverse reaction entity
"The following have been observed with BENLYSTA and are discussed in detail in the Warnings and Precautions section:     *     Mortality  [ see   Warnings and Precautions (5.1)  ]    *     Serious Infections  [ see   Warnings and Precautions (5.2)  ]    *     Malignancy  [ see   Warnings and Precautions (5.3)  ]    *     Hypersensitivity Reactions, including Anaphylaxis  [ see   Warnings and Precautions (5.4)  ]    *     Infusion Reactions  [ see   Warnings and Precautions (5.5)  ]    *     Depression  [ see   Warnings and Precautions (5.6)  ]         EXCERPT:   Common adverse reactions (>=5%) in clinical trials were: nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, and pharyngitis.",Malignancy is an adverse reaction entity
"The following have been observed with BENLYSTA and are discussed in detail in the Warnings and Precautions section:     *     Mortality  [ see   Warnings and Precautions (5.1)  ]    *     Serious Infections  [ see   Warnings and Precautions (5.2)  ]    *     Malignancy  [ see   Warnings and Precautions (5.3)  ]    *     Hypersensitivity Reactions, including Anaphylaxis  [ see   Warnings and Precautions (5.4)  ]    *     Infusion Reactions  [ see   Warnings and Precautions (5.5)  ]    *     Depression  [ see   Warnings and Precautions (5.6)  ]         EXCERPT:   Common adverse reactions (>=5%) in clinical trials were: nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, and pharyngitis.",Hypersensitivity Reactions is an adverse reaction entity
"The following have been observed with BENLYSTA and are discussed in detail in the Warnings and Precautions section:     *     Mortality  [ see   Warnings and Precautions (5.1)  ]    *     Serious Infections  [ see   Warnings and Precautions (5.2)  ]    *     Malignancy  [ see   Warnings and Precautions (5.3)  ]    *     Hypersensitivity Reactions, including Anaphylaxis  [ see   Warnings and Precautions (5.4)  ]    *     Infusion Reactions  [ see   Warnings and Precautions (5.5)  ]    *     Depression  [ see   Warnings and Precautions (5.6)  ]         EXCERPT:   Common adverse reactions (>=5%) in clinical trials were: nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, and pharyngitis.",Anaphylaxis is an adverse reaction entity
"The following have been observed with BENLYSTA and are discussed in detail in the Warnings and Precautions section:     *     Mortality  [ see   Warnings and Precautions (5.1)  ]    *     Serious Infections  [ see   Warnings and Precautions (5.2)  ]    *     Malignancy  [ see   Warnings and Precautions (5.3)  ]    *     Hypersensitivity Reactions, including Anaphylaxis  [ see   Warnings and Precautions (5.4)  ]    *     Infusion Reactions  [ see   Warnings and Precautions (5.5)  ]    *     Depression  [ see   Warnings and Precautions (5.6)  ]         EXCERPT:   Common adverse reactions (>=5%) in clinical trials were: nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, and pharyngitis.",Infusion Reactions is an adverse reaction entity
"The following have been observed with BENLYSTA and are discussed in detail in the Warnings and Precautions section:     *     Mortality  [ see   Warnings and Precautions (5.1)  ]    *     Serious Infections  [ see   Warnings and Precautions (5.2)  ]    *     Malignancy  [ see   Warnings and Precautions (5.3)  ]    *     Hypersensitivity Reactions, including Anaphylaxis  [ see   Warnings and Precautions (5.4)  ]    *     Infusion Reactions  [ see   Warnings and Precautions (5.5)  ]    *     Depression  [ see   Warnings and Precautions (5.6)  ]         EXCERPT:   Common adverse reactions (>=5%) in clinical trials were: nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, and pharyngitis.",Depression is an adverse reaction entity
"The following have been observed with BENLYSTA and are discussed in detail in the Warnings and Precautions section:     *     Mortality  [ see   Warnings and Precautions (5.1)  ]    *     Serious Infections  [ see   Warnings and Precautions (5.2)  ]    *     Malignancy  [ see   Warnings and Precautions (5.3)  ]    *     Hypersensitivity Reactions, including Anaphylaxis  [ see   Warnings and Precautions (5.4)  ]    *     Infusion Reactions  [ see   Warnings and Precautions (5.5)  ]    *     Depression  [ see   Warnings and Precautions (5.6)  ]         EXCERPT:   Common adverse reactions (>=5%) in clinical trials were: nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, and pharyngitis.",nausea is an adverse reaction entity
"The following have been observed with BENLYSTA and are discussed in detail in the Warnings and Precautions section:     *     Mortality  [ see   Warnings and Precautions (5.1)  ]    *     Serious Infections  [ see   Warnings and Precautions (5.2)  ]    *     Malignancy  [ see   Warnings and Precautions (5.3)  ]    *     Hypersensitivity Reactions, including Anaphylaxis  [ see   Warnings and Precautions (5.4)  ]    *     Infusion Reactions  [ see   Warnings and Precautions (5.5)  ]    *     Depression  [ see   Warnings and Precautions (5.6)  ]         EXCERPT:   Common adverse reactions (>=5%) in clinical trials were: nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, and pharyngitis.",diarrhea is an adverse reaction entity
"The following have been observed with BENLYSTA and are discussed in detail in the Warnings and Precautions section:     *     Mortality  [ see   Warnings and Precautions (5.1)  ]    *     Serious Infections  [ see   Warnings and Precautions (5.2)  ]    *     Malignancy  [ see   Warnings and Precautions (5.3)  ]    *     Hypersensitivity Reactions, including Anaphylaxis  [ see   Warnings and Precautions (5.4)  ]    *     Infusion Reactions  [ see   Warnings and Precautions (5.5)  ]    *     Depression  [ see   Warnings and Precautions (5.6)  ]         EXCERPT:   Common adverse reactions (>=5%) in clinical trials were: nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, and pharyngitis.",pyrexia is an adverse reaction entity
"The following have been observed with BENLYSTA and are discussed in detail in the Warnings and Precautions section:     *     Mortality  [ see   Warnings and Precautions (5.1)  ]    *     Serious Infections  [ see   Warnings and Precautions (5.2)  ]    *     Malignancy  [ see   Warnings and Precautions (5.3)  ]    *     Hypersensitivity Reactions, including Anaphylaxis  [ see   Warnings and Precautions (5.4)  ]    *     Infusion Reactions  [ see   Warnings and Precautions (5.5)  ]    *     Depression  [ see   Warnings and Precautions (5.6)  ]         EXCERPT:   Common adverse reactions (>=5%) in clinical trials were: nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, and pharyngitis.",nasopharyngitis is an adverse reaction entity
"The following have been observed with BENLYSTA and are discussed in detail in the Warnings and Precautions section:     *     Mortality  [ see   Warnings and Precautions (5.1)  ]    *     Serious Infections  [ see   Warnings and Precautions (5.2)  ]    *     Malignancy  [ see   Warnings and Precautions (5.3)  ]    *     Hypersensitivity Reactions, including Anaphylaxis  [ see   Warnings and Precautions (5.4)  ]    *     Infusion Reactions  [ see   Warnings and Precautions (5.5)  ]    *     Depression  [ see   Warnings and Precautions (5.6)  ]         EXCERPT:   Common adverse reactions (>=5%) in clinical trials were: nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, and pharyngitis.",bronchitis is an adverse reaction entity
"The following have been observed with BENLYSTA and are discussed in detail in the Warnings and Precautions section:     *     Mortality  [ see   Warnings and Precautions (5.1)  ]    *     Serious Infections  [ see   Warnings and Precautions (5.2)  ]    *     Malignancy  [ see   Warnings and Precautions (5.3)  ]    *     Hypersensitivity Reactions, including Anaphylaxis  [ see   Warnings and Precautions (5.4)  ]    *     Infusion Reactions  [ see   Warnings and Precautions (5.5)  ]    *     Depression  [ see   Warnings and Precautions (5.6)  ]         EXCERPT:   Common adverse reactions (>=5%) in clinical trials were: nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, and pharyngitis.",insomnia is an adverse reaction entity
"The following have been observed with BENLYSTA and are discussed in detail in the Warnings and Precautions section:     *     Mortality  [ see   Warnings and Precautions (5.1)  ]    *     Serious Infections  [ see   Warnings and Precautions (5.2)  ]    *     Malignancy  [ see   Warnings and Precautions (5.3)  ]    *     Hypersensitivity Reactions, including Anaphylaxis  [ see   Warnings and Precautions (5.4)  ]    *     Infusion Reactions  [ see   Warnings and Precautions (5.5)  ]    *     Depression  [ see   Warnings and Precautions (5.6)  ]         EXCERPT:   Common adverse reactions (>=5%) in clinical trials were: nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, and pharyngitis.",pain in extremity is an adverse reaction entity
"The following have been observed with BENLYSTA and are discussed in detail in the Warnings and Precautions section:     *     Mortality  [ see   Warnings and Precautions (5.1)  ]    *     Serious Infections  [ see   Warnings and Precautions (5.2)  ]    *     Malignancy  [ see   Warnings and Precautions (5.3)  ]    *     Hypersensitivity Reactions, including Anaphylaxis  [ see   Warnings and Precautions (5.4)  ]    *     Infusion Reactions  [ see   Warnings and Precautions (5.5)  ]    *     Depression  [ see   Warnings and Precautions (5.6)  ]         EXCERPT:   Common adverse reactions (>=5%) in clinical trials were: nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, and pharyngitis.",depression is an adverse reaction entity
"The following have been observed with BENLYSTA and are discussed in detail in the Warnings and Precautions section:     *     Mortality  [ see   Warnings and Precautions (5.1)  ]    *     Serious Infections  [ see   Warnings and Precautions (5.2)  ]    *     Malignancy  [ see   Warnings and Precautions (5.3)  ]    *     Hypersensitivity Reactions, including Anaphylaxis  [ see   Warnings and Precautions (5.4)  ]    *     Infusion Reactions  [ see   Warnings and Precautions (5.5)  ]    *     Depression  [ see   Warnings and Precautions (5.6)  ]         EXCERPT:   Common adverse reactions (>=5%) in clinical trials were: nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, and pharyngitis.",migraine is an adverse reaction entity
"The following have been observed with BENLYSTA and are discussed in detail in the Warnings and Precautions section:     *     Mortality  [ see   Warnings and Precautions (5.1)  ]    *     Serious Infections  [ see   Warnings and Precautions (5.2)  ]    *     Malignancy  [ see   Warnings and Precautions (5.3)  ]    *     Hypersensitivity Reactions, including Anaphylaxis  [ see   Warnings and Precautions (5.4)  ]    *     Infusion Reactions  [ see   Warnings and Precautions (5.5)  ]    *     Depression  [ see   Warnings and Precautions (5.6)  ]         EXCERPT:   Common adverse reactions (>=5%) in clinical trials were: nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, and pharyngitis.",pharyngitis is an adverse reaction entity
"The most frequent infections (>5% of patients receiving BENLYSTA) were upper respiratory tract infection, urinary tract infection, nasopharyngitis, sinusitis, bronchitis, and influenza.",infections is an adverse reaction entity
"The most frequent infections (>5% of patients receiving BENLYSTA) were upper respiratory tract infection, urinary tract infection, nasopharyngitis, sinusitis, bronchitis, and influenza.",upper respiratory tract infection is an adverse reaction entity
"The most frequent infections (>5% of patients receiving BENLYSTA) were upper respiratory tract infection, urinary tract infection, nasopharyngitis, sinusitis, bronchitis, and influenza.",urinary tract infection is an adverse reaction entity
"The most frequent infections (>5% of patients receiving BENLYSTA) were upper respiratory tract infection, urinary tract infection, nasopharyngitis, sinusitis, bronchitis, and influenza.",nasopharyngitis is an adverse reaction entity
"The most frequent infections (>5% of patients receiving BENLYSTA) were upper respiratory tract infection, urinary tract infection, nasopharyngitis, sinusitis, bronchitis, and influenza.",sinusitis is an adverse reaction entity
"The most frequent infections (>5% of patients receiving BENLYSTA) were upper respiratory tract infection, urinary tract infection, nasopharyngitis, sinusitis, bronchitis, and influenza.",bronchitis is an adverse reaction entity
"The most frequent infections (>5% of patients receiving BENLYSTA) were upper respiratory tract infection, urinary tract infection, nasopharyngitis, sinusitis, bronchitis, and influenza.",influenza is an adverse reaction entity
Serious infections occurred in 6.0% of patients treated with BENLYSTA and in 5.2% of patients who received placebo.,infections is an adverse reaction entity
"Manifestations included hypotension, angioedema, urticaria or other rash, pruritus, and dyspnea.",hypotension is an adverse reaction entity
"Manifestations included hypotension, angioedema, urticaria or other rash, pruritus, and dyspnea.",angioedema is an adverse reaction entity
"Manifestations included hypotension, angioedema, urticaria or other rash, pruritus, and dyspnea.",urticaria is an adverse reaction entity
"Manifestations included hypotension, angioedema, urticaria or other rash, pruritus, and dyspnea.",rash is an adverse reaction entity
"Manifestations included hypotension, angioedema, urticaria or other rash, pruritus, and dyspnea.",pruritus is an adverse reaction entity
"Manifestations included hypotension, angioedema, urticaria or other rash, pruritus, and dyspnea.",dyspnea is an adverse reaction entity
"Anaphylaxis was observed in 0.6% (9/1,458) of patients receiving BENLYSTA and 0.4% (3/675) of patients receiving placebo.",Anaphylaxis is an adverse reaction entity
Infections leading to discontinuation of treatment occurred in 0.7% of patients receiving BENLYSTA and 1.0% of patients receiving placebo.,Infections is an adverse reaction entity
"5.4 Hypersensitivity Reactions, including Anaphylaxis      Acute hypersensitivity reactions, including anaphylaxis and death, have been reported in association with BENLYSTA.",Acute hypersensitivity reactions is an adverse reaction entity
"5.4 Hypersensitivity Reactions, including Anaphylaxis      Acute hypersensitivity reactions, including anaphylaxis and death, have been reported in association with BENLYSTA.",anaphylaxis is an adverse reaction entity
"5.4 Hypersensitivity Reactions, including Anaphylaxis      Acute hypersensitivity reactions, including anaphylaxis and death, have been reported in association with BENLYSTA.",death is an adverse reaction entity
"In a 52-week, double-blind, comparator-controlled trial that included primarily adult patients with schizophrenia, the mean increase from baseline of ALT was 1.7 units/L.",increase of ALT is an adverse reaction entity
"In short-term placebo-controlled bipolar mania adult trials, the incidence of EPS-related events, excluding events related to akathisia, for SAPHRIS-treated patients was 7% versus 2% for placebo; and the incidence of akathisia-related events for SAPHRIS-treated patients was 4% versus 2% for placebo.",EPS-related events is an adverse reaction entity
"In short-term placebo-controlled bipolar mania adult trials, the incidence of EPS-related events, excluding events related to akathisia, for SAPHRIS-treated patients was 7% versus 2% for placebo; and the incidence of akathisia-related events for SAPHRIS-treated patients was 4% versus 2% for placebo.",akathisia is an adverse reaction entity
"In short-term placebo-controlled bipolar mania adult trials, the incidence of EPS-related events, excluding events related to akathisia, for SAPHRIS-treated patients was 7% versus 2% for placebo; and the incidence of akathisia-related events for SAPHRIS-treated patients was 4% versus 2% for placebo.",akathisia is an adverse reaction entity
The proportion of patients with a >=7% increase in body weight (at Endpoint) was 14.7%.Table 5provides the mean weight change from baseline and the proportion of patients with a weight gain of >=7% categorized by Body Mass Index (BMI) at baseline.,increase in body weight is an adverse reaction entity
The proportion of patients with a >=7% increase in body weight (at Endpoint) was 14.7%.Table 5provides the mean weight change from baseline and the proportion of patients with a weight gain of >=7% categorized by Body Mass Index (BMI) at baseline.,weight change is an adverse reaction entity
The proportion of patients with a >=7% increase in body weight (at Endpoint) was 14.7%.Table 5provides the mean weight change from baseline and the proportion of patients with a weight gain of >=7% categorized by Body Mass Index (BMI) at baseline.,weight gain is an adverse reaction entity
The proportion of patients with transaminase elevations >=3 times upper limit of normal (ULN) (at Endpoint) was 2.5% for SAPHRIS-treated patients versus 0.6% for placebo-treated patients.,transaminase elevations is an adverse reaction entity
5.5 Metabolic Changes        Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk.,metabolic changes is an adverse reaction entity
5.5 Metabolic Changes        Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk.,increase cardiovascular risk is an adverse reaction entity
5.5 Metabolic Changes        Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk.,increase cerebrovascular risk is an adverse reaction entity
"In a 3-week, placebo-controlled pediatric trial with bipolar I disorder, transient elevations in serum transaminases (primarily ALT) were more common in treated patients.",elevations in serum transaminases is an adverse reaction entity
"In a 3-week, placebo-controlled pediatric trial with bipolar I disorder, transient elevations in serum transaminases (primarily ALT) were more common in treated patients.",elevations in ALT is an adverse reaction entity
"(5.7)   *   Leukopenia, Neutropenia, and Agranulocytosis have been reported with antipsychotics.",Leukopenia is an adverse reaction entity
"(5.7)   *   Leukopenia, Neutropenia, and Agranulocytosis have been reported with antipsychotics.",Neutropenia is an adverse reaction entity
"(5.7)   *   Leukopenia, Neutropenia, and Agranulocytosis have been reported with antipsychotics.",Agranulocytosis is an adverse reaction entity
"Creatine Kinase (CK):  The proportion of adult patients with CK elevations >3 times ULN at any time were 6.4% and 11.1% for patients treated with SAPHRIS 5 mg twice daily and 10 mg twice daily, respectively, as compared to 6.7% for placebo-treated patients in short-term, fixed-dose trials in schizophrenia and bipolar mania.",CK elevations is an adverse reaction entity
There were no reports of prolactin elevations >=4 times ULN (at Endpoint) for patients treated with SAPHRIS or placebo.,prolactin elevations is an adverse reaction entity
"An elevated risk of acute dystonia is observed in males and younger age groups  [see Dosage and Administration (2.3), Use in Specific Populations (8.4), and Clinical Pharmacology (12.3)]  .",acute dystonia is an adverse reaction entity
"*  Application site reactions, primarily in the sublingual area, have been reported.",Application site reactions is an adverse reaction entity
"*  Application site reactions, primarily in the sublingual area, have been reported.",Application site reactions sublingual area is an adverse reaction entity
Post-baseline QT prolongations exceeding 500 msec were reported at comparable rates for SAPHRIS and placebo in these short-term trials.,QT prolongations is an adverse reaction entity
"5.8 Leukopenia, Neutropenia, and Agranulocytosis        In clinical trial and postmarketing experience, leukopenia and neutropenia have been reported temporally related to antipsychotic agents, including SAPHRIS.",leukopenia is an adverse reaction entity
"5.8 Leukopenia, Neutropenia, and Agranulocytosis        In clinical trial and postmarketing experience, leukopenia and neutropenia have been reported temporally related to antipsychotic agents, including SAPHRIS.",neutropenia is an adverse reaction entity
The proportion of patients with prolactin elevations >=4 times ULN (at Endpoint) were 2.3% for SAPHRIS-treated patients versus 0.7% for placebo-treated patients.,prolactin elevations is an adverse reaction entity
"In a 3-week, bipolar mania pediatric trial, syncope was reported in 1% (1/104) of patients treated with SAPHRIS 2.5 mg twice daily, 1% (1/99) of patients treated with SAPHRIS 5 mg twice daily, and 0% (0/99) for patients treated with SAPHRIS 10 mg twice daily compared to 0% (0/101) for patients treated with placebo.",syncope is an adverse reaction entity
"2Includes the preferred terms oral hypoesthesia, oral paresthesia, and oral dysesthesia.",oral hypoesthesia is an adverse reaction entity
"2Includes the preferred terms oral hypoesthesia, oral paresthesia, and oral dysesthesia.",oral paresthesia is an adverse reaction entity
"2Includes the preferred terms oral hypoesthesia, oral paresthesia, and oral dysesthesia.",oral dysesthesia is an adverse reaction entity
"In short-term, fixed-dose, placebo-controlled schizophrenia adult trials, somnolence was reported in 15% (41/274) of patients on SAPHRIS 5 mg twice daily and in 13% (26/208) of patients on SAPHRIS 10 mg twice daily compared to 7% (26/378) of placebo patients.",somnolence is an adverse reaction entity
"In short-term, placebo-controlled bipolar mania adult trials, the mean increase in prolactin levels was 4.9 ng/mL for SAPHRIS-treated patients compared to a decrease of 0.2 ng/mL for placebo-treated patients.",increase in prolactin levels is an adverse reaction entity
"The most common adverse reactions (>=5% and at least twice the rate of placebo) reported with acute monotherapy treatment of manic or mixed episodes associated with bipolar I disorder in adults were somnolence, dizziness, extrapyramidal symptoms other than akathisia, and increased weight and during the adjunctive therapy trial in bipolar I disorder in adults were somnolence and oral hypoesthesia.",somnolence is an adverse reaction entity
"The most common adverse reactions (>=5% and at least twice the rate of placebo) reported with acute monotherapy treatment of manic or mixed episodes associated with bipolar I disorder in adults were somnolence, dizziness, extrapyramidal symptoms other than akathisia, and increased weight and during the adjunctive therapy trial in bipolar I disorder in adults were somnolence and oral hypoesthesia.",dizziness is an adverse reaction entity
"The most common adverse reactions (>=5% and at least twice the rate of placebo) reported with acute monotherapy treatment of manic or mixed episodes associated with bipolar I disorder in adults were somnolence, dizziness, extrapyramidal symptoms other than akathisia, and increased weight and during the adjunctive therapy trial in bipolar I disorder in adults were somnolence and oral hypoesthesia.",extrapyramidal symptoms is an adverse reaction entity
"The most common adverse reactions (>=5% and at least twice the rate of placebo) reported with acute monotherapy treatment of manic or mixed episodes associated with bipolar I disorder in adults were somnolence, dizziness, extrapyramidal symptoms other than akathisia, and increased weight and during the adjunctive therapy trial in bipolar I disorder in adults were somnolence and oral hypoesthesia.",akathisia is an adverse reaction entity
"The most common adverse reactions (>=5% and at least twice the rate of placebo) reported with acute monotherapy treatment of manic or mixed episodes associated with bipolar I disorder in adults were somnolence, dizziness, extrapyramidal symptoms other than akathisia, and increased weight and during the adjunctive therapy trial in bipolar I disorder in adults were somnolence and oral hypoesthesia.",increased weight is an adverse reaction entity
"The most common adverse reactions (>=5% and at least twice the rate of placebo) reported with acute monotherapy treatment of manic or mixed episodes associated with bipolar I disorder in adults were somnolence, dizziness, extrapyramidal symptoms other than akathisia, and increased weight and during the adjunctive therapy trial in bipolar I disorder in adults were somnolence and oral hypoesthesia.",somnolence is an adverse reaction entity
"The most common adverse reactions (>=5% and at least twice the rate of placebo) reported with acute monotherapy treatment of manic or mixed episodes associated with bipolar I disorder in adults were somnolence, dizziness, extrapyramidal symptoms other than akathisia, and increased weight and during the adjunctive therapy trial in bipolar I disorder in adults were somnolence and oral hypoesthesia.",oral hypoesthesia is an adverse reaction entity
5.13 Body Temperature Regulation        Disruption of the body's ability to reduce core body temperature has been attributed to antipsychotic agents.,Disruption of the body's ability to reduce core body temperature is an adverse reaction entity
"At these doses, SAPHRIS was associated with increases in QTc interval ranging from 2 to 5 msec compared to placebo.",increases in QTc interval is an adverse reaction entity
The proportion of patients with prolactin elevations >=4 times ULN (at Endpoint) were 2.6% for SAPHRIS-treated patients versus 0.6% for placebo-treated patients.,prolactin elevations is an adverse reaction entity
Other Findings:  Oral hypoesthesia and/or oral paresthesia may occur directly after administration of SAPHRIS and usually resolves within 1 hour.,Oral hypoesthesia is an adverse reaction entity
Other Findings:  Oral hypoesthesia and/or oral paresthesia may occur directly after administration of SAPHRIS and usually resolves within 1 hour.,oral paresthesia is an adverse reaction entity
"During adult pre-marketing clinical trials with SAPHRIS, including long-term trials without comparison to placebo, seizures were reported in 0.3% (5/1953) of patients treated with SAPHRIS.",seizures is an adverse reaction entity
"During adult pre-marketing clinical trials with SAPHRIS, including long-term trials without comparison to placebo, somnolence was reported in 18% (358/1953) of patients treated with SAPHRIS.",somnolence is an adverse reaction entity
"5.7 Orthostatic Hypotension, Syncope, and Other Hemodynamic Effects        SAPHRIS may induce orthostatic hypotension and syncope in some patients, especially early in treatment, because of its alpha1-adrenergic antagonist activity.",orthostatic hypotension is an adverse reaction entity
"5.7 Orthostatic Hypotension, Syncope, and Other Hemodynamic Effects        SAPHRIS may induce orthostatic hypotension and syncope in some patients, especially early in treatment, because of its alpha1-adrenergic antagonist activity.",syncope is an adverse reaction entity
"*      Eye disorders:  infrequent: diplopia, vision blurred   *      Gastrointestinal disorders:  infrequent: gastroesophageal reflux disease   *      Injury, Poisoning, and Procedural Complications:  infrequent : fall   *      Skin and subcutaneous tissue disorders:  infrequent: photosensitivity reaction   *      Renal and urinary disorders: infrequent:  enuresis         6.2 Postmarketing Experience    The following adverse reactions have been identified during post-approval use of SAPHRIS.",diplopia is an adverse reaction entity
"*      Eye disorders:  infrequent: diplopia, vision blurred   *      Gastrointestinal disorders:  infrequent: gastroesophageal reflux disease   *      Injury, Poisoning, and Procedural Complications:  infrequent : fall   *      Skin and subcutaneous tissue disorders:  infrequent: photosensitivity reaction   *      Renal and urinary disorders: infrequent:  enuresis         6.2 Postmarketing Experience    The following adverse reactions have been identified during post-approval use of SAPHRIS.",vision blurred is an adverse reaction entity
"*      Eye disorders:  infrequent: diplopia, vision blurred   *      Gastrointestinal disorders:  infrequent: gastroesophageal reflux disease   *      Injury, Poisoning, and Procedural Complications:  infrequent : fall   *      Skin and subcutaneous tissue disorders:  infrequent: photosensitivity reaction   *      Renal and urinary disorders: infrequent:  enuresis         6.2 Postmarketing Experience    The following adverse reactions have been identified during post-approval use of SAPHRIS.",gastroesophageal reflux disease is an adverse reaction entity
"*      Eye disorders:  infrequent: diplopia, vision blurred   *      Gastrointestinal disorders:  infrequent: gastroesophageal reflux disease   *      Injury, Poisoning, and Procedural Complications:  infrequent : fall   *      Skin and subcutaneous tissue disorders:  infrequent: photosensitivity reaction   *      Renal and urinary disorders: infrequent:  enuresis         6.2 Postmarketing Experience    The following adverse reactions have been identified during post-approval use of SAPHRIS.",fall is an adverse reaction entity
"*      Eye disorders:  infrequent: diplopia, vision blurred   *      Gastrointestinal disorders:  infrequent: gastroesophageal reflux disease   *      Injury, Poisoning, and Procedural Complications:  infrequent : fall   *      Skin and subcutaneous tissue disorders:  infrequent: photosensitivity reaction   *      Renal and urinary disorders: infrequent:  enuresis         6.2 Postmarketing Experience    The following adverse reactions have been identified during post-approval use of SAPHRIS.",photosensitivity reaction is an adverse reaction entity
"*      Eye disorders:  infrequent: diplopia, vision blurred   *      Gastrointestinal disorders:  infrequent: gastroesophageal reflux disease   *      Injury, Poisoning, and Procedural Complications:  infrequent : fall   *      Skin and subcutaneous tissue disorders:  infrequent: photosensitivity reaction   *      Renal and urinary disorders: infrequent:  enuresis         6.2 Postmarketing Experience    The following adverse reactions have been identified during post-approval use of SAPHRIS.",enuresis is an adverse reaction entity
"Adult Patients:  Pooled data on mean changes in body weight and the proportion of subjects meeting a weight gain criterion of >=7% of body weight from the short-term, placebo-controlled schizophrenia and bipolar mania trials are presented in  Table 5.",weight gain is an adverse reaction entity
BOXED WARNING: WARNING: SUPINE HYPERTENSION      WARNING: SUPINE HYPERTENSION        Monitor supine blood pressure prior to and during treatment and more frequently when increasing doses.,SUPINE HYPERTENSION is an adverse reaction entity
BOXED WARNING: WARNING: SUPINE HYPERTENSION      WARNING: SUPINE HYPERTENSION        Monitor supine blood pressure prior to and during treatment and more frequently when increasing doses.,SUPINE HYPERTENSION is an adverse reaction entity
5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons.,allergic-type reactions is an adverse reaction entity
5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons.,bronchial asthma is an adverse reaction entity
"5.3 Ischemic Heart Disease, Arrhythmias, and Congestive Heart Failure      NORTHERA may exacerbate existing ischemic heart disease, arrhythmias, and congestive heart failure.",exacerbate ischemic heart disease is an adverse reaction entity
"5.3 Ischemic Heart Disease, Arrhythmias, and Congestive Heart Failure      NORTHERA may exacerbate existing ischemic heart disease, arrhythmias, and congestive heart failure.",exacerbate arrhythmias is an adverse reaction entity
"5.3 Ischemic Heart Disease, Arrhythmias, and Congestive Heart Failure      NORTHERA may exacerbate existing ischemic heart disease, arrhythmias, and congestive heart failure.",exacerbate congestive heart failure is an adverse reaction entity
"EXCERPT:   Most common adverse reactions (incidence 1% or greater) are: systemic hypersensitivity, hyperglycemia, transaminases abnormal, fever, pancreatitis, local reactions, vomiting, nausea, thrombosis, hyperbilirubinemia, abdominal pain/discomfort, and diarrhea.",systemic hypersensitivity is an adverse reaction entity
"EXCERPT:   Most common adverse reactions (incidence 1% or greater) are: systemic hypersensitivity, hyperglycemia, transaminases abnormal, fever, pancreatitis, local reactions, vomiting, nausea, thrombosis, hyperbilirubinemia, abdominal pain/discomfort, and diarrhea.",hyperglycemia is an adverse reaction entity
"EXCERPT:   Most common adverse reactions (incidence 1% or greater) are: systemic hypersensitivity, hyperglycemia, transaminases abnormal, fever, pancreatitis, local reactions, vomiting, nausea, thrombosis, hyperbilirubinemia, abdominal pain/discomfort, and diarrhea.",transaminases abnormal is an adverse reaction entity
"EXCERPT:   Most common adverse reactions (incidence 1% or greater) are: systemic hypersensitivity, hyperglycemia, transaminases abnormal, fever, pancreatitis, local reactions, vomiting, nausea, thrombosis, hyperbilirubinemia, abdominal pain/discomfort, and diarrhea.",fever is an adverse reaction entity
"EXCERPT:   Most common adverse reactions (incidence 1% or greater) are: systemic hypersensitivity, hyperglycemia, transaminases abnormal, fever, pancreatitis, local reactions, vomiting, nausea, thrombosis, hyperbilirubinemia, abdominal pain/discomfort, and diarrhea.",pancreatitis is an adverse reaction entity
"EXCERPT:   Most common adverse reactions (incidence 1% or greater) are: systemic hypersensitivity, hyperglycemia, transaminases abnormal, fever, pancreatitis, local reactions, vomiting, nausea, thrombosis, hyperbilirubinemia, abdominal pain/discomfort, and diarrhea.",local reactions is an adverse reaction entity
"EXCERPT:   Most common adverse reactions (incidence 1% or greater) are: systemic hypersensitivity, hyperglycemia, transaminases abnormal, fever, pancreatitis, local reactions, vomiting, nausea, thrombosis, hyperbilirubinemia, abdominal pain/discomfort, and diarrhea.",vomiting is an adverse reaction entity
"EXCERPT:   Most common adverse reactions (incidence 1% or greater) are: systemic hypersensitivity, hyperglycemia, transaminases abnormal, fever, pancreatitis, local reactions, vomiting, nausea, thrombosis, hyperbilirubinemia, abdominal pain/discomfort, and diarrhea.",nausea is an adverse reaction entity
"EXCERPT:   Most common adverse reactions (incidence 1% or greater) are: systemic hypersensitivity, hyperglycemia, transaminases abnormal, fever, pancreatitis, local reactions, vomiting, nausea, thrombosis, hyperbilirubinemia, abdominal pain/discomfort, and diarrhea.",thrombosis is an adverse reaction entity
"EXCERPT:   Most common adverse reactions (incidence 1% or greater) are: systemic hypersensitivity, hyperglycemia, transaminases abnormal, fever, pancreatitis, local reactions, vomiting, nausea, thrombosis, hyperbilirubinemia, abdominal pain/discomfort, and diarrhea.",hyperbilirubinemia is an adverse reaction entity
"EXCERPT:   Most common adverse reactions (incidence 1% or greater) are: systemic hypersensitivity, hyperglycemia, transaminases abnormal, fever, pancreatitis, local reactions, vomiting, nausea, thrombosis, hyperbilirubinemia, abdominal pain/discomfort, and diarrhea.",abdominal pain is an adverse reaction entity
"EXCERPT:   Most common adverse reactions (incidence 1% or greater) are: systemic hypersensitivity, hyperglycemia, transaminases abnormal, fever, pancreatitis, local reactions, vomiting, nausea, thrombosis, hyperbilirubinemia, abdominal pain/discomfort, and diarrhea.",abdominal discomfort is an adverse reaction entity
"EXCERPT:   Most common adverse reactions (incidence 1% or greater) are: systemic hypersensitivity, hyperglycemia, transaminases abnormal, fever, pancreatitis, local reactions, vomiting, nausea, thrombosis, hyperbilirubinemia, abdominal pain/discomfort, and diarrhea.",diarrhea is an adverse reaction entity
"Of these 6 ADA positive patients, one experienced a hypersensitivity reaction during Study 1 (2%, 1 of 56).",hypersensitivity reaction is an adverse reaction entity
"Fourteen (24%) patients stopped therapy prior to completion; seven due to allergic reactions, five due to physician or patient choice, one due to disease progression, and one due to discontinuation during frontline protocol.",allergic reactions is an adverse reaction entity
Long-term cumulative radiation exposure is associated with an increased risk of cancer.,Long-term cumulative radiation exposure is an adverse reaction entity
Long-term cumulative radiation exposure is associated with an increased risk of cancer.,cancer is an adverse reaction entity
"Ensure safe handling to protect patients and health care workers from unintentional radiation exposure (  2.1  ,  5.3  )             5.1 Hypersensitivity Reactions      Hypersensitivity reactions such as flushing and dyspnea have been observed within minutes following Vizamyl administration.",Hypersensitivity reactions is an adverse reaction entity
"Ensure safe handling to protect patients and health care workers from unintentional radiation exposure (  2.1  ,  5.3  )             5.1 Hypersensitivity Reactions      Hypersensitivity reactions such as flushing and dyspnea have been observed within minutes following Vizamyl administration.",flushing is an adverse reaction entity
"Ensure safe handling to protect patients and health care workers from unintentional radiation exposure (  2.1  ,  5.3  )             5.1 Hypersensitivity Reactions      Hypersensitivity reactions such as flushing and dyspnea have been observed within minutes following Vizamyl administration.",dyspnea is an adverse reaction entity
"The most common adverse reactions to CERDELGA (occurring in >=10% of the 126 GD1 patients treated with CERDELGA across Trials 1 and 2) were fatigue, headache, nausea, diarrhea, back pain, pain in extremities, and upper abdominal pain.",fatigue is an adverse reaction entity
"The most common adverse reactions to CERDELGA (occurring in >=10% of the 126 GD1 patients treated with CERDELGA across Trials 1 and 2) were fatigue, headache, nausea, diarrhea, back pain, pain in extremities, and upper abdominal pain.",headache is an adverse reaction entity
"The most common adverse reactions to CERDELGA (occurring in >=10% of the 126 GD1 patients treated with CERDELGA across Trials 1 and 2) were fatigue, headache, nausea, diarrhea, back pain, pain in extremities, and upper abdominal pain.",nausea is an adverse reaction entity
"The most common adverse reactions to CERDELGA (occurring in >=10% of the 126 GD1 patients treated with CERDELGA across Trials 1 and 2) were fatigue, headache, nausea, diarrhea, back pain, pain in extremities, and upper abdominal pain.",diarrhea is an adverse reaction entity
"The most common adverse reactions to CERDELGA (occurring in >=10% of the 126 GD1 patients treated with CERDELGA across Trials 1 and 2) were fatigue, headache, nausea, diarrhea, back pain, pain in extremities, and upper abdominal pain.",back pain is an adverse reaction entity
"The most common adverse reactions to CERDELGA (occurring in >=10% of the 126 GD1 patients treated with CERDELGA across Trials 1 and 2) were fatigue, headache, nausea, diarrhea, back pain, pain in extremities, and upper abdominal pain.",pain in extremities is an adverse reaction entity
"The most common adverse reactions to CERDELGA (occurring in >=10% of the 126 GD1 patients treated with CERDELGA across Trials 1 and 2) were fatigue, headache, nausea, diarrhea, back pain, pain in extremities, and upper abdominal pain.",upper abdominal pain is an adverse reaction entity
The incidence of grade >= 2 hematuria was 6% in JEVTANA-treated patients and 2% in mitoxantrone-treated patients.,hematuria is an adverse reaction entity
The majority (4 of 5 patients) of fatal infection-related adverse reactions occurred after a single dose of JEVTANA.,fatal is an adverse reaction entity
The majority (4 of 5 patients) of fatal infection-related adverse reactions occurred after a single dose of JEVTANA.,infection-related adverse reactions is an adverse reaction entity
"5.4 Renal Failure      In the randomized clinical trial, renal failure of any grade occurred in 4% of the patients being treated with JEVTANA, including four cases with fatal outcome.",renal failure is an adverse reaction entity
"5.4 Renal Failure      In the randomized clinical trial, renal failure of any grade occurred in 4% of the patients being treated with JEVTANA, including four cases with fatal outcome.",fatal is an adverse reaction entity
"5.2 Hypersensitivity Reactions      Hypersensitivity reactions may occur within a few minutes following the initiation of the infusion of JEVTANA, thus facilities and equipment for the treatment of hypotension and bronchospasm should be available.",Hypersensitivity reactions is an adverse reaction entity
Deaths due to causes other than disease progression within 30 days of last study drug dose were reported in 18 (5%) JEVTANA-treated patients and 3 (< 1%) mitoxantrone-treated patients.,Deaths is an adverse reaction entity
(  2.2  )(  4  )(  5.1  )   *  Hypersensitivity: Severe hypersensitivity reactions can occur.,Hypersensitivity is an adverse reaction entity
(  2.2  )(  4  )(  5.1  )   *  Hypersensitivity: Severe hypersensitivity reactions can occur.,hypersensitivity reactions is an adverse reaction entity
One additional patient's death was attributed to neutropenia without a documented infection.,death is an adverse reaction entity
One additional patient's death was attributed to neutropenia without a documented infection.,neutropenia is an adverse reaction entity
One additional patient's death was attributed to neutropenia without a documented infection.,infection is an adverse reaction entity
"Severe hypersensitivity:   Severe hypersensitivity reactions can occur and may include generalized rash/erythema, hypotension and bronchospasm.",hypersensitivity reactions is an adverse reaction entity
"Severe hypersensitivity:   Severe hypersensitivity reactions can occur and may include generalized rash/erythema, hypotension and bronchospasm.",generalized rash is an adverse reaction entity
"Severe hypersensitivity:   Severe hypersensitivity reactions can occur and may include generalized rash/erythema, hypotension and bronchospasm.",erythema is an adverse reaction entity
"Severe hypersensitivity:   Severe hypersensitivity reactions can occur and may include generalized rash/erythema, hypotension and bronchospasm.",hypotension is an adverse reaction entity
"Severe hypersensitivity:   Severe hypersensitivity reactions can occur and may include generalized rash/erythema, hypotension and bronchospasm.",bronchospasm is an adverse reaction entity
"EXCERPT:   Most common all grades adverse reactions (>=10%) are neutropenia, anemia, leukopenia, thrombocytopenia, diarrhea, fatigue, nausea, vomiting, constipation, asthenia, abdominal pain, hematuria, back pain, anorexia, peripheral neuropathy, pyrexia, dyspnea, dysgeusia, cough, arthralgia, and alopecia.",neutropenia is an adverse reaction entity
"EXCERPT:   Most common all grades adverse reactions (>=10%) are neutropenia, anemia, leukopenia, thrombocytopenia, diarrhea, fatigue, nausea, vomiting, constipation, asthenia, abdominal pain, hematuria, back pain, anorexia, peripheral neuropathy, pyrexia, dyspnea, dysgeusia, cough, arthralgia, and alopecia.",anemia is an adverse reaction entity
"EXCERPT:   Most common all grades adverse reactions (>=10%) are neutropenia, anemia, leukopenia, thrombocytopenia, diarrhea, fatigue, nausea, vomiting, constipation, asthenia, abdominal pain, hematuria, back pain, anorexia, peripheral neuropathy, pyrexia, dyspnea, dysgeusia, cough, arthralgia, and alopecia.",leukopenia is an adverse reaction entity
"EXCERPT:   Most common all grades adverse reactions (>=10%) are neutropenia, anemia, leukopenia, thrombocytopenia, diarrhea, fatigue, nausea, vomiting, constipation, asthenia, abdominal pain, hematuria, back pain, anorexia, peripheral neuropathy, pyrexia, dyspnea, dysgeusia, cough, arthralgia, and alopecia.",thrombocytopenia is an adverse reaction entity
"EXCERPT:   Most common all grades adverse reactions (>=10%) are neutropenia, anemia, leukopenia, thrombocytopenia, diarrhea, fatigue, nausea, vomiting, constipation, asthenia, abdominal pain, hematuria, back pain, anorexia, peripheral neuropathy, pyrexia, dyspnea, dysgeusia, cough, arthralgia, and alopecia.",diarrhea is an adverse reaction entity
"EXCERPT:   Most common all grades adverse reactions (>=10%) are neutropenia, anemia, leukopenia, thrombocytopenia, diarrhea, fatigue, nausea, vomiting, constipation, asthenia, abdominal pain, hematuria, back pain, anorexia, peripheral neuropathy, pyrexia, dyspnea, dysgeusia, cough, arthralgia, and alopecia.",fatigue is an adverse reaction entity
"EXCERPT:   Most common all grades adverse reactions (>=10%) are neutropenia, anemia, leukopenia, thrombocytopenia, diarrhea, fatigue, nausea, vomiting, constipation, asthenia, abdominal pain, hematuria, back pain, anorexia, peripheral neuropathy, pyrexia, dyspnea, dysgeusia, cough, arthralgia, and alopecia.",nausea is an adverse reaction entity
"EXCERPT:   Most common all grades adverse reactions (>=10%) are neutropenia, anemia, leukopenia, thrombocytopenia, diarrhea, fatigue, nausea, vomiting, constipation, asthenia, abdominal pain, hematuria, back pain, anorexia, peripheral neuropathy, pyrexia, dyspnea, dysgeusia, cough, arthralgia, and alopecia.",vomiting is an adverse reaction entity
"EXCERPT:   Most common all grades adverse reactions (>=10%) are neutropenia, anemia, leukopenia, thrombocytopenia, diarrhea, fatigue, nausea, vomiting, constipation, asthenia, abdominal pain, hematuria, back pain, anorexia, peripheral neuropathy, pyrexia, dyspnea, dysgeusia, cough, arthralgia, and alopecia.",constipation is an adverse reaction entity
"EXCERPT:   Most common all grades adverse reactions (>=10%) are neutropenia, anemia, leukopenia, thrombocytopenia, diarrhea, fatigue, nausea, vomiting, constipation, asthenia, abdominal pain, hematuria, back pain, anorexia, peripheral neuropathy, pyrexia, dyspnea, dysgeusia, cough, arthralgia, and alopecia.",asthenia is an adverse reaction entity
"EXCERPT:   Most common all grades adverse reactions (>=10%) are neutropenia, anemia, leukopenia, thrombocytopenia, diarrhea, fatigue, nausea, vomiting, constipation, asthenia, abdominal pain, hematuria, back pain, anorexia, peripheral neuropathy, pyrexia, dyspnea, dysgeusia, cough, arthralgia, and alopecia.",abdominal pain is an adverse reaction entity
"EXCERPT:   Most common all grades adverse reactions (>=10%) are neutropenia, anemia, leukopenia, thrombocytopenia, diarrhea, fatigue, nausea, vomiting, constipation, asthenia, abdominal pain, hematuria, back pain, anorexia, peripheral neuropathy, pyrexia, dyspnea, dysgeusia, cough, arthralgia, and alopecia.",hematuria is an adverse reaction entity
"EXCERPT:   Most common all grades adverse reactions (>=10%) are neutropenia, anemia, leukopenia, thrombocytopenia, diarrhea, fatigue, nausea, vomiting, constipation, asthenia, abdominal pain, hematuria, back pain, anorexia, peripheral neuropathy, pyrexia, dyspnea, dysgeusia, cough, arthralgia, and alopecia.",back pain is an adverse reaction entity
"EXCERPT:   Most common all grades adverse reactions (>=10%) are neutropenia, anemia, leukopenia, thrombocytopenia, diarrhea, fatigue, nausea, vomiting, constipation, asthenia, abdominal pain, hematuria, back pain, anorexia, peripheral neuropathy, pyrexia, dyspnea, dysgeusia, cough, arthralgia, and alopecia.",anorexia is an adverse reaction entity
"EXCERPT:   Most common all grades adverse reactions (>=10%) are neutropenia, anemia, leukopenia, thrombocytopenia, diarrhea, fatigue, nausea, vomiting, constipation, asthenia, abdominal pain, hematuria, back pain, anorexia, peripheral neuropathy, pyrexia, dyspnea, dysgeusia, cough, arthralgia, and alopecia.",peripheral neuropathy is an adverse reaction entity
"EXCERPT:   Most common all grades adverse reactions (>=10%) are neutropenia, anemia, leukopenia, thrombocytopenia, diarrhea, fatigue, nausea, vomiting, constipation, asthenia, abdominal pain, hematuria, back pain, anorexia, peripheral neuropathy, pyrexia, dyspnea, dysgeusia, cough, arthralgia, and alopecia.",pyrexia is an adverse reaction entity
"EXCERPT:   Most common all grades adverse reactions (>=10%) are neutropenia, anemia, leukopenia, thrombocytopenia, diarrhea, fatigue, nausea, vomiting, constipation, asthenia, abdominal pain, hematuria, back pain, anorexia, peripheral neuropathy, pyrexia, dyspnea, dysgeusia, cough, arthralgia, and alopecia.",dyspnea is an adverse reaction entity
"EXCERPT:   Most common all grades adverse reactions (>=10%) are neutropenia, anemia, leukopenia, thrombocytopenia, diarrhea, fatigue, nausea, vomiting, constipation, asthenia, abdominal pain, hematuria, back pain, anorexia, peripheral neuropathy, pyrexia, dyspnea, dysgeusia, cough, arthralgia, and alopecia.",dysgeusia is an adverse reaction entity
"EXCERPT:   Most common all grades adverse reactions (>=10%) are neutropenia, anemia, leukopenia, thrombocytopenia, diarrhea, fatigue, nausea, vomiting, constipation, asthenia, abdominal pain, hematuria, back pain, anorexia, peripheral neuropathy, pyrexia, dyspnea, dysgeusia, cough, arthralgia, and alopecia.",cough is an adverse reaction entity
"EXCERPT:   Most common all grades adverse reactions (>=10%) are neutropenia, anemia, leukopenia, thrombocytopenia, diarrhea, fatigue, nausea, vomiting, constipation, asthenia, abdominal pain, hematuria, back pain, anorexia, peripheral neuropathy, pyrexia, dyspnea, dysgeusia, cough, arthralgia, and alopecia.",arthralgia is an adverse reaction entity
"EXCERPT:   Most common all grades adverse reactions (>=10%) are neutropenia, anemia, leukopenia, thrombocytopenia, diarrhea, fatigue, nausea, vomiting, constipation, asthenia, abdominal pain, hematuria, back pain, anorexia, peripheral neuropathy, pyrexia, dyspnea, dysgeusia, cough, arthralgia, and alopecia.",alopecia is an adverse reaction entity
"(2.2)(4)   *  Severe hypersensitivity can occur and may include generalized rash/erythema, hypotension and bronchospasm.",hypersensitivity is an adverse reaction entity
"(2.2)(4)   *  Severe hypersensitivity can occur and may include generalized rash/erythema, hypotension and bronchospasm.",generalized rash is an adverse reaction entity
"(2.2)(4)   *  Severe hypersensitivity can occur and may include generalized rash/erythema, hypotension and bronchospasm.",erythema is an adverse reaction entity
"(2.2)(4)   *  Severe hypersensitivity can occur and may include generalized rash/erythema, hypotension and bronchospasm.",hypotension is an adverse reaction entity
"(2.2)(4)   *  Severe hypersensitivity can occur and may include generalized rash/erythema, hypotension and bronchospasm.",bronchospasm is an adverse reaction entity
No adverse reactions representing hemolytic anemia were reported in any treatment group.,hemolytic anemia is an adverse reaction entity
5.3 Direct Coombs' Test Seroconversion      Seroconversion from a negative to a positive direct Coombs' test result occurred in 120/1114 (10.8%) of patients receiving Teflaro and 49/1116 (4.4%) of patients receiving comparator drugs in the four pooled Phase 3 trials.,Seroconversion from a negative to a positive direct Coombs' test result is an adverse reaction entity
*  Radiation risk: Choline C 11 Injection contributes to a patient's long-term cumulative radiation exposure.,Radiation risk is an adverse reaction entity
Bleeding in Patients with Nonvalvular Atrial Fibrillation in ARISTOTLE and AVERROES    Tables 1 and 2 show the number of patients experiencing major bleeding during the treatment period and the bleeding rate (percentage of subjects with at least one bleeding event per 100 patient-years) in ARISTOTLE and AVERROES.,bleeding is an adverse reaction entity
Bleeding in Patients with Nonvalvular Atrial Fibrillation in ARISTOTLE and AVERROES    Tables 1 and 2 show the number of patients experiencing major bleeding during the treatment period and the bleeding rate (percentage of subjects with at least one bleeding event per 100 patient-years) in ARISTOTLE and AVERROES.,bleeding is an adverse reaction entity
Bleeding in Patients with Nonvalvular Atrial Fibrillation in ARISTOTLE and AVERROES    Tables 1 and 2 show the number of patients experiencing major bleeding during the treatment period and the bleeding rate (percentage of subjects with at least one bleeding event per 100 patient-years) in ARISTOTLE and AVERROES.,bleeding is an adverse reaction entity
**  Fatal bleeding is an adjudicated death with the primary cause of death as intracranial bleeding or non-intracranial bleeding during the on-treatment period.,Fatal is an adverse reaction entity
**  Fatal bleeding is an adjudicated death with the primary cause of death as intracranial bleeding or non-intracranial bleeding during the on-treatment period.,bleeding is an adverse reaction entity
**  Fatal bleeding is an adjudicated death with the primary cause of death as intracranial bleeding or non-intracranial bleeding during the on-treatment period.,death is an adverse reaction entity
**  Fatal bleeding is an adjudicated death with the primary cause of death as intracranial bleeding or non-intracranial bleeding during the on-treatment period.,death is an adverse reaction entity
**  Fatal bleeding is an adjudicated death with the primary cause of death as intracranial bleeding or non-intracranial bleeding during the on-treatment period.,intracranial bleeding is an adverse reaction entity
**  Fatal bleeding is an adjudicated death with the primary cause of death as intracranial bleeding or non-intracranial bleeding during the on-treatment period.,non-intracranial bleeding is an adverse reaction entity
"Major                          15 (0.6)                  49 (1.8)                 0.31 (0.17, 0.55)p<0.0001       CRNM*                          103 (3.9)                 215 (8.0)                                              Major + CRNM                   115 (4.3)                 261 (9.7)                                              Minor                          313 (11.7)                505 (18.8)                                             All                            402 (15.0)                676 (25.1)                                                     Adverse reactions occurring in >=1% of patients in the AMPLIFY study are listed in Table 6.",CRNM is an adverse reaction entity
"Major                          15 (0.6)                  49 (1.8)                 0.31 (0.17, 0.55)p<0.0001       CRNM*                          103 (3.9)                 215 (8.0)                                              Major + CRNM                   115 (4.3)                 261 (9.7)                                              Minor                          313 (11.7)                505 (18.8)                                             All                            402 (15.0)                676 (25.1)                                                     Adverse reactions occurring in >=1% of patients in the AMPLIFY study are listed in Table 6.",CRNM is an adverse reaction entity
"The most common reason for treatment discontinuation in both studies was for bleeding-related adverse reactions; in ARISTOTLE this occurred in 1.7% and 2.5% of patients treated with ELIQUIS and warfarin, respectively, and in AVERROES, in 1.5% and 1.3% on ELIQUIS and aspirin, respectively.",bleeding-related adverse reactions is an adverse reaction entity
"Table 1:     Bleeding Events in Patients with Nonvalvular Atrial Fibrillation in ARISTOTLE*                              ELIQUISN=9088n (per 100 pt-year)  WarfarinN=9052n (per 100 pt-year)  Hazard Ratio(95% CI)  P-value                *  Bleeding events within each subcategory were counted once per subject, but subjects may have contributed events to multiple endpoints.",Bleeding is an adverse reaction entity
"Table 1:     Bleeding Events in Patients with Nonvalvular Atrial Fibrillation in ARISTOTLE*                              ELIQUISN=9088n (per 100 pt-year)  WarfarinN=9052n (per 100 pt-year)  Hazard Ratio(95% CI)  P-value                *  Bleeding events within each subcategory were counted once per subject, but subjects may have contributed events to multiple endpoints.",Bleeding is an adverse reaction entity
"Major                      327 (2.13)             462 (3.09)           0.69 (0.60, 0.80)     <0.0001               Intracranial (ICH)?",ICH is an adverse reaction entity
(B) SPINAL/EPIDURAL HEMATOMA         Epidural or spinal hematomas may occur in patients treated with ELIQUIS who are receiving neuraxial anesthesia or undergoing spinal puncture.,Epidural hematomas is an adverse reaction entity
(B) SPINAL/EPIDURAL HEMATOMA         Epidural or spinal hematomas may occur in patients treated with ELIQUIS who are receiving neuraxial anesthesia or undergoing spinal puncture.,spinal hematomas is an adverse reaction entity
The discontinuation rate due to bleeding events was approximately 1% in the ELIQUIS-treated patients compared to 0.4% in those patients in the placebo group in the AMPLIFY-EXT study.,bleeding is an adverse reaction entity
Includes 13 subjects with major bleeding events that occurred before the first dose of apixaban (administered 12 to 24 hours post surgery).,bleeding is an adverse reaction entity
"Factors that can increase the risk of developing epidural or spinal hematomas in these patients include:       *  ?use of indwelling epidural catheters   *  ?concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants   *  ?a history of traumatic or repeated epidural or spinal punctures   *  ?a history of spinal deformity or spinal surgery   *  ?optimal timing between the administration of ELIQUIS and neuraxial procedures is not known          [see Warnings and Precautions (5.3)]           Monitor patients frequently for signs and symptoms of neurological impairment.",epidural hematomas is an adverse reaction entity
"Factors that can increase the risk of developing epidural or spinal hematomas in these patients include:       *  ?use of indwelling epidural catheters   *  ?concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants   *  ?a history of traumatic or repeated epidural or spinal punctures   *  ?a history of spinal deformity or spinal surgery   *  ?optimal timing between the administration of ELIQUIS and neuraxial procedures is not known          [see Warnings and Precautions (5.3)]           Monitor patients frequently for signs and symptoms of neurological impairment.",spinal hematomas is an adverse reaction entity
"(  6.1  )   *    Asthma: Most common adverse reactions (incidence greater than or equal to 2%) are nasopharyngitis, oral candidiasis, headache, influenza, upper respiratory tract infection, bronchitis, sinusitis, oropharyngeal pain, dysphonia, and cough.",nasopharyngitis is an adverse reaction entity
"(  6.1  )   *    Asthma: Most common adverse reactions (incidence greater than or equal to 2%) are nasopharyngitis, oral candidiasis, headache, influenza, upper respiratory tract infection, bronchitis, sinusitis, oropharyngeal pain, dysphonia, and cough.",oral candidiasis is an adverse reaction entity
"(  6.1  )   *    Asthma: Most common adverse reactions (incidence greater than or equal to 2%) are nasopharyngitis, oral candidiasis, headache, influenza, upper respiratory tract infection, bronchitis, sinusitis, oropharyngeal pain, dysphonia, and cough.",headache is an adverse reaction entity
"(  6.1  )   *    Asthma: Most common adverse reactions (incidence greater than or equal to 2%) are nasopharyngitis, oral candidiasis, headache, influenza, upper respiratory tract infection, bronchitis, sinusitis, oropharyngeal pain, dysphonia, and cough.",influenza is an adverse reaction entity
"(  6.1  )   *    Asthma: Most common adverse reactions (incidence greater than or equal to 2%) are nasopharyngitis, oral candidiasis, headache, influenza, upper respiratory tract infection, bronchitis, sinusitis, oropharyngeal pain, dysphonia, and cough.",upper respiratory tract infection is an adverse reaction entity
"(  6.1  )   *    Asthma: Most common adverse reactions (incidence greater than or equal to 2%) are nasopharyngitis, oral candidiasis, headache, influenza, upper respiratory tract infection, bronchitis, sinusitis, oropharyngeal pain, dysphonia, and cough.",bronchitis is an adverse reaction entity
"(  6.1  )   *    Asthma: Most common adverse reactions (incidence greater than or equal to 2%) are nasopharyngitis, oral candidiasis, headache, influenza, upper respiratory tract infection, bronchitis, sinusitis, oropharyngeal pain, dysphonia, and cough.",sinusitis is an adverse reaction entity
"(  6.1  )   *    Asthma: Most common adverse reactions (incidence greater than or equal to 2%) are nasopharyngitis, oral candidiasis, headache, influenza, upper respiratory tract infection, bronchitis, sinusitis, oropharyngeal pain, dysphonia, and cough.",oropharyngeal pain is an adverse reaction entity
"(  6.1  )   *    Asthma: Most common adverse reactions (incidence greater than or equal to 2%) are nasopharyngitis, oral candidiasis, headache, influenza, upper respiratory tract infection, bronchitis, sinusitis, oropharyngeal pain, dysphonia, and cough.",dysphonia is an adverse reaction entity
"(  6.1  )   *    Asthma: Most common adverse reactions (incidence greater than or equal to 2%) are nasopharyngitis, oral candidiasis, headache, influenza, upper respiratory tract infection, bronchitis, sinusitis, oropharyngeal pain, dysphonia, and cough.",cough is an adverse reaction entity
"5.12 Cardiovascular Effects      Vilanterol, like other beta2-agonists, can produce a clinically significant cardiovascular effect in some patients as measured by increases in pulse rate, systolic or diastolic blood pressure, and also cardiac arrhythmias, such as supraventricular tachycardia and extrasystoles.",increases in pulse rate is an adverse reaction entity
"5.12 Cardiovascular Effects      Vilanterol, like other beta2-agonists, can produce a clinically significant cardiovascular effect in some patients as measured by increases in pulse rate, systolic or diastolic blood pressure, and also cardiac arrhythmias, such as supraventricular tachycardia and extrasystoles.",increases systolic blood pressure is an adverse reaction entity
"5.12 Cardiovascular Effects      Vilanterol, like other beta2-agonists, can produce a clinically significant cardiovascular effect in some patients as measured by increases in pulse rate, systolic or diastolic blood pressure, and also cardiac arrhythmias, such as supraventricular tachycardia and extrasystoles.",increases diastolic blood pressure is an adverse reaction entity
"5.12 Cardiovascular Effects      Vilanterol, like other beta2-agonists, can produce a clinically significant cardiovascular effect in some patients as measured by increases in pulse rate, systolic or diastolic blood pressure, and also cardiac arrhythmias, such as supraventricular tachycardia and extrasystoles.",cardiac arrhythmias is an adverse reaction entity
"5.12 Cardiovascular Effects      Vilanterol, like other beta2-agonists, can produce a clinically significant cardiovascular effect in some patients as measured by increases in pulse rate, systolic or diastolic blood pressure, and also cardiac arrhythmias, such as supraventricular tachycardia and extrasystoles.",supraventricular tachycardia is an adverse reaction entity
"5.12 Cardiovascular Effects      Vilanterol, like other beta2-agonists, can produce a clinically significant cardiovascular effect in some patients as measured by increases in pulse rate, systolic or diastolic blood pressure, and also cardiac arrhythmias, such as supraventricular tachycardia and extrasystoles.",extrasystoles is an adverse reaction entity
There were no asthma-related deaths or asthma-related intubations observed in this trial.,deaths is an adverse reaction entity
"Systemic and local corticosteroid use may result in the following:     *     Candida albicans infection [see Warnings and Precautions (5.4)]    *    Increased risk of pneumonia in COPD [see Warnings and Precautions (5.5)]    *    Immunosuppression [see Warnings and Precautions (5.6)]    *    Hypercorticism and adrenal suppression [see Warnings and Precautions (5.8)]    *    Reduction in bone mineral density [see Warnings and Precautions (5.13)]       Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.",Candida albicans infection is an adverse reaction entity
"Systemic and local corticosteroid use may result in the following:     *     Candida albicans infection [see Warnings and Precautions (5.4)]    *    Increased risk of pneumonia in COPD [see Warnings and Precautions (5.5)]    *    Immunosuppression [see Warnings and Precautions (5.6)]    *    Hypercorticism and adrenal suppression [see Warnings and Precautions (5.8)]    *    Reduction in bone mineral density [see Warnings and Precautions (5.13)]       Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.",pneumonia is an adverse reaction entity
"Systemic and local corticosteroid use may result in the following:     *     Candida albicans infection [see Warnings and Precautions (5.4)]    *    Increased risk of pneumonia in COPD [see Warnings and Precautions (5.5)]    *    Immunosuppression [see Warnings and Precautions (5.6)]    *    Hypercorticism and adrenal suppression [see Warnings and Precautions (5.8)]    *    Reduction in bone mineral density [see Warnings and Precautions (5.13)]       Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.",Immunosuppression is an adverse reaction entity
"Systemic and local corticosteroid use may result in the following:     *     Candida albicans infection [see Warnings and Precautions (5.4)]    *    Increased risk of pneumonia in COPD [see Warnings and Precautions (5.5)]    *    Immunosuppression [see Warnings and Precautions (5.6)]    *    Hypercorticism and adrenal suppression [see Warnings and Precautions (5.8)]    *    Reduction in bone mineral density [see Warnings and Precautions (5.13)]       Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.",Hypercorticism is an adverse reaction entity
"Systemic and local corticosteroid use may result in the following:     *     Candida albicans infection [see Warnings and Precautions (5.4)]    *    Increased risk of pneumonia in COPD [see Warnings and Precautions (5.5)]    *    Immunosuppression [see Warnings and Precautions (5.6)]    *    Hypercorticism and adrenal suppression [see Warnings and Precautions (5.8)]    *    Reduction in bone mineral density [see Warnings and Precautions (5.13)]       Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.",adrenal suppression is an adverse reaction entity
"Systemic and local corticosteroid use may result in the following:     *     Candida albicans infection [see Warnings and Precautions (5.4)]    *    Increased risk of pneumonia in COPD [see Warnings and Precautions (5.5)]    *    Immunosuppression [see Warnings and Precautions (5.6)]    *    Hypercorticism and adrenal suppression [see Warnings and Precautions (5.8)]    *    Reduction in bone mineral density [see Warnings and Precautions (5.13)]       Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.",Reduction in bone mineral density is an adverse reaction entity
"In addition, beta-agonists have been reported to produce electrocardiographic changes, such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression, although the clinical significance of these findings is unknown.",electrocardiographic changes is an adverse reaction entity
"In addition, beta-agonists have been reported to produce electrocardiographic changes, such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression, although the clinical significance of these findings is unknown.",flattening of the T wave is an adverse reaction entity
"In addition, beta-agonists have been reported to produce electrocardiographic changes, such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression, although the clinical significance of these findings is unknown.",prolongation of the QTc interval is an adverse reaction entity
"In addition, beta-agonists have been reported to produce electrocardiographic changes, such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression, although the clinical significance of these findings is unknown.",ST segment depression is an adverse reaction entity
"However, exceeding the recommended dosage or coadministration with a strong cytochrome P450 3A4 (CYP3A4) inhibitor may result in HPA dysfunction [see Warnings and Precautions (5.9), Drug Interactions (7.1)]  .",HPA dysfunction is an adverse reaction entity
"The decrease in serum potassium is usually transient, not requiring supplementation.",decrease in serum potassium is an adverse reaction entity
"(  5.16  )             5.1 Asthma-Related Death       LABA, such as vilanterol, one of the active ingredients in BREO ELLIPTA, increase the risk of asthma-related death.",death is an adverse reaction entity
"Doses of the related beta2-adrenoceptor agonist albuterol, when administered intravenously, have been reported to aggravate preexisting diabetes mellitus and ketoacidosis.",aggravate preexisting diabetes mellitus is an adverse reaction entity
"Doses of the related beta2-adrenoceptor agonist albuterol, when administered intravenously, have been reported to aggravate preexisting diabetes mellitus and ketoacidosis.",aggravate preexisting ketoacidosis is an adverse reaction entity
EXCERPT:   WARNING: ASTHMA-RELATED DEATH       See full prescribing information for complete boxed warning.,DEATH is an adverse reaction entity
(  5.7  )   *    Hypercorticism and adrenal suppression may occur with very high dosages or at the regular dosage in susceptible individuals.,Hypercorticism is an adverse reaction entity
(  5.7  )   *    Hypercorticism and adrenal suppression may occur with very high dosages or at the regular dosage in susceptible individuals.,adrenal suppression is an adverse reaction entity
There was also an increased incidence of pneumonias resulting in hospitalization.,pneumonias is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *    Thrombocytopenia, leukopenia (neutropenia and lymphopenia), and anemia: Monitor blood counts and modify dosage for hematologic toxicities.",Thrombocytopenia is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *    Thrombocytopenia, leukopenia (neutropenia and lymphopenia), and anemia: Monitor blood counts and modify dosage for hematologic toxicities.",leukopenia is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *    Thrombocytopenia, leukopenia (neutropenia and lymphopenia), and anemia: Monitor blood counts and modify dosage for hematologic toxicities.",neutropenia is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *    Thrombocytopenia, leukopenia (neutropenia and lymphopenia), and anemia: Monitor blood counts and modify dosage for hematologic toxicities.",lymphopenia is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *    Thrombocytopenia, leukopenia (neutropenia and lymphopenia), and anemia: Monitor blood counts and modify dosage for hematologic toxicities.",anemia is an adverse reaction entity
One treatment-related death associated with hepatic failure was reported in the trial.,death is an adverse reaction entity
One treatment-related death associated with hepatic failure was reported in the trial.,hepatic failure is an adverse reaction entity
5.4 Tumor Lysis Syndrome      Tumor lysis syndrome has occurred in Beleodaq-treated patients in the clinical trial of patients with relapsed or refractory PTCL  [see    Clinical Studies  (   14    ) ]  .,Tumor lysis syndrome is an adverse reaction entity
(   5.4   )   *    Embryo-fetal toxicity: Beleodaq may cause fetal harm when administered to a pregnant woman.,Embryo-fetal toxicity is an adverse reaction entity
(   5.4   )   *    Embryo-fetal toxicity: Beleodaq may cause fetal harm when administered to a pregnant woman.,fetal harm is an adverse reaction entity
Dronedarone caused fetal harm in animal studies at doses equivalent to recommended human doses.,fetal harm is an adverse reaction entity
"In a placebo controlled study in patients with permanent AF increased rates of heart failure were observed in patients with normal left ventricular function and no history of symptomatic heart failure, as well as those with a history of heart failure or left ventricular dysfunction.",heart failure is an adverse reaction entity
5.2 Cardiovascular Death and Heart Failure in Permanent AF      MULTAQ doubles the risk of cardiovascular death (largely arrhythmic) and heart failure events in patients with permanent AF.,cardiovascular death is an adverse reaction entity
5.2 Cardiovascular Death and Heart Failure in Permanent AF      MULTAQ doubles the risk of cardiovascular death (largely arrhythmic) and heart failure events in patients with permanent AF.,cardiovascular death arrhythmic is an adverse reaction entity
5.2 Cardiovascular Death and Heart Failure in Permanent AF      MULTAQ doubles the risk of cardiovascular death (largely arrhythmic) and heart failure events in patients with permanent AF.,heart failure events is an adverse reaction entity
"5.9 Renal Impairment and Failure       Marked increase in serum creatinine, pre-renal azotemia and acute renal failure, often in the setting of heart failure [ see       Warnings and Precautions (5.4)     ] or hypovolemia, have been reported in patients taking MULTAQ.",increase in serum creatinine is an adverse reaction entity
"5.9 Renal Impairment and Failure       Marked increase in serum creatinine, pre-renal azotemia and acute renal failure, often in the setting of heart failure [ see       Warnings and Precautions (5.4)     ] or hypovolemia, have been reported in patients taking MULTAQ.",pre-renal azotemia is an adverse reaction entity
"5.9 Renal Impairment and Failure       Marked increase in serum creatinine, pre-renal azotemia and acute renal failure, often in the setting of heart failure [ see       Warnings and Precautions (5.4)     ] or hypovolemia, have been reported in patients taking MULTAQ.",acute renal failure is an adverse reaction entity
"5.9 Renal Impairment and Failure       Marked increase in serum creatinine, pre-renal azotemia and acute renal failure, often in the setting of heart failure [ see       Warnings and Precautions (5.4)     ] or hypovolemia, have been reported in patients taking MULTAQ.",heart failure is an adverse reaction entity
"5.9 Renal Impairment and Failure       Marked increase in serum creatinine, pre-renal azotemia and acute renal failure, often in the setting of heart failure [ see       Warnings and Precautions (5.4)     ] or hypovolemia, have been reported in patients taking MULTAQ.",hypovolemia is an adverse reaction entity
No comparator-treated subject with normal baseline transaminases had post-baseline ALT elevation greater than 10 times ULN.,ALT elevation is an adverse reaction entity
"Overall, abnormalities in liver tests (ALT, AST, bilirubin) were reported with similar frequency in the DALVANCE and comparator arms [see Adverse Reactions (  6.1  )].",abnormalities in ALT is an adverse reaction entity
"Overall, abnormalities in liver tests (ALT, AST, bilirubin) were reported with similar frequency in the DALVANCE and comparator arms [see Adverse Reactions (  6.1  )].",abnormalities in AST is an adverse reaction entity
"Overall, abnormalities in liver tests (ALT, AST, bilirubin) were reported with similar frequency in the DALVANCE and comparator arms [see Adverse Reactions (  6.1  )].",abnormalities in bilirubin is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  Serious hypersensitivity (anaphylactic) and skin reactions have been reported with glycopeptide antibacterial agents, including DALVANCE; exercise caution in patients with known hypersensitivity to glycopeptides.",hypersensitivity reactions is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  Serious hypersensitivity (anaphylactic) and skin reactions have been reported with glycopeptide antibacterial agents, including DALVANCE; exercise caution in patients with known hypersensitivity to glycopeptides.",anaphylactic reactions is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  Serious hypersensitivity (anaphylactic) and skin reactions have been reported with glycopeptide antibacterial agents, including DALVANCE; exercise caution in patients with known hypersensitivity to glycopeptides.",skin reactions is an adverse reaction entity
"The most common adverse reactions reported with Prolia in men with osteoporosis are back pain, arthralgia, and nasopharyngitis.",back pain is an adverse reaction entity
"The most common adverse reactions reported with Prolia in men with osteoporosis are back pain, arthralgia, and nasopharyngitis.",arthralgia is an adverse reaction entity
"The most common adverse reactions reported with Prolia in men with osteoporosis are back pain, arthralgia, and nasopharyngitis.",nasopharyngitis is an adverse reaction entity
The most common adverse reactions leading to discontinuation of Prolia in patients with postmenopausal osteoporosis are back pain and constipation.,back pain is an adverse reaction entity
The most common adverse reactions leading to discontinuation of Prolia in patients with postmenopausal osteoporosis are back pain and constipation.,constipation is an adverse reaction entity
The incidence of all-cause mortality was 2.3% (n = 90) in the placebo group and 1.8% (n = 70) in the Prolia group.,mortality is an adverse reaction entity
"They may be bilateral and many patients report prodromal pain in the affected area, usually presenting as dull, aching thigh pain, weeks to months before a complete fracture occurs.",thigh pain is an adverse reaction entity
"No evidence of altered pharmacokinetic profile, toxicity profile, or clinical response was associated with binding antibody development.",toxicity is an adverse reaction entity
Pain in extremity (7.7% placebo vs. 9.9% Prolia) and musculoskeletal pain (3.8% placebo vs. 6.0% Prolia) have also been reported in clinical trials.,Pain in extremity is an adverse reaction entity
Pain in extremity (7.7% placebo vs. 9.9% Prolia) and musculoskeletal pain (3.8% placebo vs. 6.0% Prolia) have also been reported in clinical trials.,musculoskeletal pain is an adverse reaction entity
"Serious skin infections, as well as infections of the abdomen, urinary tract, and ear, were more frequent in patients treated with Prolia.",skin infections is an adverse reaction entity
"Serious skin infections, as well as infections of the abdomen, urinary tract, and ear, were more frequent in patients treated with Prolia.",infections of the abdomen is an adverse reaction entity
"Serious skin infections, as well as infections of the abdomen, urinary tract, and ear, were more frequent in patients treated with Prolia.",infections of the urinary tract is an adverse reaction entity
"Serious skin infections, as well as infections of the abdomen, urinary tract, and ear, were more frequent in patients treated with Prolia.",infections of the ear is an adverse reaction entity
"Hospitalizations due to serious infections in the abdomen (0.7% placebo vs. 0.9% Prolia), urinary tract (0.5% placebo vs. 0.7% Prolia), and ear (0.0% placebo vs. 0.1% Prolia) were reported.",infections in the abdomen is an adverse reaction entity
"Hospitalizations due to serious infections in the abdomen (0.7% placebo vs. 0.9% Prolia), urinary tract (0.5% placebo vs. 0.7% Prolia), and ear (0.0% placebo vs. 0.1% Prolia) were reported.",infections in the urinary tract is an adverse reaction entity
"Hospitalizations due to serious infections in the abdomen (0.7% placebo vs. 0.9% Prolia), urinary tract (0.5% placebo vs. 0.7% Prolia), and ear (0.0% placebo vs. 0.1% Prolia) were reported.",infections in the ear is an adverse reaction entity
Patients on concomitant immunosuppressant agents or with impaired immune systems may be at increased risk for serious infections.,infections is an adverse reaction entity
"The long-term consequences of the degree of suppression of bone remodeling observed with Prolia may contribute to adverse outcomes such as osteonecrosis of the jaw, atypical fractures, and delayed fracture healing.",suppression of bone remodeling is an adverse reaction entity
"The long-term consequences of the degree of suppression of bone remodeling observed with Prolia may contribute to adverse outcomes such as osteonecrosis of the jaw, atypical fractures, and delayed fracture healing.",osteonecrosis of the jaw is an adverse reaction entity
"The long-term consequences of the degree of suppression of bone remodeling observed with Prolia may contribute to adverse outcomes such as osteonecrosis of the jaw, atypical fractures, and delayed fracture healing.",atypical fractures is an adverse reaction entity
"The long-term consequences of the degree of suppression of bone remodeling observed with Prolia may contribute to adverse outcomes such as osteonecrosis of the jaw, atypical fractures, and delayed fracture healing.",delayed fracture healing is an adverse reaction entity
5.5 Atypical Subtrochanteric and Diaphyseal Femoral Fractures      Atypical low-energy or low trauma fractures of the shaft have been reported in patients receiving Prolia [see Adverse Reactions (  6.1  )]  .,Femoral Atypical fractures of the shaft is an adverse reaction entity
"In the clinical study of 7808 postmenopausal women with osteoporosis, the incidence of infections resulting in death was 0.2% in both placebo and Prolia treatment groups.",infections is an adverse reaction entity
"In the clinical study of 7808 postmenopausal women with osteoporosis, the incidence of infections resulting in death was 0.2% in both placebo and Prolia treatment groups.",death is an adverse reaction entity
New Malignancies  The overall incidence of new malignancies was 4.3% in the placebo and 4.8% in the Prolia groups.,malignancies is an adverse reaction entity
"The incidence of opportunistic infections was similar between placebo and Prolia groups, and the overall incidence of infections was similar between the treatment groups.",opportunistic infections is an adverse reaction entity
"The incidence of opportunistic infections was similar between placebo and Prolia groups, and the overall incidence of infections was similar between the treatment groups.",infections is an adverse reaction entity
"Adverse reactions occurring less frequently but possibly related to TREANDA treatment were hemolysis, dysgeusia/taste disorder, atypical pneumonia, sepsis, herpes zoster, erythema, dermatitis, and skin necrosis.",hemolysis is an adverse reaction entity
"Adverse reactions occurring less frequently but possibly related to TREANDA treatment were hemolysis, dysgeusia/taste disorder, atypical pneumonia, sepsis, herpes zoster, erythema, dermatitis, and skin necrosis.",dysgeusia is an adverse reaction entity
"Adverse reactions occurring less frequently but possibly related to TREANDA treatment were hemolysis, dysgeusia/taste disorder, atypical pneumonia, sepsis, herpes zoster, erythema, dermatitis, and skin necrosis.",taste disorder is an adverse reaction entity
"Adverse reactions occurring less frequently but possibly related to TREANDA treatment were hemolysis, dysgeusia/taste disorder, atypical pneumonia, sepsis, herpes zoster, erythema, dermatitis, and skin necrosis.",atypical pneumonia is an adverse reaction entity
"Adverse reactions occurring less frequently but possibly related to TREANDA treatment were hemolysis, dysgeusia/taste disorder, atypical pneumonia, sepsis, herpes zoster, erythema, dermatitis, and skin necrosis.",sepsis is an adverse reaction entity
"Adverse reactions occurring less frequently but possibly related to TREANDA treatment were hemolysis, dysgeusia/taste disorder, atypical pneumonia, sepsis, herpes zoster, erythema, dermatitis, and skin necrosis.",herpes zoster is an adverse reaction entity
"Adverse reactions occurring less frequently but possibly related to TREANDA treatment were hemolysis, dysgeusia/taste disorder, atypical pneumonia, sepsis, herpes zoster, erythema, dermatitis, and skin necrosis.",erythema is an adverse reaction entity
"Adverse reactions occurring less frequently but possibly related to TREANDA treatment were hemolysis, dysgeusia/taste disorder, atypical pneumonia, sepsis, herpes zoster, erythema, dermatitis, and skin necrosis.",dermatitis is an adverse reaction entity
"Adverse reactions occurring less frequently but possibly related to TREANDA treatment were hemolysis, dysgeusia/taste disorder, atypical pneumonia, sepsis, herpes zoster, erythema, dermatitis, and skin necrosis.",skin necrosis is an adverse reaction entity
The most common serious adverse reactions occurring in >=5% of patients were febrile neutropenia and pneumonia.,febrile neutropenia is an adverse reaction entity
The most common serious adverse reactions occurring in >=5% of patients were febrile neutropenia and pneumonia.,pneumonia is an adverse reaction entity
Patients with myelosuppression following treatment with TREANDA are more susceptible to infections.,myelosuppression is an adverse reaction entity
Patients with myelosuppression following treatment with TREANDA are more susceptible to infections.,infections is an adverse reaction entity
(  5.3  )   *    Tumor Lysis Syndrome:  Acute renal failure and death; anticipate and use supportive measures.,Tumor Lysis Syndrome is an adverse reaction entity
(  5.3  )   *    Tumor Lysis Syndrome:  Acute renal failure and death; anticipate and use supportive measures.,Acute renal failure is an adverse reaction entity
(  5.3  )   *    Tumor Lysis Syndrome:  Acute renal failure and death; anticipate and use supportive measures.,death is an adverse reaction entity
"Cases of Stevens-Johnson syndrome (SJS) and TEN, some fatal, have been reported when TREANDA was administered concomitantly with allopurinol and other medications known to cause these syndromes.",Stevens-Johnson syndrome is an adverse reaction entity
"Cases of Stevens-Johnson syndrome (SJS) and TEN, some fatal, have been reported when TREANDA was administered concomitantly with allopurinol and other medications known to cause these syndromes.",SJS is an adverse reaction entity
"Cases of Stevens-Johnson syndrome (SJS) and TEN, some fatal, have been reported when TREANDA was administered concomitantly with allopurinol and other medications known to cause these syndromes.",TEN is an adverse reaction entity
"Cases of Stevens-Johnson syndrome (SJS) and TEN, some fatal, have been reported when TREANDA was administered concomitantly with allopurinol and other medications known to cause these syndromes.",fatal is an adverse reaction entity
Skin reactions including SJS and TEN have occurred when TREANDA was administered concomitantly with allopurinol and other medications known to cause these syndromes.,Skin reactions is an adverse reaction entity
Skin reactions including SJS and TEN have occurred when TREANDA was administered concomitantly with allopurinol and other medications known to cause these syndromes.,SJS is an adverse reaction entity
Skin reactions including SJS and TEN have occurred when TREANDA was administered concomitantly with allopurinol and other medications known to cause these syndromes.,TEN is an adverse reaction entity
"In rare instances severe anaphylactic and anaphylactoid reactions have occurred, particularly in the second and subsequent cycles of therapy.",anaphylactic reactions is an adverse reaction entity
"In rare instances severe anaphylactic and anaphylactoid reactions have occurred, particularly in the second and subsequent cycles of therapy.",anaphylactoid reactions is an adverse reaction entity
"[see  Dosage and Administration  (  2.2  ) and (  2.3  )]          5.2  Infections      Infection, including pneumonia, sepsis, septic shock, and death have occurred in adult and pediatric patients in clinical trials and in postmarketing reports.",Infection is an adverse reaction entity
"[see  Dosage and Administration  (  2.2  ) and (  2.3  )]          5.2  Infections      Infection, including pneumonia, sepsis, septic shock, and death have occurred in adult and pediatric patients in clinical trials and in postmarketing reports.",pneumonia is an adverse reaction entity
"[see  Dosage and Administration  (  2.2  ) and (  2.3  )]          5.2  Infections      Infection, including pneumonia, sepsis, septic shock, and death have occurred in adult and pediatric patients in clinical trials and in postmarketing reports.",sepsis is an adverse reaction entity
"[see  Dosage and Administration  (  2.2  ) and (  2.3  )]          5.2  Infections      Infection, including pneumonia, sepsis, septic shock, and death have occurred in adult and pediatric patients in clinical trials and in postmarketing reports.",septic shock is an adverse reaction entity
"[see  Dosage and Administration  (  2.2  ) and (  2.3  )]          5.2  Infections      Infection, including pneumonia, sepsis, septic shock, and death have occurred in adult and pediatric patients in clinical trials and in postmarketing reports.",death is an adverse reaction entity
"In a study of TREANDA (90 mg/m  2  ) in combination with rituximab, one case of toxic epidermal necrolysis (TEN) occurred.",toxic epidermal necrolysis is an adverse reaction entity
"In a study of TREANDA (90 mg/m  2  ) in combination with rituximab, one case of toxic epidermal necrolysis (TEN) occurred.",TEN is an adverse reaction entity
"Other important serious adverse reactions reported in clinical trials and/or postmarketing experience were acute renal failure, cardiac failure, hypersensitivity, skin reactions, pulmonary fibrosis, and myelodysplastic syndrome.",acute renal failure is an adverse reaction entity
"Other important serious adverse reactions reported in clinical trials and/or postmarketing experience were acute renal failure, cardiac failure, hypersensitivity, skin reactions, pulmonary fibrosis, and myelodysplastic syndrome.",cardiac failure is an adverse reaction entity
"Other important serious adverse reactions reported in clinical trials and/or postmarketing experience were acute renal failure, cardiac failure, hypersensitivity, skin reactions, pulmonary fibrosis, and myelodysplastic syndrome.",hypersensitivity is an adverse reaction entity
"Other important serious adverse reactions reported in clinical trials and/or postmarketing experience were acute renal failure, cardiac failure, hypersensitivity, skin reactions, pulmonary fibrosis, and myelodysplastic syndrome.",skin reactions is an adverse reaction entity
"Other important serious adverse reactions reported in clinical trials and/or postmarketing experience were acute renal failure, cardiac failure, hypersensitivity, skin reactions, pulmonary fibrosis, and myelodysplastic syndrome.",pulmonary fibrosis is an adverse reaction entity
"Other important serious adverse reactions reported in clinical trials and/or postmarketing experience were acute renal failure, cardiac failure, hypersensitivity, skin reactions, pulmonary fibrosis, and myelodysplastic syndrome.",myelodysplastic syndrome is an adverse reaction entity
"5.2 Radiation Risk      Neuraceq, similar to other radiopharmaceuticals, contributes to a patient's overall long-term cumulative radiation exposure.",long-term cumulative radiation exposure is an adverse reaction entity
"In short-term trials with ENTEREG(r)    , no increased risk of myocardial infarction was observed     [see Warnings and Precautions (5.1)].",myocardial infarction is an adverse reaction entity
*  Increased incidence of myocardial infarction was seen in a clinical trial of patients taking alvimopan for long-term use.,myocardial infarction is an adverse reaction entity
"The majority of seizures occurred at the recommended dose and in patients without a history of seizures, and generally within days to weeks of starting therapy.",seizures is an adverse reaction entity
Discontinue and do not restart AMPYRA if this occurs (  5.4  )             5.1 Seizures      AMPYRA can cause seizures.,seizures is an adverse reaction entity
Increased incidence of seizures has been observed at 20 mg twice daily in controlled clinical studies of 9-14 weeks duration with dalfampridine in patients with MS.,seizures is an adverse reaction entity
Eye events were serious in 0.7% of APTIOM-treated patients (and 0 placebo patients) and led to discontinuation in 4% of APTIOM-treated patients (and 0.2% of placebo-treated patients).,Eye events is an adverse reaction entity
Eye events were serious in 0.7% of APTIOM-treated patients (and 0 placebo patients) and led to discontinuation in 4% of APTIOM-treated patients (and 0.2% of placebo-treated patients).,Eye events is an adverse reaction entity
"5.3 Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan Hypersensitivity      Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), also known as Multiorgan Hypersensitivity, has been reported in patients taking APTIOM.",Drug Reaction with Eosinophilia and Systemic Symptoms is an adverse reaction entity
"5.3 Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan Hypersensitivity      Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), also known as Multiorgan Hypersensitivity, has been reported in patients taking APTIOM.",DRESS is an adverse reaction entity
"5.3 Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan Hypersensitivity      Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), also known as Multiorgan Hypersensitivity, has been reported in patients taking APTIOM.",Multiorgan Hypersensitivity is an adverse reaction entity
The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed.,suicidal thoughts is an adverse reaction entity
The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed.,suicidal behavior is an adverse reaction entity
"The incidence of diplopia was greater with the concomitant use of APTIOM and carbamazepine compared to the use of APTIOM without carbamazepine (up to 16% vs. 6%, respectively) [see Dosage and Administration (  2.3  )]  .",diplopia is an adverse reaction entity
5.5 Hyponatremia      Clinically significant hyponatremia (sodium <125 mEq/L) can develop in patients taking APTIOM.,hyponatremia is an adverse reaction entity
"(  5.5  )   *  Neurological Adverse Reactions: Monitor for dizziness, disturbance in gait and coordination, somnolence, fatigue, cognitive dysfunction, and visual changes.",Neurological Adverse Reactions is an adverse reaction entity
"(  5.8  )             5.1 Suicidal Behavior and Ideation      Antiepileptic drugs (AEDs), including APTIOM, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication.",suicidal thoughts is an adverse reaction entity
"(  5.8  )             5.1 Suicidal Behavior and Ideation      Antiepileptic drugs (AEDs), including APTIOM, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication.",suicidal behavior is an adverse reaction entity
The increased risk of suicidal thoughts or behavior with AEDs was observed as early as one week after starting treatment with AEDs and persisted for the duration of treatment assessed.,suicidal thoughts is an adverse reaction entity
The increased risk of suicidal thoughts or behavior with AEDs was observed as early as one week after starting treatment with AEDs and persisted for the duration of treatment assessed.,suicidal behavior is an adverse reaction entity
5.4 Anaphylactic Reactions and Angioedema      Rare cases of anaphylaxis and angioedema have been reported in patients taking APTIOM.,anaphylaxis is an adverse reaction entity
5.4 Anaphylactic Reactions and Angioedema      Rare cases of anaphylaxis and angioedema have been reported in patients taking APTIOM.,angioedema is an adverse reaction entity
These changes were not associated with other abnormal thyroid function tests suggesting hypothyroidism.,abnormal thyroid function is an adverse reaction entity
These changes were not associated with other abnormal thyroid function tests suggesting hypothyroidism.,hypothyroidism is an adverse reaction entity
"5.5 Immediate Hypersensitivity Reactions    Immediate hypersensitivity reactions, including anaphylaxis, angioedema (including swelling of the lips, tongue, or throat), urticaria, rash, bronchospasm, or itching, have occurred after administration of TUDORZA PRESSAIR.",Immediate hypersensitivity reactions is an adverse reaction entity
"5.5 Immediate Hypersensitivity Reactions    Immediate hypersensitivity reactions, including anaphylaxis, angioedema (including swelling of the lips, tongue, or throat), urticaria, rash, bronchospasm, or itching, have occurred after administration of TUDORZA PRESSAIR.",anaphylaxis is an adverse reaction entity
"5.5 Immediate Hypersensitivity Reactions    Immediate hypersensitivity reactions, including anaphylaxis, angioedema (including swelling of the lips, tongue, or throat), urticaria, rash, bronchospasm, or itching, have occurred after administration of TUDORZA PRESSAIR.",angioedema is an adverse reaction entity
"5.5 Immediate Hypersensitivity Reactions    Immediate hypersensitivity reactions, including anaphylaxis, angioedema (including swelling of the lips, tongue, or throat), urticaria, rash, bronchospasm, or itching, have occurred after administration of TUDORZA PRESSAIR.",swelling of the lips is an adverse reaction entity
"5.5 Immediate Hypersensitivity Reactions    Immediate hypersensitivity reactions, including anaphylaxis, angioedema (including swelling of the lips, tongue, or throat), urticaria, rash, bronchospasm, or itching, have occurred after administration of TUDORZA PRESSAIR.",swelling of the tongue is an adverse reaction entity
"5.5 Immediate Hypersensitivity Reactions    Immediate hypersensitivity reactions, including anaphylaxis, angioedema (including swelling of the lips, tongue, or throat), urticaria, rash, bronchospasm, or itching, have occurred after administration of TUDORZA PRESSAIR.",swelling of the throat is an adverse reaction entity
"5.5 Immediate Hypersensitivity Reactions    Immediate hypersensitivity reactions, including anaphylaxis, angioedema (including swelling of the lips, tongue, or throat), urticaria, rash, bronchospasm, or itching, have occurred after administration of TUDORZA PRESSAIR.",urticaria is an adverse reaction entity
"5.5 Immediate Hypersensitivity Reactions    Immediate hypersensitivity reactions, including anaphylaxis, angioedema (including swelling of the lips, tongue, or throat), urticaria, rash, bronchospasm, or itching, have occurred after administration of TUDORZA PRESSAIR.",rash is an adverse reaction entity
"5.5 Immediate Hypersensitivity Reactions    Immediate hypersensitivity reactions, including anaphylaxis, angioedema (including swelling of the lips, tongue, or throat), urticaria, rash, bronchospasm, or itching, have occurred after administration of TUDORZA PRESSAIR.",bronchospasm is an adverse reaction entity
"5.5 Immediate Hypersensitivity Reactions    Immediate hypersensitivity reactions, including anaphylaxis, angioedema (including swelling of the lips, tongue, or throat), urticaria, rash, bronchospasm, or itching, have occurred after administration of TUDORZA PRESSAIR.",itching is an adverse reaction entity
The mean time to nadir was 13 days and the mean time to recovery from severe neutropenia (<500/mm  3  ) was 8 days.,neutropenia is an adverse reaction entity
"6    ADVERSE REACTIONS      EXCERPT:   The most common adverse reactions (incidence >=25%) were neutropenia, anemia, asthenia/fatigue, alopecia, peripheral neuropathy, nausea, and constipation (  6  )       To report SUSPECTED ADVERSE REACTIONS, contact Eisai Inc. at (1-877-873-4724) or contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch             6.1    Clinical Trials Experience      Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in other clinical trials and may not reflect the rates observed in clinical practice.",neutropenia is an adverse reaction entity
"6    ADVERSE REACTIONS      EXCERPT:   The most common adverse reactions (incidence >=25%) were neutropenia, anemia, asthenia/fatigue, alopecia, peripheral neuropathy, nausea, and constipation (  6  )       To report SUSPECTED ADVERSE REACTIONS, contact Eisai Inc. at (1-877-873-4724) or contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch             6.1    Clinical Trials Experience      Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in other clinical trials and may not reflect the rates observed in clinical practice.",anemia is an adverse reaction entity
"6    ADVERSE REACTIONS      EXCERPT:   The most common adverse reactions (incidence >=25%) were neutropenia, anemia, asthenia/fatigue, alopecia, peripheral neuropathy, nausea, and constipation (  6  )       To report SUSPECTED ADVERSE REACTIONS, contact Eisai Inc. at (1-877-873-4724) or contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch             6.1    Clinical Trials Experience      Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in other clinical trials and may not reflect the rates observed in clinical practice.",asthenia is an adverse reaction entity
"6    ADVERSE REACTIONS      EXCERPT:   The most common adverse reactions (incidence >=25%) were neutropenia, anemia, asthenia/fatigue, alopecia, peripheral neuropathy, nausea, and constipation (  6  )       To report SUSPECTED ADVERSE REACTIONS, contact Eisai Inc. at (1-877-873-4724) or contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch             6.1    Clinical Trials Experience      Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in other clinical trials and may not reflect the rates observed in clinical practice.",fatigue is an adverse reaction entity
"6    ADVERSE REACTIONS      EXCERPT:   The most common adverse reactions (incidence >=25%) were neutropenia, anemia, asthenia/fatigue, alopecia, peripheral neuropathy, nausea, and constipation (  6  )       To report SUSPECTED ADVERSE REACTIONS, contact Eisai Inc. at (1-877-873-4724) or contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch             6.1    Clinical Trials Experience      Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in other clinical trials and may not reflect the rates observed in clinical practice.",alopecia is an adverse reaction entity
"6    ADVERSE REACTIONS      EXCERPT:   The most common adverse reactions (incidence >=25%) were neutropenia, anemia, asthenia/fatigue, alopecia, peripheral neuropathy, nausea, and constipation (  6  )       To report SUSPECTED ADVERSE REACTIONS, contact Eisai Inc. at (1-877-873-4724) or contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch             6.1    Clinical Trials Experience      Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in other clinical trials and may not reflect the rates observed in clinical practice.",peripheral neuropathy is an adverse reaction entity
"6    ADVERSE REACTIONS      EXCERPT:   The most common adverse reactions (incidence >=25%) were neutropenia, anemia, asthenia/fatigue, alopecia, peripheral neuropathy, nausea, and constipation (  6  )       To report SUSPECTED ADVERSE REACTIONS, contact Eisai Inc. at (1-877-873-4724) or contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch             6.1    Clinical Trials Experience      Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in other clinical trials and may not reflect the rates observed in clinical practice.",nausea is an adverse reaction entity
"6    ADVERSE REACTIONS      EXCERPT:   The most common adverse reactions (incidence >=25%) were neutropenia, anemia, asthenia/fatigue, alopecia, peripheral neuropathy, nausea, and constipation (  6  )       To report SUSPECTED ADVERSE REACTIONS, contact Eisai Inc. at (1-877-873-4724) or contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch             6.1    Clinical Trials Experience      Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in other clinical trials and may not reflect the rates observed in clinical practice.",constipation is an adverse reaction entity
"Less Common Adverse Reactions  :     The following additional adverse reactions were reported in >=5% to <10% of the HALAVEN-treated group:     *   Eye Disorders: increased lacrimation   *   Gastrointestinal Disorders: dyspepsia, abdominal pain, stomatitis, dry mouth   *   General Disorders and Administration Site Conditions: peripheral edema   *   Infections and Infestations: upper respiratory tract infection   *   Metabolism and Nutrition Disorders: hypokalemia   *   Musculoskeletal and Connective Tissue Disorders:    muscle spasms, muscular weakness   *   Nervous System Disorders: dysgeusia, dizziness   *   Psychiatric Disorders: insomnia, depression   *   Skin and Subcutaneous Tissue Disorders: rash          6.",increased lacrimation is an adverse reaction entity
"Less Common Adverse Reactions  :     The following additional adverse reactions were reported in >=5% to <10% of the HALAVEN-treated group:     *   Eye Disorders: increased lacrimation   *   Gastrointestinal Disorders: dyspepsia, abdominal pain, stomatitis, dry mouth   *   General Disorders and Administration Site Conditions: peripheral edema   *   Infections and Infestations: upper respiratory tract infection   *   Metabolism and Nutrition Disorders: hypokalemia   *   Musculoskeletal and Connective Tissue Disorders:    muscle spasms, muscular weakness   *   Nervous System Disorders: dysgeusia, dizziness   *   Psychiatric Disorders: insomnia, depression   *   Skin and Subcutaneous Tissue Disorders: rash          6.",dyspepsia is an adverse reaction entity
"Less Common Adverse Reactions  :     The following additional adverse reactions were reported in >=5% to <10% of the HALAVEN-treated group:     *   Eye Disorders: increased lacrimation   *   Gastrointestinal Disorders: dyspepsia, abdominal pain, stomatitis, dry mouth   *   General Disorders and Administration Site Conditions: peripheral edema   *   Infections and Infestations: upper respiratory tract infection   *   Metabolism and Nutrition Disorders: hypokalemia   *   Musculoskeletal and Connective Tissue Disorders:    muscle spasms, muscular weakness   *   Nervous System Disorders: dysgeusia, dizziness   *   Psychiatric Disorders: insomnia, depression   *   Skin and Subcutaneous Tissue Disorders: rash          6.",abdominal pain is an adverse reaction entity
"Less Common Adverse Reactions  :     The following additional adverse reactions were reported in >=5% to <10% of the HALAVEN-treated group:     *   Eye Disorders: increased lacrimation   *   Gastrointestinal Disorders: dyspepsia, abdominal pain, stomatitis, dry mouth   *   General Disorders and Administration Site Conditions: peripheral edema   *   Infections and Infestations: upper respiratory tract infection   *   Metabolism and Nutrition Disorders: hypokalemia   *   Musculoskeletal and Connective Tissue Disorders:    muscle spasms, muscular weakness   *   Nervous System Disorders: dysgeusia, dizziness   *   Psychiatric Disorders: insomnia, depression   *   Skin and Subcutaneous Tissue Disorders: rash          6.",stomatitis is an adverse reaction entity
"Less Common Adverse Reactions  :     The following additional adverse reactions were reported in >=5% to <10% of the HALAVEN-treated group:     *   Eye Disorders: increased lacrimation   *   Gastrointestinal Disorders: dyspepsia, abdominal pain, stomatitis, dry mouth   *   General Disorders and Administration Site Conditions: peripheral edema   *   Infections and Infestations: upper respiratory tract infection   *   Metabolism and Nutrition Disorders: hypokalemia   *   Musculoskeletal and Connective Tissue Disorders:    muscle spasms, muscular weakness   *   Nervous System Disorders: dysgeusia, dizziness   *   Psychiatric Disorders: insomnia, depression   *   Skin and Subcutaneous Tissue Disorders: rash          6.",dry mouth is an adverse reaction entity
"Less Common Adverse Reactions  :     The following additional adverse reactions were reported in >=5% to <10% of the HALAVEN-treated group:     *   Eye Disorders: increased lacrimation   *   Gastrointestinal Disorders: dyspepsia, abdominal pain, stomatitis, dry mouth   *   General Disorders and Administration Site Conditions: peripheral edema   *   Infections and Infestations: upper respiratory tract infection   *   Metabolism and Nutrition Disorders: hypokalemia   *   Musculoskeletal and Connective Tissue Disorders:    muscle spasms, muscular weakness   *   Nervous System Disorders: dysgeusia, dizziness   *   Psychiatric Disorders: insomnia, depression   *   Skin and Subcutaneous Tissue Disorders: rash          6.",peripheral edema is an adverse reaction entity
"Less Common Adverse Reactions  :     The following additional adverse reactions were reported in >=5% to <10% of the HALAVEN-treated group:     *   Eye Disorders: increased lacrimation   *   Gastrointestinal Disorders: dyspepsia, abdominal pain, stomatitis, dry mouth   *   General Disorders and Administration Site Conditions: peripheral edema   *   Infections and Infestations: upper respiratory tract infection   *   Metabolism and Nutrition Disorders: hypokalemia   *   Musculoskeletal and Connective Tissue Disorders:    muscle spasms, muscular weakness   *   Nervous System Disorders: dysgeusia, dizziness   *   Psychiatric Disorders: insomnia, depression   *   Skin and Subcutaneous Tissue Disorders: rash          6.",upper respiratory tract infection is an adverse reaction entity
"Less Common Adverse Reactions  :     The following additional adverse reactions were reported in >=5% to <10% of the HALAVEN-treated group:     *   Eye Disorders: increased lacrimation   *   Gastrointestinal Disorders: dyspepsia, abdominal pain, stomatitis, dry mouth   *   General Disorders and Administration Site Conditions: peripheral edema   *   Infections and Infestations: upper respiratory tract infection   *   Metabolism and Nutrition Disorders: hypokalemia   *   Musculoskeletal and Connective Tissue Disorders:    muscle spasms, muscular weakness   *   Nervous System Disorders: dysgeusia, dizziness   *   Psychiatric Disorders: insomnia, depression   *   Skin and Subcutaneous Tissue Disorders: rash          6.",hypokalemia is an adverse reaction entity
"Less Common Adverse Reactions  :     The following additional adverse reactions were reported in >=5% to <10% of the HALAVEN-treated group:     *   Eye Disorders: increased lacrimation   *   Gastrointestinal Disorders: dyspepsia, abdominal pain, stomatitis, dry mouth   *   General Disorders and Administration Site Conditions: peripheral edema   *   Infections and Infestations: upper respiratory tract infection   *   Metabolism and Nutrition Disorders: hypokalemia   *   Musculoskeletal and Connective Tissue Disorders:    muscle spasms, muscular weakness   *   Nervous System Disorders: dysgeusia, dizziness   *   Psychiatric Disorders: insomnia, depression   *   Skin and Subcutaneous Tissue Disorders: rash          6.",muscle spasms is an adverse reaction entity
"Less Common Adverse Reactions  :     The following additional adverse reactions were reported in >=5% to <10% of the HALAVEN-treated group:     *   Eye Disorders: increased lacrimation   *   Gastrointestinal Disorders: dyspepsia, abdominal pain, stomatitis, dry mouth   *   General Disorders and Administration Site Conditions: peripheral edema   *   Infections and Infestations: upper respiratory tract infection   *   Metabolism and Nutrition Disorders: hypokalemia   *   Musculoskeletal and Connective Tissue Disorders:    muscle spasms, muscular weakness   *   Nervous System Disorders: dysgeusia, dizziness   *   Psychiatric Disorders: insomnia, depression   *   Skin and Subcutaneous Tissue Disorders: rash          6.",muscular weakness is an adverse reaction entity
"Less Common Adverse Reactions  :     The following additional adverse reactions were reported in >=5% to <10% of the HALAVEN-treated group:     *   Eye Disorders: increased lacrimation   *   Gastrointestinal Disorders: dyspepsia, abdominal pain, stomatitis, dry mouth   *   General Disorders and Administration Site Conditions: peripheral edema   *   Infections and Infestations: upper respiratory tract infection   *   Metabolism and Nutrition Disorders: hypokalemia   *   Musculoskeletal and Connective Tissue Disorders:    muscle spasms, muscular weakness   *   Nervous System Disorders: dysgeusia, dizziness   *   Psychiatric Disorders: insomnia, depression   *   Skin and Subcutaneous Tissue Disorders: rash          6.",dysgeusia is an adverse reaction entity
"Less Common Adverse Reactions  :     The following additional adverse reactions were reported in >=5% to <10% of the HALAVEN-treated group:     *   Eye Disorders: increased lacrimation   *   Gastrointestinal Disorders: dyspepsia, abdominal pain, stomatitis, dry mouth   *   General Disorders and Administration Site Conditions: peripheral edema   *   Infections and Infestations: upper respiratory tract infection   *   Metabolism and Nutrition Disorders: hypokalemia   *   Musculoskeletal and Connective Tissue Disorders:    muscle spasms, muscular weakness   *   Nervous System Disorders: dysgeusia, dizziness   *   Psychiatric Disorders: insomnia, depression   *   Skin and Subcutaneous Tissue Disorders: rash          6.",dizziness is an adverse reaction entity
"Less Common Adverse Reactions  :     The following additional adverse reactions were reported in >=5% to <10% of the HALAVEN-treated group:     *   Eye Disorders: increased lacrimation   *   Gastrointestinal Disorders: dyspepsia, abdominal pain, stomatitis, dry mouth   *   General Disorders and Administration Site Conditions: peripheral edema   *   Infections and Infestations: upper respiratory tract infection   *   Metabolism and Nutrition Disorders: hypokalemia   *   Musculoskeletal and Connective Tissue Disorders:    muscle spasms, muscular weakness   *   Nervous System Disorders: dysgeusia, dizziness   *   Psychiatric Disorders: insomnia, depression   *   Skin and Subcutaneous Tissue Disorders: rash          6.",insomnia is an adverse reaction entity
"Less Common Adverse Reactions  :     The following additional adverse reactions were reported in >=5% to <10% of the HALAVEN-treated group:     *   Eye Disorders: increased lacrimation   *   Gastrointestinal Disorders: dyspepsia, abdominal pain, stomatitis, dry mouth   *   General Disorders and Administration Site Conditions: peripheral edema   *   Infections and Infestations: upper respiratory tract infection   *   Metabolism and Nutrition Disorders: hypokalemia   *   Musculoskeletal and Connective Tissue Disorders:    muscle spasms, muscular weakness   *   Nervous System Disorders: dysgeusia, dizziness   *   Psychiatric Disorders: insomnia, depression   *   Skin and Subcutaneous Tissue Disorders: rash          6.",depression is an adverse reaction entity
"Less Common Adverse Reactions  :     The following additional adverse reactions were reported in >=5% to <10% of the HALAVEN-treated group:     *   Eye Disorders: increased lacrimation   *   Gastrointestinal Disorders: dyspepsia, abdominal pain, stomatitis, dry mouth   *   General Disorders and Administration Site Conditions: peripheral edema   *   Infections and Infestations: upper respiratory tract infection   *   Metabolism and Nutrition Disorders: hypokalemia   *   Musculoskeletal and Connective Tissue Disorders:    muscle spasms, muscular weakness   *   Nervous System Disorders: dysgeusia, dizziness   *   Psychiatric Disorders: insomnia, depression   *   Skin and Subcutaneous Tissue Disorders: rash          6.",rash is an adverse reaction entity
Patients with bilirubin > 1.5 * ULN also had a higher incidence of Grade 4 neutropenia and febrile neutropenia.,neutropenia is an adverse reaction entity
Patients with bilirubin > 1.5 * ULN also had a higher incidence of Grade 4 neutropenia and febrile neutropenia.,febrile neutropenia is an adverse reaction entity
"Cytopenias:  Grade 3 neutropenia occurred in 28% (143/503) of patients who received HALAVEN in Study 1, and 29% (144/503) of patients experienced Grade 4 neutropenia.",neutropenia is an adverse reaction entity
"Cytopenias:  Grade 3 neutropenia occurred in 28% (143/503) of patients who received HALAVEN in Study 1, and 29% (144/503) of patients experienced Grade 4 neutropenia.",neutropenia is an adverse reaction entity
Febrile neutropenia occurred in 5% (23/503) of patients; two patients (0.4%) died from complications of febrile neutropenia.,Febrile neutropenia is an adverse reaction entity
Febrile neutropenia occurred in 5% (23/503) of patients; two patients (0.4%) died from complications of febrile neutropenia.,died is an adverse reaction entity
Febrile neutropenia occurred in 5% (23/503) of patients; two patients (0.4%) died from complications of febrile neutropenia.,febrile neutropenia is an adverse reaction entity
No severe injection-site reactions were reported and none led to discontinuation of treatment.,injection-site reactions is an adverse reaction entity
5.3     Hypersensitivity      Hypersensitivity reactions have been reported with ILARIS therapy.,Hypersensitivity reactions is an adverse reaction entity
The most frequently reported adverse drug reactions were infections predominantly of the upper respiratory tract.,infections is an adverse reaction entity
The most frequently reported adverse drug reactions were infections predominantly of the upper respiratory tract.,infections of the upper respiratory tract is an adverse reaction entity
Treatment with medications that work through inhibition of IL-1 has been associated with an increased risk of serious infections.,infections is an adverse reaction entity
"In the randomized, placebo-controlled portion of SJIA Study 2, high ALT and/or AST greater than or equal to 3 times upper limit of normal (ULN) were reported in 2 (4.1%) ILARIS-treated patients and 1 (2.0%) placebo patient.",high ALT is an adverse reaction entity
"In the randomized, placebo-controlled portion of SJIA Study 2, high ALT and/or AST greater than or equal to 3 times upper limit of normal (ULN) were reported in 2 (4.1%) ILARIS-treated patients and 1 (2.0%) placebo patient.",high AST is an adverse reaction entity
"EXCERPT:     CAPS:  The most common adverse reactions greater than 10% reported by patients with CAPS treated with ILARIS are nasopharyngitis, diarrhea, influenza, headache and nausea.",nasopharyngitis is an adverse reaction entity
"EXCERPT:     CAPS:  The most common adverse reactions greater than 10% reported by patients with CAPS treated with ILARIS are nasopharyngitis, diarrhea, influenza, headache and nausea.",diarrhea is an adverse reaction entity
"EXCERPT:     CAPS:  The most common adverse reactions greater than 10% reported by patients with CAPS treated with ILARIS are nasopharyngitis, diarrhea, influenza, headache and nausea.",influenza is an adverse reaction entity
"EXCERPT:     CAPS:  The most common adverse reactions greater than 10% reported by patients with CAPS treated with ILARIS are nasopharyngitis, diarrhea, influenza, headache and nausea.",headache is an adverse reaction entity
"EXCERPT:     CAPS:  The most common adverse reactions greater than 10% reported by patients with CAPS treated with ILARIS are nasopharyngitis, diarrhea, influenza, headache and nausea.",nausea is an adverse reaction entity
"6.4     Laboratory Findings      Hematology       During clinical trials with ILARIS, mean values decreased for white blood cells, neutrophils and platelets.",decreased white blood cells is an adverse reaction entity
"6.4     Laboratory Findings      Hematology       During clinical trials with ILARIS, mean values decreased for white blood cells, neutrophils and platelets.",decreased neutrophils is an adverse reaction entity
"6.4     Laboratory Findings      Hematology       During clinical trials with ILARIS, mean values decreased for white blood cells, neutrophils and platelets.",decreased platelets is an adverse reaction entity
"Falls and Fall-related Injuries  In the two randomized clinical trials, falls including fall-related injuries, occurred in 9% of patients treated with XTANDI compared to 4% of patients treated with placebo.",falls is an adverse reaction entity
"Falls and Fall-related Injuries  In the two randomized clinical trials, falls including fall-related injuries, occurred in 9% of patients treated with XTANDI compared to 4% of patients treated with placebo.",fall-related injuries is an adverse reaction entity
Grade 1-4 elevations in bilirubin occurred in 3% of patients treated with XTANDI (0.1% Grade 3-4) and 2% of patients treated with placebo (no Grade 3-4).,elevations in bilirubin is an adverse reaction entity
Grade 1-4 elevations in bilirubin occurred in 3% of patients treated with XTANDI (0.1% Grade 3-4) and 2% of patients treated with placebo (no Grade 3-4).,elevations in bilirubin is an adverse reaction entity
Grade 1-4 elevations in bilirubin occurred in 3% of patients treated with XTANDI (0.1% Grade 3-4) and 2% of patients treated with placebo (no Grade 3-4).,elevations in bilirubin is an adverse reaction entity
"6 ADVERSE REACTIONS    The following is discussed in more detail in other sections of the labeling:     *    Seizure [see  Warnings and Precautions  (  5.1  )]         EXCERPT:   The most common adverse reactions (>= 10%) are asthenia/fatigue, back pain, decreased appetite, constipation, arthralgia, diarrhea, hot flush, upper respiratory tract infection, peripheral edema, dyspnea, musculoskeletal pain, weight decreased, headache, hypertension, and dizziness/vertigo.",Seizure is an adverse reaction entity
"6 ADVERSE REACTIONS    The following is discussed in more detail in other sections of the labeling:     *    Seizure [see  Warnings and Precautions  (  5.1  )]         EXCERPT:   The most common adverse reactions (>= 10%) are asthenia/fatigue, back pain, decreased appetite, constipation, arthralgia, diarrhea, hot flush, upper respiratory tract infection, peripheral edema, dyspnea, musculoskeletal pain, weight decreased, headache, hypertension, and dizziness/vertigo.",asthenia is an adverse reaction entity
"6 ADVERSE REACTIONS    The following is discussed in more detail in other sections of the labeling:     *    Seizure [see  Warnings and Precautions  (  5.1  )]         EXCERPT:   The most common adverse reactions (>= 10%) are asthenia/fatigue, back pain, decreased appetite, constipation, arthralgia, diarrhea, hot flush, upper respiratory tract infection, peripheral edema, dyspnea, musculoskeletal pain, weight decreased, headache, hypertension, and dizziness/vertigo.",fatigue is an adverse reaction entity
"6 ADVERSE REACTIONS    The following is discussed in more detail in other sections of the labeling:     *    Seizure [see  Warnings and Precautions  (  5.1  )]         EXCERPT:   The most common adverse reactions (>= 10%) are asthenia/fatigue, back pain, decreased appetite, constipation, arthralgia, diarrhea, hot flush, upper respiratory tract infection, peripheral edema, dyspnea, musculoskeletal pain, weight decreased, headache, hypertension, and dizziness/vertigo.",back pain is an adverse reaction entity
"6 ADVERSE REACTIONS    The following is discussed in more detail in other sections of the labeling:     *    Seizure [see  Warnings and Precautions  (  5.1  )]         EXCERPT:   The most common adverse reactions (>= 10%) are asthenia/fatigue, back pain, decreased appetite, constipation, arthralgia, diarrhea, hot flush, upper respiratory tract infection, peripheral edema, dyspnea, musculoskeletal pain, weight decreased, headache, hypertension, and dizziness/vertigo.",decreased appetite is an adverse reaction entity
"6 ADVERSE REACTIONS    The following is discussed in more detail in other sections of the labeling:     *    Seizure [see  Warnings and Precautions  (  5.1  )]         EXCERPT:   The most common adverse reactions (>= 10%) are asthenia/fatigue, back pain, decreased appetite, constipation, arthralgia, diarrhea, hot flush, upper respiratory tract infection, peripheral edema, dyspnea, musculoskeletal pain, weight decreased, headache, hypertension, and dizziness/vertigo.",constipation is an adverse reaction entity
"6 ADVERSE REACTIONS    The following is discussed in more detail in other sections of the labeling:     *    Seizure [see  Warnings and Precautions  (  5.1  )]         EXCERPT:   The most common adverse reactions (>= 10%) are asthenia/fatigue, back pain, decreased appetite, constipation, arthralgia, diarrhea, hot flush, upper respiratory tract infection, peripheral edema, dyspnea, musculoskeletal pain, weight decreased, headache, hypertension, and dizziness/vertigo.",arthralgia is an adverse reaction entity
"6 ADVERSE REACTIONS    The following is discussed in more detail in other sections of the labeling:     *    Seizure [see  Warnings and Precautions  (  5.1  )]         EXCERPT:   The most common adverse reactions (>= 10%) are asthenia/fatigue, back pain, decreased appetite, constipation, arthralgia, diarrhea, hot flush, upper respiratory tract infection, peripheral edema, dyspnea, musculoskeletal pain, weight decreased, headache, hypertension, and dizziness/vertigo.",diarrhea is an adverse reaction entity
"6 ADVERSE REACTIONS    The following is discussed in more detail in other sections of the labeling:     *    Seizure [see  Warnings and Precautions  (  5.1  )]         EXCERPT:   The most common adverse reactions (>= 10%) are asthenia/fatigue, back pain, decreased appetite, constipation, arthralgia, diarrhea, hot flush, upper respiratory tract infection, peripheral edema, dyspnea, musculoskeletal pain, weight decreased, headache, hypertension, and dizziness/vertigo.",hot flush is an adverse reaction entity
"6 ADVERSE REACTIONS    The following is discussed in more detail in other sections of the labeling:     *    Seizure [see  Warnings and Precautions  (  5.1  )]         EXCERPT:   The most common adverse reactions (>= 10%) are asthenia/fatigue, back pain, decreased appetite, constipation, arthralgia, diarrhea, hot flush, upper respiratory tract infection, peripheral edema, dyspnea, musculoskeletal pain, weight decreased, headache, hypertension, and dizziness/vertigo.",upper respiratory tract infection is an adverse reaction entity
"6 ADVERSE REACTIONS    The following is discussed in more detail in other sections of the labeling:     *    Seizure [see  Warnings and Precautions  (  5.1  )]         EXCERPT:   The most common adverse reactions (>= 10%) are asthenia/fatigue, back pain, decreased appetite, constipation, arthralgia, diarrhea, hot flush, upper respiratory tract infection, peripheral edema, dyspnea, musculoskeletal pain, weight decreased, headache, hypertension, and dizziness/vertigo.",peripheral edema is an adverse reaction entity
"6 ADVERSE REACTIONS    The following is discussed in more detail in other sections of the labeling:     *    Seizure [see  Warnings and Precautions  (  5.1  )]         EXCERPT:   The most common adverse reactions (>= 10%) are asthenia/fatigue, back pain, decreased appetite, constipation, arthralgia, diarrhea, hot flush, upper respiratory tract infection, peripheral edema, dyspnea, musculoskeletal pain, weight decreased, headache, hypertension, and dizziness/vertigo.",dyspnea is an adverse reaction entity
"6 ADVERSE REACTIONS    The following is discussed in more detail in other sections of the labeling:     *    Seizure [see  Warnings and Precautions  (  5.1  )]         EXCERPT:   The most common adverse reactions (>= 10%) are asthenia/fatigue, back pain, decreased appetite, constipation, arthralgia, diarrhea, hot flush, upper respiratory tract infection, peripheral edema, dyspnea, musculoskeletal pain, weight decreased, headache, hypertension, and dizziness/vertigo.",musculoskeletal pain is an adverse reaction entity
"6 ADVERSE REACTIONS    The following is discussed in more detail in other sections of the labeling:     *    Seizure [see  Warnings and Precautions  (  5.1  )]         EXCERPT:   The most common adverse reactions (>= 10%) are asthenia/fatigue, back pain, decreased appetite, constipation, arthralgia, diarrhea, hot flush, upper respiratory tract infection, peripheral edema, dyspnea, musculoskeletal pain, weight decreased, headache, hypertension, and dizziness/vertigo.",weight decreased is an adverse reaction entity
"6 ADVERSE REACTIONS    The following is discussed in more detail in other sections of the labeling:     *    Seizure [see  Warnings and Precautions  (  5.1  )]         EXCERPT:   The most common adverse reactions (>= 10%) are asthenia/fatigue, back pain, decreased appetite, constipation, arthralgia, diarrhea, hot flush, upper respiratory tract infection, peripheral edema, dyspnea, musculoskeletal pain, weight decreased, headache, hypertension, and dizziness/vertigo.",headache is an adverse reaction entity
"6 ADVERSE REACTIONS    The following is discussed in more detail in other sections of the labeling:     *    Seizure [see  Warnings and Precautions  (  5.1  )]         EXCERPT:   The most common adverse reactions (>= 10%) are asthenia/fatigue, back pain, decreased appetite, constipation, arthralgia, diarrhea, hot flush, upper respiratory tract infection, peripheral edema, dyspnea, musculoskeletal pain, weight decreased, headache, hypertension, and dizziness/vertigo.",hypertension is an adverse reaction entity
"6 ADVERSE REACTIONS    The following is discussed in more detail in other sections of the labeling:     *    Seizure [see  Warnings and Precautions  (  5.1  )]         EXCERPT:   The most common adverse reactions (>= 10%) are asthenia/fatigue, back pain, decreased appetite, constipation, arthralgia, diarrhea, hot flush, upper respiratory tract infection, peripheral edema, dyspnea, musculoskeletal pain, weight decreased, headache, hypertension, and dizziness/vertigo.",dizziness is an adverse reaction entity
"6 ADVERSE REACTIONS    The following is discussed in more detail in other sections of the labeling:     *    Seizure [see  Warnings and Precautions  (  5.1  )]         EXCERPT:   The most common adverse reactions (>= 10%) are asthenia/fatigue, back pain, decreased appetite, constipation, arthralgia, diarrhea, hot flush, upper respiratory tract infection, peripheral edema, dyspnea, musculoskeletal pain, weight decreased, headache, hypertension, and dizziness/vertigo.",vertigo is an adverse reaction entity
The incidence of Grade 1-4 thrombocytopenia was 6% of patients treated with XTANDI (0.3% Grade 3-4) and 5% of patients treated with placebo (0.5% Grade 3-4).,thrombocytopenia is an adverse reaction entity
The incidence of Grade 1-4 thrombocytopenia was 6% of patients treated with XTANDI (0.3% Grade 3-4) and 5% of patients treated with placebo (0.5% Grade 3-4).,thrombocytopenia is an adverse reaction entity
The incidence of Grade 1-4 thrombocytopenia was 6% of patients treated with XTANDI (0.3% Grade 3-4) and 5% of patients treated with placebo (0.5% Grade 3-4).,thrombocytopenia is an adverse reaction entity
WARNINGS AND PRECAUTIONS       EXCERPT:    *  Infections: Monitor patients for signs or symptoms and treat appropriately.,Infections is an adverse reaction entity
Life-threatening or fatal CRS was infrequently reported in patients receiving BLINCYTO.,fatal is an adverse reaction entity
Life-threatening or fatal CRS was infrequently reported in patients receiving BLINCYTO.,CRS is an adverse reaction entity
Life-threatening or fatal CRS was infrequently reported in patients receiving BLINCYTO.,CRS is an adverse reaction entity
"*  Neurological toxicities, which may be severe, life-threatening, or fatal, occurred in patients receiving BLINCYTO.",Neurological toxicities is an adverse reaction entity
"*  Neurological toxicities, which may be severe, life-threatening, or fatal, occurred in patients receiving BLINCYTO.",Neurological toxicities is an adverse reaction entity
"*  Neurological toxicities, which may be severe, life-threatening, or fatal, occurred in patients receiving BLINCYTO.",fatal is an adverse reaction entity
"5.5     Neutropenia and Febrile Neutropenia      Neutropenia and febrile neutropenia, including life-threatening cases, have been observed in patients receiving BLINCYTO.",Neutropenia is an adverse reaction entity
"5.5     Neutropenia and Febrile Neutropenia      Neutropenia and febrile neutropenia, including life-threatening cases, have been observed in patients receiving BLINCYTO.",Neutropenia is an adverse reaction entity
"5.5     Neutropenia and Febrile Neutropenia      Neutropenia and febrile neutropenia, including life-threatening cases, have been observed in patients receiving BLINCYTO.",febrile neutropenia is an adverse reaction entity
"5.5     Neutropenia and Febrile Neutropenia      Neutropenia and febrile neutropenia, including life-threatening cases, have been observed in patients receiving BLINCYTO.",febrile neutropenia is an adverse reaction entity
"Adverse Reactions With >= 10% Incidence for Any Grade or >= 5% Incidence for Grade 3 or Higher (N = 212)    Adverse Reaction    Any GradeGrading based on NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0(%)    Grade 3 or Higher(%)          Blood and lymphatic system disorders       Febrile neutropenia     Anemia     Neutropenia     Thrombocytopenia     Leukopenia             251816119         23131588       Gastrointestinal disorders       Nausea     Constipation     DiarrheaDiarrhea includes the following terms: colitis, diarrhea, enteritis, and neutropenic colitis.",Febrile neutropenia is an adverse reaction entity
"Adverse Reactions With >= 10% Incidence for Any Grade or >= 5% Incidence for Grade 3 or Higher (N = 212)    Adverse Reaction    Any GradeGrading based on NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0(%)    Grade 3 or Higher(%)          Blood and lymphatic system disorders       Febrile neutropenia     Anemia     Neutropenia     Thrombocytopenia     Leukopenia             251816119         23131588       Gastrointestinal disorders       Nausea     Constipation     DiarrheaDiarrhea includes the following terms: colitis, diarrhea, enteritis, and neutropenic colitis.",Anemia is an adverse reaction entity
"Adverse Reactions With >= 10% Incidence for Any Grade or >= 5% Incidence for Grade 3 or Higher (N = 212)    Adverse Reaction    Any GradeGrading based on NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0(%)    Grade 3 or Higher(%)          Blood and lymphatic system disorders       Febrile neutropenia     Anemia     Neutropenia     Thrombocytopenia     Leukopenia             251816119         23131588       Gastrointestinal disorders       Nausea     Constipation     DiarrheaDiarrhea includes the following terms: colitis, diarrhea, enteritis, and neutropenic colitis.",Neutropenia is an adverse reaction entity
"Adverse Reactions With >= 10% Incidence for Any Grade or >= 5% Incidence for Grade 3 or Higher (N = 212)    Adverse Reaction    Any GradeGrading based on NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0(%)    Grade 3 or Higher(%)          Blood and lymphatic system disorders       Febrile neutropenia     Anemia     Neutropenia     Thrombocytopenia     Leukopenia             251816119         23131588       Gastrointestinal disorders       Nausea     Constipation     DiarrheaDiarrhea includes the following terms: colitis, diarrhea, enteritis, and neutropenic colitis.",Thrombocytopenia is an adverse reaction entity
"Adverse Reactions With >= 10% Incidence for Any Grade or >= 5% Incidence for Grade 3 or Higher (N = 212)    Adverse Reaction    Any GradeGrading based on NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0(%)    Grade 3 or Higher(%)          Blood and lymphatic system disorders       Febrile neutropenia     Anemia     Neutropenia     Thrombocytopenia     Leukopenia             251816119         23131588       Gastrointestinal disorders       Nausea     Constipation     DiarrheaDiarrhea includes the following terms: colitis, diarrhea, enteritis, and neutropenic colitis.",Leukopenia is an adverse reaction entity
"Adverse Reactions With >= 10% Incidence for Any Grade or >= 5% Incidence for Grade 3 or Higher (N = 212)    Adverse Reaction    Any GradeGrading based on NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0(%)    Grade 3 or Higher(%)          Blood and lymphatic system disorders       Febrile neutropenia     Anemia     Neutropenia     Thrombocytopenia     Leukopenia             251816119         23131588       Gastrointestinal disorders       Nausea     Constipation     DiarrheaDiarrhea includes the following terms: colitis, diarrhea, enteritis, and neutropenic colitis.",Nausea is an adverse reaction entity
"Adverse Reactions With >= 10% Incidence for Any Grade or >= 5% Incidence for Grade 3 or Higher (N = 212)    Adverse Reaction    Any GradeGrading based on NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0(%)    Grade 3 or Higher(%)          Blood and lymphatic system disorders       Febrile neutropenia     Anemia     Neutropenia     Thrombocytopenia     Leukopenia             251816119         23131588       Gastrointestinal disorders       Nausea     Constipation     DiarrheaDiarrhea includes the following terms: colitis, diarrhea, enteritis, and neutropenic colitis.",Constipation is an adverse reaction entity
"Adverse Reactions With >= 10% Incidence for Any Grade or >= 5% Incidence for Grade 3 or Higher (N = 212)    Adverse Reaction    Any GradeGrading based on NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0(%)    Grade 3 or Higher(%)          Blood and lymphatic system disorders       Febrile neutropenia     Anemia     Neutropenia     Thrombocytopenia     Leukopenia             251816119         23131588       Gastrointestinal disorders       Nausea     Constipation     DiarrheaDiarrhea includes the following terms: colitis, diarrhea, enteritis, and neutropenic colitis.",Diarrhea is an adverse reaction entity
"Adverse Reactions With >= 10% Incidence for Any Grade or >= 5% Incidence for Grade 3 or Higher (N = 212)    Adverse Reaction    Any GradeGrading based on NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0(%)    Grade 3 or Higher(%)          Blood and lymphatic system disorders       Febrile neutropenia     Anemia     Neutropenia     Thrombocytopenia     Leukopenia             251816119         23131588       Gastrointestinal disorders       Nausea     Constipation     DiarrheaDiarrhea includes the following terms: colitis, diarrhea, enteritis, and neutropenic colitis.",Diarrhea is an adverse reaction entity
"Adverse Reactions With >= 10% Incidence for Any Grade or >= 5% Incidence for Grade 3 or Higher (N = 212)    Adverse Reaction    Any GradeGrading based on NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0(%)    Grade 3 or Higher(%)          Blood and lymphatic system disorders       Febrile neutropenia     Anemia     Neutropenia     Thrombocytopenia     Leukopenia             251816119         23131588       Gastrointestinal disorders       Nausea     Constipation     DiarrheaDiarrhea includes the following terms: colitis, diarrhea, enteritis, and neutropenic colitis.",colitis is an adverse reaction entity
"Adverse Reactions With >= 10% Incidence for Any Grade or >= 5% Incidence for Grade 3 or Higher (N = 212)    Adverse Reaction    Any GradeGrading based on NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0(%)    Grade 3 or Higher(%)          Blood and lymphatic system disorders       Febrile neutropenia     Anemia     Neutropenia     Thrombocytopenia     Leukopenia             251816119         23131588       Gastrointestinal disorders       Nausea     Constipation     DiarrheaDiarrhea includes the following terms: colitis, diarrhea, enteritis, and neutropenic colitis.",diarrhea is an adverse reaction entity
"Adverse Reactions With >= 10% Incidence for Any Grade or >= 5% Incidence for Grade 3 or Higher (N = 212)    Adverse Reaction    Any GradeGrading based on NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0(%)    Grade 3 or Higher(%)          Blood and lymphatic system disorders       Febrile neutropenia     Anemia     Neutropenia     Thrombocytopenia     Leukopenia             251816119         23131588       Gastrointestinal disorders       Nausea     Constipation     DiarrheaDiarrhea includes the following terms: colitis, diarrhea, enteritis, and neutropenic colitis.",enteritis is an adverse reaction entity
"Adverse Reactions With >= 10% Incidence for Any Grade or >= 5% Incidence for Grade 3 or Higher (N = 212)    Adverse Reaction    Any GradeGrading based on NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0(%)    Grade 3 or Higher(%)          Blood and lymphatic system disorders       Febrile neutropenia     Anemia     Neutropenia     Thrombocytopenia     Leukopenia             251816119         23131588       Gastrointestinal disorders       Nausea     Constipation     DiarrheaDiarrhea includes the following terms: colitis, diarrhea, enteritis, and neutropenic colitis.",neutropenic colitis is an adverse reaction entity
"(2.3), (5.1)   *  Neurological toxicities, which may be severe, life-threatening, or fatal, occurred in patients receiving BLINCYTO.",Neurological toxicities is an adverse reaction entity
"(2.3), (5.1)   *  Neurological toxicities, which may be severe, life-threatening, or fatal, occurred in patients receiving BLINCYTO.",Neurological toxicities is an adverse reaction entity
"(2.3), (5.1)   *  Neurological toxicities, which may be severe, life-threatening, or fatal, occurred in patients receiving BLINCYTO.",fatal is an adverse reaction entity
"If unexplained or clinically significant weight loss occurs, evaluate weight loss and consider discontinuation of OTEZLA (5.2)   *   Drug Interactions : Use with strong cytochrome P450 enzyme inducers (e.g., rifampin, phenobarbital, carbamazepine, phenytoin) is not recommended because loss of efficacy may occur (5.3,7.1)          5.1 Depression    Treatment with OTEZLA is associated with an increase in adverse reactions of depression.",depression is an adverse reaction entity
"The most common adverse reactions leading to discontinuation for subjects taking OTEZLA were nausea (1.6%), diarrhea (1.0%), and headache (0.8%).",nausea is an adverse reaction entity
"The most common adverse reactions leading to discontinuation for subjects taking OTEZLA were nausea (1.6%), diarrhea (1.0%), and headache (0.8%).",diarrhea is an adverse reaction entity
"The most common adverse reactions leading to discontinuation for subjects taking OTEZLA were nausea (1.6%), diarrhea (1.0%), and headache (0.8%).",headache is an adverse reaction entity
"Depression was reported as serious in 0.2% (3/1441) of subjects exposed to OTEZLA, compared to none in placebo-treated subjects (0/495).",Depression is an adverse reaction entity
"Table 2: Adverse Reactions Reported in >=2% of Patients on OTEZLA 30 mg Twice Daily and >=1% Than That Observed in Patients on Placebo for up to Day 112 (Week 16)     a  Of the reported gastrointestinal adverse reactions, 1 subject experienced a serious adverse reaction of nausea and vomiting in OTEZLA 30 mg twice daily; 1 subject treated with OTEZLA 20 mg twice daily experienced a serious adverse reaction of diarrhea; 1 patient treated with OTEZLA 30 mg twice daily experienced a serious adverse reaction of headache.",gastrointestinal adverse reactions is an adverse reaction entity
"Table 2: Adverse Reactions Reported in >=2% of Patients on OTEZLA 30 mg Twice Daily and >=1% Than That Observed in Patients on Placebo for up to Day 112 (Week 16)     a  Of the reported gastrointestinal adverse reactions, 1 subject experienced a serious adverse reaction of nausea and vomiting in OTEZLA 30 mg twice daily; 1 subject treated with OTEZLA 20 mg twice daily experienced a serious adverse reaction of diarrhea; 1 patient treated with OTEZLA 30 mg twice daily experienced a serious adverse reaction of headache.",nausea is an adverse reaction entity
"Table 2: Adverse Reactions Reported in >=2% of Patients on OTEZLA 30 mg Twice Daily and >=1% Than That Observed in Patients on Placebo for up to Day 112 (Week 16)     a  Of the reported gastrointestinal adverse reactions, 1 subject experienced a serious adverse reaction of nausea and vomiting in OTEZLA 30 mg twice daily; 1 subject treated with OTEZLA 20 mg twice daily experienced a serious adverse reaction of diarrhea; 1 patient treated with OTEZLA 30 mg twice daily experienced a serious adverse reaction of headache.",vomiting is an adverse reaction entity
"Table 2: Adverse Reactions Reported in >=2% of Patients on OTEZLA 30 mg Twice Daily and >=1% Than That Observed in Patients on Placebo for up to Day 112 (Week 16)     a  Of the reported gastrointestinal adverse reactions, 1 subject experienced a serious adverse reaction of nausea and vomiting in OTEZLA 30 mg twice daily; 1 subject treated with OTEZLA 20 mg twice daily experienced a serious adverse reaction of diarrhea; 1 patient treated with OTEZLA 30 mg twice daily experienced a serious adverse reaction of headache.",diarrhea is an adverse reaction entity
"Table 2: Adverse Reactions Reported in >=2% of Patients on OTEZLA 30 mg Twice Daily and >=1% Than That Observed in Patients on Placebo for up to Day 112 (Week 16)     a  Of the reported gastrointestinal adverse reactions, 1 subject experienced a serious adverse reaction of nausea and vomiting in OTEZLA 30 mg twice daily; 1 subject treated with OTEZLA 20 mg twice daily experienced a serious adverse reaction of diarrhea; 1 patient treated with OTEZLA 30 mg twice daily experienced a serious adverse reaction of headache.",headache is an adverse reaction entity
"5 WARNINGS AND PRECAUTIONS       EXCERPT:    *   Depression : Advise patients, their caregivers, and families to be alert for the emergence or worsening of depression, suicidal thoughts or other mood changes and if such changes occur to contact their healthcare provider.",Depression is an adverse reaction entity
"5.5 Renal Impairment    In patients treated with GLP-1 receptor agonists, there have been postmarketing reports of acute renal failure and worsening of chronic renal failure, which may sometimes require hemodialysis.",acute renal failure is an adverse reaction entity
"5.5 Renal Impairment    In patients treated with GLP-1 receptor agonists, there have been postmarketing reports of acute renal failure and worsening of chronic renal failure, which may sometimes require hemodialysis.",worsening of chronic renal failure is an adverse reaction entity
Human relevance of GLP-1 receptor agonist induced C-cell tumors in rodents has not been determined.,C-cell tumors is an adverse reaction entity
"(5.2)   *     Hypoglycemia: Can occur when used in combination with insulin secretagogues (e.g., sulfonylureas) or insulin.",Hypoglycemia is an adverse reaction entity
"5.4 Hypersensitivity Reactions    Across 8 Phase III clinical trials  [see Clinical Studies (14)]  , a serious hypersensitivity reaction with pruritus, rash, and dyspnea occurred in a patient treated with TANZEUM.",hypersensitivity reaction is an adverse reaction entity
"5.4 Hypersensitivity Reactions    Across 8 Phase III clinical trials  [see Clinical Studies (14)]  , a serious hypersensitivity reaction with pruritus, rash, and dyspnea occurred in a patient treated with TANZEUM.",pruritus is an adverse reaction entity
"5.4 Hypersensitivity Reactions    Across 8 Phase III clinical trials  [see Clinical Studies (14)]  , a serious hypersensitivity reaction with pruritus, rash, and dyspnea occurred in a patient treated with TANZEUM.",rash is an adverse reaction entity
"5.4 Hypersensitivity Reactions    Across 8 Phase III clinical trials  [see Clinical Studies (14)]  , a serious hypersensitivity reaction with pruritus, rash, and dyspnea occurred in a patient treated with TANZEUM.",dyspnea is an adverse reaction entity
"*  Carcinogenicity of albiglutide could not be assessed in rodents, but other glucagon-like peptide-1 (GLP-1) receptor agonists have caused thyroid C-cell tumors in rodents at clinically relevant exposures.",thyroid C-cell tumors is an adverse reaction entity
"In the pool of placebo- and active-controlled trials, the types and frequency of common adverse reactions excluding hypoglycemia were similar to those listed in Table 1.",hypoglycemia is an adverse reaction entity
"Across 8 Phase III clinical trials  [see Clinical Studies (14)]  , pancreatitis adjudicated as likely related to therapy occurred more frequently in patients receiving TANZEUM (6 of 2,365 [0.3%]) than in patients receiving placebo (0 of 468 [0%]) or active comparators (2 of 2,065 [0.1%]).",pancreatitis is an adverse reaction entity
Human relevance of GLP-1 receptor agonist induced C-cell tumors in rodents has not been determined.,C-cell tumors is an adverse reaction entity
Discontinuation due to GI adverse reactions occurred in 2% of individuals on TANZEUM or placebo.,GI adverse reactions is an adverse reaction entity
The long-term clinical effects of the increase in heart rate have not been established  [see Warnings and Precautions (5.6)]  .,increase in heart rate is an adverse reaction entity
*       e  Rate of documented symptomatic hypoglycemia for active controls 18% (glimepiride) and 2% (sitagliptin).,hypoglycemia is an adverse reaction entity
In one of the 3 cases an alternate etiology was identified to explain the rise in liver enzyme (acute viral hepatitis).,rise in liver enzyme is an adverse reaction entity
"EXCERPT:   The most common adverse reactions (>=10% in Vimizim patients and occurring at a higher incidence than placebo-treated patients) were pyrexia, vomiting, headache, nausea, abdominal pain, chills, and fatigue (  6.1  ).",pyrexia is an adverse reaction entity
"EXCERPT:   The most common adverse reactions (>=10% in Vimizim patients and occurring at a higher incidence than placebo-treated patients) were pyrexia, vomiting, headache, nausea, abdominal pain, chills, and fatigue (  6.1  ).",vomiting is an adverse reaction entity
"EXCERPT:   The most common adverse reactions (>=10% in Vimizim patients and occurring at a higher incidence than placebo-treated patients) were pyrexia, vomiting, headache, nausea, abdominal pain, chills, and fatigue (  6.1  ).",headache is an adverse reaction entity
"EXCERPT:   The most common adverse reactions (>=10% in Vimizim patients and occurring at a higher incidence than placebo-treated patients) were pyrexia, vomiting, headache, nausea, abdominal pain, chills, and fatigue (  6.1  ).",nausea is an adverse reaction entity
"EXCERPT:   The most common adverse reactions (>=10% in Vimizim patients and occurring at a higher incidence than placebo-treated patients) were pyrexia, vomiting, headache, nausea, abdominal pain, chills, and fatigue (  6.1  ).",abdominal pain is an adverse reaction entity
"EXCERPT:   The most common adverse reactions (>=10% in Vimizim patients and occurring at a higher incidence than placebo-treated patients) were pyrexia, vomiting, headache, nausea, abdominal pain, chills, and fatigue (  6.1  ).",chills is an adverse reaction entity
"EXCERPT:   The most common adverse reactions (>=10% in Vimizim patients and occurring at a higher incidence than placebo-treated patients) were pyrexia, vomiting, headache, nausea, abdominal pain, chills, and fatigue (  6.1  ).",fatigue is an adverse reaction entity
Anaphylaxis and hypersensitivity reactions  [    see Warnings and Precautions (  5.1  )].,Anaphylaxis is an adverse reaction entity
Anaphylaxis and hypersensitivity reactions  [    see Warnings and Precautions (  5.1  )].,hypersensitivity reactions is an adverse reaction entity
"In premarketing clinical trials, 18 of 235 (7.7%) patients treated with Vimizim experienced signs and symptoms consistent with anaphylaxis.",anaphylaxis is an adverse reaction entity
5.1 Anaphylaxis and Hypersensitivity Reactions      Anaphylaxis and hypersensitivity reactions have been reported in patients treated with Vimizim.,Anaphylaxis is an adverse reaction entity
5.1 Anaphylaxis and Hypersensitivity Reactions      Anaphylaxis and hypersensitivity reactions have been reported in patients treated with Vimizim.,hypersensitivity is an adverse reaction entity
"(5.3,7.2,7.3)          5.1     Prolongation of the QT Interval    Some antimalarials (e.g., halofantrine, quinine, quinidine) including Coartem Tablets have been associated with prolongation of the QT interval on the electrocardiogram.",prolongation of the QT interval is an adverse reaction entity
"In children, the adverse reactions were pyrexia, cough, vomiting, anorexia, and headache.",pyrexia is an adverse reaction entity
"In children, the adverse reactions were pyrexia, cough, vomiting, anorexia, and headache.",cough is an adverse reaction entity
"In children, the adverse reactions were pyrexia, cough, vomiting, anorexia, and headache.",vomiting is an adverse reaction entity
"In children, the adverse reactions were pyrexia, cough, vomiting, anorexia, and headache.",anorexia is an adverse reaction entity
"In children, the adverse reactions were pyrexia, cough, vomiting, anorexia, and headache.",headache is an adverse reaction entity
"Proteinuria (all grades) occurred in 52% of subjects receiving STRIBILD, 41% of subjects receiving ATRIPLA, and 42% of subjects receiving ATV + RTV + TRUVADA.",Proteinuria is an adverse reaction entity
"(  5.8  )             5.1 Lactic Acidosis/Severe Hepatomegaly with Steatosis      Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including tenofovir DF, a component of STRIBILD, in combination with other antiretrovirals.",Lactic acidosis is an adverse reaction entity
"(  5.8  )             5.1 Lactic Acidosis/Severe Hepatomegaly with Steatosis      Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including tenofovir DF, a component of STRIBILD, in combination with other antiretrovirals.",hepatomegaly is an adverse reaction entity
"(  5.8  )             5.1 Lactic Acidosis/Severe Hepatomegaly with Steatosis      Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including tenofovir DF, a component of STRIBILD, in combination with other antiretrovirals.",steatosis is an adverse reaction entity
"(  5.8  )             5.1 Lactic Acidosis/Severe Hepatomegaly with Steatosis      Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including tenofovir DF, a component of STRIBILD, in combination with other antiretrovirals.",fatal is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse drug reactions are discussed in other sections of the labeling:     *  Lactic Acidosis/Severe Hepatomegaly with Steatosis [see  Boxed Warning  ,  Warnings and Precautions (5.1)  ] .",Lactic Acidosis is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse drug reactions are discussed in other sections of the labeling:     *  Lactic Acidosis/Severe Hepatomegaly with Steatosis [see  Boxed Warning  ,  Warnings and Precautions (5.1)  ] .",Hepatomegaly is an adverse reaction entity
"6 ADVERSE REACTIONS    The following adverse drug reactions are discussed in other sections of the labeling:     *  Lactic Acidosis/Severe Hepatomegaly with Steatosis [see  Boxed Warning  ,  Warnings and Precautions (5.1)  ] .",Steatosis is an adverse reaction entity
"*  Severe Acute Exacerbations of Hepatitis B [see  Boxed Warning  ,  Warnings and Precautions (5.2)  ] .",Acute Exacerbations of Hepatitis B is an adverse reaction entity
(  5.5  )   *  Decreases in bone mineral density (BMD): Consider monitoring BMD in patients with a history of pathologic fracture or other risk factors of osteoporosis or bone loss.,Decreases in bone mineral density is an adverse reaction entity
(  5.5  )   *  Decreases in bone mineral density (BMD): Consider monitoring BMD in patients with a history of pathologic fracture or other risk factors of osteoporosis or bone loss.,Decreases in BMD is an adverse reaction entity
The cobicistat component of STRIBILD has been shown to increase serum creatinine and decrease estimated creatinine clearance due to inhibition of tubular secretion of creatinine without affecting renal glomerular function.,increase serum creatinine is an adverse reaction entity
The cobicistat component of STRIBILD has been shown to increase serum creatinine and decrease estimated creatinine clearance due to inhibition of tubular secretion of creatinine without affecting renal glomerular function.,decrease estimated creatinine clearance is an adverse reaction entity
The cobicistat component of STRIBILD has been shown to increase serum creatinine and decrease estimated creatinine clearance due to inhibition of tubular secretion of creatinine without affecting renal glomerular function.,affecting renal glomerular function is an adverse reaction entity
"*  Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including tenofovir disoproxil fumarate (DF), a component of STRIBILD.",Lactic acidosis is an adverse reaction entity
"*  Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including tenofovir disoproxil fumarate (DF), a component of STRIBILD.",hepatomegaly is an adverse reaction entity
"*  Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including tenofovir disoproxil fumarate (DF), a component of STRIBILD.",steatosis is an adverse reaction entity
"*  Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogs, including tenofovir disoproxil fumarate (DF), a component of STRIBILD.",fatal is an adverse reaction entity
Arthralgias and muscle pain or weakness have also been reported in cases of proximal renal tubulopathy.,Arthralgias is an adverse reaction entity
Arthralgias and muscle pain or weakness have also been reported in cases of proximal renal tubulopathy.,muscle pain is an adverse reaction entity
Arthralgias and muscle pain or weakness have also been reported in cases of proximal renal tubulopathy.,muscle weakness is an adverse reaction entity
Arthralgias and muscle pain or weakness have also been reported in cases of proximal renal tubulopathy.,proximal renal tubulopathy is an adverse reaction entity
"6     ADVERSE REACTIONS        L    ong    -    acting beta    2    -adrenergic agonists    , such as A    RCAPTA NEOHALER    ,    increase the risk of asthma-related death    .",asthma is an adverse reaction entity
"6     ADVERSE REACTIONS        L    ong    -    acting beta    2    -adrenergic agonists    , such as A    RCAPTA NEOHALER    ,    increase the risk of asthma-related death    .",death is an adverse reaction entity
EXCERPT:     WARNING    : ASTHMA-RELATED DEATH         See full prescribing information for complete boxed warning       *  Long-acting beta2-adrenergic agonists (LABA) increase the risk of asthma-related death (5.1).,DEATH is an adverse reaction entity
EXCERPT:     WARNING    : ASTHMA-RELATED DEATH         See full prescribing information for complete boxed warning       *  Long-acting beta2-adrenergic agonists (LABA) increase the risk of asthma-related death (5.1).,death is an adverse reaction entity
The cough usually occurred within 15 seconds following inhalation and lasted for no more than 15 seconds.,cough is an adverse reaction entity
"Of these patients, there were 2 respiratory-related deaths in the ARCAPTA NEOHALER 300 mcg dose group.",deaths is an adverse reaction entity
"(5.1)   *  This finding of an increased risk of asthma-related death with salmeterol is considered a class effect of LABA, including indacaterol, the active ingredient in ARCAPTA NEOHALER.",death is an adverse reaction entity
"The increased risk of asthma-related death is considered a class effect of the long-acting beta  2  -adrenergic agonists, including  ARCAPTA NEOHALER  .",death is an adverse reaction entity
Excessive use or use in conjunction with other medications containing LABA can result in clinically significant cardiovascular effects and may be fatal (  5.3  )   *  Immediate hypersensitivity reactions may occur.,cardiovascular effects is an adverse reaction entity
Excessive use or use in conjunction with other medications containing LABA can result in clinically significant cardiovascular effects and may be fatal (  5.3  )   *  Immediate hypersensitivity reactions may occur.,fatal is an adverse reaction entity
Excessive use or use in conjunction with other medications containing LABA can result in clinically significant cardiovascular effects and may be fatal (  5.3  )   *  Immediate hypersensitivity reactions may occur.,hypersensitivity reactions is an adverse reaction entity
(5.2)     *  Dihydropyridine calcium channel blockers can produce negative inotropic effects and exacerbate heart failure.,negative inotropic effects is an adverse reaction entity
(5.2)     *  Dihydropyridine calcium channel blockers can produce negative inotropic effects and exacerbate heart failure.,exacerbate heart failure is an adverse reaction entity
"The following adverse reactions have been identified during post-approval use of Cleviprex: increased blood triglycerides, ileus, hypersensitivity, hypotension, nausea, decreased oxygen saturation (possible pulmonary shunting) and reflex tachycardia.",increased blood triglycerides is an adverse reaction entity
"The following adverse reactions have been identified during post-approval use of Cleviprex: increased blood triglycerides, ileus, hypersensitivity, hypotension, nausea, decreased oxygen saturation (possible pulmonary shunting) and reflex tachycardia.",ileus is an adverse reaction entity
"The following adverse reactions have been identified during post-approval use of Cleviprex: increased blood triglycerides, ileus, hypersensitivity, hypotension, nausea, decreased oxygen saturation (possible pulmonary shunting) and reflex tachycardia.",hypersensitivity is an adverse reaction entity
"The following adverse reactions have been identified during post-approval use of Cleviprex: increased blood triglycerides, ileus, hypersensitivity, hypotension, nausea, decreased oxygen saturation (possible pulmonary shunting) and reflex tachycardia.",hypotension is an adverse reaction entity
"The following adverse reactions have been identified during post-approval use of Cleviprex: increased blood triglycerides, ileus, hypersensitivity, hypotension, nausea, decreased oxygen saturation (possible pulmonary shunting) and reflex tachycardia.",nausea is an adverse reaction entity
"The following adverse reactions have been identified during post-approval use of Cleviprex: increased blood triglycerides, ileus, hypersensitivity, hypotension, nausea, decreased oxygen saturation (possible pulmonary shunting) and reflex tachycardia.",decreased oxygen saturation is an adverse reaction entity
"The following adverse reactions have been identified during post-approval use of Cleviprex: increased blood triglycerides, ileus, hypersensitivity, hypotension, nausea, decreased oxygen saturation (possible pulmonary shunting) and reflex tachycardia.",pulmonary shunting is an adverse reaction entity
"The following adverse reactions have been identified during post-approval use of Cleviprex: increased blood triglycerides, ileus, hypersensitivity, hypotension, nausea, decreased oxygen saturation (possible pulmonary shunting) and reflex tachycardia.",reflex tachycardia is an adverse reaction entity
"(  2.3  ,  5.4  )   *  Renal Toxicity Monitor patients for renal function at baseline and during therapy with BOSULIF (  5.5  )   *  Embryofetal Toxicity: May cause fetal harm.",Renal Toxicity is an adverse reaction entity
"(  2.3  ,  5.4  )   *  Renal Toxicity Monitor patients for renal function at baseline and during therapy with BOSULIF (  5.5  )   *  Embryofetal Toxicity: May cause fetal harm.",Embryofetal Toxicity is an adverse reaction entity
"(  2.3  ,  5.4  )   *  Renal Toxicity Monitor patients for renal function at baseline and during therapy with BOSULIF (  5.5  )   *  Embryofetal Toxicity: May cause fetal harm.",fetal harm is an adverse reaction entity
"Baseline             Follow Up       Renal Function Status        n       Normaln (%)  Mildn (%)   Mild to Moderaten (%)  Moderate to Severen (%)  Severen (%)  Kidney Failuren (%)        Notes: Grading is based on Modification in Diet in Renal Disease method (MDRD).KDIGO Classification by eGFR: Normal: greater than or equal to 90, Mild: 60 to less than 90, Mild to Moderate: 45 to less than 60, Moderate to Severe: 30 to less than 45, Severe: 15 to less than 30, Kidney Failure: less than 15 ml/min/1.73 m  2  .",Kidney Failure is an adverse reaction entity
5.5 Renal Toxicity       An on-treatment decline in estimated glomerular filtration rate (eGFR) has occurred in patients treated with BOSULIF.,decline in estimated glomerular filtration rate is an adverse reaction entity
"Serious adverse reactions reported include anaphylactic shock  [see  Contraindications (4)  ]  , myelosuppression, gastrointestinal toxicity (diarrhea), fluid retention, hepatotoxicity and rash.",anaphylactic shock is an adverse reaction entity
"Serious adverse reactions reported include anaphylactic shock  [see  Contraindications (4)  ]  , myelosuppression, gastrointestinal toxicity (diarrhea), fluid retention, hepatotoxicity and rash.",myelosuppression is an adverse reaction entity
"Serious adverse reactions reported include anaphylactic shock  [see  Contraindications (4)  ]  , myelosuppression, gastrointestinal toxicity (diarrhea), fluid retention, hepatotoxicity and rash.",gastrointestinal toxicity is an adverse reaction entity
"Serious adverse reactions reported include anaphylactic shock  [see  Contraindications (4)  ]  , myelosuppression, gastrointestinal toxicity (diarrhea), fluid retention, hepatotoxicity and rash.",diarrhea is an adverse reaction entity
"Serious adverse reactions reported include anaphylactic shock  [see  Contraindications (4)  ]  , myelosuppression, gastrointestinal toxicity (diarrhea), fluid retention, hepatotoxicity and rash.",fluid retention is an adverse reaction entity
"Serious adverse reactions reported include anaphylactic shock  [see  Contraindications (4)  ]  , myelosuppression, gastrointestinal toxicity (diarrhea), fluid retention, hepatotoxicity and rash.",hepatotoxicity is an adverse reaction entity
"Serious adverse reactions reported include anaphylactic shock  [see  Contraindications (4)  ]  , myelosuppression, gastrointestinal toxicity (diarrhea), fluid retention, hepatotoxicity and rash.",rash is an adverse reaction entity
"The median time to onset of increased ALT and AST was 30 and 33 days, respectively, and the median duration for each was 21 days.",increased ALT is an adverse reaction entity
"The median time to onset of increased ALT and AST was 30 and 33 days, respectively, and the median duration for each was 21 days.",increased AST is an adverse reaction entity
"(  5.1  )   *  Acute hypersensitivity reactions (angioedema, dyspnea, pruritus, and rash) have been reported.",Acute hypersensitivity reactions is an adverse reaction entity
"(  5.1  )   *  Acute hypersensitivity reactions (angioedema, dyspnea, pruritus, and rash) have been reported.",angioedema is an adverse reaction entity
"(  5.1  )   *  Acute hypersensitivity reactions (angioedema, dyspnea, pruritus, and rash) have been reported.",dyspnea is an adverse reaction entity
"(  5.1  )   *  Acute hypersensitivity reactions (angioedema, dyspnea, pruritus, and rash) have been reported.",pruritus is an adverse reaction entity
"(  5.1  )   *  Acute hypersensitivity reactions (angioedema, dyspnea, pruritus, and rash) have been reported.",rash is an adverse reaction entity
"Table 3: Monitored Adverse Reactions - Pruritus, Erythema, Pyoderma and Ocular Irritation with Onset After Treatment   Signs/Symptoms   ULESFIA    (r)    Lotion  Vehicle             Pruritus         12% (14/116)     4% (3/67)           Erythema         10% (32/309)     9% (19/217)         Pyoderma         7% (22/308)      4% (10/230)         Ocular irritation  6% (26/428)      1% (3/313)                        Other less common reactions (less than 1% but more than 0.1%) were, in decreasing order of incidence: application site dryness, application site excoriation, paraesthesia, application site dermatitis, excoriation, thermal burn, dandruff, erythema, rash, and skin exfoliation.",Pruritus is an adverse reaction entity
"Table 3: Monitored Adverse Reactions - Pruritus, Erythema, Pyoderma and Ocular Irritation with Onset After Treatment   Signs/Symptoms   ULESFIA    (r)    Lotion  Vehicle             Pruritus         12% (14/116)     4% (3/67)           Erythema         10% (32/309)     9% (19/217)         Pyoderma         7% (22/308)      4% (10/230)         Ocular irritation  6% (26/428)      1% (3/313)                        Other less common reactions (less than 1% but more than 0.1%) were, in decreasing order of incidence: application site dryness, application site excoriation, paraesthesia, application site dermatitis, excoriation, thermal burn, dandruff, erythema, rash, and skin exfoliation.",Erythema is an adverse reaction entity
"Table 3: Monitored Adverse Reactions - Pruritus, Erythema, Pyoderma and Ocular Irritation with Onset After Treatment   Signs/Symptoms   ULESFIA    (r)    Lotion  Vehicle             Pruritus         12% (14/116)     4% (3/67)           Erythema         10% (32/309)     9% (19/217)         Pyoderma         7% (22/308)      4% (10/230)         Ocular irritation  6% (26/428)      1% (3/313)                        Other less common reactions (less than 1% but more than 0.1%) were, in decreasing order of incidence: application site dryness, application site excoriation, paraesthesia, application site dermatitis, excoriation, thermal burn, dandruff, erythema, rash, and skin exfoliation.",Pyoderma is an adverse reaction entity
"Table 3: Monitored Adverse Reactions - Pruritus, Erythema, Pyoderma and Ocular Irritation with Onset After Treatment   Signs/Symptoms   ULESFIA    (r)    Lotion  Vehicle             Pruritus         12% (14/116)     4% (3/67)           Erythema         10% (32/309)     9% (19/217)         Pyoderma         7% (22/308)      4% (10/230)         Ocular irritation  6% (26/428)      1% (3/313)                        Other less common reactions (less than 1% but more than 0.1%) were, in decreasing order of incidence: application site dryness, application site excoriation, paraesthesia, application site dermatitis, excoriation, thermal burn, dandruff, erythema, rash, and skin exfoliation.",Ocular Irritation is an adverse reaction entity
"Table 3: Monitored Adverse Reactions - Pruritus, Erythema, Pyoderma and Ocular Irritation with Onset After Treatment   Signs/Symptoms   ULESFIA    (r)    Lotion  Vehicle             Pruritus         12% (14/116)     4% (3/67)           Erythema         10% (32/309)     9% (19/217)         Pyoderma         7% (22/308)      4% (10/230)         Ocular irritation  6% (26/428)      1% (3/313)                        Other less common reactions (less than 1% but more than 0.1%) were, in decreasing order of incidence: application site dryness, application site excoriation, paraesthesia, application site dermatitis, excoriation, thermal burn, dandruff, erythema, rash, and skin exfoliation.",Pruritus is an adverse reaction entity
"Table 3: Monitored Adverse Reactions - Pruritus, Erythema, Pyoderma and Ocular Irritation with Onset After Treatment   Signs/Symptoms   ULESFIA    (r)    Lotion  Vehicle             Pruritus         12% (14/116)     4% (3/67)           Erythema         10% (32/309)     9% (19/217)         Pyoderma         7% (22/308)      4% (10/230)         Ocular irritation  6% (26/428)      1% (3/313)                        Other less common reactions (less than 1% but more than 0.1%) were, in decreasing order of incidence: application site dryness, application site excoriation, paraesthesia, application site dermatitis, excoriation, thermal burn, dandruff, erythema, rash, and skin exfoliation.",Erythema is an adverse reaction entity
"Table 3: Monitored Adverse Reactions - Pruritus, Erythema, Pyoderma and Ocular Irritation with Onset After Treatment   Signs/Symptoms   ULESFIA    (r)    Lotion  Vehicle             Pruritus         12% (14/116)     4% (3/67)           Erythema         10% (32/309)     9% (19/217)         Pyoderma         7% (22/308)      4% (10/230)         Ocular irritation  6% (26/428)      1% (3/313)                        Other less common reactions (less than 1% but more than 0.1%) were, in decreasing order of incidence: application site dryness, application site excoriation, paraesthesia, application site dermatitis, excoriation, thermal burn, dandruff, erythema, rash, and skin exfoliation.",Pyoderma is an adverse reaction entity
"Table 3: Monitored Adverse Reactions - Pruritus, Erythema, Pyoderma and Ocular Irritation with Onset After Treatment   Signs/Symptoms   ULESFIA    (r)    Lotion  Vehicle             Pruritus         12% (14/116)     4% (3/67)           Erythema         10% (32/309)     9% (19/217)         Pyoderma         7% (22/308)      4% (10/230)         Ocular irritation  6% (26/428)      1% (3/313)                        Other less common reactions (less than 1% but more than 0.1%) were, in decreasing order of incidence: application site dryness, application site excoriation, paraesthesia, application site dermatitis, excoriation, thermal burn, dandruff, erythema, rash, and skin exfoliation.",Ocular irritation is an adverse reaction entity
"Table 3: Monitored Adverse Reactions - Pruritus, Erythema, Pyoderma and Ocular Irritation with Onset After Treatment   Signs/Symptoms   ULESFIA    (r)    Lotion  Vehicle             Pruritus         12% (14/116)     4% (3/67)           Erythema         10% (32/309)     9% (19/217)         Pyoderma         7% (22/308)      4% (10/230)         Ocular irritation  6% (26/428)      1% (3/313)                        Other less common reactions (less than 1% but more than 0.1%) were, in decreasing order of incidence: application site dryness, application site excoriation, paraesthesia, application site dermatitis, excoriation, thermal burn, dandruff, erythema, rash, and skin exfoliation.",application site dryness is an adverse reaction entity
"Table 3: Monitored Adverse Reactions - Pruritus, Erythema, Pyoderma and Ocular Irritation with Onset After Treatment   Signs/Symptoms   ULESFIA    (r)    Lotion  Vehicle             Pruritus         12% (14/116)     4% (3/67)           Erythema         10% (32/309)     9% (19/217)         Pyoderma         7% (22/308)      4% (10/230)         Ocular irritation  6% (26/428)      1% (3/313)                        Other less common reactions (less than 1% but more than 0.1%) were, in decreasing order of incidence: application site dryness, application site excoriation, paraesthesia, application site dermatitis, excoriation, thermal burn, dandruff, erythema, rash, and skin exfoliation.",application site excoriation is an adverse reaction entity
"Table 3: Monitored Adverse Reactions - Pruritus, Erythema, Pyoderma and Ocular Irritation with Onset After Treatment   Signs/Symptoms   ULESFIA    (r)    Lotion  Vehicle             Pruritus         12% (14/116)     4% (3/67)           Erythema         10% (32/309)     9% (19/217)         Pyoderma         7% (22/308)      4% (10/230)         Ocular irritation  6% (26/428)      1% (3/313)                        Other less common reactions (less than 1% but more than 0.1%) were, in decreasing order of incidence: application site dryness, application site excoriation, paraesthesia, application site dermatitis, excoriation, thermal burn, dandruff, erythema, rash, and skin exfoliation.",paraesthesia is an adverse reaction entity
"Table 3: Monitored Adverse Reactions - Pruritus, Erythema, Pyoderma and Ocular Irritation with Onset After Treatment   Signs/Symptoms   ULESFIA    (r)    Lotion  Vehicle             Pruritus         12% (14/116)     4% (3/67)           Erythema         10% (32/309)     9% (19/217)         Pyoderma         7% (22/308)      4% (10/230)         Ocular irritation  6% (26/428)      1% (3/313)                        Other less common reactions (less than 1% but more than 0.1%) were, in decreasing order of incidence: application site dryness, application site excoriation, paraesthesia, application site dermatitis, excoriation, thermal burn, dandruff, erythema, rash, and skin exfoliation.",application site dermatitis is an adverse reaction entity
"Table 3: Monitored Adverse Reactions - Pruritus, Erythema, Pyoderma and Ocular Irritation with Onset After Treatment   Signs/Symptoms   ULESFIA    (r)    Lotion  Vehicle             Pruritus         12% (14/116)     4% (3/67)           Erythema         10% (32/309)     9% (19/217)         Pyoderma         7% (22/308)      4% (10/230)         Ocular irritation  6% (26/428)      1% (3/313)                        Other less common reactions (less than 1% but more than 0.1%) were, in decreasing order of incidence: application site dryness, application site excoriation, paraesthesia, application site dermatitis, excoriation, thermal burn, dandruff, erythema, rash, and skin exfoliation.",excoriation is an adverse reaction entity
"Table 3: Monitored Adverse Reactions - Pruritus, Erythema, Pyoderma and Ocular Irritation with Onset After Treatment   Signs/Symptoms   ULESFIA    (r)    Lotion  Vehicle             Pruritus         12% (14/116)     4% (3/67)           Erythema         10% (32/309)     9% (19/217)         Pyoderma         7% (22/308)      4% (10/230)         Ocular irritation  6% (26/428)      1% (3/313)                        Other less common reactions (less than 1% but more than 0.1%) were, in decreasing order of incidence: application site dryness, application site excoriation, paraesthesia, application site dermatitis, excoriation, thermal burn, dandruff, erythema, rash, and skin exfoliation.",thermal burn is an adverse reaction entity
"Table 3: Monitored Adverse Reactions - Pruritus, Erythema, Pyoderma and Ocular Irritation with Onset After Treatment   Signs/Symptoms   ULESFIA    (r)    Lotion  Vehicle             Pruritus         12% (14/116)     4% (3/67)           Erythema         10% (32/309)     9% (19/217)         Pyoderma         7% (22/308)      4% (10/230)         Ocular irritation  6% (26/428)      1% (3/313)                        Other less common reactions (less than 1% but more than 0.1%) were, in decreasing order of incidence: application site dryness, application site excoriation, paraesthesia, application site dermatitis, excoriation, thermal burn, dandruff, erythema, rash, and skin exfoliation.",dandruff is an adverse reaction entity
"Table 3: Monitored Adverse Reactions - Pruritus, Erythema, Pyoderma and Ocular Irritation with Onset After Treatment   Signs/Symptoms   ULESFIA    (r)    Lotion  Vehicle             Pruritus         12% (14/116)     4% (3/67)           Erythema         10% (32/309)     9% (19/217)         Pyoderma         7% (22/308)      4% (10/230)         Ocular irritation  6% (26/428)      1% (3/313)                        Other less common reactions (less than 1% but more than 0.1%) were, in decreasing order of incidence: application site dryness, application site excoriation, paraesthesia, application site dermatitis, excoriation, thermal burn, dandruff, erythema, rash, and skin exfoliation.",erythema is an adverse reaction entity
"Table 3: Monitored Adverse Reactions - Pruritus, Erythema, Pyoderma and Ocular Irritation with Onset After Treatment   Signs/Symptoms   ULESFIA    (r)    Lotion  Vehicle             Pruritus         12% (14/116)     4% (3/67)           Erythema         10% (32/309)     9% (19/217)         Pyoderma         7% (22/308)      4% (10/230)         Ocular irritation  6% (26/428)      1% (3/313)                        Other less common reactions (less than 1% but more than 0.1%) were, in decreasing order of incidence: application site dryness, application site excoriation, paraesthesia, application site dermatitis, excoriation, thermal burn, dandruff, erythema, rash, and skin exfoliation.",rash is an adverse reaction entity
"Table 3: Monitored Adverse Reactions - Pruritus, Erythema, Pyoderma and Ocular Irritation with Onset After Treatment   Signs/Symptoms   ULESFIA    (r)    Lotion  Vehicle             Pruritus         12% (14/116)     4% (3/67)           Erythema         10% (32/309)     9% (19/217)         Pyoderma         7% (22/308)      4% (10/230)         Ocular irritation  6% (26/428)      1% (3/313)                        Other less common reactions (less than 1% but more than 0.1%) were, in decreasing order of incidence: application site dryness, application site excoriation, paraesthesia, application site dermatitis, excoriation, thermal burn, dandruff, erythema, rash, and skin exfoliation.",skin exfoliation is an adverse reaction entity
5           WARNINGS AND PRECAUTIONS         EXCERPT:    *  Neonatal toxicity: Risk of gasping syndrome if benzyl alcohol is used in neonates.,Neonatal toxicity is an adverse reaction entity
5           WARNINGS AND PRECAUTIONS         EXCERPT:    *  Neonatal toxicity: Risk of gasping syndrome if benzyl alcohol is used in neonates.,gasping syndrome is an adverse reaction entity
"In Phase 3 clinical trials, Grade 3 and 4 rashes were reported in 1.3% of subjects receiving INTELENCE  (r)  compared to 0.2% of placebo subjects.",rashes is an adverse reaction entity
AST and ALT abnormalities occurred more frequently in hepatitis B and/or hepatitis C virus co-infected subjects for both treatment groups.,AST abnormalities is an adverse reaction entity
AST and ALT abnormalities occurred more frequently in hepatitis B and/or hepatitis C virus co-infected subjects for both treatment groups.,ALT abnormalities is an adverse reaction entity
"Autoimmune disorders (such as Graves' disease, polymyositis, and Guillain-Barre syndrome) have also been reported to occur in the setting of immune reconstitution; however, the time to onset is more variable, and can occur many months after initiation of treatment.",Autoimmune disorders is an adverse reaction entity
"Autoimmune disorders (such as Graves' disease, polymyositis, and Guillain-Barre syndrome) have also been reported to occur in the setting of immune reconstitution; however, the time to onset is more variable, and can occur many months after initiation of treatment.",Graves' disease is an adverse reaction entity
"Autoimmune disorders (such as Graves' disease, polymyositis, and Guillain-Barre syndrome) have also been reported to occur in the setting of immune reconstitution; however, the time to onset is more variable, and can occur many months after initiation of treatment.",polymyositis is an adverse reaction entity
"Autoimmune disorders (such as Graves' disease, polymyositis, and Guillain-Barre syndrome) have also been reported to occur in the setting of immune reconstitution; however, the time to onset is more variable, and can occur many months after initiation of treatment.",Guillain-Barre syndrome is an adverse reaction entity
"Hypersensitivity reactions including Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) have also been reported and were characterized by rash, constitutional findings, and sometimes organ dysfunction, including hepatic failure.",Hypersensitivity reactions is an adverse reaction entity
"Hypersensitivity reactions including Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) have also been reported and were characterized by rash, constitutional findings, and sometimes organ dysfunction, including hepatic failure.",Drug Rash with Eosinophilia and Systemic Symptoms is an adverse reaction entity
"Hypersensitivity reactions including Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) have also been reported and were characterized by rash, constitutional findings, and sometimes organ dysfunction, including hepatic failure.",DRESS is an adverse reaction entity
"Hypersensitivity reactions including Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) have also been reported and were characterized by rash, constitutional findings, and sometimes organ dysfunction, including hepatic failure.",rash is an adverse reaction entity
"Hypersensitivity reactions including Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) have also been reported and were characterized by rash, constitutional findings, and sometimes organ dysfunction, including hepatic failure.",organ dysfunction is an adverse reaction entity
"Hypersensitivity reactions including Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) have also been reported and were characterized by rash, constitutional findings, and sometimes organ dysfunction, including hepatic failure.",hepatic failure is an adverse reaction entity
The most common adverse drug reactions in at least 2% of pediatric subjects were rash and diarrhea.,rash is an adverse reaction entity
The most common adverse drug reactions in at least 2% of pediatric subjects were rash and diarrhea.,diarrhea is an adverse reaction entity
Rash was self-limiting and generally resolved within 1 week on continued therapy.,Rash is an adverse reaction entity
"The most frequent second primary malignancy was non-melanoma skin cancer (range, 4 to 11 %).",second primary malignancy is an adverse reaction entity
"The most frequent second primary malignancy was non-melanoma skin cancer (range, 4 to 11 %).",non-melanoma skin cancer is an adverse reaction entity
"Grade 3 or higher bleeding events (subdural hematoma, gastrointestinal bleeding, hematuria and post procedural hemorrhage) have occurred in up to 6% of patients.",bleeding events is an adverse reaction entity
"Grade 3 or higher bleeding events (subdural hematoma, gastrointestinal bleeding, hematuria and post procedural hemorrhage) have occurred in up to 6% of patients.",subdural hematoma is an adverse reaction entity
"Grade 3 or higher bleeding events (subdural hematoma, gastrointestinal bleeding, hematuria and post procedural hemorrhage) have occurred in up to 6% of patients.",gastrointestinal bleeding is an adverse reaction entity
"Grade 3 or higher bleeding events (subdural hematoma, gastrointestinal bleeding, hematuria and post procedural hemorrhage) have occurred in up to 6% of patients.",hematuria is an adverse reaction entity
"Grade 3 or higher bleeding events (subdural hematoma, gastrointestinal bleeding, hematuria and post procedural hemorrhage) have occurred in up to 6% of patients.",post procedural hemorrhage is an adverse reaction entity
"*  Second Primary Malignancies: Other malignancies have occurred in patients, including skin cancers, and other carcinomas (  5.5  ).",Second Primary Malignancies is an adverse reaction entity
"*  Second Primary Malignancies: Other malignancies have occurred in patients, including skin cancers, and other carcinomas (  5.5  ).",malignancies is an adverse reaction entity
"*  Second Primary Malignancies: Other malignancies have occurred in patients, including skin cancers, and other carcinomas (  5.5  ).",skin cancers is an adverse reaction entity
"*  Second Primary Malignancies: Other malignancies have occurred in patients, including skin cancers, and other carcinomas (  5.5  ).",carcinomas is an adverse reaction entity
5.2 Infections      Fatal and non-fatal infections have occurred with IMBRUVICA therapy.,Fatal is an adverse reaction entity
5.2 Infections      Fatal and non-fatal infections have occurred with IMBRUVICA therapy.,infections is an adverse reaction entity
Cases of progressive multifocal leukoencephalopathy (PML) have occurred in patients treated with IMBRUVICA.,progressive multifocal leukoencephalopathy is an adverse reaction entity
Cases of progressive multifocal leukoencephalopathy (PML) have occurred in patients treated with IMBRUVICA.,PML is an adverse reaction entity
"Ibrutinib caused malformations in rats at exposures 14 times those reported in patients with MCL and 20 times those reported in patients with CLL or WM, receiving the ibrutinib dose of 560 mg per day and 420 mg per day, respectively.",malformations is an adverse reaction entity
"(  2.4  ,  5.1  )   *     Cardiovascular Events : A higher rate of cardiovascular thromboembolic events was observed in patients treated with ULORIC than allopurinol in clinical trials.",Cardiovascular Events is an adverse reaction entity
"(  2.4  ,  5.1  )   *     Cardiovascular Events : A higher rate of cardiovascular thromboembolic events was observed in patients treated with ULORIC than allopurinol in clinical trials.",cardiovascular thromboembolic events is an adverse reaction entity
"Psychiatric Disorders  : agitation, anxiety, depression, insomnia, irritability, libido decreased, nervousness, panic attack, personality change.",agitation is an adverse reaction entity
"Psychiatric Disorders  : agitation, anxiety, depression, insomnia, irritability, libido decreased, nervousness, panic attack, personality change.",anxiety is an adverse reaction entity
"Psychiatric Disorders  : agitation, anxiety, depression, insomnia, irritability, libido decreased, nervousness, panic attack, personality change.",depression is an adverse reaction entity
"Psychiatric Disorders  : agitation, anxiety, depression, insomnia, irritability, libido decreased, nervousness, panic attack, personality change.",insomnia is an adverse reaction entity
"Psychiatric Disorders  : agitation, anxiety, depression, insomnia, irritability, libido decreased, nervousness, panic attack, personality change.",irritability is an adverse reaction entity
"Psychiatric Disorders  : agitation, anxiety, depression, insomnia, irritability, libido decreased, nervousness, panic attack, personality change.",libido decreased is an adverse reaction entity
"Psychiatric Disorders  : agitation, anxiety, depression, insomnia, irritability, libido decreased, nervousness, panic attack, personality change.",nervousness is an adverse reaction entity
"Psychiatric Disorders  : agitation, anxiety, depression, insomnia, irritability, libido decreased, nervousness, panic attack, personality change.",panic attack is an adverse reaction entity
"Psychiatric Disorders  : agitation, anxiety, depression, insomnia, irritability, libido decreased, nervousness, panic attack, personality change.",personality change is an adverse reaction entity
"During randomized controlled studies, transaminase elevations greater than three times the upper limit of normal (ULN) were observed (AST: 2%, 2%, and ALT: 3%, 2% in ULORIC and allopurinol-treated patients, respectively).",transaminase elevations is an adverse reaction entity
"(  5.2  )   *     Hepatic Effects: Postmarketing reports of hepatic failure, sometimes fatal.",Hepatic Effects is an adverse reaction entity
"(  5.2  )   *     Hepatic Effects: Postmarketing reports of hepatic failure, sometimes fatal.",hepatic failure is an adverse reaction entity
"(  5.2  )   *     Hepatic Effects: Postmarketing reports of hepatic failure, sometimes fatal.",fatal is an adverse reaction entity
"Cardiac Disorders  : angina pectoris, atrial fibrillation/flutter, cardiac murmur, ECG abnormal, palpitations, sinus bradycardia, tachycardia.",angina pectoris is an adverse reaction entity
"Cardiac Disorders  : angina pectoris, atrial fibrillation/flutter, cardiac murmur, ECG abnormal, palpitations, sinus bradycardia, tachycardia.",atrial fibrillation is an adverse reaction entity
"Cardiac Disorders  : angina pectoris, atrial fibrillation/flutter, cardiac murmur, ECG abnormal, palpitations, sinus bradycardia, tachycardia.",atrial flutter is an adverse reaction entity
"Cardiac Disorders  : angina pectoris, atrial fibrillation/flutter, cardiac murmur, ECG abnormal, palpitations, sinus bradycardia, tachycardia.",cardiac murmur is an adverse reaction entity
"Cardiac Disorders  : angina pectoris, atrial fibrillation/flutter, cardiac murmur, ECG abnormal, palpitations, sinus bradycardia, tachycardia.",ECG abnormal is an adverse reaction entity
"Cardiac Disorders  : angina pectoris, atrial fibrillation/flutter, cardiac murmur, ECG abnormal, palpitations, sinus bradycardia, tachycardia.",palpitations is an adverse reaction entity
"Cardiac Disorders  : angina pectoris, atrial fibrillation/flutter, cardiac murmur, ECG abnormal, palpitations, sinus bradycardia, tachycardia.",sinus bradycardia is an adverse reaction entity
"Cardiac Disorders  : angina pectoris, atrial fibrillation/flutter, cardiac murmur, ECG abnormal, palpitations, sinus bradycardia, tachycardia.",tachycardia is an adverse reaction entity
"Respiratory, Thoracic and Mediastinal Disorders  : bronchitis, cough, dyspnea, epistaxis, nasal dryness, paranasal sinus hypersecretion, pharyngeal edema, respiratory tract congestion, sneezing, throat irritation, upper respiratory tract infection.",bronchitis is an adverse reaction entity
"Respiratory, Thoracic and Mediastinal Disorders  : bronchitis, cough, dyspnea, epistaxis, nasal dryness, paranasal sinus hypersecretion, pharyngeal edema, respiratory tract congestion, sneezing, throat irritation, upper respiratory tract infection.",cough is an adverse reaction entity
"Respiratory, Thoracic and Mediastinal Disorders  : bronchitis, cough, dyspnea, epistaxis, nasal dryness, paranasal sinus hypersecretion, pharyngeal edema, respiratory tract congestion, sneezing, throat irritation, upper respiratory tract infection.",dyspnea is an adverse reaction entity
"Respiratory, Thoracic and Mediastinal Disorders  : bronchitis, cough, dyspnea, epistaxis, nasal dryness, paranasal sinus hypersecretion, pharyngeal edema, respiratory tract congestion, sneezing, throat irritation, upper respiratory tract infection.",epistaxis is an adverse reaction entity
"Respiratory, Thoracic and Mediastinal Disorders  : bronchitis, cough, dyspnea, epistaxis, nasal dryness, paranasal sinus hypersecretion, pharyngeal edema, respiratory tract congestion, sneezing, throat irritation, upper respiratory tract infection.",nasal dryness is an adverse reaction entity
"Respiratory, Thoracic and Mediastinal Disorders  : bronchitis, cough, dyspnea, epistaxis, nasal dryness, paranasal sinus hypersecretion, pharyngeal edema, respiratory tract congestion, sneezing, throat irritation, upper respiratory tract infection.",paranasal sinus hypersecretion is an adverse reaction entity
"Respiratory, Thoracic and Mediastinal Disorders  : bronchitis, cough, dyspnea, epistaxis, nasal dryness, paranasal sinus hypersecretion, pharyngeal edema, respiratory tract congestion, sneezing, throat irritation, upper respiratory tract infection.",pharyngeal edema is an adverse reaction entity
"Respiratory, Thoracic and Mediastinal Disorders  : bronchitis, cough, dyspnea, epistaxis, nasal dryness, paranasal sinus hypersecretion, pharyngeal edema, respiratory tract congestion, sneezing, throat irritation, upper respiratory tract infection.",respiratory tract congestion is an adverse reaction entity
"Respiratory, Thoracic and Mediastinal Disorders  : bronchitis, cough, dyspnea, epistaxis, nasal dryness, paranasal sinus hypersecretion, pharyngeal edema, respiratory tract congestion, sneezing, throat irritation, upper respiratory tract infection.",sneezing is an adverse reaction entity
"Respiratory, Thoracic and Mediastinal Disorders  : bronchitis, cough, dyspnea, epistaxis, nasal dryness, paranasal sinus hypersecretion, pharyngeal edema, respiratory tract congestion, sneezing, throat irritation, upper respiratory tract infection.",throat irritation is an adverse reaction entity
"Respiratory, Thoracic and Mediastinal Disorders  : bronchitis, cough, dyspnea, epistaxis, nasal dryness, paranasal sinus hypersecretion, pharyngeal edema, respiratory tract congestion, sneezing, throat irritation, upper respiratory tract infection.",upper respiratory tract infection is an adverse reaction entity
"In the XIAFLEX controlled trials in Peyronie's disease (Studies 1 and 2), 65.5% of XIAFLEX-treated patients developed penile hematoma, and 14.5% developed penile ecchymosis (see Table 4).",penile hematoma is an adverse reaction entity
"In the XIAFLEX controlled trials in Peyronie's disease (Studies 1 and 2), 65.5% of XIAFLEX-treated patients developed penile hematoma, and 14.5% developed penile ecchymosis (see Table 4).",penile ecchymosis is an adverse reaction entity
Adverse Reactions Occurring in >= 5% of XIAFLEX-Treated Patients with Dupuytren's Contracture and at a Greater Incidence than Placebo in the Placebo-Controlled Trials Through Day 90 After Up to 3 Injections      a  Most of these events were swelling of the injected hand.,swelling of the injected hand is an adverse reaction entity
BOXED WARNING: WARNING:     CORPORAL RUPTURE (PENILE FRACTURE) OR  OTHER SERIOUS PENILE INJURY IN THE TREATMENT OF PEYRONIE'S DISEASE    WARNING:     CORPORAL RUPTURE (PENILE FRACTURE) OR  OTHER SERIOUS PENILE INJURY IN THE TREATMENT OF PEYRONIE'S DISEASE    Corporal rupture (penile fracture) was reported as an adverse reaction in 5 of 1044 (0.5%) XIAFLEX-treated patients in clinical studies.,CORPORAL RUPTURE is an adverse reaction entity
BOXED WARNING: WARNING:     CORPORAL RUPTURE (PENILE FRACTURE) OR  OTHER SERIOUS PENILE INJURY IN THE TREATMENT OF PEYRONIE'S DISEASE    WARNING:     CORPORAL RUPTURE (PENILE FRACTURE) OR  OTHER SERIOUS PENILE INJURY IN THE TREATMENT OF PEYRONIE'S DISEASE    Corporal rupture (penile fracture) was reported as an adverse reaction in 5 of 1044 (0.5%) XIAFLEX-treated patients in clinical studies.,PENILE FRACTURE is an adverse reaction entity
BOXED WARNING: WARNING:     CORPORAL RUPTURE (PENILE FRACTURE) OR  OTHER SERIOUS PENILE INJURY IN THE TREATMENT OF PEYRONIE'S DISEASE    WARNING:     CORPORAL RUPTURE (PENILE FRACTURE) OR  OTHER SERIOUS PENILE INJURY IN THE TREATMENT OF PEYRONIE'S DISEASE    Corporal rupture (penile fracture) was reported as an adverse reaction in 5 of 1044 (0.5%) XIAFLEX-treated patients in clinical studies.,PENILE INJURY is an adverse reaction entity
BOXED WARNING: WARNING:     CORPORAL RUPTURE (PENILE FRACTURE) OR  OTHER SERIOUS PENILE INJURY IN THE TREATMENT OF PEYRONIE'S DISEASE    WARNING:     CORPORAL RUPTURE (PENILE FRACTURE) OR  OTHER SERIOUS PENILE INJURY IN THE TREATMENT OF PEYRONIE'S DISEASE    Corporal rupture (penile fracture) was reported as an adverse reaction in 5 of 1044 (0.5%) XIAFLEX-treated patients in clinical studies.,CORPORAL RUPTURE is an adverse reaction entity
BOXED WARNING: WARNING:     CORPORAL RUPTURE (PENILE FRACTURE) OR  OTHER SERIOUS PENILE INJURY IN THE TREATMENT OF PEYRONIE'S DISEASE    WARNING:     CORPORAL RUPTURE (PENILE FRACTURE) OR  OTHER SERIOUS PENILE INJURY IN THE TREATMENT OF PEYRONIE'S DISEASE    Corporal rupture (penile fracture) was reported as an adverse reaction in 5 of 1044 (0.5%) XIAFLEX-treated patients in clinical studies.,PENILE FRACTURE is an adverse reaction entity
BOXED WARNING: WARNING:     CORPORAL RUPTURE (PENILE FRACTURE) OR  OTHER SERIOUS PENILE INJURY IN THE TREATMENT OF PEYRONIE'S DISEASE    WARNING:     CORPORAL RUPTURE (PENILE FRACTURE) OR  OTHER SERIOUS PENILE INJURY IN THE TREATMENT OF PEYRONIE'S DISEASE    Corporal rupture (penile fracture) was reported as an adverse reaction in 5 of 1044 (0.5%) XIAFLEX-treated patients in clinical studies.,PENILE INJURY is an adverse reaction entity
BOXED WARNING: WARNING:     CORPORAL RUPTURE (PENILE FRACTURE) OR  OTHER SERIOUS PENILE INJURY IN THE TREATMENT OF PEYRONIE'S DISEASE    WARNING:     CORPORAL RUPTURE (PENILE FRACTURE) OR  OTHER SERIOUS PENILE INJURY IN THE TREATMENT OF PEYRONIE'S DISEASE    Corporal rupture (penile fracture) was reported as an adverse reaction in 5 of 1044 (0.5%) XIAFLEX-treated patients in clinical studies.,Corporal rupture is an adverse reaction entity
BOXED WARNING: WARNING:     CORPORAL RUPTURE (PENILE FRACTURE) OR  OTHER SERIOUS PENILE INJURY IN THE TREATMENT OF PEYRONIE'S DISEASE    WARNING:     CORPORAL RUPTURE (PENILE FRACTURE) OR  OTHER SERIOUS PENILE INJURY IN THE TREATMENT OF PEYRONIE'S DISEASE    Corporal rupture (penile fracture) was reported as an adverse reaction in 5 of 1044 (0.5%) XIAFLEX-treated patients in clinical studies.,penile fracture is an adverse reaction entity
"(  5.1  )   *  Corporal rupture (penile fracture) or other serious injury to the penis: Avoid injecting into the urethra, nerves, blood vessels, corpora cavernosa or other collagen-containing structures of the penis.",Corporal rupture is an adverse reaction entity
"(  5.1  )   *  Corporal rupture (penile fracture) or other serious injury to the penis: Avoid injecting into the urethra, nerves, blood vessels, corpora cavernosa or other collagen-containing structures of the penis.",penile fracture is an adverse reaction entity
"(  5.1  )   *  Corporal rupture (penile fracture) or other serious injury to the penis: Avoid injecting into the urethra, nerves, blood vessels, corpora cavernosa or other collagen-containing structures of the penis.",injury to the penis is an adverse reaction entity
Injection of XIAFLEX into collagen-containing structures such as tendons or ligaments of the hand may result in damage to those structures and possible permanent injury such as tendon rupture or ligament damage.,collagen-containing structures damage is an adverse reaction entity
Injection of XIAFLEX into collagen-containing structures such as tendons or ligaments of the hand may result in damage to those structures and possible permanent injury such as tendon rupture or ligament damage.,tendons of the hand damage is an adverse reaction entity
Injection of XIAFLEX into collagen-containing structures such as tendons or ligaments of the hand may result in damage to those structures and possible permanent injury such as tendon rupture or ligament damage.,ligaments of the hand damage is an adverse reaction entity
Injection of XIAFLEX into collagen-containing structures such as tendons or ligaments of the hand may result in damage to those structures and possible permanent injury such as tendon rupture or ligament damage.,permanent injury is an adverse reaction entity
Injection of XIAFLEX into collagen-containing structures such as tendons or ligaments of the hand may result in damage to those structures and possible permanent injury such as tendon rupture or ligament damage.,tendon rupture is an adverse reaction entity
Injection of XIAFLEX into collagen-containing structures such as tendons or ligaments of the hand may result in damage to those structures and possible permanent injury such as tendon rupture or ligament damage.,ligament damage is an adverse reaction entity
Anaphylaxis was reported in a post-marketing clinical trial (Study 3) in one patient who had previous exposure to XIAFLEX for the treatment of Dupuytren's contracture.,Anaphylaxis is an adverse reaction entity
"The most frequently reported adverse drug reactions (>= 25%) in the XIAFLEX clinical trials in patients with Peyronie's disease were penile hematoma, penile swelling, and penile pain.",penile hematoma is an adverse reaction entity
"The most frequently reported adverse drug reactions (>= 25%) in the XIAFLEX clinical trials in patients with Peyronie's disease were penile hematoma, penile swelling, and penile pain.",penile swelling is an adverse reaction entity
"The most frequently reported adverse drug reactions (>= 25%) in the XIAFLEX clinical trials in patients with Peyronie's disease were penile hematoma, penile swelling, and penile pain.",penile pain is an adverse reaction entity
"d  Includes: contusion, ecchymoses, penile hemorrhage, and injection site hemorrhage.",contusion is an adverse reaction entity
"d  Includes: contusion, ecchymoses, penile hemorrhage, and injection site hemorrhage.",ecchymoses is an adverse reaction entity
"d  Includes: contusion, ecchymoses, penile hemorrhage, and injection site hemorrhage.",penile hemorrhage is an adverse reaction entity
"d  Includes: contusion, ecchymoses, penile hemorrhage, and injection site hemorrhage.",injection site hemorrhage is an adverse reaction entity
"Because XIAFLEX contains foreign proteins, severe allergic reactions to XIAFLEX can occur.",allergic reactions is an adverse reaction entity
"In other XIAFLEX-treated patients (9 of 1044; 0.9%), a combination of penile ecchymoses or hematoma, sudden penile detumescence, and/or a penile ""popping"" sound or sensation was reported, and in these cases, a diagnosis of corporal rupture can not be excluded.",penile ecchymoses is an adverse reaction entity
"In other XIAFLEX-treated patients (9 of 1044; 0.9%), a combination of penile ecchymoses or hematoma, sudden penile detumescence, and/or a penile ""popping"" sound or sensation was reported, and in these cases, a diagnosis of corporal rupture can not be excluded.",penile hematoma is an adverse reaction entity
"In other XIAFLEX-treated patients (9 of 1044; 0.9%), a combination of penile ecchymoses or hematoma, sudden penile detumescence, and/or a penile ""popping"" sound or sensation was reported, and in these cases, a diagnosis of corporal rupture can not be excluded.",penile detumescence is an adverse reaction entity
"In other XIAFLEX-treated patients (9 of 1044; 0.9%), a combination of penile ecchymoses or hematoma, sudden penile detumescence, and/or a penile ""popping"" sound or sensation was reported, and in these cases, a diagnosis of corporal rupture can not be excluded.","penile ""popping"" sound is an adverse reaction entity"
"In other XIAFLEX-treated patients (9 of 1044; 0.9%), a combination of penile ecchymoses or hematoma, sudden penile detumescence, and/or a penile ""popping"" sound or sensation was reported, and in these cases, a diagnosis of corporal rupture can not be excluded.","penile ""popping"" sensation is an adverse reaction entity"
"In other XIAFLEX-treated patients (9 of 1044; 0.9%), a combination of penile ecchymoses or hematoma, sudden penile detumescence, and/or a penile ""popping"" sound or sensation was reported, and in these cases, a diagnosis of corporal rupture can not be excluded.",corporal rupture is an adverse reaction entity
Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations.,oligohydramnios is an adverse reaction entity
Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations.,fetal lung hypoplasia is an adverse reaction entity
Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations.,fetal skeletal deformations is an adverse reaction entity
"Other adverse reactions with a plausible relationship to treatment that have been reported with an incidence of >=0.3% and greater than placebo in more than 3300 patients treated with Edarbi in controlled trials are listed below:       Gastrointestinal Disorders:  nausea       General Disorders and Administration Site Conditions:  asthenia, fatigue       Musculoskeletal and Connective Tissue Disorders:  muscle spasm       Nervous System Disorders:  dizziness, dizziness postural       Respiratory, Thoracic, and Mediastinal Disorders:  cough       6.2 Clinical Laboratory Findings    In controlled clinical trials, clinically relevant changes in standard laboratory parameters were uncommon with administration of Edarbi.",nausea is an adverse reaction entity
"Other adverse reactions with a plausible relationship to treatment that have been reported with an incidence of >=0.3% and greater than placebo in more than 3300 patients treated with Edarbi in controlled trials are listed below:       Gastrointestinal Disorders:  nausea       General Disorders and Administration Site Conditions:  asthenia, fatigue       Musculoskeletal and Connective Tissue Disorders:  muscle spasm       Nervous System Disorders:  dizziness, dizziness postural       Respiratory, Thoracic, and Mediastinal Disorders:  cough       6.2 Clinical Laboratory Findings    In controlled clinical trials, clinically relevant changes in standard laboratory parameters were uncommon with administration of Edarbi.",asthenia is an adverse reaction entity
"Other adverse reactions with a plausible relationship to treatment that have been reported with an incidence of >=0.3% and greater than placebo in more than 3300 patients treated with Edarbi in controlled trials are listed below:       Gastrointestinal Disorders:  nausea       General Disorders and Administration Site Conditions:  asthenia, fatigue       Musculoskeletal and Connective Tissue Disorders:  muscle spasm       Nervous System Disorders:  dizziness, dizziness postural       Respiratory, Thoracic, and Mediastinal Disorders:  cough       6.2 Clinical Laboratory Findings    In controlled clinical trials, clinically relevant changes in standard laboratory parameters were uncommon with administration of Edarbi.",fatigue is an adverse reaction entity
"Other adverse reactions with a plausible relationship to treatment that have been reported with an incidence of >=0.3% and greater than placebo in more than 3300 patients treated with Edarbi in controlled trials are listed below:       Gastrointestinal Disorders:  nausea       General Disorders and Administration Site Conditions:  asthenia, fatigue       Musculoskeletal and Connective Tissue Disorders:  muscle spasm       Nervous System Disorders:  dizziness, dizziness postural       Respiratory, Thoracic, and Mediastinal Disorders:  cough       6.2 Clinical Laboratory Findings    In controlled clinical trials, clinically relevant changes in standard laboratory parameters were uncommon with administration of Edarbi.",muscle spasm is an adverse reaction entity
"Other adverse reactions with a plausible relationship to treatment that have been reported with an incidence of >=0.3% and greater than placebo in more than 3300 patients treated with Edarbi in controlled trials are listed below:       Gastrointestinal Disorders:  nausea       General Disorders and Administration Site Conditions:  asthenia, fatigue       Musculoskeletal and Connective Tissue Disorders:  muscle spasm       Nervous System Disorders:  dizziness, dizziness postural       Respiratory, Thoracic, and Mediastinal Disorders:  cough       6.2 Clinical Laboratory Findings    In controlled clinical trials, clinically relevant changes in standard laboratory parameters were uncommon with administration of Edarbi.",dizziness is an adverse reaction entity
"Other adverse reactions with a plausible relationship to treatment that have been reported with an incidence of >=0.3% and greater than placebo in more than 3300 patients treated with Edarbi in controlled trials are listed below:       Gastrointestinal Disorders:  nausea       General Disorders and Administration Site Conditions:  asthenia, fatigue       Musculoskeletal and Connective Tissue Disorders:  muscle spasm       Nervous System Disorders:  dizziness, dizziness postural       Respiratory, Thoracic, and Mediastinal Disorders:  cough       6.2 Clinical Laboratory Findings    In controlled clinical trials, clinically relevant changes in standard laboratory parameters were uncommon with administration of Edarbi.",dizziness postural is an adverse reaction entity
"Other adverse reactions with a plausible relationship to treatment that have been reported with an incidence of >=0.3% and greater than placebo in more than 3300 patients treated with Edarbi in controlled trials are listed below:       Gastrointestinal Disorders:  nausea       General Disorders and Administration Site Conditions:  asthenia, fatigue       Musculoskeletal and Connective Tissue Disorders:  muscle spasm       Nervous System Disorders:  dizziness, dizziness postural       Respiratory, Thoracic, and Mediastinal Disorders:  cough       6.2 Clinical Laboratory Findings    In controlled clinical trials, clinically relevant changes in standard laboratory parameters were uncommon with administration of Edarbi.",cough is an adverse reaction entity
"In studies of ACE inhibitors in patients with unilateral or bilateral renal artery stenosis, increases in serum creatinine or blood urea nitrogen have been reported.",increases in serum creatinine is an adverse reaction entity
"In studies of ACE inhibitors in patients with unilateral or bilateral renal artery stenosis, increases in serum creatinine or blood urea nitrogen have been reported.",increases in blood urea nitrogen is an adverse reaction entity
Low and high markedly abnormal platelet and WBC counts were observed in <0.1% of subjects.,Low platelet counts is an adverse reaction entity
Low and high markedly abnormal platelet and WBC counts were observed in <0.1% of subjects.,Low WBC counts is an adverse reaction entity
Low and high markedly abnormal platelet and WBC counts were observed in <0.1% of subjects.,high WBC counts is an adverse reaction entity
Low and high markedly abnormal platelet and WBC counts were observed in <0.1% of subjects.,high platelet counts is an adverse reaction entity
Low and high markedly abnormal platelet and WBC counts were observed in <0.1% of subjects.,abnormal platelet counts is an adverse reaction entity
Low and high markedly abnormal platelet and WBC counts were observed in <0.1% of subjects.,abnormal WBC counts is an adverse reaction entity
"5.3 Thrombotic/Thromboembolic Complications      In two controlled clinical trials in patients with chronic hepatitis C and thrombocytopenia, 3% (31/955) treated with PROMACTA experienced a thrombotic event compared with 1% (5/484) on placebo.",thrombotic event is an adverse reaction entity
"PROMACTA inhibits UDP-glucuronosyltransferase (UGT)1A1 and organic anion-transporting polypeptide (OATP)1B1, which may lead to indirect hyperbilirubinemia.",indirect hyperbilirubinemia is an adverse reaction entity
"In a controlled trial in patients with chronic liver disease and thrombocytopenia not related to ITP undergoing elective invasive procedures (N = 292), the risk of thrombotic events was increased in patients treated with 75 mg of PROMACTA once daily.",thrombotic events is an adverse reaction entity
"BOXED WARNING: WARNING: RISK FOR HEPATIC DECOMPENSATION IN PATIENTS WITH CHRONIC HEPATITIS C    WARNING: RISK FOR HEPATIC DECOMPENSATION IN PATIENTS WITH CHRONIC HEPATITIS C      In patients with chronic hepatitis C, PROMACTA  (r)   in combination with interferon and ribavirin may increase the risk of hepatic decompensation   [see Warnings and Precautions (5.1)]  .",HEPATIC DECOMPENSATION is an adverse reaction entity
"BOXED WARNING: WARNING: RISK FOR HEPATIC DECOMPENSATION IN PATIENTS WITH CHRONIC HEPATITIS C    WARNING: RISK FOR HEPATIC DECOMPENSATION IN PATIENTS WITH CHRONIC HEPATITIS C      In patients with chronic hepatitis C, PROMACTA  (r)   in combination with interferon and ribavirin may increase the risk of hepatic decompensation   [see Warnings and Precautions (5.1)]  .",HEPATIC DECOMPENSATION is an adverse reaction entity
"BOXED WARNING: WARNING: RISK FOR HEPATIC DECOMPENSATION IN PATIENTS WITH CHRONIC HEPATITIS C    WARNING: RISK FOR HEPATIC DECOMPENSATION IN PATIENTS WITH CHRONIC HEPATITIS C      In patients with chronic hepatitis C, PROMACTA  (r)   in combination with interferon and ribavirin may increase the risk of hepatic decompensation   [see Warnings and Precautions (5.1)]  .",hepatic decompensation is an adverse reaction entity
Five of the six patients in the group that received PROMACTA experienced a thrombotic complication within 30 days of completing treatment with PROMACTA and at a platelet count above 200 x 10  9  /L.,thrombotic complication is an adverse reaction entity
Reported thrombotic/thromboembolic complications included both venous and arterial events and were observed at low and at normal platelet counts.,thrombotic complications is an adverse reaction entity
Reported thrombotic/thromboembolic complications included both venous and arterial events and were observed at low and at normal platelet counts.,thrombotic venous events is an adverse reaction entity
Reported thrombotic/thromboembolic complications included both venous and arterial events and were observed at low and at normal platelet counts.,thrombotic arterial events is an adverse reaction entity
Reported thrombotic/thromboembolic complications included both venous and arterial events and were observed at low and at normal platelet counts.,thromboembolic complications is an adverse reaction entity
Reported thrombotic/thromboembolic complications included both venous and arterial events and were observed at low and at normal platelet counts.,thromboembolic venous events is an adverse reaction entity
Reported thrombotic/thromboembolic complications included both venous and arterial events and were observed at low and at normal platelet counts.,thromboembolic arterial events is an adverse reaction entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *    Hepatotoxicity: Monitor liver function before and during therapy.,Hepatotoxicity is an adverse reaction entity
Seven thrombotic complications (six patients) were reported in the group that received PROMACTA and three thrombotic complications were reported in the placebo group (two patients).,thrombotic complications is an adverse reaction entity
Seven thrombotic complications (six patients) were reported in the group that received PROMACTA and three thrombotic complications were reported in the placebo group (two patients).,thrombotic complications is an adverse reaction entity
"6 ADVERSE REACTIONS    EXCERPT:   The most commonly reported adverse reactions were injection site reactions, which occurred in almost all patients (97%) in clinical trials.",injection site reactions is an adverse reaction entity
"Other adverse reactions involving the female reproductive system were menorrhagia (10%), menstrual irregularities (10%), and vaginal hemorrhage (8%).",menorrhagia is an adverse reaction entity
"Other adverse reactions involving the female reproductive system were menorrhagia (10%), menstrual irregularities (10%), and vaginal hemorrhage (8%).",menstrual irregularities is an adverse reaction entity
"Other adverse reactions involving the female reproductive system were menorrhagia (10%), menstrual irregularities (10%), and vaginal hemorrhage (8%).",vaginal hemorrhage is an adverse reaction entity
"Blood Glucose and Lipids       Hyperglycemia, hyperlipidemia, and hypertriglyceridemia have been reported in patients taking AFINITOR [see Adverse Reactions (6.1, 6.2, 6.3, 6.4, 6.5)]  .",Hyperglycemia is an adverse reaction entity
"Blood Glucose and Lipids       Hyperglycemia, hyperlipidemia, and hypertriglyceridemia have been reported in patients taking AFINITOR [see Adverse Reactions (6.1, 6.2, 6.3, 6.4, 6.5)]  .",hyperlipidemia is an adverse reaction entity
"Blood Glucose and Lipids       Hyperglycemia, hyperlipidemia, and hypertriglyceridemia have been reported in patients taking AFINITOR [see Adverse Reactions (6.1, 6.2, 6.3, 6.4, 6.5)]  .",hypertriglyceridemia is an adverse reaction entity
(  5.5  )   *  Impaired wound healing: Increased risk of wound-related complications.,Impaired wound healing is an adverse reaction entity
(  5.5  )   *  Impaired wound healing: Increased risk of wound-related complications.,wound-related complications is an adverse reaction entity
The most common adverse reaction leading to AFINITOR dose adjustment was stomatitis.,stomatitis is an adverse reaction entity
"Table 3: Key Laboratory Abnormalities Reported in >= 10% of Patients with Advanced HR+ BC   Grading according to CTCAE Version 3.0  a  Exemestane (25 mg/day)  b  Reflects corresponding adverse drug reaction reports of anemia, leukopenia, lymphopenia, neutropenia, and thrombocytopenia (collectively as pancytopenia), which occurred at lower frequency.",anemia is an adverse reaction entity
"Table 3: Key Laboratory Abnormalities Reported in >= 10% of Patients with Advanced HR+ BC   Grading according to CTCAE Version 3.0  a  Exemestane (25 mg/day)  b  Reflects corresponding adverse drug reaction reports of anemia, leukopenia, lymphopenia, neutropenia, and thrombocytopenia (collectively as pancytopenia), which occurred at lower frequency.",leukopenia is an adverse reaction entity
"Table 3: Key Laboratory Abnormalities Reported in >= 10% of Patients with Advanced HR+ BC   Grading according to CTCAE Version 3.0  a  Exemestane (25 mg/day)  b  Reflects corresponding adverse drug reaction reports of anemia, leukopenia, lymphopenia, neutropenia, and thrombocytopenia (collectively as pancytopenia), which occurred at lower frequency.",lymphopenia is an adverse reaction entity
"Table 3: Key Laboratory Abnormalities Reported in >= 10% of Patients with Advanced HR+ BC   Grading according to CTCAE Version 3.0  a  Exemestane (25 mg/day)  b  Reflects corresponding adverse drug reaction reports of anemia, leukopenia, lymphopenia, neutropenia, and thrombocytopenia (collectively as pancytopenia), which occurred at lower frequency.",neutropenia is an adverse reaction entity
"Table 3: Key Laboratory Abnormalities Reported in >= 10% of Patients with Advanced HR+ BC   Grading according to CTCAE Version 3.0  a  Exemestane (25 mg/day)  b  Reflects corresponding adverse drug reaction reports of anemia, leukopenia, lymphopenia, neutropenia, and thrombocytopenia (collectively as pancytopenia), which occurred at lower frequency.",thrombocytopenia is an adverse reaction entity
"Table 3: Key Laboratory Abnormalities Reported in >= 10% of Patients with Advanced HR+ BC   Grading according to CTCAE Version 3.0  a  Exemestane (25 mg/day)  b  Reflects corresponding adverse drug reaction reports of anemia, leukopenia, lymphopenia, neutropenia, and thrombocytopenia (collectively as pancytopenia), which occurred at lower frequency.",pancytopenia is an adverse reaction entity
"(  5.6  )   *  Laboratory test alterations: Elevations of serum creatinine, urinary protein, blood glucose, and lipids may occur.",Elevations of serum creatinine is an adverse reaction entity
"(  5.6  )   *  Laboratory test alterations: Elevations of serum creatinine, urinary protein, blood glucose, and lipids may occur.",Elevations urinary protein is an adverse reaction entity
"(  5.6  )   *  Laboratory test alterations: Elevations of serum creatinine, urinary protein, blood glucose, and lipids may occur.",Elevations blood glucose is an adverse reaction entity
"(  5.6  )   *  Laboratory test alterations: Elevations of serum creatinine, urinary protein, blood glucose, and lipids may occur.",Elevations lipids is an adverse reaction entity
"The most common adverse reactions (incidence >= 30%) were stomatitis, rash, diarrhea, fatigue, edema, abdominal pain, nausea, fever, and headache.",stomatitis is an adverse reaction entity
"The most common adverse reactions (incidence >= 30%) were stomatitis, rash, diarrhea, fatigue, edema, abdominal pain, nausea, fever, and headache.",rash is an adverse reaction entity
"The most common adverse reactions (incidence >= 30%) were stomatitis, rash, diarrhea, fatigue, edema, abdominal pain, nausea, fever, and headache.",diarrhea is an adverse reaction entity
"The most common adverse reactions (incidence >= 30%) were stomatitis, rash, diarrhea, fatigue, edema, abdominal pain, nausea, fever, and headache.",fatigue is an adverse reaction entity
"The most common adverse reactions (incidence >= 30%) were stomatitis, rash, diarrhea, fatigue, edema, abdominal pain, nausea, fever, and headache.",edema is an adverse reaction entity
"The most common adverse reactions (incidence >= 30%) were stomatitis, rash, diarrhea, fatigue, edema, abdominal pain, nausea, fever, and headache.",abdominal pain is an adverse reaction entity
"The most common adverse reactions (incidence >= 30%) were stomatitis, rash, diarrhea, fatigue, edema, abdominal pain, nausea, fever, and headache.",nausea is an adverse reaction entity
"The most common adverse reactions (incidence >= 30%) were stomatitis, rash, diarrhea, fatigue, edema, abdominal pain, nausea, fever, and headache.",fever is an adverse reaction entity
"The most common adverse reactions (incidence >= 30%) were stomatitis, rash, diarrhea, fatigue, edema, abdominal pain, nausea, fever, and headache.",headache is an adverse reaction entity
"Table 4:  Adverse Reactions Reported >= 10% of Patients with Advanced PNET    Grading according to CTCAE Version 3.0  a   Includes stomatitis, aphthous stomatitis, gingival pain/swelling/ulceration, glossitis, glossodynia, lip ulceration, mouth ulceration, tongue ulceration, and mucosal inflammation.",stomatitis is an adverse reaction entity
"Table 4:  Adverse Reactions Reported >= 10% of Patients with Advanced PNET    Grading according to CTCAE Version 3.0  a   Includes stomatitis, aphthous stomatitis, gingival pain/swelling/ulceration, glossitis, glossodynia, lip ulceration, mouth ulceration, tongue ulceration, and mucosal inflammation.",aphthous stomatitis is an adverse reaction entity
"Table 4:  Adverse Reactions Reported >= 10% of Patients with Advanced PNET    Grading according to CTCAE Version 3.0  a   Includes stomatitis, aphthous stomatitis, gingival pain/swelling/ulceration, glossitis, glossodynia, lip ulceration, mouth ulceration, tongue ulceration, and mucosal inflammation.",gingival pain is an adverse reaction entity
"Table 4:  Adverse Reactions Reported >= 10% of Patients with Advanced PNET    Grading according to CTCAE Version 3.0  a   Includes stomatitis, aphthous stomatitis, gingival pain/swelling/ulceration, glossitis, glossodynia, lip ulceration, mouth ulceration, tongue ulceration, and mucosal inflammation.",gingival swelling is an adverse reaction entity
"Table 4:  Adverse Reactions Reported >= 10% of Patients with Advanced PNET    Grading according to CTCAE Version 3.0  a   Includes stomatitis, aphthous stomatitis, gingival pain/swelling/ulceration, glossitis, glossodynia, lip ulceration, mouth ulceration, tongue ulceration, and mucosal inflammation.",gingival ulceration is an adverse reaction entity
"Table 4:  Adverse Reactions Reported >= 10% of Patients with Advanced PNET    Grading according to CTCAE Version 3.0  a   Includes stomatitis, aphthous stomatitis, gingival pain/swelling/ulceration, glossitis, glossodynia, lip ulceration, mouth ulceration, tongue ulceration, and mucosal inflammation.",glossitis is an adverse reaction entity
"Table 4:  Adverse Reactions Reported >= 10% of Patients with Advanced PNET    Grading according to CTCAE Version 3.0  a   Includes stomatitis, aphthous stomatitis, gingival pain/swelling/ulceration, glossitis, glossodynia, lip ulceration, mouth ulceration, tongue ulceration, and mucosal inflammation.",glossodynia is an adverse reaction entity
"Table 4:  Adverse Reactions Reported >= 10% of Patients with Advanced PNET    Grading according to CTCAE Version 3.0  a   Includes stomatitis, aphthous stomatitis, gingival pain/swelling/ulceration, glossitis, glossodynia, lip ulceration, mouth ulceration, tongue ulceration, and mucosal inflammation.",lip ulceration is an adverse reaction entity
"Table 4:  Adverse Reactions Reported >= 10% of Patients with Advanced PNET    Grading according to CTCAE Version 3.0  a   Includes stomatitis, aphthous stomatitis, gingival pain/swelling/ulceration, glossitis, glossodynia, lip ulceration, mouth ulceration, tongue ulceration, and mucosal inflammation.",mouth ulceration is an adverse reaction entity
"Table 4:  Adverse Reactions Reported >= 10% of Patients with Advanced PNET    Grading according to CTCAE Version 3.0  a   Includes stomatitis, aphthous stomatitis, gingival pain/swelling/ulceration, glossitis, glossodynia, lip ulceration, mouth ulceration, tongue ulceration, and mucosal inflammation.",tongue ulceration is an adverse reaction entity
"Table 4:  Adverse Reactions Reported >= 10% of Patients with Advanced PNET    Grading according to CTCAE Version 3.0  a   Includes stomatitis, aphthous stomatitis, gingival pain/swelling/ulceration, glossitis, glossodynia, lip ulceration, mouth ulceration, tongue ulceration, and mucosal inflammation.",mucosal inflammation is an adverse reaction entity
"Grade 3 or 4 stomatitis was reported in 4%-9% of patients [see Adverse Reactions (6.1, 6.2, 6.3, 6.4, 6.5)]  .",stomatitis is an adverse reaction entity
"Some of these infections have been severe (e.g., leading to sepsis, respiratory or hepatic failure) or fatal.",infections is an adverse reaction entity
"Some of these infections have been severe (e.g., leading to sepsis, respiratory or hepatic failure) or fatal.",sepsis is an adverse reaction entity
"Some of these infections have been severe (e.g., leading to sepsis, respiratory or hepatic failure) or fatal.",respiratory failure is an adverse reaction entity
"Some of these infections have been severe (e.g., leading to sepsis, respiratory or hepatic failure) or fatal.",hepatic failure is an adverse reaction entity
"Some of these infections have been severe (e.g., leading to sepsis, respiratory or hepatic failure) or fatal.",fatal is an adverse reaction entity
6     ADVERSE REACTIONS    The following serious adverse reactions are discussed in greater detail in another section of the label  [see Warnings and Precautions (5)]  :     *  Non-infectious pneumonitis [see Warnings and Precautions (5.1)] .,Non-infectious pneumonitis is an adverse reaction entity
"b  Includes all preferred terms within the 'infections and infestations' system organ class, the most common being nasopharyngitis (6%), pneumonia (6%), urinary tract infection (5%), bronchitis (4%), and sinusitis (3%), and also including aspergillosis (<1%), candidiasis (<1%), and sepsis (<1%).",nasopharyngitis is an adverse reaction entity
"b  Includes all preferred terms within the 'infections and infestations' system organ class, the most common being nasopharyngitis (6%), pneumonia (6%), urinary tract infection (5%), bronchitis (4%), and sinusitis (3%), and also including aspergillosis (<1%), candidiasis (<1%), and sepsis (<1%).",pneumonia is an adverse reaction entity
"b  Includes all preferred terms within the 'infections and infestations' system organ class, the most common being nasopharyngitis (6%), pneumonia (6%), urinary tract infection (5%), bronchitis (4%), and sinusitis (3%), and also including aspergillosis (<1%), candidiasis (<1%), and sepsis (<1%).",urinary tract infection is an adverse reaction entity
"b  Includes all preferred terms within the 'infections and infestations' system organ class, the most common being nasopharyngitis (6%), pneumonia (6%), urinary tract infection (5%), bronchitis (4%), and sinusitis (3%), and also including aspergillosis (<1%), candidiasis (<1%), and sepsis (<1%).",bronchitis is an adverse reaction entity
"b  Includes all preferred terms within the 'infections and infestations' system organ class, the most common being nasopharyngitis (6%), pneumonia (6%), urinary tract infection (5%), bronchitis (4%), and sinusitis (3%), and also including aspergillosis (<1%), candidiasis (<1%), and sepsis (<1%).",sinusitis is an adverse reaction entity
"b  Includes all preferred terms within the 'infections and infestations' system organ class, the most common being nasopharyngitis (6%), pneumonia (6%), urinary tract infection (5%), bronchitis (4%), and sinusitis (3%), and also including aspergillosis (<1%), candidiasis (<1%), and sepsis (<1%).",aspergillosis is an adverse reaction entity
"b  Includes all preferred terms within the 'infections and infestations' system organ class, the most common being nasopharyngitis (6%), pneumonia (6%), urinary tract infection (5%), bronchitis (4%), and sinusitis (3%), and also including aspergillosis (<1%), candidiasis (<1%), and sepsis (<1%).",candidiasis is an adverse reaction entity
"b  Includes all preferred terms within the 'infections and infestations' system organ class, the most common being nasopharyngitis (6%), pneumonia (6%), urinary tract infection (5%), bronchitis (4%), and sinusitis (3%), and also including aspergillosis (<1%), candidiasis (<1%), and sepsis (<1%).",sepsis is an adverse reaction entity
The most common key laboratory abnormalities (incidence >= 50%) were hypercholesterolemia and elevated partial thromboplastin time.,hypercholesterolemia is an adverse reaction entity
The most common key laboratory abnormalities (incidence >= 50%) were hypercholesterolemia and elevated partial thromboplastin time.,elevated partial thromboplastin time is an adverse reaction entity
(  6.4  )     SEGA with TSC: Most common adverse reactions (incidence >= 30%) are stomatitis and respiratory tract infection.,stomatitis is an adverse reaction entity
(  6.4  )     SEGA with TSC: Most common adverse reactions (incidence >= 30%) are stomatitis and respiratory tract infection.,respiratory tract infection is an adverse reaction entity
"The most common adverse reactions (incidence >= 30%) were stomatitis, infections, asthenia, fatigue, cough, and diarrhea.",stomatitis is an adverse reaction entity
"The most common adverse reactions (incidence >= 30%) were stomatitis, infections, asthenia, fatigue, cough, and diarrhea.",infections is an adverse reaction entity
"The most common adverse reactions (incidence >= 30%) were stomatitis, infections, asthenia, fatigue, cough, and diarrhea.",asthenia is an adverse reaction entity
"The most common adverse reactions (incidence >= 30%) were stomatitis, infections, asthenia, fatigue, cough, and diarrhea.",fatigue is an adverse reaction entity
"The most common adverse reactions (incidence >= 30%) were stomatitis, infections, asthenia, fatigue, cough, and diarrhea.",cough is an adverse reaction entity
"The most common adverse reactions (incidence >= 30%) were stomatitis, infections, asthenia, fatigue, cough, and diarrhea.",diarrhea is an adverse reaction entity
Everolimus caused embryo-fetal toxicities in animals at maternal exposures that were lower than human exposures.,embryo-fetal toxicities is an adverse reaction entity
The most common adverse reaction leading to AFINITOR dose adjustment was stomatitis.,stomatitis is an adverse reaction entity
"After cross-over to open-label AFINITOR, there were three additional deaths, one due to hypoglycemia and cardiac arrest in a patient with insulinoma, one due to myocardial infarction with congestive heart failure, and the other due to sudden death.",deaths is an adverse reaction entity
"After cross-over to open-label AFINITOR, there were three additional deaths, one due to hypoglycemia and cardiac arrest in a patient with insulinoma, one due to myocardial infarction with congestive heart failure, and the other due to sudden death.",hypoglycemia is an adverse reaction entity
"After cross-over to open-label AFINITOR, there were three additional deaths, one due to hypoglycemia and cardiac arrest in a patient with insulinoma, one due to myocardial infarction with congestive heart failure, and the other due to sudden death.",cardiac arrest is an adverse reaction entity
"After cross-over to open-label AFINITOR, there were three additional deaths, one due to hypoglycemia and cardiac arrest in a patient with insulinoma, one due to myocardial infarction with congestive heart failure, and the other due to sudden death.",myocardial infarction is an adverse reaction entity
"After cross-over to open-label AFINITOR, there were three additional deaths, one due to hypoglycemia and cardiac arrest in a patient with insulinoma, one due to myocardial infarction with congestive heart failure, and the other due to sudden death.",congestive heart failure is an adverse reaction entity
"After cross-over to open-label AFINITOR, there were three additional deaths, one due to hypoglycemia and cardiac arrest in a patient with insulinoma, one due to myocardial infarction with congestive heart failure, and the other due to sudden death.",sudden death is an adverse reaction entity
"c  Confidence interval                               Patients         Major bleeding event  a                                                                   Bleeding sites for MBE  b                                                                                                                                                                       Clinically relevant non-major bleeding      Any bleeding            In the RE-MEDY study, the rate of any gastrointestinal bleeds in patients receiving PRADAXA 150 mg was 3.1% (2.2% on warfarin).",bleeding is an adverse reaction entity
"c  Confidence interval                               Patients         Major bleeding event  a                                                                   Bleeding sites for MBE  b                                                                                                                                                                       Clinically relevant non-major bleeding      Any bleeding            In the RE-MEDY study, the rate of any gastrointestinal bleeds in patients receiving PRADAXA 150 mg was 3.1% (2.2% on warfarin).",Bleeding is an adverse reaction entity
"c  Confidence interval                               Patients         Major bleeding event  a                                                                   Bleeding sites for MBE  b                                                                                                                                                                       Clinically relevant non-major bleeding      Any bleeding            In the RE-MEDY study, the rate of any gastrointestinal bleeds in patients receiving PRADAXA 150 mg was 3.1% (2.2% on warfarin).",MBE is an adverse reaction entity
"c  Confidence interval                               Patients         Major bleeding event  a                                                                   Bleeding sites for MBE  b                                                                                                                                                                       Clinically relevant non-major bleeding      Any bleeding            In the RE-MEDY study, the rate of any gastrointestinal bleeds in patients receiving PRADAXA 150 mg was 3.1% (2.2% on warfarin).",bleeding is an adverse reaction entity
"c  Confidence interval                               Patients         Major bleeding event  a                                                                   Bleeding sites for MBE  b                                                                                                                                                                       Clinically relevant non-major bleeding      Any bleeding            In the RE-MEDY study, the rate of any gastrointestinal bleeds in patients receiving PRADAXA 150 mg was 3.1% (2.2% on warfarin).",bleeding is an adverse reaction entity
"c  Confidence interval                               Patients         Major bleeding event  a                                                                   Bleeding sites for MBE  b                                                                                                                                                                       Clinically relevant non-major bleeding      Any bleeding            In the RE-MEDY study, the rate of any gastrointestinal bleeds in patients receiving PRADAXA 150 mg was 3.1% (2.2% on warfarin).",gastrointestinal bleeds is an adverse reaction entity
"Dyspepsia (including abdominal pain upper, abdominal pain, abdominal discomfort, and epigastric discomfort) occurred in patients on PRADAXA in 7.5% vs. 5.5% on warfarin, and gastritis-like symptoms (including gastritis, GERD, esophagitis, erosive gastritis and gastric hemorrhage) occurred at 3.0% vs. 1.7%, respectively.",Dyspepsia is an adverse reaction entity
"Dyspepsia (including abdominal pain upper, abdominal pain, abdominal discomfort, and epigastric discomfort) occurred in patients on PRADAXA in 7.5% vs. 5.5% on warfarin, and gastritis-like symptoms (including gastritis, GERD, esophagitis, erosive gastritis and gastric hemorrhage) occurred at 3.0% vs. 1.7%, respectively.",abdominal pain upper is an adverse reaction entity
"Dyspepsia (including abdominal pain upper, abdominal pain, abdominal discomfort, and epigastric discomfort) occurred in patients on PRADAXA in 7.5% vs. 5.5% on warfarin, and gastritis-like symptoms (including gastritis, GERD, esophagitis, erosive gastritis and gastric hemorrhage) occurred at 3.0% vs. 1.7%, respectively.",abdominal pain is an adverse reaction entity
"Dyspepsia (including abdominal pain upper, abdominal pain, abdominal discomfort, and epigastric discomfort) occurred in patients on PRADAXA in 7.5% vs. 5.5% on warfarin, and gastritis-like symptoms (including gastritis, GERD, esophagitis, erosive gastritis and gastric hemorrhage) occurred at 3.0% vs. 1.7%, respectively.",abdominal discomfort is an adverse reaction entity
"Dyspepsia (including abdominal pain upper, abdominal pain, abdominal discomfort, and epigastric discomfort) occurred in patients on PRADAXA in 7.5% vs. 5.5% on warfarin, and gastritis-like symptoms (including gastritis, GERD, esophagitis, erosive gastritis and gastric hemorrhage) occurred at 3.0% vs. 1.7%, respectively.",epigastric discomfort is an adverse reaction entity
"Dyspepsia (including abdominal pain upper, abdominal pain, abdominal discomfort, and epigastric discomfort) occurred in patients on PRADAXA in 7.5% vs. 5.5% on warfarin, and gastritis-like symptoms (including gastritis, GERD, esophagitis, erosive gastritis and gastric hemorrhage) occurred at 3.0% vs. 1.7%, respectively.",gastritis is an adverse reaction entity
"Dyspepsia (including abdominal pain upper, abdominal pain, abdominal discomfort, and epigastric discomfort) occurred in patients on PRADAXA in 7.5% vs. 5.5% on warfarin, and gastritis-like symptoms (including gastritis, GERD, esophagitis, erosive gastritis and gastric hemorrhage) occurred at 3.0% vs. 1.7%, respectively.",gastritis is an adverse reaction entity
"Dyspepsia (including abdominal pain upper, abdominal pain, abdominal discomfort, and epigastric discomfort) occurred in patients on PRADAXA in 7.5% vs. 5.5% on warfarin, and gastritis-like symptoms (including gastritis, GERD, esophagitis, erosive gastritis and gastric hemorrhage) occurred at 3.0% vs. 1.7%, respectively.",GERD is an adverse reaction entity
"Dyspepsia (including abdominal pain upper, abdominal pain, abdominal discomfort, and epigastric discomfort) occurred in patients on PRADAXA in 7.5% vs. 5.5% on warfarin, and gastritis-like symptoms (including gastritis, GERD, esophagitis, erosive gastritis and gastric hemorrhage) occurred at 3.0% vs. 1.7%, respectively.",esophagitis is an adverse reaction entity
"Dyspepsia (including abdominal pain upper, abdominal pain, abdominal discomfort, and epigastric discomfort) occurred in patients on PRADAXA in 7.5% vs. 5.5% on warfarin, and gastritis-like symptoms (including gastritis, GERD, esophagitis, erosive gastritis and gastric hemorrhage) occurred at 3.0% vs. 1.7%, respectively.",erosive gastritis is an adverse reaction entity
"Dyspepsia (including abdominal pain upper, abdominal pain, abdominal discomfort, and epigastric discomfort) occurred in patients on PRADAXA in 7.5% vs. 5.5% on warfarin, and gastritis-like symptoms (including gastritis, GERD, esophagitis, erosive gastritis and gastric hemorrhage) occurred at 3.0% vs. 1.7%, respectively.",gastric hemorrhage is an adverse reaction entity
"Clinical Myocardial Infarction Events  In the active-controlled VTE studies, a higher rate of clinical myocardial infarction was reported in patients who received PRADAXA [20 (0.66 per 100 patient-years)] than in those who received warfarin [5 (0.17 per 100 patient-years)].",myocardial infarction is an adverse reaction entity
"5  WARNINGS AND PRECAUTIONS       EXCERPT:    *  Bleeding: PRADAXA can cause serious and fatal bleeding  (5.2)     *  Bioprosthetic heart valves: PRADAXA use not recommended  (5.4)               5.1 Increased Risk of Thrombotic Events after Premature Discontinuation      Premature discontinuation of any oral anticoagulant, including PRADAXA, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events.",Bleeding is an adverse reaction entity
"5  WARNINGS AND PRECAUTIONS       EXCERPT:    *  Bleeding: PRADAXA can cause serious and fatal bleeding  (5.2)     *  Bioprosthetic heart valves: PRADAXA use not recommended  (5.4)               5.1 Increased Risk of Thrombotic Events after Premature Discontinuation      Premature discontinuation of any oral anticoagulant, including PRADAXA, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events.",fatal is an adverse reaction entity
"5  WARNINGS AND PRECAUTIONS       EXCERPT:    *  Bleeding: PRADAXA can cause serious and fatal bleeding  (5.2)     *  Bioprosthetic heart valves: PRADAXA use not recommended  (5.4)               5.1 Increased Risk of Thrombotic Events after Premature Discontinuation      Premature discontinuation of any oral anticoagulant, including PRADAXA, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events.",bleeding is an adverse reaction entity
"5  WARNINGS AND PRECAUTIONS       EXCERPT:    *  Bleeding: PRADAXA can cause serious and fatal bleeding  (5.2)     *  Bioprosthetic heart valves: PRADAXA use not recommended  (5.4)               5.1 Increased Risk of Thrombotic Events after Premature Discontinuation      Premature discontinuation of any oral anticoagulant, including PRADAXA, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events.",bleeding is an adverse reaction entity
"dIntracranial bleed included intracerebral (hemorrhagic stroke), subarachnoid, and subdural bleeds.",Intracranial bleed is an adverse reaction entity
"dIntracranial bleed included intracerebral (hemorrhagic stroke), subarachnoid, and subdural bleeds.",intracerebral bleeds is an adverse reaction entity
"dIntracranial bleed included intracerebral (hemorrhagic stroke), subarachnoid, and subdural bleeds.",hemorrhagic stroke is an adverse reaction entity
"dIntracranial bleed included intracerebral (hemorrhagic stroke), subarachnoid, and subdural bleeds.",subarachnoid bleeds is an adverse reaction entity
"dIntracranial bleed included intracerebral (hemorrhagic stroke), subarachnoid, and subdural bleeds.",subdural bleeds is an adverse reaction entity
Table 5 Bleeding Events in RE-SONATE Treated Patients   Note: MBE can belong to more than one criterion.,Bleeding is an adverse reaction entity
Table 5 Bleeding Events in RE-SONATE Treated Patients   Note: MBE can belong to more than one criterion.,MBE is an adverse reaction entity
Table 2 Adjudicated Major Bleeding Events in Treated Patientsa    aPatients during treatment or within 2 days of stopping study treatment.,Bleeding is an adverse reaction entity
"Bleeding          [see Warnings and Precautions  (5.2)  ]         Table 2 shows the number of adjudicated major bleeding events during the treatment period in the RE-LY study, with the bleeding rate per 100 subject-years (%).",bleeding is an adverse reaction entity
"Bleeding          [see Warnings and Precautions  (5.2)  ]         Table 2 shows the number of adjudicated major bleeding events during the treatment period in the RE-LY study, with the bleeding rate per 100 subject-years (%).",bleeding is an adverse reaction entity
c  Confidence interval                                                   Patients         Major bleeding event  a                                                                   Bleeding sites for MBE  b                                                                                                                                                   Clinically relevant non-major bleeding      Any bleeding            The rate of any gastrointestinal bleeds in patients receiving PRADAXA 150 mg in the full treatment period was 3.1% (2.4% on warfarin).,bleeding is an adverse reaction entity
c  Confidence interval                                                   Patients         Major bleeding event  a                                                                   Bleeding sites for MBE  b                                                                                                                                                   Clinically relevant non-major bleeding      Any bleeding            The rate of any gastrointestinal bleeds in patients receiving PRADAXA 150 mg in the full treatment period was 3.1% (2.4% on warfarin).,Bleeding is an adverse reaction entity
c  Confidence interval                                                   Patients         Major bleeding event  a                                                                   Bleeding sites for MBE  b                                                                                                                                                   Clinically relevant non-major bleeding      Any bleeding            The rate of any gastrointestinal bleeds in patients receiving PRADAXA 150 mg in the full treatment period was 3.1% (2.4% on warfarin).,MBE is an adverse reaction entity
c  Confidence interval                                                   Patients         Major bleeding event  a                                                                   Bleeding sites for MBE  b                                                                                                                                                   Clinically relevant non-major bleeding      Any bleeding            The rate of any gastrointestinal bleeds in patients receiving PRADAXA 150 mg in the full treatment period was 3.1% (2.4% on warfarin).,bleeding is an adverse reaction entity
c  Confidence interval                                                   Patients         Major bleeding event  a                                                                   Bleeding sites for MBE  b                                                                                                                                                   Clinically relevant non-major bleeding      Any bleeding            The rate of any gastrointestinal bleeds in patients receiving PRADAXA 150 mg in the full treatment period was 3.1% (2.4% on warfarin).,bleeding is an adverse reaction entity
c  Confidence interval                                                   Patients         Major bleeding event  a                                                                   Bleeding sites for MBE  b                                                                                                                                                   Clinically relevant non-major bleeding      Any bleeding            The rate of any gastrointestinal bleeds in patients receiving PRADAXA 150 mg in the full treatment period was 3.1% (2.4% on warfarin).,gastrointestinal bleeds is an adverse reaction entity
"Eye disorders, including severe eye pain, chemical conjunctivitis, corneal burn, eyelid edema, eyelid ptosis, periorbital edema can occur after exposure [see Adverse Reactions (  6  )]   .",Eye disorders is an adverse reaction entity
"Eye disorders, including severe eye pain, chemical conjunctivitis, corneal burn, eyelid edema, eyelid ptosis, periorbital edema can occur after exposure [see Adverse Reactions (  6  )]   .",eye pain is an adverse reaction entity
"Eye disorders, including severe eye pain, chemical conjunctivitis, corneal burn, eyelid edema, eyelid ptosis, periorbital edema can occur after exposure [see Adverse Reactions (  6  )]   .",chemical conjunctivitis is an adverse reaction entity
"Eye disorders, including severe eye pain, chemical conjunctivitis, corneal burn, eyelid edema, eyelid ptosis, periorbital edema can occur after exposure [see Adverse Reactions (  6  )]   .",corneal burn is an adverse reaction entity
"Eye disorders, including severe eye pain, chemical conjunctivitis, corneal burn, eyelid edema, eyelid ptosis, periorbital edema can occur after exposure [see Adverse Reactions (  6  )]   .",eyelid edema is an adverse reaction entity
"Eye disorders, including severe eye pain, chemical conjunctivitis, corneal burn, eyelid edema, eyelid ptosis, periorbital edema can occur after exposure [see Adverse Reactions (  6  )]   .",eyelid ptosis is an adverse reaction entity
"Eye disorders, including severe eye pain, chemical conjunctivitis, corneal burn, eyelid edema, eyelid ptosis, periorbital edema can occur after exposure [see Adverse Reactions (  6  )]   .",periorbital edema is an adverse reaction entity
"6.2 Postmarketing Experience    The following adverse reactions have been identified during post approval use of Picato  (r)  (ingenol mebutate) gel, 0.015% and 0.05%: hypersensitivity, allergic contact dermatitis, herpes zoster, chemical conjunctivitis, and corneal burn.",hypersensitivity is an adverse reaction entity
"6.2 Postmarketing Experience    The following adverse reactions have been identified during post approval use of Picato  (r)  (ingenol mebutate) gel, 0.015% and 0.05%: hypersensitivity, allergic contact dermatitis, herpes zoster, chemical conjunctivitis, and corneal burn.",allergic contact dermatitis is an adverse reaction entity
"6.2 Postmarketing Experience    The following adverse reactions have been identified during post approval use of Picato  (r)  (ingenol mebutate) gel, 0.015% and 0.05%: hypersensitivity, allergic contact dermatitis, herpes zoster, chemical conjunctivitis, and corneal burn.",herpes zoster is an adverse reaction entity
"6.2 Postmarketing Experience    The following adverse reactions have been identified during post approval use of Picato  (r)  (ingenol mebutate) gel, 0.015% and 0.05%: hypersensitivity, allergic contact dermatitis, herpes zoster, chemical conjunctivitis, and corneal burn.",chemical conjunctivitis is an adverse reaction entity
"6.2 Postmarketing Experience    The following adverse reactions have been identified during post approval use of Picato  (r)  (ingenol mebutate) gel, 0.015% and 0.05%: hypersensitivity, allergic contact dermatitis, herpes zoster, chemical conjunctivitis, and corneal burn.",corneal burn is an adverse reaction entity
There were no reported thromboembolic events in the patients treated with EYLEA in the first six months of the RVO studies.,thromboembolic events is an adverse reaction entity
"The most common adverse reactions (>=5%) reported in patients receiving EYLEA were conjunctival hemorrhage, eye pain, cataract, vitreous floaters, intraocular pressure increased, and vitreous detachment.",conjunctival hemorrhage is an adverse reaction entity
"The most common adverse reactions (>=5%) reported in patients receiving EYLEA were conjunctival hemorrhage, eye pain, cataract, vitreous floaters, intraocular pressure increased, and vitreous detachment.",eye pain is an adverse reaction entity
"The most common adverse reactions (>=5%) reported in patients receiving EYLEA were conjunctival hemorrhage, eye pain, cataract, vitreous floaters, intraocular pressure increased, and vitreous detachment.",cataract is an adverse reaction entity
"The most common adverse reactions (>=5%) reported in patients receiving EYLEA were conjunctival hemorrhage, eye pain, cataract, vitreous floaters, intraocular pressure increased, and vitreous detachment.",vitreous floaters is an adverse reaction entity
"The most common adverse reactions (>=5%) reported in patients receiving EYLEA were conjunctival hemorrhage, eye pain, cataract, vitreous floaters, intraocular pressure increased, and vitreous detachment.",intraocular pressure increased is an adverse reaction entity
"The most common adverse reactions (>=5%) reported in patients receiving EYLEA were conjunctival hemorrhage, eye pain, cataract, vitreous floaters, intraocular pressure increased, and vitreous detachment.",vitreous detachment is an adverse reaction entity
The incidence of reported thromboembolic events in wet AMD studies during the first year was 1.8% (32 out of 1824) in the combined group of patients treated with EYLEA.,thromboembolic events is an adverse reaction entity
5.13 Hereditary Angioedema      Exogenous estrogens may exacerbate symptoms of angioedema in women with hereditary angioedema.,exacerbate angioedema is an adverse reaction entity
"Subgroup analyses of women 50 to 59 years of age suggest no increased risk of stroke for those women receiving conjugated estrogens (0.625 mg)-alone versus those receiving placebo (18 versus 21 per 10,000 women-years).",stroke is an adverse reaction entity
"The reported endometrial cancer risk among unopposed estrogen users is about 2 to 12 times greater than in non-users, and appears dependent on duration of treatment and on estrogen dose.",endometrial cancer is an adverse reaction entity
"Increased plasma high-density lipoprotein (HDL) and HDL2 cholesterol subfraction concentrations, reduced low-density lipoprotein (LDL) cholesterol concentrations, increased triglyceride levels.",Increased plasma high-density lipoprotein is an adverse reaction entity
"Increased plasma high-density lipoprotein (HDL) and HDL2 cholesterol subfraction concentrations, reduced low-density lipoprotein (LDL) cholesterol concentrations, increased triglyceride levels.",Increased HDL is an adverse reaction entity
"Increased plasma high-density lipoprotein (HDL) and HDL2 cholesterol subfraction concentrations, reduced low-density lipoprotein (LDL) cholesterol concentrations, increased triglyceride levels.",Increased HDL2 cholesterol subfraction concentrations is an adverse reaction entity
"Increased plasma high-density lipoprotein (HDL) and HDL2 cholesterol subfraction concentrations, reduced low-density lipoprotein (LDL) cholesterol concentrations, increased triglyceride levels.",reduced low-density lipoprotein cholesterol concentrations is an adverse reaction entity
"Increased plasma high-density lipoprotein (HDL) and HDL2 cholesterol subfraction concentrations, reduced low-density lipoprotein (LDL) cholesterol concentrations, increased triglyceride levels.",reduced LDL cholesterol concentrations is an adverse reaction entity
"Increased plasma high-density lipoprotein (HDL) and HDL2 cholesterol subfraction concentrations, reduced low-density lipoprotein (LDL) cholesterol concentrations, increased triglyceride levels.",increased triglyceride levels is an adverse reaction entity
"Free hormone concentrations, such as testosterone and estradiol, may be decreased.",Free hormone concentrations decreased is an adverse reaction entity
"Free hormone concentrations, such as testosterone and estradiol, may be decreased.",testosterone decreased is an adverse reaction entity
"Free hormone concentrations, such as testosterone and estradiol, may be decreased.",estradiol decreased is an adverse reaction entity
"5.2 Cardiovascular Disorders      Estrogen agonist/antagonists (including bazedoxifene, a component of DUAVEE) and estrogens individually are known to increase the risk of VTE.",VTE is an adverse reaction entity
"Subgroup analyses of women 50 to 59 years of age suggest a statistically non-significant reduction in CHD events (CE [0.625 mg]-alone compared to placebo) in women with less than 10 years since menopause (8 versus 16 per 10,000 women-years).",CHD is an adverse reaction entity
"After an average follow-up of 5.2 years, 28 women in the estrogen-alone group and 19 women in the placebo group were diagnosed with probable dementia.",dementia is an adverse reaction entity
"In 255 HAE patients treated with intravenous or subcutaneous KALBITOR in clinical studies, 10 patients (4%) experienced anaphylaxis.",anaphylaxis is an adverse reaction entity
"Overall, the most common adverse reactions in 255 patients with HAE were headache (16%), nausea (13%), fatigue (12%), diarrhea (11%), upper respiratory tract infection (8%), injection site reactions (7%), nasopharyngitis (6%), vomiting (6%), pruritus (5%), upper abdominal pain (5%), and pyrexia (5%).",headache is an adverse reaction entity
"Overall, the most common adverse reactions in 255 patients with HAE were headache (16%), nausea (13%), fatigue (12%), diarrhea (11%), upper respiratory tract infection (8%), injection site reactions (7%), nasopharyngitis (6%), vomiting (6%), pruritus (5%), upper abdominal pain (5%), and pyrexia (5%).",nausea is an adverse reaction entity
"Overall, the most common adverse reactions in 255 patients with HAE were headache (16%), nausea (13%), fatigue (12%), diarrhea (11%), upper respiratory tract infection (8%), injection site reactions (7%), nasopharyngitis (6%), vomiting (6%), pruritus (5%), upper abdominal pain (5%), and pyrexia (5%).",fatigue is an adverse reaction entity
"Overall, the most common adverse reactions in 255 patients with HAE were headache (16%), nausea (13%), fatigue (12%), diarrhea (11%), upper respiratory tract infection (8%), injection site reactions (7%), nasopharyngitis (6%), vomiting (6%), pruritus (5%), upper abdominal pain (5%), and pyrexia (5%).",diarrhea is an adverse reaction entity
"Overall, the most common adverse reactions in 255 patients with HAE were headache (16%), nausea (13%), fatigue (12%), diarrhea (11%), upper respiratory tract infection (8%), injection site reactions (7%), nasopharyngitis (6%), vomiting (6%), pruritus (5%), upper abdominal pain (5%), and pyrexia (5%).",upper respiratory tract infection is an adverse reaction entity
"Overall, the most common adverse reactions in 255 patients with HAE were headache (16%), nausea (13%), fatigue (12%), diarrhea (11%), upper respiratory tract infection (8%), injection site reactions (7%), nasopharyngitis (6%), vomiting (6%), pruritus (5%), upper abdominal pain (5%), and pyrexia (5%).",injection site reactions is an adverse reaction entity
"Overall, the most common adverse reactions in 255 patients with HAE were headache (16%), nausea (13%), fatigue (12%), diarrhea (11%), upper respiratory tract infection (8%), injection site reactions (7%), nasopharyngitis (6%), vomiting (6%), pruritus (5%), upper abdominal pain (5%), and pyrexia (5%).",nasopharyngitis is an adverse reaction entity
"Overall, the most common adverse reactions in 255 patients with HAE were headache (16%), nausea (13%), fatigue (12%), diarrhea (11%), upper respiratory tract infection (8%), injection site reactions (7%), nasopharyngitis (6%), vomiting (6%), pruritus (5%), upper abdominal pain (5%), and pyrexia (5%).",vomiting is an adverse reaction entity
"Overall, the most common adverse reactions in 255 patients with HAE were headache (16%), nausea (13%), fatigue (12%), diarrhea (11%), upper respiratory tract infection (8%), injection site reactions (7%), nasopharyngitis (6%), vomiting (6%), pruritus (5%), upper abdominal pain (5%), and pyrexia (5%).",pruritus is an adverse reaction entity
"Overall, the most common adverse reactions in 255 patients with HAE were headache (16%), nausea (13%), fatigue (12%), diarrhea (11%), upper respiratory tract infection (8%), injection site reactions (7%), nasopharyngitis (6%), vomiting (6%), pruritus (5%), upper abdominal pain (5%), and pyrexia (5%).",upper abdominal pain is an adverse reaction entity
"Overall, the most common adverse reactions in 255 patients with HAE were headache (16%), nausea (13%), fatigue (12%), diarrhea (11%), upper respiratory tract infection (8%), injection site reactions (7%), nasopharyngitis (6%), vomiting (6%), pruritus (5%), upper abdominal pain (5%), and pyrexia (5%).",pyrexia is an adverse reaction entity
"For the subgroup of 187 patients treated with subcutaneous KALBITOR, 5 patients (3%) experienced anaphylaxis.",anaphylaxis is an adverse reaction entity
"The most common adverse reactions (5% or greater in either indication) occurring in patients receiving ZERBAXA were nausea, diarrhea, headache, and pyrexia.",nausea is an adverse reaction entity
"The most common adverse reactions (5% or greater in either indication) occurring in patients receiving ZERBAXA were nausea, diarrhea, headache, and pyrexia.",diarrhea is an adverse reaction entity
"The most common adverse reactions (5% or greater in either indication) occurring in patients receiving ZERBAXA were nausea, diarrhea, headache, and pyrexia.",headache is an adverse reaction entity
"The most common adverse reactions (5% or greater in either indication) occurring in patients receiving ZERBAXA were nausea, diarrhea, headache, and pyrexia.",pyrexia is an adverse reaction entity
"5.3 Clostridium difficile  -associated Diarrhea       Clostridium difficile  -associated diarrhea (CDAD) has been reported for nearly all systemic antibacterial agents, including ZERBAXA, and may range in severity from mild diarrhea to fatal colitis.",Clostridium difficile -associated diarrhea is an adverse reaction entity
"5.3 Clostridium difficile  -associated Diarrhea       Clostridium difficile  -associated diarrhea (CDAD) has been reported for nearly all systemic antibacterial agents, including ZERBAXA, and may range in severity from mild diarrhea to fatal colitis.",CDAD is an adverse reaction entity
"5.3 Clostridium difficile  -associated Diarrhea       Clostridium difficile  -associated diarrhea (CDAD) has been reported for nearly all systemic antibacterial agents, including ZERBAXA, and may range in severity from mild diarrhea to fatal colitis.",diarrhea is an adverse reaction entity
"5.3 Clostridium difficile  -associated Diarrhea       Clostridium difficile  -associated diarrhea (CDAD) has been reported for nearly all systemic antibacterial agents, including ZERBAXA, and may range in severity from mild diarrhea to fatal colitis.",fatal is an adverse reaction entity
"5.3 Clostridium difficile  -associated Diarrhea       Clostridium difficile  -associated diarrhea (CDAD) has been reported for nearly all systemic antibacterial agents, including ZERBAXA, and may range in severity from mild diarrhea to fatal colitis.",colitis is an adverse reaction entity
"The possibility that GRANIX acts as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia, diseases for which GRANIX is not approved, cannot be excluded.",growth factor for tumor is an adverse reaction entity
"The possibility that GRANIX acts as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia, diseases for which GRANIX is not approved, cannot be excluded.",myeloid malignancies is an adverse reaction entity
"The possibility that GRANIX acts as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia, diseases for which GRANIX is not approved, cannot be excluded.",myelodysplasia is an adverse reaction entity
"Leukocytosis       In clinical studies, leukocytosis (WBC counts > 100,000 x 10  6  /L) was observed in less than 1% patients with non-myeloid malignancies receiving GRANIX.",leukocytosis is an adverse reaction entity
"Leukocytosis       In clinical studies, leukocytosis (WBC counts > 100,000 x 10  6  /L) was observed in less than 1% patients with non-myeloid malignancies receiving GRANIX.","WBC counts > 100,000 x 10 6 /L is an adverse reaction entity"
"Discontinue GRANIX if suspected (  5.2  )   *    Allergic reactions (angioneurotic edema, dermatitis allergic, drug hypersensitivity, hypersensitivity, rash, pruritic rash and urticaria) (  5.3  )   *    Sickle cell crisis: Severe and sometimes fatal crisis can occur.",Allergic reactions is an adverse reaction entity
"Discontinue GRANIX if suspected (  5.2  )   *    Allergic reactions (angioneurotic edema, dermatitis allergic, drug hypersensitivity, hypersensitivity, rash, pruritic rash and urticaria) (  5.3  )   *    Sickle cell crisis: Severe and sometimes fatal crisis can occur.",angioneurotic edema is an adverse reaction entity
"Discontinue GRANIX if suspected (  5.2  )   *    Allergic reactions (angioneurotic edema, dermatitis allergic, drug hypersensitivity, hypersensitivity, rash, pruritic rash and urticaria) (  5.3  )   *    Sickle cell crisis: Severe and sometimes fatal crisis can occur.",dermatitis allergic is an adverse reaction entity
"Discontinue GRANIX if suspected (  5.2  )   *    Allergic reactions (angioneurotic edema, dermatitis allergic, drug hypersensitivity, hypersensitivity, rash, pruritic rash and urticaria) (  5.3  )   *    Sickle cell crisis: Severe and sometimes fatal crisis can occur.",drug hypersensitivity is an adverse reaction entity
"Discontinue GRANIX if suspected (  5.2  )   *    Allergic reactions (angioneurotic edema, dermatitis allergic, drug hypersensitivity, hypersensitivity, rash, pruritic rash and urticaria) (  5.3  )   *    Sickle cell crisis: Severe and sometimes fatal crisis can occur.",hypersensitivity is an adverse reaction entity
"Discontinue GRANIX if suspected (  5.2  )   *    Allergic reactions (angioneurotic edema, dermatitis allergic, drug hypersensitivity, hypersensitivity, rash, pruritic rash and urticaria) (  5.3  )   *    Sickle cell crisis: Severe and sometimes fatal crisis can occur.",rash is an adverse reaction entity
"Discontinue GRANIX if suspected (  5.2  )   *    Allergic reactions (angioneurotic edema, dermatitis allergic, drug hypersensitivity, hypersensitivity, rash, pruritic rash and urticaria) (  5.3  )   *    Sickle cell crisis: Severe and sometimes fatal crisis can occur.",pruritic rash is an adverse reaction entity
"Discontinue GRANIX if suspected (  5.2  )   *    Allergic reactions (angioneurotic edema, dermatitis allergic, drug hypersensitivity, hypersensitivity, rash, pruritic rash and urticaria) (  5.3  )   *    Sickle cell crisis: Severe and sometimes fatal crisis can occur.",urticaria is an adverse reaction entity
"Discontinue GRANIX if suspected (  5.2  )   *    Allergic reactions (angioneurotic edema, dermatitis allergic, drug hypersensitivity, hypersensitivity, rash, pruritic rash and urticaria) (  5.3  )   *    Sickle cell crisis: Severe and sometimes fatal crisis can occur.",Sickle cell crisis is an adverse reaction entity
"Discontinue GRANIX if suspected (  5.2  )   *    Allergic reactions (angioneurotic edema, dermatitis allergic, drug hypersensitivity, hypersensitivity, rash, pruritic rash and urticaria) (  5.3  )   *    Sickle cell crisis: Severe and sometimes fatal crisis can occur.",fatal is an adverse reaction entity
"(  5.2  ,  7.2  ,  12.3  )   *  Cataracts: Non-congenital lens opacities/cataracts have been reported in pediatric patients treated with KALYDECO.",Cataracts is an adverse reaction entity
"(  5.2  ,  7.2  ,  12.3  )   *  Cataracts: Non-congenital lens opacities/cataracts have been reported in pediatric patients treated with KALYDECO.",Non-congenital lens opacities is an adverse reaction entity
"(  5.2  ,  7.2  ,  12.3  )   *  Cataracts: Non-congenital lens opacities/cataracts have been reported in pediatric patients treated with KALYDECO.",Non-congenital cataracts is an adverse reaction entity
5.3 Cataracts       Cases of non-congenital lens opacities/cataracts have been reported in pediatric patients treated with KALYDECO.,non-congenital lens opacities is an adverse reaction entity
5.3 Cataracts       Cases of non-congenital lens opacities/cataracts have been reported in pediatric patients treated with KALYDECO.,non-congenital cataracts is an adverse reaction entity
(  5.3  )             5.1 Transaminase (ALT or AST) Elevations       Elevated transaminases have been reported in patients with CF receiving KALYDECO.,Elevated transaminases is an adverse reaction entity
"NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs.",NSF is an adverse reaction entity
"NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs.",fatal is an adverse reaction entity
"NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs.",fibrosis is an adverse reaction entity
BOXED WARNING: WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)    WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)      Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs.,NEPHROGENIC SYSTEMIC FIBROSIS is an adverse reaction entity
BOXED WARNING: WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)    WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)      Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs.,NSF is an adverse reaction entity
BOXED WARNING: WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)    WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)      Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs.,NEPHROGENIC SYSTEMIC FIBROSIS is an adverse reaction entity
BOXED WARNING: WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)    WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)      Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs.,NSF is an adverse reaction entity
BOXED WARNING: WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)    WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)      Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs.,NSF is an adverse reaction entity
"5.3 Acute Kidney Injury      In patients with chronically reduced renal function, acute kidney injury requiring dialysis has occurred with the use of GBCAs.",acute kidney injury is an adverse reaction entity
"NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs.",NSF is an adverse reaction entity
"NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs.",fatal is an adverse reaction entity
"NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs.",fibrosis is an adverse reaction entity
"Proteinuria    At Month 1 after transplantation in Studies 1 and 2, the frequency of 2+ proteinuria on urine dipstick in patients treated with the NULOJIX recommended regimen was 33% (130/390) and 28% (107/384) in patients treated with the cyclosporine control regimen.",proteinuria is an adverse reaction entity
Non-melanoma skin cancer was reported in 1.5% (6/401) of patients treated with the recommended NULOJIX regimen and in 3.7% (15/405) of patients treated with cyclosporine [see    Warnings and Precautions (5.3)    ].,Non-melanoma skin cancer is an adverse reaction entity
"Post-Transplant Lymphoproliferative Disorder    Reported cases of post-transplant lymphoproliferative disorder (PTLD) up to 36 months post transplant were obtained for NULOJIX by pooling both dosage regimens of NULOJIX in Studies 1 and 2 (804 patients) with data from a third study in kidney transplantation (Study 3, 145 patients) which evaluated two NULOJIX dosage regimens similar, but slightly different, from those of Studies 1 and 2 (see Table 2).",post-transplant lymphoproliferative disorder is an adverse reaction entity
"Post-Transplant Lymphoproliferative Disorder    Reported cases of post-transplant lymphoproliferative disorder (PTLD) up to 36 months post transplant were obtained for NULOJIX by pooling both dosage regimens of NULOJIX in Studies 1 and 2 (804 patients) with data from a third study in kidney transplantation (Study 3, 145 patients) which evaluated two NULOJIX dosage regimens similar, but slightly different, from those of Studies 1 and 2 (see Table 2).",PTLD is an adverse reaction entity
"BOXED WARNING: WARNING: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER, OTHER MALIGNANCIES, AND SERIOUS INFECTIONS    WARNING: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER, OTHER MALIGNANCIES, AND SERIOUS INFECTIONS      Increased risk for developing post-transplant lymphoproliferative disorder (PTLD), predominantly involving the central nervous system (CNS).",POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER is an adverse reaction entity
"BOXED WARNING: WARNING: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER, OTHER MALIGNANCIES, AND SERIOUS INFECTIONS    WARNING: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER, OTHER MALIGNANCIES, AND SERIOUS INFECTIONS      Increased risk for developing post-transplant lymphoproliferative disorder (PTLD), predominantly involving the central nervous system (CNS).",MALIGNANCIES is an adverse reaction entity
"BOXED WARNING: WARNING: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER, OTHER MALIGNANCIES, AND SERIOUS INFECTIONS    WARNING: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER, OTHER MALIGNANCIES, AND SERIOUS INFECTIONS      Increased risk for developing post-transplant lymphoproliferative disorder (PTLD), predominantly involving the central nervous system (CNS).",INFECTIONS is an adverse reaction entity
"BOXED WARNING: WARNING: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER, OTHER MALIGNANCIES, AND SERIOUS INFECTIONS    WARNING: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER, OTHER MALIGNANCIES, AND SERIOUS INFECTIONS      Increased risk for developing post-transplant lymphoproliferative disorder (PTLD), predominantly involving the central nervous system (CNS).",POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER is an adverse reaction entity
"BOXED WARNING: WARNING: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER, OTHER MALIGNANCIES, AND SERIOUS INFECTIONS    WARNING: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER, OTHER MALIGNANCIES, AND SERIOUS INFECTIONS      Increased risk for developing post-transplant lymphoproliferative disorder (PTLD), predominantly involving the central nervous system (CNS).",MALIGNANCIES is an adverse reaction entity
"BOXED WARNING: WARNING: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER, OTHER MALIGNANCIES, AND SERIOUS INFECTIONS    WARNING: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER, OTHER MALIGNANCIES, AND SERIOUS INFECTIONS      Increased risk for developing post-transplant lymphoproliferative disorder (PTLD), predominantly involving the central nervous system (CNS).",INFECTIONS is an adverse reaction entity
"BOXED WARNING: WARNING: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER, OTHER MALIGNANCIES, AND SERIOUS INFECTIONS    WARNING: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER, OTHER MALIGNANCIES, AND SERIOUS INFECTIONS      Increased risk for developing post-transplant lymphoproliferative disorder (PTLD), predominantly involving the central nervous system (CNS).",post-transplant lymphoproliferative disorder is an adverse reaction entity
"BOXED WARNING: WARNING: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER, OTHER MALIGNANCIES, AND SERIOUS INFECTIONS    WARNING: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER, OTHER MALIGNANCIES, AND SERIOUS INFECTIONS      Increased risk for developing post-transplant lymphoproliferative disorder (PTLD), predominantly involving the central nervous system (CNS).",PTLD is an adverse reaction entity
"(5.8)               5.1 Post-Transplant Lymphoproliferative Disorder      NULOJIX-treated patients have an increased risk for developing post-transplant lymphoproliferative disorder (PTLD), predominantly involving the CNS, compared to patients on a cyclosporine-based regimen [see   Adverse Reactions (6.1)    and Table 2  ].",post-transplant lymphoproliferative disorder is an adverse reaction entity
"(5.8)               5.1 Post-Transplant Lymphoproliferative Disorder      NULOJIX-treated patients have an increased risk for developing post-transplant lymphoproliferative disorder (PTLD), predominantly involving the CNS, compared to patients on a cyclosporine-based regimen [see   Adverse Reactions (6.1)    and Table 2  ].",PTLD is an adverse reaction entity
"These infections may lead to serious, including fatal, outcomes [see   Boxed Warning    and   Adverse Reactions (6.1)    ].",infections is an adverse reaction entity
"These infections may lead to serious, including fatal, outcomes [see   Boxed Warning    and   Adverse Reactions (6.1)    ].",infections is an adverse reaction entity
"These infections may lead to serious, including fatal, outcomes [see   Boxed Warning    and   Adverse Reactions (6.1)    ].",fatal is an adverse reaction entity
Table 3: Overall Infections and Select Infections with Identified Etiology by Treatment Group following One and Three Years of Treatment in Studies 1 and 2*                                   Up to Year 1        Up to Year 3                                           NULOJIX    Recommended    Regimen    N=401    n (%)      Cyclosporine    N=405    n (%)      NULOJIX    Recommended    Regimen    N=401    n (%)      Cyclosporine    N=405    n (%)          *  Studies 1 and 2 were not designed to support comparative claims for NULOJIX for the adverse reactions reported in this table.,Infections is an adverse reaction entity
Table 3: Overall Infections and Select Infections with Identified Etiology by Treatment Group following One and Three Years of Treatment in Studies 1 and 2*                                   Up to Year 1        Up to Year 3                                           NULOJIX    Recommended    Regimen    N=401    n (%)      Cyclosporine    N=405    n (%)      NULOJIX    Recommended    Regimen    N=401    n (%)      Cyclosporine    N=405    n (%)          *  Studies 1 and 2 were not designed to support comparative claims for NULOJIX for the adverse reactions reported in this table.,Infections is an adverse reaction entity
"The most commonly reported adverse reactions occurring in >=20% of patients treated with the recommended dose and frequency of NULOJIX were anemia, diarrhea, urinary tract infection, peripheral edema, constipation, hypertension, pyrexia, graft dysfunction, cough, nausea, vomiting, headache, hypokalemia, hyperkalemia, and leukopenia.",anemia is an adverse reaction entity
"The most commonly reported adverse reactions occurring in >=20% of patients treated with the recommended dose and frequency of NULOJIX were anemia, diarrhea, urinary tract infection, peripheral edema, constipation, hypertension, pyrexia, graft dysfunction, cough, nausea, vomiting, headache, hypokalemia, hyperkalemia, and leukopenia.",diarrhea is an adverse reaction entity
"The most commonly reported adverse reactions occurring in >=20% of patients treated with the recommended dose and frequency of NULOJIX were anemia, diarrhea, urinary tract infection, peripheral edema, constipation, hypertension, pyrexia, graft dysfunction, cough, nausea, vomiting, headache, hypokalemia, hyperkalemia, and leukopenia.",urinary tract infection is an adverse reaction entity
"The most commonly reported adverse reactions occurring in >=20% of patients treated with the recommended dose and frequency of NULOJIX were anemia, diarrhea, urinary tract infection, peripheral edema, constipation, hypertension, pyrexia, graft dysfunction, cough, nausea, vomiting, headache, hypokalemia, hyperkalemia, and leukopenia.",peripheral edema is an adverse reaction entity
"The most commonly reported adverse reactions occurring in >=20% of patients treated with the recommended dose and frequency of NULOJIX were anemia, diarrhea, urinary tract infection, peripheral edema, constipation, hypertension, pyrexia, graft dysfunction, cough, nausea, vomiting, headache, hypokalemia, hyperkalemia, and leukopenia.",constipation is an adverse reaction entity
"The most commonly reported adverse reactions occurring in >=20% of patients treated with the recommended dose and frequency of NULOJIX were anemia, diarrhea, urinary tract infection, peripheral edema, constipation, hypertension, pyrexia, graft dysfunction, cough, nausea, vomiting, headache, hypokalemia, hyperkalemia, and leukopenia.",hypertension is an adverse reaction entity
"The most commonly reported adverse reactions occurring in >=20% of patients treated with the recommended dose and frequency of NULOJIX were anemia, diarrhea, urinary tract infection, peripheral edema, constipation, hypertension, pyrexia, graft dysfunction, cough, nausea, vomiting, headache, hypokalemia, hyperkalemia, and leukopenia.",pyrexia is an adverse reaction entity
"The most commonly reported adverse reactions occurring in >=20% of patients treated with the recommended dose and frequency of NULOJIX were anemia, diarrhea, urinary tract infection, peripheral edema, constipation, hypertension, pyrexia, graft dysfunction, cough, nausea, vomiting, headache, hypokalemia, hyperkalemia, and leukopenia.",graft dysfunction is an adverse reaction entity
"The most commonly reported adverse reactions occurring in >=20% of patients treated with the recommended dose and frequency of NULOJIX were anemia, diarrhea, urinary tract infection, peripheral edema, constipation, hypertension, pyrexia, graft dysfunction, cough, nausea, vomiting, headache, hypokalemia, hyperkalemia, and leukopenia.",cough is an adverse reaction entity
"The most commonly reported adverse reactions occurring in >=20% of patients treated with the recommended dose and frequency of NULOJIX were anemia, diarrhea, urinary tract infection, peripheral edema, constipation, hypertension, pyrexia, graft dysfunction, cough, nausea, vomiting, headache, hypokalemia, hyperkalemia, and leukopenia.",nausea is an adverse reaction entity
"The most commonly reported adverse reactions occurring in >=20% of patients treated with the recommended dose and frequency of NULOJIX were anemia, diarrhea, urinary tract infection, peripheral edema, constipation, hypertension, pyrexia, graft dysfunction, cough, nausea, vomiting, headache, hypokalemia, hyperkalemia, and leukopenia.",vomiting is an adverse reaction entity
"The most commonly reported adverse reactions occurring in >=20% of patients treated with the recommended dose and frequency of NULOJIX were anemia, diarrhea, urinary tract infection, peripheral edema, constipation, hypertension, pyrexia, graft dysfunction, cough, nausea, vomiting, headache, hypokalemia, hyperkalemia, and leukopenia.",headache is an adverse reaction entity
"The most commonly reported adverse reactions occurring in >=20% of patients treated with the recommended dose and frequency of NULOJIX were anemia, diarrhea, urinary tract infection, peripheral edema, constipation, hypertension, pyrexia, graft dysfunction, cough, nausea, vomiting, headache, hypokalemia, hyperkalemia, and leukopenia.",hypokalemia is an adverse reaction entity
"The most commonly reported adverse reactions occurring in >=20% of patients treated with the recommended dose and frequency of NULOJIX were anemia, diarrhea, urinary tract infection, peripheral edema, constipation, hypertension, pyrexia, graft dysfunction, cough, nausea, vomiting, headache, hypokalemia, hyperkalemia, and leukopenia.",hyperkalemia is an adverse reaction entity
"The most commonly reported adverse reactions occurring in >=20% of patients treated with the recommended dose and frequency of NULOJIX were anemia, diarrhea, urinary tract infection, peripheral edema, constipation, hypertension, pyrexia, graft dysfunction, cough, nausea, vomiting, headache, hypokalemia, hyperkalemia, and leukopenia.",leukopenia is an adverse reaction entity
"Among the 404 EBV seropositive recipients treated with the recommended dosage regimen of NULOJIX, three PTLD cases were detected among 99 CMV seronegative patients (3%) and there was no case detected among 303 CMV seropositive patients.",PTLD is an adverse reaction entity
S    A medically important event that may be life-threatening or result in death or hospitalization or prolongation of existing hospitalization.,death is an adverse reaction entity
PVAN is associated with serious outcomes; including deteriorating renal function and kidney graft loss [see   Adverse Reactions (6.1)    ].,PVAN is an adverse reaction entity
PVAN is associated with serious outcomes; including deteriorating renal function and kidney graft loss [see   Adverse Reactions (6.1)    ].,deteriorating renal function is an adverse reaction entity
PVAN is associated with serious outcomes; including deteriorating renal function and kidney graft loss [see   Adverse Reactions (6.1)    ].,kidney graft loss is an adverse reaction entity
The two cases of PTLD were reported among the 140 EBV seropositive patients (1.4%).,PTLD is an adverse reaction entity
(5.6)     *     Acute Rejection and Graft Loss with Corticosteroid Minimization : corticosteroid utilization should be consistent with the NULOJIX clinical trial experience.,Acute Rejection Graft is an adverse reaction entity
(5.6)     *     Acute Rejection and Graft Loss with Corticosteroid Minimization : corticosteroid utilization should be consistent with the NULOJIX clinical trial experience.,Graft Loss is an adverse reaction entity
EBV Serostatus      The risk of PTLD was higher in EBV seronegative patients compared to EBV seropositive patients.,PTLD is an adverse reaction entity
"Pooled analyses of 199 placebo-controlled clinical trials (mono- and adjunctive therapy) of 11 different AEDs showed that patients randomized to one of the AEDs had approximately twice the risk (adjusted relative risk 1.8, 95% confidence interval [CI]: 1.2, 2.7) of suicidal thinking or behavior compared to patients randomized to placebo.",suicidal thinking is an adverse reaction entity
"Pooled analyses of 199 placebo-controlled clinical trials (mono- and adjunctive therapy) of 11 different AEDs showed that patients randomized to one of the AEDs had approximately twice the risk (adjusted relative risk 1.8, 95% confidence interval [CI]: 1.2, 2.7) of suicidal thinking or behavior compared to patients randomized to placebo.",suicidal behavior is an adverse reaction entity
"Blood Disorders:    Anemia, eosinophilia, leukopenia, thrombocytopenia    Eye Disorders:    Diplopia, vision blurred    Gastrointestinal Disorders:    Abdominal distention    General Disorders and Administration Site Conditions:    Hypothermia    Investigations:    Hepatic enzyme increased    Musculoskeletal:    Muscle spasms    Psychiatric Disorders:    Agitation, anxiety, apathy, confusional state, depression, delirium, delusion, hallucination    Renal and Urinary Disorders:    Urinary retention    Respiratory Disorders:    Aspiration, respiratory depression    Skin and Subcutaneous Tissue Disorders:    Rash, urticaria, angioedema, and facial and lip edema",Anemia is an adverse reaction entity
"Blood Disorders:    Anemia, eosinophilia, leukopenia, thrombocytopenia    Eye Disorders:    Diplopia, vision blurred    Gastrointestinal Disorders:    Abdominal distention    General Disorders and Administration Site Conditions:    Hypothermia    Investigations:    Hepatic enzyme increased    Musculoskeletal:    Muscle spasms    Psychiatric Disorders:    Agitation, anxiety, apathy, confusional state, depression, delirium, delusion, hallucination    Renal and Urinary Disorders:    Urinary retention    Respiratory Disorders:    Aspiration, respiratory depression    Skin and Subcutaneous Tissue Disorders:    Rash, urticaria, angioedema, and facial and lip edema",eosinophilia is an adverse reaction entity
"Blood Disorders:    Anemia, eosinophilia, leukopenia, thrombocytopenia    Eye Disorders:    Diplopia, vision blurred    Gastrointestinal Disorders:    Abdominal distention    General Disorders and Administration Site Conditions:    Hypothermia    Investigations:    Hepatic enzyme increased    Musculoskeletal:    Muscle spasms    Psychiatric Disorders:    Agitation, anxiety, apathy, confusional state, depression, delirium, delusion, hallucination    Renal and Urinary Disorders:    Urinary retention    Respiratory Disorders:    Aspiration, respiratory depression    Skin and Subcutaneous Tissue Disorders:    Rash, urticaria, angioedema, and facial and lip edema",leukopenia is an adverse reaction entity
"Blood Disorders:    Anemia, eosinophilia, leukopenia, thrombocytopenia    Eye Disorders:    Diplopia, vision blurred    Gastrointestinal Disorders:    Abdominal distention    General Disorders and Administration Site Conditions:    Hypothermia    Investigations:    Hepatic enzyme increased    Musculoskeletal:    Muscle spasms    Psychiatric Disorders:    Agitation, anxiety, apathy, confusional state, depression, delirium, delusion, hallucination    Renal and Urinary Disorders:    Urinary retention    Respiratory Disorders:    Aspiration, respiratory depression    Skin and Subcutaneous Tissue Disorders:    Rash, urticaria, angioedema, and facial and lip edema",thrombocytopenia is an adverse reaction entity
"Blood Disorders:    Anemia, eosinophilia, leukopenia, thrombocytopenia    Eye Disorders:    Diplopia, vision blurred    Gastrointestinal Disorders:    Abdominal distention    General Disorders and Administration Site Conditions:    Hypothermia    Investigations:    Hepatic enzyme increased    Musculoskeletal:    Muscle spasms    Psychiatric Disorders:    Agitation, anxiety, apathy, confusional state, depression, delirium, delusion, hallucination    Renal and Urinary Disorders:    Urinary retention    Respiratory Disorders:    Aspiration, respiratory depression    Skin and Subcutaneous Tissue Disorders:    Rash, urticaria, angioedema, and facial and lip edema",Diplopia is an adverse reaction entity
"Blood Disorders:    Anemia, eosinophilia, leukopenia, thrombocytopenia    Eye Disorders:    Diplopia, vision blurred    Gastrointestinal Disorders:    Abdominal distention    General Disorders and Administration Site Conditions:    Hypothermia    Investigations:    Hepatic enzyme increased    Musculoskeletal:    Muscle spasms    Psychiatric Disorders:    Agitation, anxiety, apathy, confusional state, depression, delirium, delusion, hallucination    Renal and Urinary Disorders:    Urinary retention    Respiratory Disorders:    Aspiration, respiratory depression    Skin and Subcutaneous Tissue Disorders:    Rash, urticaria, angioedema, and facial and lip edema",vision blurred is an adverse reaction entity
"Blood Disorders:    Anemia, eosinophilia, leukopenia, thrombocytopenia    Eye Disorders:    Diplopia, vision blurred    Gastrointestinal Disorders:    Abdominal distention    General Disorders and Administration Site Conditions:    Hypothermia    Investigations:    Hepatic enzyme increased    Musculoskeletal:    Muscle spasms    Psychiatric Disorders:    Agitation, anxiety, apathy, confusional state, depression, delirium, delusion, hallucination    Renal and Urinary Disorders:    Urinary retention    Respiratory Disorders:    Aspiration, respiratory depression    Skin and Subcutaneous Tissue Disorders:    Rash, urticaria, angioedema, and facial and lip edema",Abdominal distention is an adverse reaction entity
"Blood Disorders:    Anemia, eosinophilia, leukopenia, thrombocytopenia    Eye Disorders:    Diplopia, vision blurred    Gastrointestinal Disorders:    Abdominal distention    General Disorders and Administration Site Conditions:    Hypothermia    Investigations:    Hepatic enzyme increased    Musculoskeletal:    Muscle spasms    Psychiatric Disorders:    Agitation, anxiety, apathy, confusional state, depression, delirium, delusion, hallucination    Renal and Urinary Disorders:    Urinary retention    Respiratory Disorders:    Aspiration, respiratory depression    Skin and Subcutaneous Tissue Disorders:    Rash, urticaria, angioedema, and facial and lip edema",Hypothermia is an adverse reaction entity
"Blood Disorders:    Anemia, eosinophilia, leukopenia, thrombocytopenia    Eye Disorders:    Diplopia, vision blurred    Gastrointestinal Disorders:    Abdominal distention    General Disorders and Administration Site Conditions:    Hypothermia    Investigations:    Hepatic enzyme increased    Musculoskeletal:    Muscle spasms    Psychiatric Disorders:    Agitation, anxiety, apathy, confusional state, depression, delirium, delusion, hallucination    Renal and Urinary Disorders:    Urinary retention    Respiratory Disorders:    Aspiration, respiratory depression    Skin and Subcutaneous Tissue Disorders:    Rash, urticaria, angioedema, and facial and lip edema",Hepatic enzyme increased is an adverse reaction entity
"Blood Disorders:    Anemia, eosinophilia, leukopenia, thrombocytopenia    Eye Disorders:    Diplopia, vision blurred    Gastrointestinal Disorders:    Abdominal distention    General Disorders and Administration Site Conditions:    Hypothermia    Investigations:    Hepatic enzyme increased    Musculoskeletal:    Muscle spasms    Psychiatric Disorders:    Agitation, anxiety, apathy, confusional state, depression, delirium, delusion, hallucination    Renal and Urinary Disorders:    Urinary retention    Respiratory Disorders:    Aspiration, respiratory depression    Skin and Subcutaneous Tissue Disorders:    Rash, urticaria, angioedema, and facial and lip edema",Muscle spasms is an adverse reaction entity
"Blood Disorders:    Anemia, eosinophilia, leukopenia, thrombocytopenia    Eye Disorders:    Diplopia, vision blurred    Gastrointestinal Disorders:    Abdominal distention    General Disorders and Administration Site Conditions:    Hypothermia    Investigations:    Hepatic enzyme increased    Musculoskeletal:    Muscle spasms    Psychiatric Disorders:    Agitation, anxiety, apathy, confusional state, depression, delirium, delusion, hallucination    Renal and Urinary Disorders:    Urinary retention    Respiratory Disorders:    Aspiration, respiratory depression    Skin and Subcutaneous Tissue Disorders:    Rash, urticaria, angioedema, and facial and lip edema",Agitation is an adverse reaction entity
"Blood Disorders:    Anemia, eosinophilia, leukopenia, thrombocytopenia    Eye Disorders:    Diplopia, vision blurred    Gastrointestinal Disorders:    Abdominal distention    General Disorders and Administration Site Conditions:    Hypothermia    Investigations:    Hepatic enzyme increased    Musculoskeletal:    Muscle spasms    Psychiatric Disorders:    Agitation, anxiety, apathy, confusional state, depression, delirium, delusion, hallucination    Renal and Urinary Disorders:    Urinary retention    Respiratory Disorders:    Aspiration, respiratory depression    Skin and Subcutaneous Tissue Disorders:    Rash, urticaria, angioedema, and facial and lip edema",anxiety is an adverse reaction entity
"Blood Disorders:    Anemia, eosinophilia, leukopenia, thrombocytopenia    Eye Disorders:    Diplopia, vision blurred    Gastrointestinal Disorders:    Abdominal distention    General Disorders and Administration Site Conditions:    Hypothermia    Investigations:    Hepatic enzyme increased    Musculoskeletal:    Muscle spasms    Psychiatric Disorders:    Agitation, anxiety, apathy, confusional state, depression, delirium, delusion, hallucination    Renal and Urinary Disorders:    Urinary retention    Respiratory Disorders:    Aspiration, respiratory depression    Skin and Subcutaneous Tissue Disorders:    Rash, urticaria, angioedema, and facial and lip edema",apathy is an adverse reaction entity
"Blood Disorders:    Anemia, eosinophilia, leukopenia, thrombocytopenia    Eye Disorders:    Diplopia, vision blurred    Gastrointestinal Disorders:    Abdominal distention    General Disorders and Administration Site Conditions:    Hypothermia    Investigations:    Hepatic enzyme increased    Musculoskeletal:    Muscle spasms    Psychiatric Disorders:    Agitation, anxiety, apathy, confusional state, depression, delirium, delusion, hallucination    Renal and Urinary Disorders:    Urinary retention    Respiratory Disorders:    Aspiration, respiratory depression    Skin and Subcutaneous Tissue Disorders:    Rash, urticaria, angioedema, and facial and lip edema",confusional state is an adverse reaction entity
"Blood Disorders:    Anemia, eosinophilia, leukopenia, thrombocytopenia    Eye Disorders:    Diplopia, vision blurred    Gastrointestinal Disorders:    Abdominal distention    General Disorders and Administration Site Conditions:    Hypothermia    Investigations:    Hepatic enzyme increased    Musculoskeletal:    Muscle spasms    Psychiatric Disorders:    Agitation, anxiety, apathy, confusional state, depression, delirium, delusion, hallucination    Renal and Urinary Disorders:    Urinary retention    Respiratory Disorders:    Aspiration, respiratory depression    Skin and Subcutaneous Tissue Disorders:    Rash, urticaria, angioedema, and facial and lip edema",depression is an adverse reaction entity
"Blood Disorders:    Anemia, eosinophilia, leukopenia, thrombocytopenia    Eye Disorders:    Diplopia, vision blurred    Gastrointestinal Disorders:    Abdominal distention    General Disorders and Administration Site Conditions:    Hypothermia    Investigations:    Hepatic enzyme increased    Musculoskeletal:    Muscle spasms    Psychiatric Disorders:    Agitation, anxiety, apathy, confusional state, depression, delirium, delusion, hallucination    Renal and Urinary Disorders:    Urinary retention    Respiratory Disorders:    Aspiration, respiratory depression    Skin and Subcutaneous Tissue Disorders:    Rash, urticaria, angioedema, and facial and lip edema",delirium is an adverse reaction entity
"Blood Disorders:    Anemia, eosinophilia, leukopenia, thrombocytopenia    Eye Disorders:    Diplopia, vision blurred    Gastrointestinal Disorders:    Abdominal distention    General Disorders and Administration Site Conditions:    Hypothermia    Investigations:    Hepatic enzyme increased    Musculoskeletal:    Muscle spasms    Psychiatric Disorders:    Agitation, anxiety, apathy, confusional state, depression, delirium, delusion, hallucination    Renal and Urinary Disorders:    Urinary retention    Respiratory Disorders:    Aspiration, respiratory depression    Skin and Subcutaneous Tissue Disorders:    Rash, urticaria, angioedema, and facial and lip edema",delusion is an adverse reaction entity
"Blood Disorders:    Anemia, eosinophilia, leukopenia, thrombocytopenia    Eye Disorders:    Diplopia, vision blurred    Gastrointestinal Disorders:    Abdominal distention    General Disorders and Administration Site Conditions:    Hypothermia    Investigations:    Hepatic enzyme increased    Musculoskeletal:    Muscle spasms    Psychiatric Disorders:    Agitation, anxiety, apathy, confusional state, depression, delirium, delusion, hallucination    Renal and Urinary Disorders:    Urinary retention    Respiratory Disorders:    Aspiration, respiratory depression    Skin and Subcutaneous Tissue Disorders:    Rash, urticaria, angioedema, and facial and lip edema",hallucination is an adverse reaction entity
"Blood Disorders:    Anemia, eosinophilia, leukopenia, thrombocytopenia    Eye Disorders:    Diplopia, vision blurred    Gastrointestinal Disorders:    Abdominal distention    General Disorders and Administration Site Conditions:    Hypothermia    Investigations:    Hepatic enzyme increased    Musculoskeletal:    Muscle spasms    Psychiatric Disorders:    Agitation, anxiety, apathy, confusional state, depression, delirium, delusion, hallucination    Renal and Urinary Disorders:    Urinary retention    Respiratory Disorders:    Aspiration, respiratory depression    Skin and Subcutaneous Tissue Disorders:    Rash, urticaria, angioedema, and facial and lip edema",Urinary retention is an adverse reaction entity
"Blood Disorders:    Anemia, eosinophilia, leukopenia, thrombocytopenia    Eye Disorders:    Diplopia, vision blurred    Gastrointestinal Disorders:    Abdominal distention    General Disorders and Administration Site Conditions:    Hypothermia    Investigations:    Hepatic enzyme increased    Musculoskeletal:    Muscle spasms    Psychiatric Disorders:    Agitation, anxiety, apathy, confusional state, depression, delirium, delusion, hallucination    Renal and Urinary Disorders:    Urinary retention    Respiratory Disorders:    Aspiration, respiratory depression    Skin and Subcutaneous Tissue Disorders:    Rash, urticaria, angioedema, and facial and lip edema",Aspiration is an adverse reaction entity
"Blood Disorders:    Anemia, eosinophilia, leukopenia, thrombocytopenia    Eye Disorders:    Diplopia, vision blurred    Gastrointestinal Disorders:    Abdominal distention    General Disorders and Administration Site Conditions:    Hypothermia    Investigations:    Hepatic enzyme increased    Musculoskeletal:    Muscle spasms    Psychiatric Disorders:    Agitation, anxiety, apathy, confusional state, depression, delirium, delusion, hallucination    Renal and Urinary Disorders:    Urinary retention    Respiratory Disorders:    Aspiration, respiratory depression    Skin and Subcutaneous Tissue Disorders:    Rash, urticaria, angioedema, and facial and lip edema",respiratory depression is an adverse reaction entity
"Blood Disorders:    Anemia, eosinophilia, leukopenia, thrombocytopenia    Eye Disorders:    Diplopia, vision blurred    Gastrointestinal Disorders:    Abdominal distention    General Disorders and Administration Site Conditions:    Hypothermia    Investigations:    Hepatic enzyme increased    Musculoskeletal:    Muscle spasms    Psychiatric Disorders:    Agitation, anxiety, apathy, confusional state, depression, delirium, delusion, hallucination    Renal and Urinary Disorders:    Urinary retention    Respiratory Disorders:    Aspiration, respiratory depression    Skin and Subcutaneous Tissue Disorders:    Rash, urticaria, angioedema, and facial and lip edema",Rash is an adverse reaction entity
"Blood Disorders:    Anemia, eosinophilia, leukopenia, thrombocytopenia    Eye Disorders:    Diplopia, vision blurred    Gastrointestinal Disorders:    Abdominal distention    General Disorders and Administration Site Conditions:    Hypothermia    Investigations:    Hepatic enzyme increased    Musculoskeletal:    Muscle spasms    Psychiatric Disorders:    Agitation, anxiety, apathy, confusional state, depression, delirium, delusion, hallucination    Renal and Urinary Disorders:    Urinary retention    Respiratory Disorders:    Aspiration, respiratory depression    Skin and Subcutaneous Tissue Disorders:    Rash, urticaria, angioedema, and facial and lip edema",urticaria is an adverse reaction entity
"Blood Disorders:    Anemia, eosinophilia, leukopenia, thrombocytopenia    Eye Disorders:    Diplopia, vision blurred    Gastrointestinal Disorders:    Abdominal distention    General Disorders and Administration Site Conditions:    Hypothermia    Investigations:    Hepatic enzyme increased    Musculoskeletal:    Muscle spasms    Psychiatric Disorders:    Agitation, anxiety, apathy, confusional state, depression, delirium, delusion, hallucination    Renal and Urinary Disorders:    Urinary retention    Respiratory Disorders:    Aspiration, respiratory depression    Skin and Subcutaneous Tissue Disorders:    Rash, urticaria, angioedema, and facial and lip edema",angioedema is an adverse reaction entity
"Blood Disorders:    Anemia, eosinophilia, leukopenia, thrombocytopenia    Eye Disorders:    Diplopia, vision blurred    Gastrointestinal Disorders:    Abdominal distention    General Disorders and Administration Site Conditions:    Hypothermia    Investigations:    Hepatic enzyme increased    Musculoskeletal:    Muscle spasms    Psychiatric Disorders:    Agitation, anxiety, apathy, confusional state, depression, delirium, delusion, hallucination    Renal and Urinary Disorders:    Urinary retention    Respiratory Disorders:    Aspiration, respiratory depression    Skin and Subcutaneous Tissue Disorders:    Rash, urticaria, angioedema, and facial and lip edema",facial edema is an adverse reaction entity
"Blood Disorders:    Anemia, eosinophilia, leukopenia, thrombocytopenia    Eye Disorders:    Diplopia, vision blurred    Gastrointestinal Disorders:    Abdominal distention    General Disorders and Administration Site Conditions:    Hypothermia    Investigations:    Hepatic enzyme increased    Musculoskeletal:    Muscle spasms    Psychiatric Disorders:    Agitation, anxiety, apathy, confusional state, depression, delirium, delusion, hallucination    Renal and Urinary Disorders:    Urinary retention    Respiratory Disorders:    Aspiration, respiratory depression    Skin and Subcutaneous Tissue Disorders:    Rash, urticaria, angioedema, and facial and lip edema",lip edema is an adverse reaction entity
"Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed.",suicidal thoughts is an adverse reaction entity
"Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed.",suicidal behavior is an adverse reaction entity
The increased risk of suicidal thoughts or behavior with AEDs was observed as early as one week after starting drug treatment with AEDs and persisted for the duration of treatment assessed.,suicidal thoughts is an adverse reaction entity
The increased risk of suicidal thoughts or behavior with AEDs was observed as early as one week after starting drug treatment with AEDs and persisted for the duration of treatment assessed.,suicidal behavior is an adverse reaction entity
"Hyperglycemia and Diabetes Mellitus       Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics including FANAPT.",Hyperglycemia is an adverse reaction entity
"Hyperglycemia and Diabetes Mellitus       Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics including FANAPT.",Hyperglycemia is an adverse reaction entity
"Hyperglycemia and Diabetes Mellitus       Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics including FANAPT.",ketoacidosis is an adverse reaction entity
"Hyperglycemia and Diabetes Mellitus       Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics including FANAPT.",hyperosmolar coma is an adverse reaction entity
"Hyperglycemia and Diabetes Mellitus       Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics including FANAPT.",death is an adverse reaction entity
"In short-term placebo-controlled trials (4- to 6-weeks), there were 1.0% (13/1342) iloperidone-treated patients with hematocrit at least one time below the extended normal range during post-randomization treatment, compared to 0.3% (2/585) on placebo.",hematocrit below the extended normal range is an adverse reaction entity
"Cerebrovascular Adverse Events, Including Stroke       In placebo-controlled trials with risperidone, aripiprazole, and olanzapine in elderly patients with dementia, there was a higher incidence of cerebrovascular adverse events (cerebrovascular accidents and transient ischemic attacks) including fatalities compared to placebo-treated patients.",cerebrovascular adverse events is an adverse reaction entity
"Cerebrovascular Adverse Events, Including Stroke       In placebo-controlled trials with risperidone, aripiprazole, and olanzapine in elderly patients with dementia, there was a higher incidence of cerebrovascular adverse events (cerebrovascular accidents and transient ischemic attacks) including fatalities compared to placebo-treated patients.",cerebrovascular accidents is an adverse reaction entity
"Cerebrovascular Adverse Events, Including Stroke       In placebo-controlled trials with risperidone, aripiprazole, and olanzapine in elderly patients with dementia, there was a higher incidence of cerebrovascular adverse events (cerebrovascular accidents and transient ischemic attacks) including fatalities compared to placebo-treated patients.",transient ischemic attacks is an adverse reaction entity
"Cerebrovascular Adverse Events, Including Stroke       In placebo-controlled trials with risperidone, aripiprazole, and olanzapine in elderly patients with dementia, there was a higher incidence of cerebrovascular adverse events (cerebrovascular accidents and transient ischemic attacks) including fatalities compared to placebo-treated patients.",fatalities is an adverse reaction entity
"Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure.",elevated creatine phosphokinase is an adverse reaction entity
"Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure.",myoglobinuria is an adverse reaction entity
"Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure.",rhabdomyolysis is an adverse reaction entity
"Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure.",acute renal failure is an adverse reaction entity
5.1     Increased Risks in Elderly Patients with Dementia-Related Psychosis       Increased Mortality        Elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo.,death is an adverse reaction entity
"5     WARNINGS AND PRECAUTIONS       EXCERPT:    *   Elderly patients with dementia-related psychosis who are treated with atypical antipsychotic drugs are at an increased risk of death and cerebrovascular-related adverse events, including stroke.",death is an adverse reaction entity
"5     WARNINGS AND PRECAUTIONS       EXCERPT:    *   Elderly patients with dementia-related psychosis who are treated with atypical antipsychotic drugs are at an increased risk of death and cerebrovascular-related adverse events, including stroke.",cerebrovascular-related adverse events is an adverse reaction entity
"5     WARNINGS AND PRECAUTIONS       EXCERPT:    *   Elderly patients with dementia-related psychosis who are treated with atypical antipsychotic drugs are at an increased risk of death and cerebrovascular-related adverse events, including stroke.",stroke is an adverse reaction entity
"(  5.4  )   *  *   Hyperglycemia and diabetes mellitus: Monitor patients for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness.",Hyperglycemia is an adverse reaction entity
"(  5.4  )   *  *   Hyperglycemia and diabetes mellitus: Monitor patients for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness.",diabetes mellitus is an adverse reaction entity
(  5.5  )   *   Seizures: Use cautiously in patients with a history of seizures or with conditions that lower seizure threshold.,Seizures is an adverse reaction entity
"Extrapyramidal Symptoms (EPS) in Clinical Trials       Pooled data from the 4 placebo-controlled, 4- or 6-week, fixed- or flexible-dose studies provided information regarding treatment-emergent EPS.",EPS is an adverse reaction entity
"6     ADVERSE REACTIONS    EXCERPT:   Commonly observed adverse reactions (incidence >=5% and 2-fold greater than placebo) were: dizziness, dry mouth, fatigue, nasal congestion, orthostatic hypotension, somnolence, tachycardia, and weight increased.",dizziness is an adverse reaction entity
"6     ADVERSE REACTIONS    EXCERPT:   Commonly observed adverse reactions (incidence >=5% and 2-fold greater than placebo) were: dizziness, dry mouth, fatigue, nasal congestion, orthostatic hypotension, somnolence, tachycardia, and weight increased.",dry mouth is an adverse reaction entity
"6     ADVERSE REACTIONS    EXCERPT:   Commonly observed adverse reactions (incidence >=5% and 2-fold greater than placebo) were: dizziness, dry mouth, fatigue, nasal congestion, orthostatic hypotension, somnolence, tachycardia, and weight increased.",fatigue is an adverse reaction entity
"6     ADVERSE REACTIONS    EXCERPT:   Commonly observed adverse reactions (incidence >=5% and 2-fold greater than placebo) were: dizziness, dry mouth, fatigue, nasal congestion, orthostatic hypotension, somnolence, tachycardia, and weight increased.",nasal congestion is an adverse reaction entity
"6     ADVERSE REACTIONS    EXCERPT:   Commonly observed adverse reactions (incidence >=5% and 2-fold greater than placebo) were: dizziness, dry mouth, fatigue, nasal congestion, orthostatic hypotension, somnolence, tachycardia, and weight increased.",orthostatic hypotension is an adverse reaction entity
"6     ADVERSE REACTIONS    EXCERPT:   Commonly observed adverse reactions (incidence >=5% and 2-fold greater than placebo) were: dizziness, dry mouth, fatigue, nasal congestion, orthostatic hypotension, somnolence, tachycardia, and weight increased.",somnolence is an adverse reaction entity
"6     ADVERSE REACTIONS    EXCERPT:   Commonly observed adverse reactions (incidence >=5% and 2-fold greater than placebo) were: dizziness, dry mouth, fatigue, nasal congestion, orthostatic hypotension, somnolence, tachycardia, and weight increased.",tachycardia is an adverse reaction entity
"6     ADVERSE REACTIONS    EXCERPT:   Commonly observed adverse reactions (incidence >=5% and 2-fold greater than placebo) were: dizziness, dry mouth, fatigue, nasal congestion, orthostatic hypotension, somnolence, tachycardia, and weight increased.",weight increased is an adverse reaction entity
"However, epidemiological studies suggest an increased risk of treatment-emergent hyperglycemia-related adverse events in patients treated with the atypical antipsychotics included in these studies.",hyperglycemia-related adverse events is an adverse reaction entity
"Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.",death is an adverse reaction entity
"Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.",deaths is an adverse reaction entity
"Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.",heart failure is an adverse reaction entity
"Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.",sudden death is an adverse reaction entity
"Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.",pneumonia is an adverse reaction entity
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.,death is an adverse reaction entity
(  5.5  )      Metabolic Changes: Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk.,Metabolic Changes is an adverse reaction entity
(  5.5  )      Metabolic Changes: Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk.,cardiovascular risk is an adverse reaction entity
(  5.5  )      Metabolic Changes: Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk.,cerebrovascular risk is an adverse reaction entity
5.12 Embryo-fetal Toxicity      COMETRIQ can cause fetal harm when administered to a pregnant woman.,fetal harm is an adverse reaction entity
"(  5.11  ,  8.1  )             5.1 Perforations and Fistulas      Gastrointestinal (GI) perforations and fistulas were reported in 3% and 1% of COMETRIQ-treated patients, respectively.",Gastrointestinal perforations is an adverse reaction entity
"(  5.11  ,  8.1  )             5.1 Perforations and Fistulas      Gastrointestinal (GI) perforations and fistulas were reported in 3% and 1% of COMETRIQ-treated patients, respectively.",Gastrointestinal fistulas is an adverse reaction entity
"(  5.11  ,  8.1  )             5.1 Perforations and Fistulas      Gastrointestinal (GI) perforations and fistulas were reported in 3% and 1% of COMETRIQ-treated patients, respectively.",GI perforations is an adverse reaction entity
"(  5.11  ,  8.1  )             5.1 Perforations and Fistulas      Gastrointestinal (GI) perforations and fistulas were reported in 3% and 1% of COMETRIQ-treated patients, respectively.",GI fistulas is an adverse reaction entity
(  5.8  )   *  Reversible posterior leukoencephalopathy syndrome (RPLS): Discontinue COMETRIQ.,Reversible posterior leukoencephalopathy syndrome is an adverse reaction entity
(  5.8  )   *  Reversible posterior leukoencephalopathy syndrome (RPLS): Discontinue COMETRIQ.,RPLS is an adverse reaction entity
"The most frequent adverse reactions leading to permanent discontinuation in patients treated with COMETRIQ were: hypocalcemia, increased lipase, PPES, diarrhea, fatigue, hypertension, nausea, pancreatitis, tracheal fistula formation and vomiting.",hypocalcemia is an adverse reaction entity
"The most frequent adverse reactions leading to permanent discontinuation in patients treated with COMETRIQ were: hypocalcemia, increased lipase, PPES, diarrhea, fatigue, hypertension, nausea, pancreatitis, tracheal fistula formation and vomiting.",increased lipase is an adverse reaction entity
"The most frequent adverse reactions leading to permanent discontinuation in patients treated with COMETRIQ were: hypocalcemia, increased lipase, PPES, diarrhea, fatigue, hypertension, nausea, pancreatitis, tracheal fistula formation and vomiting.",PPES is an adverse reaction entity
"The most frequent adverse reactions leading to permanent discontinuation in patients treated with COMETRIQ were: hypocalcemia, increased lipase, PPES, diarrhea, fatigue, hypertension, nausea, pancreatitis, tracheal fistula formation and vomiting.",diarrhea is an adverse reaction entity
"The most frequent adverse reactions leading to permanent discontinuation in patients treated with COMETRIQ were: hypocalcemia, increased lipase, PPES, diarrhea, fatigue, hypertension, nausea, pancreatitis, tracheal fistula formation and vomiting.",fatigue is an adverse reaction entity
"The most frequent adverse reactions leading to permanent discontinuation in patients treated with COMETRIQ were: hypocalcemia, increased lipase, PPES, diarrhea, fatigue, hypertension, nausea, pancreatitis, tracheal fistula formation and vomiting.",hypertension is an adverse reaction entity
"The most frequent adverse reactions leading to permanent discontinuation in patients treated with COMETRIQ were: hypocalcemia, increased lipase, PPES, diarrhea, fatigue, hypertension, nausea, pancreatitis, tracheal fistula formation and vomiting.",nausea is an adverse reaction entity
"The most frequent adverse reactions leading to permanent discontinuation in patients treated with COMETRIQ were: hypocalcemia, increased lipase, PPES, diarrhea, fatigue, hypertension, nausea, pancreatitis, tracheal fistula formation and vomiting.",pancreatitis is an adverse reaction entity
"The most frequent adverse reactions leading to permanent discontinuation in patients treated with COMETRIQ were: hypocalcemia, increased lipase, PPES, diarrhea, fatigue, hypertension, nausea, pancreatitis, tracheal fistula formation and vomiting.",tracheal fistula formation is an adverse reaction entity
"The most frequent adverse reactions leading to permanent discontinuation in patients treated with COMETRIQ were: hypocalcemia, increased lipase, PPES, diarrhea, fatigue, hypertension, nausea, pancreatitis, tracheal fistula formation and vomiting.",vomiting is an adverse reaction entity
Non-GI fistulas including tracheal/esophageal were reported in 4% of COMETRIQ-treated patients.,Non-GI fistulas is an adverse reaction entity
Non-GI fistulas including tracheal/esophageal were reported in 4% of COMETRIQ-treated patients.,fistulas tracheal is an adverse reaction entity
Non-GI fistulas including tracheal/esophageal were reported in 4% of COMETRIQ-treated patients.,fistulas esophageal is an adverse reaction entity
"ONJ can manifest as jaw pain, osteomyelitis, osteitis, bone erosion, tooth or periodontal infection, toothache, gingival ulceration or erosion, persistent jaw pain or slow healing of the mouth or jaw after dental surgery.",ONJ is an adverse reaction entity
"ONJ can manifest as jaw pain, osteomyelitis, osteitis, bone erosion, tooth or periodontal infection, toothache, gingival ulceration or erosion, persistent jaw pain or slow healing of the mouth or jaw after dental surgery.",jaw pain is an adverse reaction entity
"ONJ can manifest as jaw pain, osteomyelitis, osteitis, bone erosion, tooth or periodontal infection, toothache, gingival ulceration or erosion, persistent jaw pain or slow healing of the mouth or jaw after dental surgery.",osteomyelitis is an adverse reaction entity
"ONJ can manifest as jaw pain, osteomyelitis, osteitis, bone erosion, tooth or periodontal infection, toothache, gingival ulceration or erosion, persistent jaw pain or slow healing of the mouth or jaw after dental surgery.",osteitis is an adverse reaction entity
"ONJ can manifest as jaw pain, osteomyelitis, osteitis, bone erosion, tooth or periodontal infection, toothache, gingival ulceration or erosion, persistent jaw pain or slow healing of the mouth or jaw after dental surgery.",bone erosion is an adverse reaction entity
"ONJ can manifest as jaw pain, osteomyelitis, osteitis, bone erosion, tooth or periodontal infection, toothache, gingival ulceration or erosion, persistent jaw pain or slow healing of the mouth or jaw after dental surgery.",tooth infection is an adverse reaction entity
"ONJ can manifest as jaw pain, osteomyelitis, osteitis, bone erosion, tooth or periodontal infection, toothache, gingival ulceration or erosion, persistent jaw pain or slow healing of the mouth or jaw after dental surgery.",periodontal infection is an adverse reaction entity
"ONJ can manifest as jaw pain, osteomyelitis, osteitis, bone erosion, tooth or periodontal infection, toothache, gingival ulceration or erosion, persistent jaw pain or slow healing of the mouth or jaw after dental surgery.",toothache is an adverse reaction entity
"ONJ can manifest as jaw pain, osteomyelitis, osteitis, bone erosion, tooth or periodontal infection, toothache, gingival ulceration or erosion, persistent jaw pain or slow healing of the mouth or jaw after dental surgery.",gingival ulceration is an adverse reaction entity
"ONJ can manifest as jaw pain, osteomyelitis, osteitis, bone erosion, tooth or periodontal infection, toothache, gingival ulceration or erosion, persistent jaw pain or slow healing of the mouth or jaw after dental surgery.",gingival erosion is an adverse reaction entity
"ONJ can manifest as jaw pain, osteomyelitis, osteitis, bone erosion, tooth or periodontal infection, toothache, gingival ulceration or erosion, persistent jaw pain or slow healing of the mouth or jaw after dental surgery.",persistent jaw pain is an adverse reaction entity
"ONJ can manifest as jaw pain, osteomyelitis, osteitis, bone erosion, tooth or periodontal infection, toothache, gingival ulceration or erosion, persistent jaw pain or slow healing of the mouth or jaw after dental surgery.",slow healing of the mouth after dental surgery is an adverse reaction entity
"ONJ can manifest as jaw pain, osteomyelitis, osteitis, bone erosion, tooth or periodontal infection, toothache, gingival ulceration or erosion, persistent jaw pain or slow healing of the mouth or jaw after dental surgery.",slow healing of the jaw after dental surgery is an adverse reaction entity
"Fatal adverse reactions occurred in 5% of patients receiving placebo and resulted from septicemia, pneumonia, and general deterioration.",Fatal is an adverse reaction entity
"Fatal adverse reactions occurred in 5% of patients receiving placebo and resulted from septicemia, pneumonia, and general deterioration.",septicemia is an adverse reaction entity
"Fatal adverse reactions occurred in 5% of patients receiving placebo and resulted from septicemia, pneumonia, and general deterioration.",pneumonia is an adverse reaction entity
"Fatal adverse reactions occurred in 5% of patients receiving placebo and resulted from septicemia, pneumonia, and general deterioration.",general deterioration is an adverse reaction entity
"In clinical studies, there were uncommon reports of ischemic cardiac adverse reactions, including myocardial ischemia, myocardial infarction, and coronary occlusion requiring revascularization; these patients had multiple underlying cardiac risk factors.",ischemic cardiac adverse reactions is an adverse reaction entity
"In clinical studies, there were uncommon reports of ischemic cardiac adverse reactions, including myocardial ischemia, myocardial infarction, and coronary occlusion requiring revascularization; these patients had multiple underlying cardiac risk factors.",myocardial ischemia is an adverse reaction entity
"In clinical studies, there were uncommon reports of ischemic cardiac adverse reactions, including myocardial ischemia, myocardial infarction, and coronary occlusion requiring revascularization; these patients had multiple underlying cardiac risk factors.",myocardial infarction is an adverse reaction entity
"In clinical studies, there were uncommon reports of ischemic cardiac adverse reactions, including myocardial ischemia, myocardial infarction, and coronary occlusion requiring revascularization; these patients had multiple underlying cardiac risk factors.",coronary occlusion is an adverse reaction entity
"5.9 Hyponatremia      Hyponatremia may occur as a result of treatment with SSRIs and SNRIs, including PRISTIQ.",Hyponatremia is an adverse reaction entity
"5.2 Serotonin Syndrome      The development of a potentially life-threatening serotonin syndrome has been reported with SNRIs and SSRIs, including PRISTIQ, alone but particularly with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John's Wort), and with drugs that impair metabolism of serotonin (in particular, MAOIs, both those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).",serotonin syndrome is an adverse reaction entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure:         Skin and subcutaneous tissue disorders    - Stevens-Johnson syndrome.",Stevens-Johnson syndrome is an adverse reaction entity
"*  Increased risk of suicidal thinking and behavior in children, adolescents and young adults taking antidepressants (5.1).",suicidal thinking is an adverse reaction entity
"*  Increased risk of suicidal thinking and behavior in children, adolescents and young adults taking antidepressants (5.1).",suicidal behavior is an adverse reaction entity
"Table 1    Age Range           Drug-Placebo Difference in Number of Cases of Suicidality per 1,000 Patients Treated                               Increases Compared to Placebo                                             <18                 14 additional cases                                                       18 to 24            5 additional cases                                                                            Decreases Compared to Placebo                                             25 to 64            1 fewer case                                                              >=65                6 fewer cases                                                                   No suicides occurred in any of the pediatric studies.",Suicidality is an adverse reaction entity
"Table 1    Age Range           Drug-Placebo Difference in Number of Cases of Suicidality per 1,000 Patients Treated                               Increases Compared to Placebo                                             <18                 14 additional cases                                                       18 to 24            5 additional cases                                                                            Decreases Compared to Placebo                                             25 to 64            1 fewer case                                                              >=65                6 fewer cases                                                                   No suicides occurred in any of the pediatric studies.",suicides is an adverse reaction entity
"In many cases, this hyponatremia appears to be the result of the syndrome of inappropriate antidiuretic hormone secretion (SIADH).",hyponatremia is an adverse reaction entity
"In many cases, this hyponatremia appears to be the result of the syndrome of inappropriate antidiuretic hormone secretion (SIADH).",syndrome of inappropriate antidiuretic hormone secretion is an adverse reaction entity
"In many cases, this hyponatremia appears to be the result of the syndrome of inappropriate antidiuretic hormone secretion (SIADH).",SIADH is an adverse reaction entity
"Abrupt discontinuation or dose reduction has been associated with the appearance of new symptoms that include dizziness, nausea, headache, irritability, insomnia, diarrhea, anxiety, fatigue, abnormal dreams, and hyperhidrosis.",dizziness is an adverse reaction entity
"Abrupt discontinuation or dose reduction has been associated with the appearance of new symptoms that include dizziness, nausea, headache, irritability, insomnia, diarrhea, anxiety, fatigue, abnormal dreams, and hyperhidrosis.",nausea is an adverse reaction entity
"Abrupt discontinuation or dose reduction has been associated with the appearance of new symptoms that include dizziness, nausea, headache, irritability, insomnia, diarrhea, anxiety, fatigue, abnormal dreams, and hyperhidrosis.",headache is an adverse reaction entity
"Abrupt discontinuation or dose reduction has been associated with the appearance of new symptoms that include dizziness, nausea, headache, irritability, insomnia, diarrhea, anxiety, fatigue, abnormal dreams, and hyperhidrosis.",irritability is an adverse reaction entity
"Abrupt discontinuation or dose reduction has been associated with the appearance of new symptoms that include dizziness, nausea, headache, irritability, insomnia, diarrhea, anxiety, fatigue, abnormal dreams, and hyperhidrosis.",insomnia is an adverse reaction entity
"Abrupt discontinuation or dose reduction has been associated with the appearance of new symptoms that include dizziness, nausea, headache, irritability, insomnia, diarrhea, anxiety, fatigue, abnormal dreams, and hyperhidrosis.",diarrhea is an adverse reaction entity
"Abrupt discontinuation or dose reduction has been associated with the appearance of new symptoms that include dizziness, nausea, headache, irritability, insomnia, diarrhea, anxiety, fatigue, abnormal dreams, and hyperhidrosis.",anxiety is an adverse reaction entity
"Abrupt discontinuation or dose reduction has been associated with the appearance of new symptoms that include dizziness, nausea, headache, irritability, insomnia, diarrhea, anxiety, fatigue, abnormal dreams, and hyperhidrosis.",fatigue is an adverse reaction entity
"Abrupt discontinuation or dose reduction has been associated with the appearance of new symptoms that include dizziness, nausea, headache, irritability, insomnia, diarrhea, anxiety, fatigue, abnormal dreams, and hyperhidrosis.",abnormal dreams is an adverse reaction entity
"Abrupt discontinuation or dose reduction has been associated with the appearance of new symptoms that include dizziness, nausea, headache, irritability, insomnia, diarrhea, anxiety, fatigue, abnormal dreams, and hyperhidrosis.",hyperhidrosis is an adverse reaction entity
"Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea).",Serotonin syndrome is an adverse reaction entity
"Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea).",mental status changes is an adverse reaction entity
"Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea).",agitation is an adverse reaction entity
"Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea).",hallucinations is an adverse reaction entity
"Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea).",delirium is an adverse reaction entity
"Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea).",coma is an adverse reaction entity
"Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea).",autonomic instability is an adverse reaction entity
"Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea).",tachycardia is an adverse reaction entity
"Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea).",labile blood pressure is an adverse reaction entity
"Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea).",dizziness is an adverse reaction entity
"Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea).",diaphoresis is an adverse reaction entity
"Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea).",flushing is an adverse reaction entity
"Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea).",hyperthermia is an adverse reaction entity
"Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea).",neuromuscular symptoms is an adverse reaction entity
"Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea).",tremor is an adverse reaction entity
"Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea).",rigidity is an adverse reaction entity
"Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea).",myoclonus is an adverse reaction entity
"Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea).",hyperreflexia is an adverse reaction entity
"Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea).",incoordination is an adverse reaction entity
"Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea).",seizures is an adverse reaction entity
"Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea).",gastrointestinal symptoms is an adverse reaction entity
"Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea).",nausea is an adverse reaction entity
"Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea).",vomiting is an adverse reaction entity
"Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea).",diarrhea is an adverse reaction entity
*     Interstitial Lung Disease and Eosinophilic Pneumonia: Can occur (  5.10  ).,Interstitial Lung Disease is an adverse reaction entity
*     Interstitial Lung Disease and Eosinophilic Pneumonia: Can occur (  5.10  ).,Eosinophilic Pneumonia is an adverse reaction entity
It is generally believed (though not established in controlled studies) that treating such an episode with an antidepressant alone may increase the likelihood of precipitation of a mixed/manic episode in patients at risk for bipolar disorder.,precipitation of a manic episode is an adverse reaction entity
It is generally believed (though not established in controlled studies) that treating such an episode with an antidepressant alone may increase the likelihood of precipitation of a mixed/manic episode in patients at risk for bipolar disorder.,precipitation of a mixed episode is an adverse reaction entity
Cases of elevated blood pressure requiring immediate treatment have been reported with PRISTIQ.,elevated blood pressure is an adverse reaction entity
"In clinical trials with VICTRELIS, the proportion of subjects who experienced hemoglobin values less than 10 g per dL and less than 8.5 g per dL was higher in subjects treated with the combination of VICTRELIS with PegIntron  (r)  /REBETOL  (r)  than in those treated with PegIntron/REBETOL alone (see  Table 4  ).",hemoglobin values less than 10 g per dL is an adverse reaction entity
"In clinical trials with VICTRELIS, the proportion of subjects who experienced hemoglobin values less than 10 g per dL and less than 8.5 g per dL was higher in subjects treated with the combination of VICTRELIS with PegIntron  (r)  /REBETOL  (r)  than in those treated with PegIntron/REBETOL alone (see  Table 4  ).",hemoglobin values less than 8.5 g per dL is an adverse reaction entity
The proportion of subjects who discontinued study drug due to anemia was 1% in subjects treated with the combination of VICTRELIS with PegIntron/REBETOL and 1% in subjects who received PegIntron/REBETOL.,anemia is an adverse reaction entity
Three percent of subjects receiving the combination of VICTRELIS with PegIntron/REBETOL had platelet counts of less than 50 * 10  9  per L compared to 1% of subjects receiving PegIntron/REBETOL alone.,platelet counts of less than 50 * 10 9 per L is an adverse reaction entity
"Blood and Lymphatic System Disorders:  agranulocytosis, pancytopenia  ,  thrombocytopenia  [see  Warnings and Precautions (5.4)  ]         Gastrointestinal Disorders:  mouth ulceration, stomatitis       Infections and Infestations:  pneumonia, sepsis       Skin and Subcutaneous Tissue Disorders:  angioedema, urticaria  [see  Warnings and Precautions (5.5)  ]  ; drug rash with eosinophilia and systemic symptoms (DRESS) syndrome, exfoliative rash, exfoliative dermatitis, Stevens-Johnson syndrome, toxic skin eruption, toxicoderma",agranulocytosis is an adverse reaction entity
"Blood and Lymphatic System Disorders:  agranulocytosis, pancytopenia  ,  thrombocytopenia  [see  Warnings and Precautions (5.4)  ]         Gastrointestinal Disorders:  mouth ulceration, stomatitis       Infections and Infestations:  pneumonia, sepsis       Skin and Subcutaneous Tissue Disorders:  angioedema, urticaria  [see  Warnings and Precautions (5.5)  ]  ; drug rash with eosinophilia and systemic symptoms (DRESS) syndrome, exfoliative rash, exfoliative dermatitis, Stevens-Johnson syndrome, toxic skin eruption, toxicoderma",pancytopenia is an adverse reaction entity
"Blood and Lymphatic System Disorders:  agranulocytosis, pancytopenia  ,  thrombocytopenia  [see  Warnings and Precautions (5.4)  ]         Gastrointestinal Disorders:  mouth ulceration, stomatitis       Infections and Infestations:  pneumonia, sepsis       Skin and Subcutaneous Tissue Disorders:  angioedema, urticaria  [see  Warnings and Precautions (5.5)  ]  ; drug rash with eosinophilia and systemic symptoms (DRESS) syndrome, exfoliative rash, exfoliative dermatitis, Stevens-Johnson syndrome, toxic skin eruption, toxicoderma",thrombocytopenia is an adverse reaction entity
"Blood and Lymphatic System Disorders:  agranulocytosis, pancytopenia  ,  thrombocytopenia  [see  Warnings and Precautions (5.4)  ]         Gastrointestinal Disorders:  mouth ulceration, stomatitis       Infections and Infestations:  pneumonia, sepsis       Skin and Subcutaneous Tissue Disorders:  angioedema, urticaria  [see  Warnings and Precautions (5.5)  ]  ; drug rash with eosinophilia and systemic symptoms (DRESS) syndrome, exfoliative rash, exfoliative dermatitis, Stevens-Johnson syndrome, toxic skin eruption, toxicoderma",mouth ulceration is an adverse reaction entity
"Blood and Lymphatic System Disorders:  agranulocytosis, pancytopenia  ,  thrombocytopenia  [see  Warnings and Precautions (5.4)  ]         Gastrointestinal Disorders:  mouth ulceration, stomatitis       Infections and Infestations:  pneumonia, sepsis       Skin and Subcutaneous Tissue Disorders:  angioedema, urticaria  [see  Warnings and Precautions (5.5)  ]  ; drug rash with eosinophilia and systemic symptoms (DRESS) syndrome, exfoliative rash, exfoliative dermatitis, Stevens-Johnson syndrome, toxic skin eruption, toxicoderma",stomatitis is an adverse reaction entity
"Blood and Lymphatic System Disorders:  agranulocytosis, pancytopenia  ,  thrombocytopenia  [see  Warnings and Precautions (5.4)  ]         Gastrointestinal Disorders:  mouth ulceration, stomatitis       Infections and Infestations:  pneumonia, sepsis       Skin and Subcutaneous Tissue Disorders:  angioedema, urticaria  [see  Warnings and Precautions (5.5)  ]  ; drug rash with eosinophilia and systemic symptoms (DRESS) syndrome, exfoliative rash, exfoliative dermatitis, Stevens-Johnson syndrome, toxic skin eruption, toxicoderma",pneumonia is an adverse reaction entity
"Blood and Lymphatic System Disorders:  agranulocytosis, pancytopenia  ,  thrombocytopenia  [see  Warnings and Precautions (5.4)  ]         Gastrointestinal Disorders:  mouth ulceration, stomatitis       Infections and Infestations:  pneumonia, sepsis       Skin and Subcutaneous Tissue Disorders:  angioedema, urticaria  [see  Warnings and Precautions (5.5)  ]  ; drug rash with eosinophilia and systemic symptoms (DRESS) syndrome, exfoliative rash, exfoliative dermatitis, Stevens-Johnson syndrome, toxic skin eruption, toxicoderma",sepsis is an adverse reaction entity
"Blood and Lymphatic System Disorders:  agranulocytosis, pancytopenia  ,  thrombocytopenia  [see  Warnings and Precautions (5.4)  ]         Gastrointestinal Disorders:  mouth ulceration, stomatitis       Infections and Infestations:  pneumonia, sepsis       Skin and Subcutaneous Tissue Disorders:  angioedema, urticaria  [see  Warnings and Precautions (5.5)  ]  ; drug rash with eosinophilia and systemic symptoms (DRESS) syndrome, exfoliative rash, exfoliative dermatitis, Stevens-Johnson syndrome, toxic skin eruption, toxicoderma",angioedema is an adverse reaction entity
"Blood and Lymphatic System Disorders:  agranulocytosis, pancytopenia  ,  thrombocytopenia  [see  Warnings and Precautions (5.4)  ]         Gastrointestinal Disorders:  mouth ulceration, stomatitis       Infections and Infestations:  pneumonia, sepsis       Skin and Subcutaneous Tissue Disorders:  angioedema, urticaria  [see  Warnings and Precautions (5.5)  ]  ; drug rash with eosinophilia and systemic symptoms (DRESS) syndrome, exfoliative rash, exfoliative dermatitis, Stevens-Johnson syndrome, toxic skin eruption, toxicoderma",urticaria is an adverse reaction entity
"Blood and Lymphatic System Disorders:  agranulocytosis, pancytopenia  ,  thrombocytopenia  [see  Warnings and Precautions (5.4)  ]         Gastrointestinal Disorders:  mouth ulceration, stomatitis       Infections and Infestations:  pneumonia, sepsis       Skin and Subcutaneous Tissue Disorders:  angioedema, urticaria  [see  Warnings and Precautions (5.5)  ]  ; drug rash with eosinophilia and systemic symptoms (DRESS) syndrome, exfoliative rash, exfoliative dermatitis, Stevens-Johnson syndrome, toxic skin eruption, toxicoderma",drug rash with eosinophilia and systemic symptoms syndrome is an adverse reaction entity
"Blood and Lymphatic System Disorders:  agranulocytosis, pancytopenia  ,  thrombocytopenia  [see  Warnings and Precautions (5.4)  ]         Gastrointestinal Disorders:  mouth ulceration, stomatitis       Infections and Infestations:  pneumonia, sepsis       Skin and Subcutaneous Tissue Disorders:  angioedema, urticaria  [see  Warnings and Precautions (5.5)  ]  ; drug rash with eosinophilia and systemic symptoms (DRESS) syndrome, exfoliative rash, exfoliative dermatitis, Stevens-Johnson syndrome, toxic skin eruption, toxicoderma",DRESS syndrome is an adverse reaction entity
"Blood and Lymphatic System Disorders:  agranulocytosis, pancytopenia  ,  thrombocytopenia  [see  Warnings and Precautions (5.4)  ]         Gastrointestinal Disorders:  mouth ulceration, stomatitis       Infections and Infestations:  pneumonia, sepsis       Skin and Subcutaneous Tissue Disorders:  angioedema, urticaria  [see  Warnings and Precautions (5.5)  ]  ; drug rash with eosinophilia and systemic symptoms (DRESS) syndrome, exfoliative rash, exfoliative dermatitis, Stevens-Johnson syndrome, toxic skin eruption, toxicoderma",exfoliative rash is an adverse reaction entity
"Blood and Lymphatic System Disorders:  agranulocytosis, pancytopenia  ,  thrombocytopenia  [see  Warnings and Precautions (5.4)  ]         Gastrointestinal Disorders:  mouth ulceration, stomatitis       Infections and Infestations:  pneumonia, sepsis       Skin and Subcutaneous Tissue Disorders:  angioedema, urticaria  [see  Warnings and Precautions (5.5)  ]  ; drug rash with eosinophilia and systemic symptoms (DRESS) syndrome, exfoliative rash, exfoliative dermatitis, Stevens-Johnson syndrome, toxic skin eruption, toxicoderma",exfoliative dermatitis is an adverse reaction entity
"Blood and Lymphatic System Disorders:  agranulocytosis, pancytopenia  ,  thrombocytopenia  [see  Warnings and Precautions (5.4)  ]         Gastrointestinal Disorders:  mouth ulceration, stomatitis       Infections and Infestations:  pneumonia, sepsis       Skin and Subcutaneous Tissue Disorders:  angioedema, urticaria  [see  Warnings and Precautions (5.5)  ]  ; drug rash with eosinophilia and systemic symptoms (DRESS) syndrome, exfoliative rash, exfoliative dermatitis, Stevens-Johnson syndrome, toxic skin eruption, toxicoderma",Stevens-Johnson syndrome is an adverse reaction entity
"Blood and Lymphatic System Disorders:  agranulocytosis, pancytopenia  ,  thrombocytopenia  [see  Warnings and Precautions (5.4)  ]         Gastrointestinal Disorders:  mouth ulceration, stomatitis       Infections and Infestations:  pneumonia, sepsis       Skin and Subcutaneous Tissue Disorders:  angioedema, urticaria  [see  Warnings and Precautions (5.5)  ]  ; drug rash with eosinophilia and systemic symptoms (DRESS) syndrome, exfoliative rash, exfoliative dermatitis, Stevens-Johnson syndrome, toxic skin eruption, toxicoderma",toxic skin eruption is an adverse reaction entity
"Blood and Lymphatic System Disorders:  agranulocytosis, pancytopenia  ,  thrombocytopenia  [see  Warnings and Precautions (5.4)  ]         Gastrointestinal Disorders:  mouth ulceration, stomatitis       Infections and Infestations:  pneumonia, sepsis       Skin and Subcutaneous Tissue Disorders:  angioedema, urticaria  [see  Warnings and Precautions (5.5)  ]  ; drug rash with eosinophilia and systemic symptoms (DRESS) syndrome, exfoliative rash, exfoliative dermatitis, Stevens-Johnson syndrome, toxic skin eruption, toxicoderma",toxicoderma is an adverse reaction entity
Neutrophils and Platelets       The proportion of subjects with decreased neutrophil and platelet counts was higher in subjects treated with VICTRELIS in combination with PegIntron/REBETOL compared to subjects receiving PegIntron/REBETOL alone.,decreased neutrophil counts is an adverse reaction entity
Neutrophils and Platelets       The proportion of subjects with decreased neutrophil and platelet counts was higher in subjects treated with VICTRELIS in combination with PegIntron/REBETOL compared to subjects receiving PegIntron/REBETOL alone.,decreased platelet counts is an adverse reaction entity
The treatment discontinuation rate due to anemia was similar in subjects randomized to receive ribavirin dose reduction compared to subjects randomized to receive ESA (2% in each group).,anemia is an adverse reaction entity
The results suggest an approximate 2-fold increase in the risk of NAION within 5 half-lives of PDE5 inhibitor use.,NAION is an adverse reaction entity
"Before prescribing STENDRA, it is important to note the following:        EXCERPT:    *  Patients should not use STENDRA if sexual activity is inadvisable due to cardiovascular status or any other reason (5.1)   *  Use of STENDRA with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension (2.3,5.6,5.7)   *  Patients should seek emergency treatment if an erection lasts greater than 4 hours (5.3)   *  Patients should stop STENDRA and seek medical care if a sudden loss of vision occurs in one or both eyes, which could be a sign of Non Arteritic Ischemic Optic Neuropathy (NAION).",hypotension is an adverse reaction entity
"An observational study evaluated whether recent use of PDE5 inhibitors, as a class, was associated with acute onset of NAION.",NAION is an adverse reaction entity
"More GILOTRIF-treated patients (2.2%; n=5) experienced ventricular dysfunction (defined as diastolic dysfunction, left ventricular dysfunction, or ventricular dilation; all < Grade 3) compared to chemotherapy-treated patients (0.9%; n=1).",ventricular dysfunction is an adverse reaction entity
"More GILOTRIF-treated patients (2.2%; n=5) experienced ventricular dysfunction (defined as diastolic dysfunction, left ventricular dysfunction, or ventricular dilation; all < Grade 3) compared to chemotherapy-treated patients (0.9%; n=1).",diastolic dysfunction is an adverse reaction entity
"More GILOTRIF-treated patients (2.2%; n=5) experienced ventricular dysfunction (defined as diastolic dysfunction, left ventricular dysfunction, or ventricular dilation; all < Grade 3) compared to chemotherapy-treated patients (0.9%; n=1).",left ventricular dysfunction is an adverse reaction entity
"More GILOTRIF-treated patients (2.2%; n=5) experienced ventricular dysfunction (defined as diastolic dysfunction, left ventricular dysfunction, or ventricular dilation; all < Grade 3) compared to chemotherapy-treated patients (0.9%; n=1).",ventricular dilation is an adverse reaction entity
"In Study 1, the overall incidence of cutaneous reactions consisting of rash, erythema, and acneiform rash was 90%, and the incidence of Grade 3 cutaneous reactions was 16%.",cutaneous reactions is an adverse reaction entity
"In Study 1, the overall incidence of cutaneous reactions consisting of rash, erythema, and acneiform rash was 90%, and the incidence of Grade 3 cutaneous reactions was 16%.",rash is an adverse reaction entity
"In Study 1, the overall incidence of cutaneous reactions consisting of rash, erythema, and acneiform rash was 90%, and the incidence of Grade 3 cutaneous reactions was 16%.",erythema is an adverse reaction entity
"In Study 1, the overall incidence of cutaneous reactions consisting of rash, erythema, and acneiform rash was 90%, and the incidence of Grade 3 cutaneous reactions was 16%.",acneiform rash is an adverse reaction entity
"In Study 1, the overall incidence of cutaneous reactions consisting of rash, erythema, and acneiform rash was 90%, and the incidence of Grade 3 cutaneous reactions was 16%.",cutaneous reactions is an adverse reaction entity
"Keratitis was reported in 5 (2.2%) patients in Study 1, with Grade 3 in 1 (0.4%).",Keratitis is an adverse reaction entity
"Keratitis was reported in 5 (2.2%) patients in Study 1, with Grade 3 in 1 (0.4%).",Keratitis is an adverse reaction entity
"5.5 Keratitis    Keratitis, characterized as acute or worsening eye inflammation, lacrimation, light sensitivity, blurred vision, eye pain, and/or red eye occurred in 0.8% of patients treated with GILOTRIF among 3865 patients across clinical trials.",Keratitis is an adverse reaction entity
"5.5 Keratitis    Keratitis, characterized as acute or worsening eye inflammation, lacrimation, light sensitivity, blurred vision, eye pain, and/or red eye occurred in 0.8% of patients treated with GILOTRIF among 3865 patients across clinical trials.",acute eye inflammation is an adverse reaction entity
"5.5 Keratitis    Keratitis, characterized as acute or worsening eye inflammation, lacrimation, light sensitivity, blurred vision, eye pain, and/or red eye occurred in 0.8% of patients treated with GILOTRIF among 3865 patients across clinical trials.",worsening eye inflammation is an adverse reaction entity
"5.5 Keratitis    Keratitis, characterized as acute or worsening eye inflammation, lacrimation, light sensitivity, blurred vision, eye pain, and/or red eye occurred in 0.8% of patients treated with GILOTRIF among 3865 patients across clinical trials.",lacrimation is an adverse reaction entity
"5.5 Keratitis    Keratitis, characterized as acute or worsening eye inflammation, lacrimation, light sensitivity, blurred vision, eye pain, and/or red eye occurred in 0.8% of patients treated with GILOTRIF among 3865 patients across clinical trials.",light sensitivity is an adverse reaction entity
"5.5 Keratitis    Keratitis, characterized as acute or worsening eye inflammation, lacrimation, light sensitivity, blurred vision, eye pain, and/or red eye occurred in 0.8% of patients treated with GILOTRIF among 3865 patients across clinical trials.",blurred vision is an adverse reaction entity
"5.5 Keratitis    Keratitis, characterized as acute or worsening eye inflammation, lacrimation, light sensitivity, blurred vision, eye pain, and/or red eye occurred in 0.8% of patients treated with GILOTRIF among 3865 patients across clinical trials.",eye pain is an adverse reaction entity
"5.5 Keratitis    Keratitis, characterized as acute or worsening eye inflammation, lacrimation, light sensitivity, blurred vision, eye pain, and/or red eye occurred in 0.8% of patients treated with GILOTRIF among 3865 patients across clinical trials.",red eye is an adverse reaction entity
"The most frequent adverse reactions that led to discontinuation in GILOTRIF-treated patients were diarrhea (1.3%), ILD (0.9%), and paronychia (0.9%).",diarrhea is an adverse reaction entity
"The most frequent adverse reactions that led to discontinuation in GILOTRIF-treated patients were diarrhea (1.3%), ILD (0.9%), and paronychia (0.9%).",ILD is an adverse reaction entity
"The most frequent adverse reactions that led to discontinuation in GILOTRIF-treated patients were diarrhea (1.3%), ILD (0.9%), and paronychia (0.9%).",paronychia is an adverse reaction entity
5.5 Central Nervous System Effects      Toviaz is associated with anticholinergic central nervous sytem (CNS) effects [see  Adverse Reactions (6.2)  ].,anticholinergic central nervous sytem effects is an adverse reaction entity
5.5 Central Nervous System Effects      Toviaz is associated with anticholinergic central nervous sytem (CNS) effects [see  Adverse Reactions (6.2)  ].,anticholinergic CNS effects is an adverse reaction entity
"A variety of CNS anticholinergic effects have been reported, including headache, dizziness, and somnolence.",CNS anticholinergic effects is an adverse reaction entity
"A variety of CNS anticholinergic effects have been reported, including headache, dizziness, and somnolence.",headache is an adverse reaction entity
"A variety of CNS anticholinergic effects have been reported, including headache, dizziness, and somnolence.",dizziness is an adverse reaction entity
"A variety of CNS anticholinergic effects have been reported, including headache, dizziness, and somnolence.",somnolence is an adverse reaction entity
"6.2 Post-marketing Experience    The following events have been reported in association with fesoterodine use in worldwide post-marketing experience:    Eye disorders:    Blurred vision;    Cardiac disorders:    Palpitations;    General disorders and administrative site conditions:    Hypersensitivity reactions, including angioedema with airway obstruction, face edema;    Central nervous system disorders:    Dizziness, headache, somnolence;    Skin and subcutaneous tissue disorders  :  Urticaria, pruritus     Because these spontaneously reported events are from the worldwide post-marketing experience, the frequency of events and the role of fesoterodine in their causation cannot be reliably determined.",Blurred vision is an adverse reaction entity
"6.2 Post-marketing Experience    The following events have been reported in association with fesoterodine use in worldwide post-marketing experience:    Eye disorders:    Blurred vision;    Cardiac disorders:    Palpitations;    General disorders and administrative site conditions:    Hypersensitivity reactions, including angioedema with airway obstruction, face edema;    Central nervous system disorders:    Dizziness, headache, somnolence;    Skin and subcutaneous tissue disorders  :  Urticaria, pruritus     Because these spontaneously reported events are from the worldwide post-marketing experience, the frequency of events and the role of fesoterodine in their causation cannot be reliably determined.",Palpitations is an adverse reaction entity
"6.2 Post-marketing Experience    The following events have been reported in association with fesoterodine use in worldwide post-marketing experience:    Eye disorders:    Blurred vision;    Cardiac disorders:    Palpitations;    General disorders and administrative site conditions:    Hypersensitivity reactions, including angioedema with airway obstruction, face edema;    Central nervous system disorders:    Dizziness, headache, somnolence;    Skin and subcutaneous tissue disorders  :  Urticaria, pruritus     Because these spontaneously reported events are from the worldwide post-marketing experience, the frequency of events and the role of fesoterodine in their causation cannot be reliably determined.",Hypersensitivity reactions is an adverse reaction entity
"6.2 Post-marketing Experience    The following events have been reported in association with fesoterodine use in worldwide post-marketing experience:    Eye disorders:    Blurred vision;    Cardiac disorders:    Palpitations;    General disorders and administrative site conditions:    Hypersensitivity reactions, including angioedema with airway obstruction, face edema;    Central nervous system disorders:    Dizziness, headache, somnolence;    Skin and subcutaneous tissue disorders  :  Urticaria, pruritus     Because these spontaneously reported events are from the worldwide post-marketing experience, the frequency of events and the role of fesoterodine in their causation cannot be reliably determined.",angioedema is an adverse reaction entity
"6.2 Post-marketing Experience    The following events have been reported in association with fesoterodine use in worldwide post-marketing experience:    Eye disorders:    Blurred vision;    Cardiac disorders:    Palpitations;    General disorders and administrative site conditions:    Hypersensitivity reactions, including angioedema with airway obstruction, face edema;    Central nervous system disorders:    Dizziness, headache, somnolence;    Skin and subcutaneous tissue disorders  :  Urticaria, pruritus     Because these spontaneously reported events are from the worldwide post-marketing experience, the frequency of events and the role of fesoterodine in their causation cannot be reliably determined.",airway obstruction is an adverse reaction entity
"6.2 Post-marketing Experience    The following events have been reported in association with fesoterodine use in worldwide post-marketing experience:    Eye disorders:    Blurred vision;    Cardiac disorders:    Palpitations;    General disorders and administrative site conditions:    Hypersensitivity reactions, including angioedema with airway obstruction, face edema;    Central nervous system disorders:    Dizziness, headache, somnolence;    Skin and subcutaneous tissue disorders  :  Urticaria, pruritus     Because these spontaneously reported events are from the worldwide post-marketing experience, the frequency of events and the role of fesoterodine in their causation cannot be reliably determined.",face edema is an adverse reaction entity
"6.2 Post-marketing Experience    The following events have been reported in association with fesoterodine use in worldwide post-marketing experience:    Eye disorders:    Blurred vision;    Cardiac disorders:    Palpitations;    General disorders and administrative site conditions:    Hypersensitivity reactions, including angioedema with airway obstruction, face edema;    Central nervous system disorders:    Dizziness, headache, somnolence;    Skin and subcutaneous tissue disorders  :  Urticaria, pruritus     Because these spontaneously reported events are from the worldwide post-marketing experience, the frequency of events and the role of fesoterodine in their causation cannot be reliably determined.",Dizziness is an adverse reaction entity
"6.2 Post-marketing Experience    The following events have been reported in association with fesoterodine use in worldwide post-marketing experience:    Eye disorders:    Blurred vision;    Cardiac disorders:    Palpitations;    General disorders and administrative site conditions:    Hypersensitivity reactions, including angioedema with airway obstruction, face edema;    Central nervous system disorders:    Dizziness, headache, somnolence;    Skin and subcutaneous tissue disorders  :  Urticaria, pruritus     Because these spontaneously reported events are from the worldwide post-marketing experience, the frequency of events and the role of fesoterodine in their causation cannot be reliably determined.",headache is an adverse reaction entity
"6.2 Post-marketing Experience    The following events have been reported in association with fesoterodine use in worldwide post-marketing experience:    Eye disorders:    Blurred vision;    Cardiac disorders:    Palpitations;    General disorders and administrative site conditions:    Hypersensitivity reactions, including angioedema with airway obstruction, face edema;    Central nervous system disorders:    Dizziness, headache, somnolence;    Skin and subcutaneous tissue disorders  :  Urticaria, pruritus     Because these spontaneously reported events are from the worldwide post-marketing experience, the frequency of events and the role of fesoterodine in their causation cannot be reliably determined.",somnolence is an adverse reaction entity
"6.2 Post-marketing Experience    The following events have been reported in association with fesoterodine use in worldwide post-marketing experience:    Eye disorders:    Blurred vision;    Cardiac disorders:    Palpitations;    General disorders and administrative site conditions:    Hypersensitivity reactions, including angioedema with airway obstruction, face edema;    Central nervous system disorders:    Dizziness, headache, somnolence;    Skin and subcutaneous tissue disorders  :  Urticaria, pruritus     Because these spontaneously reported events are from the worldwide post-marketing experience, the frequency of events and the role of fesoterodine in their causation cannot be reliably determined.",Urticaria is an adverse reaction entity
"6.2 Post-marketing Experience    The following events have been reported in association with fesoterodine use in worldwide post-marketing experience:    Eye disorders:    Blurred vision;    Cardiac disorders:    Palpitations;    General disorders and administrative site conditions:    Hypersensitivity reactions, including angioedema with airway obstruction, face edema;    Central nervous system disorders:    Dizziness, headache, somnolence;    Skin and subcutaneous tissue disorders  :  Urticaria, pruritus     Because these spontaneously reported events are from the worldwide post-marketing experience, the frequency of events and the role of fesoterodine in their causation cannot be reliably determined.",pruritus is an adverse reaction entity
"6 ADVERSE REACTIONS    EXCERPT:   The most frequently reported adverse events (>=4%) for Toviaz were: dry mouth (placebo, 7%; Toviaz 4 mg, 19%; Toviaz 8 mg, 35%) and constipation (placebo, 2%; Toviaz 4 mg, 4%; Toviaz 8 mg, 6%).",dry mouth is an adverse reaction entity
"6 ADVERSE REACTIONS    EXCERPT:   The most frequently reported adverse events (>=4%) for Toviaz were: dry mouth (placebo, 7%; Toviaz 4 mg, 19%; Toviaz 8 mg, 35%) and constipation (placebo, 2%; Toviaz 4 mg, 4%; Toviaz 8 mg, 6%).",constipation is an adverse reaction entity
"(  6.2  ) In clinical trials, the most common adverse reactions, headache, nausea, vertigo, dry mouth or dizziness occurred in < 1% of subjects.",headache is an adverse reaction entity
"(  6.2  ) In clinical trials, the most common adverse reactions, headache, nausea, vertigo, dry mouth or dizziness occurred in < 1% of subjects.",nausea is an adverse reaction entity
"(  6.2  ) In clinical trials, the most common adverse reactions, headache, nausea, vertigo, dry mouth or dizziness occurred in < 1% of subjects.",vertigo is an adverse reaction entity
"(  6.2  ) In clinical trials, the most common adverse reactions, headache, nausea, vertigo, dry mouth or dizziness occurred in < 1% of subjects.",dry mouth is an adverse reaction entity
"(  6.2  ) In clinical trials, the most common adverse reactions, headache, nausea, vertigo, dry mouth or dizziness occurred in < 1% of subjects.",dizziness is an adverse reaction entity
"Other adverse reactions occurred at a rate of 1% or less and the reported events consisted of headache, nausea, vertigo, dry mouth or dizziness.",headache is an adverse reaction entity
"Other adverse reactions occurred at a rate of 1% or less and the reported events consisted of headache, nausea, vertigo, dry mouth or dizziness.",nausea is an adverse reaction entity
"Other adverse reactions occurred at a rate of 1% or less and the reported events consisted of headache, nausea, vertigo, dry mouth or dizziness.",vertigo is an adverse reaction entity
"Other adverse reactions occurred at a rate of 1% or less and the reported events consisted of headache, nausea, vertigo, dry mouth or dizziness.",dry mouth is an adverse reaction entity
"Other adverse reactions occurred at a rate of 1% or less and the reported events consisted of headache, nausea, vertigo, dry mouth or dizziness.",dizziness is an adverse reaction entity
"Grade 3-4 lymphopenia (9%), hyperglycemia (7%) and high alanine aminotransferase (6%) occurred at a greater than 5% rate in the ZYTIGA arm.",lymphopenia is an adverse reaction entity
"Grade 3-4 lymphopenia (9%), hyperglycemia (7%) and high alanine aminotransferase (6%) occurred at a greater than 5% rate in the ZYTIGA arm.",hyperglycemia is an adverse reaction entity
"Grade 3-4 lymphopenia (9%), hyperglycemia (7%) and high alanine aminotransferase (6%) occurred at a greater than 5% rate in the ZYTIGA arm.",high alanine aminotransferase is an adverse reaction entity
"Adrenocortical insufficiency was reported in patients receiving ZYTIGA in combination with prednisone, following interruption of daily steroids and/or with concurrent infection or stress.",Adrenocortical insufficiency is an adverse reaction entity
There were 7 (0.5%) deaths due to cardiorespiratory arrest in the ZYTIGA arms and 3 (0.3%) deaths in the placebo arms.,deaths is an adverse reaction entity
There were 7 (0.5%) deaths due to cardiorespiratory arrest in the ZYTIGA arms and 3 (0.3%) deaths in the placebo arms.,cardiorespiratory arrest is an adverse reaction entity
There were 7 (0.5%) deaths due to cardiorespiratory arrest in the ZYTIGA arms and 3 (0.3%) deaths in the placebo arms.,deaths is an adverse reaction entity
"(5.3)          5.1 Hypertension, Hypokalemia and Fluid Retention Due to Mineralocorticoid Excess    ZYTIGA may cause hypertension, hypokalemia, and fluid retention as a consequence of increased mineralocorticoid levels resulting from CYP17 inhibition  [seeClinical Pharmacology (12.1)]  .",hypertension is an adverse reaction entity
"(5.3)          5.1 Hypertension, Hypokalemia and Fluid Retention Due to Mineralocorticoid Excess    ZYTIGA may cause hypertension, hypokalemia, and fluid retention as a consequence of increased mineralocorticoid levels resulting from CYP17 inhibition  [seeClinical Pharmacology (12.1)]  .",hypokalemia is an adverse reaction entity
"(5.3)          5.1 Hypertension, Hypokalemia and Fluid Retention Due to Mineralocorticoid Excess    ZYTIGA may cause hypertension, hypokalemia, and fluid retention as a consequence of increased mineralocorticoid levels resulting from CYP17 inhibition  [seeClinical Pharmacology (12.1)]  .",fluid retention is an adverse reaction entity
"(5.3)          5.1 Hypertension, Hypokalemia and Fluid Retention Due to Mineralocorticoid Excess    ZYTIGA may cause hypertension, hypokalemia, and fluid retention as a consequence of increased mineralocorticoid levels resulting from CYP17 inhibition  [seeClinical Pharmacology (12.1)]  .",increased mineralocorticoid levels is an adverse reaction entity
"6 ADVERSE REACTIONS    The following are discussed in more detail in other sections of the labeling:     *  Hypertension, Hypokalemia, and Fluid Retention due to Mineralocorticoid Excess [seeWarnings and Precautions (5.1)] .",Hypertension is an adverse reaction entity
"6 ADVERSE REACTIONS    The following are discussed in more detail in other sections of the labeling:     *  Hypertension, Hypokalemia, and Fluid Retention due to Mineralocorticoid Excess [seeWarnings and Precautions (5.1)] .",Hypokalemia is an adverse reaction entity
"6 ADVERSE REACTIONS    The following are discussed in more detail in other sections of the labeling:     *  Hypertension, Hypokalemia, and Fluid Retention due to Mineralocorticoid Excess [seeWarnings and Precautions (5.1)] .",Fluid Retention is an adverse reaction entity
"6 ADVERSE REACTIONS    The following are discussed in more detail in other sections of the labeling:     *  Hypertension, Hypokalemia, and Fluid Retention due to Mineralocorticoid Excess [seeWarnings and Precautions (5.1)] .",Mineralocorticoid Excess is an adverse reaction entity
Symptoms and signs of adrenocortical insufficiency may be masked by adverse reactions associated with mineralocorticoid excess seen in patients treated with ZYTIGA.,adrenocortical insufficiency is an adverse reaction entity
Symptoms and signs of adrenocortical insufficiency may be masked by adverse reactions associated with mineralocorticoid excess seen in patients treated with ZYTIGA.,mineralocorticoid excess is an adverse reaction entity
"Grade 3/4 hemorrhagic events were reported in 5/359 (1%) patients receiving INLYTA (including cerebral hemorrhage, hematuria, hemoptysis, lower gastrointestinal hemorrhage, and melena) and 11/355 (3%) patients receiving sorafenib.",hemorrhagic events is an adverse reaction entity
"Grade 3/4 hemorrhagic events were reported in 5/359 (1%) patients receiving INLYTA (including cerebral hemorrhage, hematuria, hemoptysis, lower gastrointestinal hemorrhage, and melena) and 11/355 (3%) patients receiving sorafenib.",cerebral hemorrhage is an adverse reaction entity
"Grade 3/4 hemorrhagic events were reported in 5/359 (1%) patients receiving INLYTA (including cerebral hemorrhage, hematuria, hemoptysis, lower gastrointestinal hemorrhage, and melena) and 11/355 (3%) patients receiving sorafenib.",hematuria is an adverse reaction entity
"Grade 3/4 hemorrhagic events were reported in 5/359 (1%) patients receiving INLYTA (including cerebral hemorrhage, hematuria, hemoptysis, lower gastrointestinal hemorrhage, and melena) and 11/355 (3%) patients receiving sorafenib.",hemoptysis is an adverse reaction entity
"Grade 3/4 hemorrhagic events were reported in 5/359 (1%) patients receiving INLYTA (including cerebral hemorrhage, hematuria, hemoptysis, lower gastrointestinal hemorrhage, and melena) and 11/355 (3%) patients receiving sorafenib.",lower gastrointestinal hemorrhage is an adverse reaction entity
"Grade 3/4 hemorrhagic events were reported in 5/359 (1%) patients receiving INLYTA (including cerebral hemorrhage, hematuria, hemoptysis, lower gastrointestinal hemorrhage, and melena) and 11/355 (3%) patients receiving sorafenib.",melena is an adverse reaction entity
Grade 3 proteinuria was reported in 11/359 patients (3%) receiving INLYTA and 6/355 patients (2%) receiving sorafenib  [seeAdverse Reactions (6.1)].,proteinuria is an adverse reaction entity
Grade 3/4 cardiac failure was observed in 2/359 patients (1%) receiving INLYTA and 1/355 patients (<1%) receiving sorafenib.,cardiac failure is an adverse reaction entity
"The following risks, including appropriate action to be taken, are discussed in greater detail in other sections of the label  [seeWarnings and Precautions (5.1-5.13)]  : hypertension, arterial thromboembolic events, venous thromboembolic events, hemorrhage, cardiac failure, gastrointestinal perforation and fistula formation, thyroid dysfunction, wound healing complications, RPLS, proteinuria, elevation of liver enzymes, hepatic impairment and fetal development.",hypertension is an adverse reaction entity
"The following risks, including appropriate action to be taken, are discussed in greater detail in other sections of the label  [seeWarnings and Precautions (5.1-5.13)]  : hypertension, arterial thromboembolic events, venous thromboembolic events, hemorrhage, cardiac failure, gastrointestinal perforation and fistula formation, thyroid dysfunction, wound healing complications, RPLS, proteinuria, elevation of liver enzymes, hepatic impairment and fetal development.",arterial thromboembolic events is an adverse reaction entity
"The following risks, including appropriate action to be taken, are discussed in greater detail in other sections of the label  [seeWarnings and Precautions (5.1-5.13)]  : hypertension, arterial thromboembolic events, venous thromboembolic events, hemorrhage, cardiac failure, gastrointestinal perforation and fistula formation, thyroid dysfunction, wound healing complications, RPLS, proteinuria, elevation of liver enzymes, hepatic impairment and fetal development.",venous thromboembolic events is an adverse reaction entity
"The following risks, including appropriate action to be taken, are discussed in greater detail in other sections of the label  [seeWarnings and Precautions (5.1-5.13)]  : hypertension, arterial thromboembolic events, venous thromboembolic events, hemorrhage, cardiac failure, gastrointestinal perforation and fistula formation, thyroid dysfunction, wound healing complications, RPLS, proteinuria, elevation of liver enzymes, hepatic impairment and fetal development.",hemorrhage is an adverse reaction entity
"The following risks, including appropriate action to be taken, are discussed in greater detail in other sections of the label  [seeWarnings and Precautions (5.1-5.13)]  : hypertension, arterial thromboembolic events, venous thromboembolic events, hemorrhage, cardiac failure, gastrointestinal perforation and fistula formation, thyroid dysfunction, wound healing complications, RPLS, proteinuria, elevation of liver enzymes, hepatic impairment and fetal development.",cardiac failure is an adverse reaction entity
"The following risks, including appropriate action to be taken, are discussed in greater detail in other sections of the label  [seeWarnings and Precautions (5.1-5.13)]  : hypertension, arterial thromboembolic events, venous thromboembolic events, hemorrhage, cardiac failure, gastrointestinal perforation and fistula formation, thyroid dysfunction, wound healing complications, RPLS, proteinuria, elevation of liver enzymes, hepatic impairment and fetal development.",gastrointestinal perforation is an adverse reaction entity
"The following risks, including appropriate action to be taken, are discussed in greater detail in other sections of the label  [seeWarnings and Precautions (5.1-5.13)]  : hypertension, arterial thromboembolic events, venous thromboembolic events, hemorrhage, cardiac failure, gastrointestinal perforation and fistula formation, thyroid dysfunction, wound healing complications, RPLS, proteinuria, elevation of liver enzymes, hepatic impairment and fetal development.",fistula formation is an adverse reaction entity
"The following risks, including appropriate action to be taken, are discussed in greater detail in other sections of the label  [seeWarnings and Precautions (5.1-5.13)]  : hypertension, arterial thromboembolic events, venous thromboembolic events, hemorrhage, cardiac failure, gastrointestinal perforation and fistula formation, thyroid dysfunction, wound healing complications, RPLS, proteinuria, elevation of liver enzymes, hepatic impairment and fetal development.",thyroid dysfunction is an adverse reaction entity
"The following risks, including appropriate action to be taken, are discussed in greater detail in other sections of the label  [seeWarnings and Precautions (5.1-5.13)]  : hypertension, arterial thromboembolic events, venous thromboembolic events, hemorrhage, cardiac failure, gastrointestinal perforation and fistula formation, thyroid dysfunction, wound healing complications, RPLS, proteinuria, elevation of liver enzymes, hepatic impairment and fetal development.",wound healing complications is an adverse reaction entity
"The following risks, including appropriate action to be taken, are discussed in greater detail in other sections of the label  [seeWarnings and Precautions (5.1-5.13)]  : hypertension, arterial thromboembolic events, venous thromboembolic events, hemorrhage, cardiac failure, gastrointestinal perforation and fistula formation, thyroid dysfunction, wound healing complications, RPLS, proteinuria, elevation of liver enzymes, hepatic impairment and fetal development.",RPLS is an adverse reaction entity
"The following risks, including appropriate action to be taken, are discussed in greater detail in other sections of the label  [seeWarnings and Precautions (5.1-5.13)]  : hypertension, arterial thromboembolic events, venous thromboembolic events, hemorrhage, cardiac failure, gastrointestinal perforation and fistula formation, thyroid dysfunction, wound healing complications, RPLS, proteinuria, elevation of liver enzymes, hepatic impairment and fetal development.",proteinuria is an adverse reaction entity
"The following risks, including appropriate action to be taken, are discussed in greater detail in other sections of the label  [seeWarnings and Precautions (5.1-5.13)]  : hypertension, arterial thromboembolic events, venous thromboembolic events, hemorrhage, cardiac failure, gastrointestinal perforation and fistula formation, thyroid dysfunction, wound healing complications, RPLS, proteinuria, elevation of liver enzymes, hepatic impairment and fetal development.",elevation of liver enzymes is an adverse reaction entity
"The following risks, including appropriate action to be taken, are discussed in greater detail in other sections of the label  [seeWarnings and Precautions (5.1-5.13)]  : hypertension, arterial thromboembolic events, venous thromboembolic events, hemorrhage, cardiac failure, gastrointestinal perforation and fistula formation, thyroid dysfunction, wound healing complications, RPLS, proteinuria, elevation of liver enzymes, hepatic impairment and fetal development.",hepatic impairment is an adverse reaction entity
"RPLS is a neurological disorder which can present with headache, seizure, lethargy, confusion, blindness and other visual and neurologic disturbances.",RPLS is an adverse reaction entity
"RPLS is a neurological disorder which can present with headache, seizure, lethargy, confusion, blindness and other visual and neurologic disturbances.",headache is an adverse reaction entity
"RPLS is a neurological disorder which can present with headache, seizure, lethargy, confusion, blindness and other visual and neurologic disturbances.",seizure is an adverse reaction entity
"RPLS is a neurological disorder which can present with headache, seizure, lethargy, confusion, blindness and other visual and neurologic disturbances.",lethargy is an adverse reaction entity
"RPLS is a neurological disorder which can present with headache, seizure, lethargy, confusion, blindness and other visual and neurologic disturbances.",confusion is an adverse reaction entity
"RPLS is a neurological disorder which can present with headache, seizure, lethargy, confusion, blindness and other visual and neurologic disturbances.",blindness is an adverse reaction entity
"RPLS is a neurological disorder which can present with headache, seizure, lethargy, confusion, blindness and other visual and neurologic disturbances.",visual disturbances is an adverse reaction entity
"RPLS is a neurological disorder which can present with headache, seizure, lethargy, confusion, blindness and other visual and neurologic disturbances.",neurologic disturbances is an adverse reaction entity
"The most common (>=20%) adverse reactions observed following treatment with INLYTA were diarrhea, hypertension, fatigue, decreased appetite, nausea, dysphonia, palmar-plantar erythrodysesthesia (hand-foot) syndrome, weight decreased, vomiting, asthenia, and constipation.",diarrhea is an adverse reaction entity
"The most common (>=20%) adverse reactions observed following treatment with INLYTA were diarrhea, hypertension, fatigue, decreased appetite, nausea, dysphonia, palmar-plantar erythrodysesthesia (hand-foot) syndrome, weight decreased, vomiting, asthenia, and constipation.",hypertension is an adverse reaction entity
"The most common (>=20%) adverse reactions observed following treatment with INLYTA were diarrhea, hypertension, fatigue, decreased appetite, nausea, dysphonia, palmar-plantar erythrodysesthesia (hand-foot) syndrome, weight decreased, vomiting, asthenia, and constipation.",fatigue is an adverse reaction entity
"The most common (>=20%) adverse reactions observed following treatment with INLYTA were diarrhea, hypertension, fatigue, decreased appetite, nausea, dysphonia, palmar-plantar erythrodysesthesia (hand-foot) syndrome, weight decreased, vomiting, asthenia, and constipation.",decreased appetite is an adverse reaction entity
"The most common (>=20%) adverse reactions observed following treatment with INLYTA were diarrhea, hypertension, fatigue, decreased appetite, nausea, dysphonia, palmar-plantar erythrodysesthesia (hand-foot) syndrome, weight decreased, vomiting, asthenia, and constipation.",nausea is an adverse reaction entity
"The most common (>=20%) adverse reactions observed following treatment with INLYTA were diarrhea, hypertension, fatigue, decreased appetite, nausea, dysphonia, palmar-plantar erythrodysesthesia (hand-foot) syndrome, weight decreased, vomiting, asthenia, and constipation.",dysphonia is an adverse reaction entity
"The most common (>=20%) adverse reactions observed following treatment with INLYTA were diarrhea, hypertension, fatigue, decreased appetite, nausea, dysphonia, palmar-plantar erythrodysesthesia (hand-foot) syndrome, weight decreased, vomiting, asthenia, and constipation.",palmar-plantar erythrodysesthesia syndrome is an adverse reaction entity
"The most common (>=20%) adverse reactions observed following treatment with INLYTA were diarrhea, hypertension, fatigue, decreased appetite, nausea, dysphonia, palmar-plantar erythrodysesthesia (hand-foot) syndrome, weight decreased, vomiting, asthenia, and constipation.",hand-foot syndrome is an adverse reaction entity
"The most common (>=20%) adverse reactions observed following treatment with INLYTA were diarrhea, hypertension, fatigue, decreased appetite, nausea, dysphonia, palmar-plantar erythrodysesthesia (hand-foot) syndrome, weight decreased, vomiting, asthenia, and constipation.",weight decreased is an adverse reaction entity
"The most common (>=20%) adverse reactions observed following treatment with INLYTA were diarrhea, hypertension, fatigue, decreased appetite, nausea, dysphonia, palmar-plantar erythrodysesthesia (hand-foot) syndrome, weight decreased, vomiting, asthenia, and constipation.",vomiting is an adverse reaction entity
"The most common (>=20%) adverse reactions observed following treatment with INLYTA were diarrhea, hypertension, fatigue, decreased appetite, nausea, dysphonia, palmar-plantar erythrodysesthesia (hand-foot) syndrome, weight decreased, vomiting, asthenia, and constipation.",asthenia is an adverse reaction entity
"The most common (>=20%) adverse reactions observed following treatment with INLYTA were diarrhea, hypertension, fatigue, decreased appetite, nausea, dysphonia, palmar-plantar erythrodysesthesia (hand-foot) syndrome, weight decreased, vomiting, asthenia, and constipation.",constipation is an adverse reaction entity
"In clinical trials with INLYTA, gastrointestinal perforation was reported in 5/715 patients (1%), including one death.",gastrointestinal perforation is an adverse reaction entity
"In clinical trials with INLYTA, gastrointestinal perforation was reported in 5/715 patients (1%), including one death.",death is an adverse reaction entity
"5.6 Gastrointestinal Perforation and Fistula Formation    In a controlled clinical study with INLYTA for the treatment of patients with RCC, gastrointestinal perforation was reported in 1/359 patients (<1%) receiving INLYTA and none of the patients receiving sorafenib.",gastrointestinal perforation is an adverse reaction entity
(5.1)   *  Arterial and venous thrombotic events have been observed and can be fatal.,Arterial thrombotic events is an adverse reaction entity
(5.1)   *  Arterial and venous thrombotic events have been observed and can be fatal.,venous thrombotic events is an adverse reaction entity
(5.1)   *  Arterial and venous thrombotic events have been observed and can be fatal.,fatal is an adverse reaction entity
"In a controlled clinical study with INLYTA for the treatment of patients with RCC, venous thromboembolic events were reported in 11/359 patients (3%) receiving INLYTA and 2/355 patients (1%) receiving sorafenib.",venous thromboembolic events is an adverse reaction entity
Discontinuation from study due to genital infection occurred in 0% of placebo-treated patients and 0.2% of patients treated with FARXIGA 10 mg.,genital infection is an adverse reaction entity
FARXIGA can increase the risk of hypoglycemia when combined with insulin or an insulin secretagogue [see  Adverse Reactions (6.1)  ]  .,hypoglycemia is an adverse reaction entity
"Across the clinical program, serious anaphylactic reactions and severe cutaneous adverse reactions and angioedema were reported in 0.2% of comparator-treated patients and 0.3% of FARXIGA-treated patients.",anaphylactic reactions is an adverse reaction entity
"Across the clinical program, serious anaphylactic reactions and severe cutaneous adverse reactions and angioedema were reported in 0.2% of comparator-treated patients and 0.3% of FARXIGA-treated patients.",cutaneous adverse reactions is an adverse reaction entity
"Across the clinical program, serious anaphylactic reactions and severe cutaneous adverse reactions and angioedema were reported in 0.2% of comparator-treated patients and 0.3% of FARXIGA-treated patients.",angioedema is an adverse reaction entity
Table 5: Incidence of MajorMajor episodes of hypoglycemia were defined as symptomatic episodes requiring external (third party) assistance due to severe impairment in consciousness or behavior with a capillary or plasma glucose value <54 mg/dL and prompt recovery after glucose or glucagon administration.,hypoglycemia is an adverse reaction entity
Table 5: Incidence of MajorMajor episodes of hypoglycemia were defined as symptomatic episodes requiring external (third party) assistance due to severe impairment in consciousness or behavior with a capillary or plasma glucose value <54 mg/dL and prompt recovery after glucose or glucagon administration.,impairment in consciousness is an adverse reaction entity
Table 5: Incidence of MajorMajor episodes of hypoglycemia were defined as symptomatic episodes requiring external (third party) assistance due to severe impairment in consciousness or behavior with a capillary or plasma glucose value <54 mg/dL and prompt recovery after glucose or glucagon administration.,impairment in behavior is an adverse reaction entity
Table 5: Incidence of MajorMajor episodes of hypoglycemia were defined as symptomatic episodes requiring external (third party) assistance due to severe impairment in consciousness or behavior with a capillary or plasma glucose value <54 mg/dL and prompt recovery after glucose or glucagon administration.,capillary glucose value <54 mg/dL is an adverse reaction entity
Table 5: Incidence of MajorMajor episodes of hypoglycemia were defined as symptomatic episodes requiring external (third party) assistance due to severe impairment in consciousness or behavior with a capillary or plasma glucose value <54 mg/dL and prompt recovery after glucose or glucagon administration.,plasma glucose value <54 mg/dL is an adverse reaction entity
(5.7)               5.1 Hypotension      FARXIGA causes intravascular volume contraction.,intravascular volume contraction is an adverse reaction entity
"Adverse reactions related to volume depletion (including reports of dehydration, hypovolemia, orthostatic hypotension, or hypotension) are shown in Table 2 for the 12-study and 13-study, short-term, placebo-controlled pools  [see  Warnings and Precautions (5.1)  ]  .",volume depletion is an adverse reaction entity
"Adverse reactions related to volume depletion (including reports of dehydration, hypovolemia, orthostatic hypotension, or hypotension) are shown in Table 2 for the 12-study and 13-study, short-term, placebo-controlled pools  [see  Warnings and Precautions (5.1)  ]  .",dehydration is an adverse reaction entity
"Adverse reactions related to volume depletion (including reports of dehydration, hypovolemia, orthostatic hypotension, or hypotension) are shown in Table 2 for the 12-study and 13-study, short-term, placebo-controlled pools  [see  Warnings and Precautions (5.1)  ]  .",hypovolemia is an adverse reaction entity
"Adverse reactions related to volume depletion (including reports of dehydration, hypovolemia, orthostatic hypotension, or hypotension) are shown in Table 2 for the 12-study and 13-study, short-term, placebo-controlled pools  [see  Warnings and Precautions (5.1)  ]  .",orthostatic hypotension is an adverse reaction entity
"Adverse reactions related to volume depletion (including reports of dehydration, hypovolemia, orthostatic hypotension, or hypotension) are shown in Table 2 for the 12-study and 13-study, short-term, placebo-controlled pools  [see  Warnings and Precautions (5.1)  ]  .",hypotension is an adverse reaction entity
Adverse reactions related to renal function can occur after initiating FARXIGA [see  Adverse Reactions (6.1)  ]  .,Adverse renal function is an adverse reaction entity
"1.5           8.4                     6.9                          Nasopharyngitis                             6.2           6.6                     6.3                          Urinary tract infectionsUrinary tract infections include the following adverse reactions, listed in order of frequency reported: urinary tract infection, cystitis, Escherichia urinary tract infection, genitourinary tract infection, pyelonephritis, trigonitis, urethritis, kidney infection, and prostatitis.",Nasopharyngitis is an adverse reaction entity
"1.5           8.4                     6.9                          Nasopharyngitis                             6.2           6.6                     6.3                          Urinary tract infectionsUrinary tract infections include the following adverse reactions, listed in order of frequency reported: urinary tract infection, cystitis, Escherichia urinary tract infection, genitourinary tract infection, pyelonephritis, trigonitis, urethritis, kidney infection, and prostatitis.",Urinary tract infections is an adverse reaction entity
"1.5           8.4                     6.9                          Nasopharyngitis                             6.2           6.6                     6.3                          Urinary tract infectionsUrinary tract infections include the following adverse reactions, listed in order of frequency reported: urinary tract infection, cystitis, Escherichia urinary tract infection, genitourinary tract infection, pyelonephritis, trigonitis, urethritis, kidney infection, and prostatitis.",urinary tract infection is an adverse reaction entity
"1.5           8.4                     6.9                          Nasopharyngitis                             6.2           6.6                     6.3                          Urinary tract infectionsUrinary tract infections include the following adverse reactions, listed in order of frequency reported: urinary tract infection, cystitis, Escherichia urinary tract infection, genitourinary tract infection, pyelonephritis, trigonitis, urethritis, kidney infection, and prostatitis.",cystitis is an adverse reaction entity
"1.5           8.4                     6.9                          Nasopharyngitis                             6.2           6.6                     6.3                          Urinary tract infectionsUrinary tract infections include the following adverse reactions, listed in order of frequency reported: urinary tract infection, cystitis, Escherichia urinary tract infection, genitourinary tract infection, pyelonephritis, trigonitis, urethritis, kidney infection, and prostatitis.",Escherichia urinary tract infection is an adverse reaction entity
"1.5           8.4                     6.9                          Nasopharyngitis                             6.2           6.6                     6.3                          Urinary tract infectionsUrinary tract infections include the following adverse reactions, listed in order of frequency reported: urinary tract infection, cystitis, Escherichia urinary tract infection, genitourinary tract infection, pyelonephritis, trigonitis, urethritis, kidney infection, and prostatitis.",genitourinary tract infection is an adverse reaction entity
"1.5           8.4                     6.9                          Nasopharyngitis                             6.2           6.6                     6.3                          Urinary tract infectionsUrinary tract infections include the following adverse reactions, listed in order of frequency reported: urinary tract infection, cystitis, Escherichia urinary tract infection, genitourinary tract infection, pyelonephritis, trigonitis, urethritis, kidney infection, and prostatitis.",pyelonephritis is an adverse reaction entity
"1.5           8.4                     6.9                          Nasopharyngitis                             6.2           6.6                     6.3                          Urinary tract infectionsUrinary tract infections include the following adverse reactions, listed in order of frequency reported: urinary tract infection, cystitis, Escherichia urinary tract infection, genitourinary tract infection, pyelonephritis, trigonitis, urethritis, kidney infection, and prostatitis.",trigonitis is an adverse reaction entity
"1.5           8.4                     6.9                          Nasopharyngitis                             6.2           6.6                     6.3                          Urinary tract infectionsUrinary tract infections include the following adverse reactions, listed in order of frequency reported: urinary tract infection, cystitis, Escherichia urinary tract infection, genitourinary tract infection, pyelonephritis, trigonitis, urethritis, kidney infection, and prostatitis.",urethritis is an adverse reaction entity
"1.5           8.4                     6.9                          Nasopharyngitis                             6.2           6.6                     6.3                          Urinary tract infectionsUrinary tract infections include the following adverse reactions, listed in order of frequency reported: urinary tract infection, cystitis, Escherichia urinary tract infection, genitourinary tract infection, pyelonephritis, trigonitis, urethritis, kidney infection, and prostatitis.",kidney infection is an adverse reaction entity
"1.5           8.4                     6.9                          Nasopharyngitis                             6.2           6.6                     6.3                          Urinary tract infectionsUrinary tract infections include the following adverse reactions, listed in order of frequency reported: urinary tract infection, cystitis, Escherichia urinary tract infection, genitourinary tract infection, pyelonephritis, trigonitis, urethritis, kidney infection, and prostatitis.",prostatitis is an adverse reaction entity
"Increase in Low-Density Lipoprotein Cholesterol      In the pool of 13 placebo-controlled studies, changes from baseline in mean lipid values were reported in FARXIGA-treated patients compared to placebo-treated patients.",changes in mean lipid values is an adverse reaction entity
Eight of these 13 fractures were in patients who had a baseline eGFR of 30 to 45 mL/min/1.73 m  2  .,fractures is an adverse reaction entity
"EXCERPT:   The most common adverse reactions of moderate to severe intensity and incidence at least 2% (in those receiving TIVICAY in any one adult trial) are insomnia, fatigue, and headache.",insomnia is an adverse reaction entity
"EXCERPT:   The most common adverse reactions of moderate to severe intensity and incidence at least 2% (in those receiving TIVICAY in any one adult trial) are insomnia, fatigue, and headache.",fatigue is an adverse reaction entity
"EXCERPT:   The most common adverse reactions of moderate to severe intensity and incidence at least 2% (in those receiving TIVICAY in any one adult trial) are insomnia, fatigue, and headache.",headache is an adverse reaction entity
Creatinine increases were comparable by background NRTIs and were similar in treatment-experienced subjects.,Creatinine increases is an adverse reaction entity
The Grade 3 laboratory abnormalities were elevated total bilirubin and lipase reported in 1 subject each.,elevated total bilirubin is an adverse reaction entity
The Grade 3 laboratory abnormalities were elevated total bilirubin and lipase reported in 1 subject each.,elevated total lipase is an adverse reaction entity
"In addition, Grade 1 insomnia was reported by 1% and less than 1% of subjects receiving TIVICAY and raltegravir, respectively, in SPRING-2; whereas in SINGLE the rates were 7% and 4% for TIVICAY and ATRIPLA, respectively.",insomnia is an adverse reaction entity
"Autoimmune disorders (such as Graves' disease, polymyositis, and Guillain-Barre syndrome) have also been reported to occur in the setting of immune reconstitution; however, the time to onset is more variable and can occur many months after initiation of treatment.",Autoimmune disorders is an adverse reaction entity
"Autoimmune disorders (such as Graves' disease, polymyositis, and Guillain-Barre syndrome) have also been reported to occur in the setting of immune reconstitution; however, the time to onset is more variable and can occur many months after initiation of treatment.",Graves' disease is an adverse reaction entity
"Autoimmune disorders (such as Graves' disease, polymyositis, and Guillain-Barre syndrome) have also been reported to occur in the setting of immune reconstitution; however, the time to onset is more variable and can occur many months after initiation of treatment.",polymyositis is an adverse reaction entity
"Autoimmune disorders (such as Graves' disease, polymyositis, and Guillain-Barre syndrome) have also been reported to occur in the setting of immune reconstitution; however, the time to onset is more variable and can occur many months after initiation of treatment.",Guillain-Barre syndrome is an adverse reaction entity
"(  5.3  ,  5.4  )             5.1 Hypersensitivity Reactions      Hypersensitivity reactions have been reported and were characterized by rash, constitutional findings, and sometimes organ dysfunction, including liver injury.",Hypersensitivity is an adverse reaction entity
"(  5.3  ,  5.4  )             5.1 Hypersensitivity Reactions      Hypersensitivity reactions have been reported and were characterized by rash, constitutional findings, and sometimes organ dysfunction, including liver injury.",rash is an adverse reaction entity
"(  5.3  ,  5.4  )             5.1 Hypersensitivity Reactions      Hypersensitivity reactions have been reported and were characterized by rash, constitutional findings, and sometimes organ dysfunction, including liver injury.",organ dysfunction is an adverse reaction entity
"(  5.3  ,  5.4  )             5.1 Hypersensitivity Reactions      Hypersensitivity reactions have been reported and were characterized by rash, constitutional findings, and sometimes organ dysfunction, including liver injury.",liver injury is an adverse reaction entity
(  5.12  )   *    Posterior reversible encephalopathy syndrome (PRES): Consider neuro-radiological imaging (MRI) for onset of visual or neurological symptoms; discontinue Kyprolis if suspected.,Posterior reversible encephalopathy syndrome is an adverse reaction entity
(  5.12  )   *    Posterior reversible encephalopathy syndrome (PRES): Consider neuro-radiological imaging (MRI) for onset of visual or neurological symptoms; discontinue Kyprolis if suspected.,PRES is an adverse reaction entity
"Table 5: Common Adverse Events (>= 10% in the KRd Arm) Occurring in Cycles 1-12 (Combination Therapy)   KRd = Kyprolis, lenalidomide,and low-dose dexamethasone; Rd = lenalidomide and low-dose dexamethasone  a    Pneumonia includes preferred terms of pneumonia, bronchopneumonia  b    Peripheral neuropathies NEC includes preferred terms under HLT peripheral neuropathies NEC  c    Dyspnea includes preferred terms of dyspnea, dyspnea exertional  d    Embolic and thrombotic events, venous include preferred terms in MedDRA SMQ narrow scope search of embolic and thrombotic events, venous.",Pneumonia is an adverse reaction entity
"Table 5: Common Adverse Events (>= 10% in the KRd Arm) Occurring in Cycles 1-12 (Combination Therapy)   KRd = Kyprolis, lenalidomide,and low-dose dexamethasone; Rd = lenalidomide and low-dose dexamethasone  a    Pneumonia includes preferred terms of pneumonia, bronchopneumonia  b    Peripheral neuropathies NEC includes preferred terms under HLT peripheral neuropathies NEC  c    Dyspnea includes preferred terms of dyspnea, dyspnea exertional  d    Embolic and thrombotic events, venous include preferred terms in MedDRA SMQ narrow scope search of embolic and thrombotic events, venous.",pneumonia is an adverse reaction entity
"Table 5: Common Adverse Events (>= 10% in the KRd Arm) Occurring in Cycles 1-12 (Combination Therapy)   KRd = Kyprolis, lenalidomide,and low-dose dexamethasone; Rd = lenalidomide and low-dose dexamethasone  a    Pneumonia includes preferred terms of pneumonia, bronchopneumonia  b    Peripheral neuropathies NEC includes preferred terms under HLT peripheral neuropathies NEC  c    Dyspnea includes preferred terms of dyspnea, dyspnea exertional  d    Embolic and thrombotic events, venous include preferred terms in MedDRA SMQ narrow scope search of embolic and thrombotic events, venous.",bronchopneumonia is an adverse reaction entity
"Table 5: Common Adverse Events (>= 10% in the KRd Arm) Occurring in Cycles 1-12 (Combination Therapy)   KRd = Kyprolis, lenalidomide,and low-dose dexamethasone; Rd = lenalidomide and low-dose dexamethasone  a    Pneumonia includes preferred terms of pneumonia, bronchopneumonia  b    Peripheral neuropathies NEC includes preferred terms under HLT peripheral neuropathies NEC  c    Dyspnea includes preferred terms of dyspnea, dyspnea exertional  d    Embolic and thrombotic events, venous include preferred terms in MedDRA SMQ narrow scope search of embolic and thrombotic events, venous.",Peripheral neuropathies NEC is an adverse reaction entity
"Table 5: Common Adverse Events (>= 10% in the KRd Arm) Occurring in Cycles 1-12 (Combination Therapy)   KRd = Kyprolis, lenalidomide,and low-dose dexamethasone; Rd = lenalidomide and low-dose dexamethasone  a    Pneumonia includes preferred terms of pneumonia, bronchopneumonia  b    Peripheral neuropathies NEC includes preferred terms under HLT peripheral neuropathies NEC  c    Dyspnea includes preferred terms of dyspnea, dyspnea exertional  d    Embolic and thrombotic events, venous include preferred terms in MedDRA SMQ narrow scope search of embolic and thrombotic events, venous.",peripheral neuropathies NEC is an adverse reaction entity
"Table 5: Common Adverse Events (>= 10% in the KRd Arm) Occurring in Cycles 1-12 (Combination Therapy)   KRd = Kyprolis, lenalidomide,and low-dose dexamethasone; Rd = lenalidomide and low-dose dexamethasone  a    Pneumonia includes preferred terms of pneumonia, bronchopneumonia  b    Peripheral neuropathies NEC includes preferred terms under HLT peripheral neuropathies NEC  c    Dyspnea includes preferred terms of dyspnea, dyspnea exertional  d    Embolic and thrombotic events, venous include preferred terms in MedDRA SMQ narrow scope search of embolic and thrombotic events, venous.",Dyspnea is an adverse reaction entity
"Table 5: Common Adverse Events (>= 10% in the KRd Arm) Occurring in Cycles 1-12 (Combination Therapy)   KRd = Kyprolis, lenalidomide,and low-dose dexamethasone; Rd = lenalidomide and low-dose dexamethasone  a    Pneumonia includes preferred terms of pneumonia, bronchopneumonia  b    Peripheral neuropathies NEC includes preferred terms under HLT peripheral neuropathies NEC  c    Dyspnea includes preferred terms of dyspnea, dyspnea exertional  d    Embolic and thrombotic events, venous include preferred terms in MedDRA SMQ narrow scope search of embolic and thrombotic events, venous.",dyspnea is an adverse reaction entity
"Table 5: Common Adverse Events (>= 10% in the KRd Arm) Occurring in Cycles 1-12 (Combination Therapy)   KRd = Kyprolis, lenalidomide,and low-dose dexamethasone; Rd = lenalidomide and low-dose dexamethasone  a    Pneumonia includes preferred terms of pneumonia, bronchopneumonia  b    Peripheral neuropathies NEC includes preferred terms under HLT peripheral neuropathies NEC  c    Dyspnea includes preferred terms of dyspnea, dyspnea exertional  d    Embolic and thrombotic events, venous include preferred terms in MedDRA SMQ narrow scope search of embolic and thrombotic events, venous.",dyspnea exertional is an adverse reaction entity
"Table 5: Common Adverse Events (>= 10% in the KRd Arm) Occurring in Cycles 1-12 (Combination Therapy)   KRd = Kyprolis, lenalidomide,and low-dose dexamethasone; Rd = lenalidomide and low-dose dexamethasone  a    Pneumonia includes preferred terms of pneumonia, bronchopneumonia  b    Peripheral neuropathies NEC includes preferred terms under HLT peripheral neuropathies NEC  c    Dyspnea includes preferred terms of dyspnea, dyspnea exertional  d    Embolic and thrombotic events, venous include preferred terms in MedDRA SMQ narrow scope search of embolic and thrombotic events, venous.","Embolic and thrombotic events, venous is an adverse reaction entity"
"Table 5: Common Adverse Events (>= 10% in the KRd Arm) Occurring in Cycles 1-12 (Combination Therapy)   KRd = Kyprolis, lenalidomide,and low-dose dexamethasone; Rd = lenalidomide and low-dose dexamethasone  a    Pneumonia includes preferred terms of pneumonia, bronchopneumonia  b    Peripheral neuropathies NEC includes preferred terms under HLT peripheral neuropathies NEC  c    Dyspnea includes preferred terms of dyspnea, dyspnea exertional  d    Embolic and thrombotic events, venous include preferred terms in MedDRA SMQ narrow scope search of embolic and thrombotic events, venous.","embolic and thrombotic events, venous is an adverse reaction entity"
"Adverse events leading to discontinuation of Kyprolis occurred in 12% of patients and the most common events included pneumonia (1%), myocardial infarction (0.8%), and upper respiratory tract infection (0.8%).",pneumonia is an adverse reaction entity
"Adverse events leading to discontinuation of Kyprolis occurred in 12% of patients and the most common events included pneumonia (1%), myocardial infarction (0.8%), and upper respiratory tract infection (0.8%).",myocardial infarction is an adverse reaction entity
"Adverse events leading to discontinuation of Kyprolis occurred in 12% of patients and the most common events included pneumonia (1%), myocardial infarction (0.8%), and upper respiratory tract infection (0.8%).",upper respiratory tract infection is an adverse reaction entity
5.6 Dyspnea         Dyspnea was reported in 28% of patients treated with Kyprolis and was Grade 3 or greater in 4% of patients.,Dyspnea is an adverse reaction entity
5.6 Dyspnea         Dyspnea was reported in 28% of patients treated with Kyprolis and was Grade 3 or greater in 4% of patients.,Dyspnea is an adverse reaction entity
5.14 Embryo-fetal Toxicity         Kyprolis can cause fetal harm when administered to a pregnant woman based on its mechanism of action and findings in animals.,fetal harm is an adverse reaction entity
(  5.1  )   *    Acute Renal Failure: Monitor serum creatinine regularly (  5.2  )   *    Tumor Lysis Syndrome (TLS): Administer pre-treatment hydration.,Acute Renal Failure is an adverse reaction entity
(  5.1  )   *    Acute Renal Failure: Monitor serum creatinine regularly (  5.2  )   *    Tumor Lysis Syndrome (TLS): Administer pre-treatment hydration.,Tumor Lysis Syndrome is an adverse reaction entity
(  5.1  )   *    Acute Renal Failure: Monitor serum creatinine regularly (  5.2  )   *    Tumor Lysis Syndrome (TLS): Administer pre-treatment hydration.,TLS is an adverse reaction entity
"(  6  )      The most common adverse events occurring in at least 20% of patients treated with Kyprolis in the combination therapy trial: decreased lymphocytes, decreased absolute neutrophil count, decreased phosphorus, anemia, neutropenia, decreased total white blood cell count, decreased platelets, diarrhea, fatigue, thrombocytopenia, pyrexia, muscle spasm, cough, upper respiratory tract infection, decreased hemoglobin, hypokalemia.",decreased lymphocytes is an adverse reaction entity
"(  6  )      The most common adverse events occurring in at least 20% of patients treated with Kyprolis in the combination therapy trial: decreased lymphocytes, decreased absolute neutrophil count, decreased phosphorus, anemia, neutropenia, decreased total white blood cell count, decreased platelets, diarrhea, fatigue, thrombocytopenia, pyrexia, muscle spasm, cough, upper respiratory tract infection, decreased hemoglobin, hypokalemia.",decreased absolute neutrophil count is an adverse reaction entity
"(  6  )      The most common adverse events occurring in at least 20% of patients treated with Kyprolis in the combination therapy trial: decreased lymphocytes, decreased absolute neutrophil count, decreased phosphorus, anemia, neutropenia, decreased total white blood cell count, decreased platelets, diarrhea, fatigue, thrombocytopenia, pyrexia, muscle spasm, cough, upper respiratory tract infection, decreased hemoglobin, hypokalemia.",decreased phosphorus is an adverse reaction entity
"(  6  )      The most common adverse events occurring in at least 20% of patients treated with Kyprolis in the combination therapy trial: decreased lymphocytes, decreased absolute neutrophil count, decreased phosphorus, anemia, neutropenia, decreased total white blood cell count, decreased platelets, diarrhea, fatigue, thrombocytopenia, pyrexia, muscle spasm, cough, upper respiratory tract infection, decreased hemoglobin, hypokalemia.",anemia is an adverse reaction entity
"(  6  )      The most common adverse events occurring in at least 20% of patients treated with Kyprolis in the combination therapy trial: decreased lymphocytes, decreased absolute neutrophil count, decreased phosphorus, anemia, neutropenia, decreased total white blood cell count, decreased platelets, diarrhea, fatigue, thrombocytopenia, pyrexia, muscle spasm, cough, upper respiratory tract infection, decreased hemoglobin, hypokalemia.",neutropenia is an adverse reaction entity
"(  6  )      The most common adverse events occurring in at least 20% of patients treated with Kyprolis in the combination therapy trial: decreased lymphocytes, decreased absolute neutrophil count, decreased phosphorus, anemia, neutropenia, decreased total white blood cell count, decreased platelets, diarrhea, fatigue, thrombocytopenia, pyrexia, muscle spasm, cough, upper respiratory tract infection, decreased hemoglobin, hypokalemia.",decreased total white blood cell count is an adverse reaction entity
"(  6  )      The most common adverse events occurring in at least 20% of patients treated with Kyprolis in the combination therapy trial: decreased lymphocytes, decreased absolute neutrophil count, decreased phosphorus, anemia, neutropenia, decreased total white blood cell count, decreased platelets, diarrhea, fatigue, thrombocytopenia, pyrexia, muscle spasm, cough, upper respiratory tract infection, decreased hemoglobin, hypokalemia.",decreased platelets is an adverse reaction entity
"(  6  )      The most common adverse events occurring in at least 20% of patients treated with Kyprolis in the combination therapy trial: decreased lymphocytes, decreased absolute neutrophil count, decreased phosphorus, anemia, neutropenia, decreased total white blood cell count, decreased platelets, diarrhea, fatigue, thrombocytopenia, pyrexia, muscle spasm, cough, upper respiratory tract infection, decreased hemoglobin, hypokalemia.",diarrhea is an adverse reaction entity
"(  6  )      The most common adverse events occurring in at least 20% of patients treated with Kyprolis in the combination therapy trial: decreased lymphocytes, decreased absolute neutrophil count, decreased phosphorus, anemia, neutropenia, decreased total white blood cell count, decreased platelets, diarrhea, fatigue, thrombocytopenia, pyrexia, muscle spasm, cough, upper respiratory tract infection, decreased hemoglobin, hypokalemia.",fatigue is an adverse reaction entity
"(  6  )      The most common adverse events occurring in at least 20% of patients treated with Kyprolis in the combination therapy trial: decreased lymphocytes, decreased absolute neutrophil count, decreased phosphorus, anemia, neutropenia, decreased total white blood cell count, decreased platelets, diarrhea, fatigue, thrombocytopenia, pyrexia, muscle spasm, cough, upper respiratory tract infection, decreased hemoglobin, hypokalemia.",thrombocytopenia is an adverse reaction entity
"(  6  )      The most common adverse events occurring in at least 20% of patients treated with Kyprolis in the combination therapy trial: decreased lymphocytes, decreased absolute neutrophil count, decreased phosphorus, anemia, neutropenia, decreased total white blood cell count, decreased platelets, diarrhea, fatigue, thrombocytopenia, pyrexia, muscle spasm, cough, upper respiratory tract infection, decreased hemoglobin, hypokalemia.",pyrexia is an adverse reaction entity
"(  6  )      The most common adverse events occurring in at least 20% of patients treated with Kyprolis in the combination therapy trial: decreased lymphocytes, decreased absolute neutrophil count, decreased phosphorus, anemia, neutropenia, decreased total white blood cell count, decreased platelets, diarrhea, fatigue, thrombocytopenia, pyrexia, muscle spasm, cough, upper respiratory tract infection, decreased hemoglobin, hypokalemia.",muscle spasm is an adverse reaction entity
"(  6  )      The most common adverse events occurring in at least 20% of patients treated with Kyprolis in the combination therapy trial: decreased lymphocytes, decreased absolute neutrophil count, decreased phosphorus, anemia, neutropenia, decreased total white blood cell count, decreased platelets, diarrhea, fatigue, thrombocytopenia, pyrexia, muscle spasm, cough, upper respiratory tract infection, decreased hemoglobin, hypokalemia.",cough is an adverse reaction entity
"(  6  )      The most common adverse events occurring in at least 20% of patients treated with Kyprolis in the combination therapy trial: decreased lymphocytes, decreased absolute neutrophil count, decreased phosphorus, anemia, neutropenia, decreased total white blood cell count, decreased platelets, diarrhea, fatigue, thrombocytopenia, pyrexia, muscle spasm, cough, upper respiratory tract infection, decreased hemoglobin, hypokalemia.",upper respiratory tract infection is an adverse reaction entity
"(  6  )      The most common adverse events occurring in at least 20% of patients treated with Kyprolis in the combination therapy trial: decreased lymphocytes, decreased absolute neutrophil count, decreased phosphorus, anemia, neutropenia, decreased total white blood cell count, decreased platelets, diarrhea, fatigue, thrombocytopenia, pyrexia, muscle spasm, cough, upper respiratory tract infection, decreased hemoglobin, hypokalemia.",decreased hemoglobin is an adverse reaction entity
"(  6  )      The most common adverse events occurring in at least 20% of patients treated with Kyprolis in the combination therapy trial: decreased lymphocytes, decreased absolute neutrophil count, decreased phosphorus, anemia, neutropenia, decreased total white blood cell count, decreased platelets, diarrhea, fatigue, thrombocytopenia, pyrexia, muscle spasm, cough, upper respiratory tract infection, decreased hemoglobin, hypokalemia.",hypokalemia is an adverse reaction entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: dehydration, thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS), tumor lysis syndrome including fatal outcomes, and posterior reversible encephalopathy syndrome (PRES).",dehydration is an adverse reaction entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: dehydration, thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS), tumor lysis syndrome including fatal outcomes, and posterior reversible encephalopathy syndrome (PRES).",thrombotic thrombocytopenic purpura is an adverse reaction entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: dehydration, thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS), tumor lysis syndrome including fatal outcomes, and posterior reversible encephalopathy syndrome (PRES).",hemolytic uremic syndrome is an adverse reaction entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: dehydration, thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS), tumor lysis syndrome including fatal outcomes, and posterior reversible encephalopathy syndrome (PRES).",TTP is an adverse reaction entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: dehydration, thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS), tumor lysis syndrome including fatal outcomes, and posterior reversible encephalopathy syndrome (PRES).",HUS is an adverse reaction entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: dehydration, thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS), tumor lysis syndrome including fatal outcomes, and posterior reversible encephalopathy syndrome (PRES).",tumor lysis syndrome is an adverse reaction entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: dehydration, thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS), tumor lysis syndrome including fatal outcomes, and posterior reversible encephalopathy syndrome (PRES).",fatal is an adverse reaction entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: dehydration, thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS), tumor lysis syndrome including fatal outcomes, and posterior reversible encephalopathy syndrome (PRES).",posterior reversible encephalopathy syndrome is an adverse reaction entity
"Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: dehydration, thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS), tumor lysis syndrome including fatal outcomes, and posterior reversible encephalopathy syndrome (PRES).",PRES is an adverse reaction entity
5.13 Posterior Reversible Encephalopathy Syndrome (PRES)         Cases of PRES have been reported in patients receiving Kyprolis.,PRES is an adverse reaction entity
"(  2.1  ,  5.9  )   *    Thrombocytopenia: Monitor platelet counts; interrupt or reduce Kyprolis dosing as clinically indicated.",Thrombocytopenia is an adverse reaction entity
In the controlled portions of clinical trials of TNF-blockers including the subcutaneous formulation of golimumab more cases of lymphoma have been observed among patients receiving anti-TNF treatment compared with patients in the control groups.,lymphoma is an adverse reaction entity
"In the controlled and uncontrolled portions of Trial 1, 958 total patient-years of follow-up with a median follow-up of approximately 92 weeks, the incidence per 100 patient-years of all serious infections was 4.07 (CI: 2.90, 5.57) in patients receiving SIMPONI ARIA  [see  Warnings and Precautions (5.1)  ]  .",infections is an adverse reaction entity
"The other cases represented a variety of malignancies, including rare malignancies that are usually associated with immunosuppression, and malignancies that are not usually observed in children and adolescents.",malignancies is an adverse reaction entity
"The other cases represented a variety of malignancies, including rare malignancies that are usually associated with immunosuppression, and malignancies that are not usually observed in children and adolescents.",rare malignancies is an adverse reaction entity
"The other cases represented a variety of malignancies, including rare malignancies that are usually associated with immunosuppression, and malignancies that are not usually observed in children and adolescents.",immunosuppression is an adverse reaction entity
Patients with tuberculosis have frequently presented with disseminated or extrapulmonary disease.,tuberculosis is an adverse reaction entity
Patients with tuberculosis have frequently presented with disseminated or extrapulmonary disease.,tuberculosis disseminated is an adverse reaction entity
Patients with tuberculosis have frequently presented with disseminated or extrapulmonary disease.,tuberculosis extrapulmonary is an adverse reaction entity
"Autoimmune Disorders and Autoantibodies       The use of TNF-blockers, of which SIMPONI ARIA is a member, has been associated with the formation of autoantibodies and, rarely, with the development of a lupus-like syndrome.",formation of autoantibodies is an adverse reaction entity
"Autoimmune Disorders and Autoantibodies       The use of TNF-blockers, of which SIMPONI ARIA is a member, has been associated with the formation of autoantibodies and, rarely, with the development of a lupus-like syndrome.",lupus-like syndrome is an adverse reaction entity
"Through Week 24, the incidence of serious infections per 100 patient-years of follow-up was 2.2 (95% CI 0.61, 5.71) for the SIMPONI ARIA group, and 0 (0.00, 3.79) for the placebo group.",infections is an adverse reaction entity
"Administration Reactions       In the controlled phase of Trial 1 through Week 24, 1.1% of SIMPONI ARIA infusions were associated with an infusion reaction compared with 0.2% of infusions in the control group.",infusion reaction is an adverse reaction entity
"Tuberculosis       Cases of reactivation of tuberculosis or new tuberculosis infections have been observed in patients receiving TNF-blockers, including patients who have previously received treatment for latent or active tuberculosis.",reactivation of tuberculosis is an adverse reaction entity
"Tuberculosis       Cases of reactivation of tuberculosis or new tuberculosis infections have been observed in patients receiving TNF-blockers, including patients who have previously received treatment for latent or active tuberculosis.",new tuberculosis infections is an adverse reaction entity
"In clinical studies, cases of pancytopenia, leukopenia, neutropenia, and thrombocytopenia have also occurred in SIMPONI ARIA-treated patients.",pancytopenia is an adverse reaction entity
"In clinical studies, cases of pancytopenia, leukopenia, neutropenia, and thrombocytopenia have also occurred in SIMPONI ARIA-treated patients.",leukopenia is an adverse reaction entity
"In clinical studies, cases of pancytopenia, leukopenia, neutropenia, and thrombocytopenia have also occurred in SIMPONI ARIA-treated patients.",neutropenia is an adverse reaction entity
"In clinical studies, cases of pancytopenia, leukopenia, neutropenia, and thrombocytopenia have also occurred in SIMPONI ARIA-treated patients.",thrombocytopenia is an adverse reaction entity
Liver Enzyme Elevations       There have been reports of severe hepatic reactions including acute liver failure in patients receiving TNF-blockers.,hepatic reactions is an adverse reaction entity
Liver Enzyme Elevations       There have been reports of severe hepatic reactions including acute liver failure in patients receiving TNF-blockers.,acute liver failure is an adverse reaction entity
"6 ADVERSE REACTIONS    The most serious adverse reactions were:     *  Serious Infections [see  Warnings and Precautions (5.1)  ]    *  Malignancies [see  Warnings and Precautions (5.2)  ]         EXCERPT:   Most common adverse reactions (incidence >=3%) are: upper respiratory tract infection, viral infection, bronchitis, hypertension, and rash (  6.1  ).",Infections is an adverse reaction entity
"6 ADVERSE REACTIONS    The most serious adverse reactions were:     *  Serious Infections [see  Warnings and Precautions (5.1)  ]    *  Malignancies [see  Warnings and Precautions (5.2)  ]         EXCERPT:   Most common adverse reactions (incidence >=3%) are: upper respiratory tract infection, viral infection, bronchitis, hypertension, and rash (  6.1  ).",Malignancies is an adverse reaction entity
"6 ADVERSE REACTIONS    The most serious adverse reactions were:     *  Serious Infections [see  Warnings and Precautions (5.1)  ]    *  Malignancies [see  Warnings and Precautions (5.2)  ]         EXCERPT:   Most common adverse reactions (incidence >=3%) are: upper respiratory tract infection, viral infection, bronchitis, hypertension, and rash (  6.1  ).",upper respiratory tract infection is an adverse reaction entity
"6 ADVERSE REACTIONS    The most serious adverse reactions were:     *  Serious Infections [see  Warnings and Precautions (5.1)  ]    *  Malignancies [see  Warnings and Precautions (5.2)  ]         EXCERPT:   Most common adverse reactions (incidence >=3%) are: upper respiratory tract infection, viral infection, bronchitis, hypertension, and rash (  6.1  ).",viral infection is an adverse reaction entity
"6 ADVERSE REACTIONS    The most serious adverse reactions were:     *  Serious Infections [see  Warnings and Precautions (5.1)  ]    *  Malignancies [see  Warnings and Precautions (5.2)  ]         EXCERPT:   Most common adverse reactions (incidence >=3%) are: upper respiratory tract infection, viral infection, bronchitis, hypertension, and rash (  6.1  ).",bronchitis is an adverse reaction entity
"6 ADVERSE REACTIONS    The most serious adverse reactions were:     *  Serious Infections [see  Warnings and Precautions (5.1)  ]    *  Malignancies [see  Warnings and Precautions (5.2)  ]         EXCERPT:   Most common adverse reactions (incidence >=3%) are: upper respiratory tract infection, viral infection, bronchitis, hypertension, and rash (  6.1  ).",hypertension is an adverse reaction entity
"6 ADVERSE REACTIONS    The most serious adverse reactions were:     *  Serious Infections [see  Warnings and Precautions (5.1)  ]    *  Malignancies [see  Warnings and Precautions (5.2)  ]         EXCERPT:   Most common adverse reactions (incidence >=3%) are: upper respiratory tract infection, viral infection, bronchitis, hypertension, and rash (  6.1  ).",rash is an adverse reaction entity
"Approximately half the cases were lymphomas, including Hodgkin's and non-Hodgkin's lymphoma.",lymphomas is an adverse reaction entity
"Approximately half the cases were lymphomas, including Hodgkin's and non-Hodgkin's lymphoma.",Hodgkin's lymphoma is an adverse reaction entity
"Approximately half the cases were lymphomas, including Hodgkin's and non-Hodgkin's lymphoma.",non-Hodgkin's lymphoma is an adverse reaction entity
*  Hypersensitivity reactions: Serious systemic hypersensitivity reactions including anaphylaxis may occur (  5.10  ).,Hypersensitivity reactions is an adverse reaction entity
*  Hypersensitivity reactions: Serious systemic hypersensitivity reactions including anaphylaxis may occur (  5.10  ).,systemic hypersensitivity reactions is an adverse reaction entity
*  Hypersensitivity reactions: Serious systemic hypersensitivity reactions including anaphylaxis may occur (  5.10  ).,anaphylaxis is an adverse reaction entity
(  5.4  )   *     Carbohydrate and lipid metabolic effects : Monitor prediabetic and diabetic women taking Natazia.,Carbohydrate metabolic effects is an adverse reaction entity
(  5.4  )   *     Carbohydrate and lipid metabolic effects : Monitor prediabetic and diabetic women taking Natazia.,lipid metabolic effects is an adverse reaction entity
"Studies also do not suggest a teratogenic effect, particularly in so far as cardiac anomalies and limb-reduction defects are concerned, when taken inadvertently during early pregnancy.",teratogenic effect is an adverse reaction entity
"Studies also do not suggest a teratogenic effect, particularly in so far as cardiac anomalies and limb-reduction defects are concerned, when taken inadvertently during early pregnancy.",cardiac anomalies is an adverse reaction entity
"Studies also do not suggest a teratogenic effect, particularly in so far as cardiac anomalies and limb-reduction defects are concerned, when taken inadvertently during early pregnancy.",limb-reduction defects is an adverse reaction entity
"The risk of VTE in women using COCs has been estimated to be 3 to 9 per 10,000 woman-years.",VTE is an adverse reaction entity
"Adverse Reactions Leading to Study Discontinuation  : 11.4% of the women discontinued from the clinical trials due to an adverse reaction; the most frequent adverse reactions leading to discontinuation were menstrual disorder (metrorrhagia, menorrhagia, menstruation irregular, genital hemorrhage, vaginal hemorrhage, dysfunctional uterine bleeding) (2.3%); mood changes (depression, mood swings, mood altered, depressed mood, dysthymic disorder, crying) (1.2%); acne (1.1%), headache (including migraines) (1.1%), and weight increased (0.7 %).",menstrual disorder is an adverse reaction entity
"Adverse Reactions Leading to Study Discontinuation  : 11.4% of the women discontinued from the clinical trials due to an adverse reaction; the most frequent adverse reactions leading to discontinuation were menstrual disorder (metrorrhagia, menorrhagia, menstruation irregular, genital hemorrhage, vaginal hemorrhage, dysfunctional uterine bleeding) (2.3%); mood changes (depression, mood swings, mood altered, depressed mood, dysthymic disorder, crying) (1.2%); acne (1.1%), headache (including migraines) (1.1%), and weight increased (0.7 %).",metrorrhagia is an adverse reaction entity
"Adverse Reactions Leading to Study Discontinuation  : 11.4% of the women discontinued from the clinical trials due to an adverse reaction; the most frequent adverse reactions leading to discontinuation were menstrual disorder (metrorrhagia, menorrhagia, menstruation irregular, genital hemorrhage, vaginal hemorrhage, dysfunctional uterine bleeding) (2.3%); mood changes (depression, mood swings, mood altered, depressed mood, dysthymic disorder, crying) (1.2%); acne (1.1%), headache (including migraines) (1.1%), and weight increased (0.7 %).",menorrhagia is an adverse reaction entity
"Adverse Reactions Leading to Study Discontinuation  : 11.4% of the women discontinued from the clinical trials due to an adverse reaction; the most frequent adverse reactions leading to discontinuation were menstrual disorder (metrorrhagia, menorrhagia, menstruation irregular, genital hemorrhage, vaginal hemorrhage, dysfunctional uterine bleeding) (2.3%); mood changes (depression, mood swings, mood altered, depressed mood, dysthymic disorder, crying) (1.2%); acne (1.1%), headache (including migraines) (1.1%), and weight increased (0.7 %).",menstruation irregular is an adverse reaction entity
"Adverse Reactions Leading to Study Discontinuation  : 11.4% of the women discontinued from the clinical trials due to an adverse reaction; the most frequent adverse reactions leading to discontinuation were menstrual disorder (metrorrhagia, menorrhagia, menstruation irregular, genital hemorrhage, vaginal hemorrhage, dysfunctional uterine bleeding) (2.3%); mood changes (depression, mood swings, mood altered, depressed mood, dysthymic disorder, crying) (1.2%); acne (1.1%), headache (including migraines) (1.1%), and weight increased (0.7 %).",genital hemorrhage is an adverse reaction entity
"Adverse Reactions Leading to Study Discontinuation  : 11.4% of the women discontinued from the clinical trials due to an adverse reaction; the most frequent adverse reactions leading to discontinuation were menstrual disorder (metrorrhagia, menorrhagia, menstruation irregular, genital hemorrhage, vaginal hemorrhage, dysfunctional uterine bleeding) (2.3%); mood changes (depression, mood swings, mood altered, depressed mood, dysthymic disorder, crying) (1.2%); acne (1.1%), headache (including migraines) (1.1%), and weight increased (0.7 %).",vaginal hemorrhage is an adverse reaction entity
"Adverse Reactions Leading to Study Discontinuation  : 11.4% of the women discontinued from the clinical trials due to an adverse reaction; the most frequent adverse reactions leading to discontinuation were menstrual disorder (metrorrhagia, menorrhagia, menstruation irregular, genital hemorrhage, vaginal hemorrhage, dysfunctional uterine bleeding) (2.3%); mood changes (depression, mood swings, mood altered, depressed mood, dysthymic disorder, crying) (1.2%); acne (1.1%), headache (including migraines) (1.1%), and weight increased (0.7 %).",dysfunctional uterine bleeding is an adverse reaction entity
"Adverse Reactions Leading to Study Discontinuation  : 11.4% of the women discontinued from the clinical trials due to an adverse reaction; the most frequent adverse reactions leading to discontinuation were menstrual disorder (metrorrhagia, menorrhagia, menstruation irregular, genital hemorrhage, vaginal hemorrhage, dysfunctional uterine bleeding) (2.3%); mood changes (depression, mood swings, mood altered, depressed mood, dysthymic disorder, crying) (1.2%); acne (1.1%), headache (including migraines) (1.1%), and weight increased (0.7 %).",mood changes is an adverse reaction entity
"Adverse Reactions Leading to Study Discontinuation  : 11.4% of the women discontinued from the clinical trials due to an adverse reaction; the most frequent adverse reactions leading to discontinuation were menstrual disorder (metrorrhagia, menorrhagia, menstruation irregular, genital hemorrhage, vaginal hemorrhage, dysfunctional uterine bleeding) (2.3%); mood changes (depression, mood swings, mood altered, depressed mood, dysthymic disorder, crying) (1.2%); acne (1.1%), headache (including migraines) (1.1%), and weight increased (0.7 %).",depression is an adverse reaction entity
"Adverse Reactions Leading to Study Discontinuation  : 11.4% of the women discontinued from the clinical trials due to an adverse reaction; the most frequent adverse reactions leading to discontinuation were menstrual disorder (metrorrhagia, menorrhagia, menstruation irregular, genital hemorrhage, vaginal hemorrhage, dysfunctional uterine bleeding) (2.3%); mood changes (depression, mood swings, mood altered, depressed mood, dysthymic disorder, crying) (1.2%); acne (1.1%), headache (including migraines) (1.1%), and weight increased (0.7 %).",mood swings is an adverse reaction entity
"Adverse Reactions Leading to Study Discontinuation  : 11.4% of the women discontinued from the clinical trials due to an adverse reaction; the most frequent adverse reactions leading to discontinuation were menstrual disorder (metrorrhagia, menorrhagia, menstruation irregular, genital hemorrhage, vaginal hemorrhage, dysfunctional uterine bleeding) (2.3%); mood changes (depression, mood swings, mood altered, depressed mood, dysthymic disorder, crying) (1.2%); acne (1.1%), headache (including migraines) (1.1%), and weight increased (0.7 %).",mood altered is an adverse reaction entity
"Adverse Reactions Leading to Study Discontinuation  : 11.4% of the women discontinued from the clinical trials due to an adverse reaction; the most frequent adverse reactions leading to discontinuation were menstrual disorder (metrorrhagia, menorrhagia, menstruation irregular, genital hemorrhage, vaginal hemorrhage, dysfunctional uterine bleeding) (2.3%); mood changes (depression, mood swings, mood altered, depressed mood, dysthymic disorder, crying) (1.2%); acne (1.1%), headache (including migraines) (1.1%), and weight increased (0.7 %).",depressed mood is an adverse reaction entity
"Adverse Reactions Leading to Study Discontinuation  : 11.4% of the women discontinued from the clinical trials due to an adverse reaction; the most frequent adverse reactions leading to discontinuation were menstrual disorder (metrorrhagia, menorrhagia, menstruation irregular, genital hemorrhage, vaginal hemorrhage, dysfunctional uterine bleeding) (2.3%); mood changes (depression, mood swings, mood altered, depressed mood, dysthymic disorder, crying) (1.2%); acne (1.1%), headache (including migraines) (1.1%), and weight increased (0.7 %).",dysthymic disorder is an adverse reaction entity
"Adverse Reactions Leading to Study Discontinuation  : 11.4% of the women discontinued from the clinical trials due to an adverse reaction; the most frequent adverse reactions leading to discontinuation were menstrual disorder (metrorrhagia, menorrhagia, menstruation irregular, genital hemorrhage, vaginal hemorrhage, dysfunctional uterine bleeding) (2.3%); mood changes (depression, mood swings, mood altered, depressed mood, dysthymic disorder, crying) (1.2%); acne (1.1%), headache (including migraines) (1.1%), and weight increased (0.7 %).",crying is an adverse reaction entity
"Adverse Reactions Leading to Study Discontinuation  : 11.4% of the women discontinued from the clinical trials due to an adverse reaction; the most frequent adverse reactions leading to discontinuation were menstrual disorder (metrorrhagia, menorrhagia, menstruation irregular, genital hemorrhage, vaginal hemorrhage, dysfunctional uterine bleeding) (2.3%); mood changes (depression, mood swings, mood altered, depressed mood, dysthymic disorder, crying) (1.2%); acne (1.1%), headache (including migraines) (1.1%), and weight increased (0.7 %).",acne is an adverse reaction entity
"Adverse Reactions Leading to Study Discontinuation  : 11.4% of the women discontinued from the clinical trials due to an adverse reaction; the most frequent adverse reactions leading to discontinuation were menstrual disorder (metrorrhagia, menorrhagia, menstruation irregular, genital hemorrhage, vaginal hemorrhage, dysfunctional uterine bleeding) (2.3%); mood changes (depression, mood swings, mood altered, depressed mood, dysthymic disorder, crying) (1.2%); acne (1.1%), headache (including migraines) (1.1%), and weight increased (0.7 %).",headache is an adverse reaction entity
"Adverse Reactions Leading to Study Discontinuation  : 11.4% of the women discontinued from the clinical trials due to an adverse reaction; the most frequent adverse reactions leading to discontinuation were menstrual disorder (metrorrhagia, menorrhagia, menstruation irregular, genital hemorrhage, vaginal hemorrhage, dysfunctional uterine bleeding) (2.3%); mood changes (depression, mood swings, mood altered, depressed mood, dysthymic disorder, crying) (1.2%); acne (1.1%), headache (including migraines) (1.1%), and weight increased (0.7 %).",migraines is an adverse reaction entity
"Adverse Reactions Leading to Study Discontinuation  : 11.4% of the women discontinued from the clinical trials due to an adverse reaction; the most frequent adverse reactions leading to discontinuation were menstrual disorder (metrorrhagia, menorrhagia, menstruation irregular, genital hemorrhage, vaginal hemorrhage, dysfunctional uterine bleeding) (2.3%); mood changes (depression, mood swings, mood altered, depressed mood, dysthymic disorder, crying) (1.2%); acne (1.1%), headache (including migraines) (1.1%), and weight increased (0.7 %).",weight increased is an adverse reaction entity
"5.14 Other Conditions      In women with hereditary angioedema, exogenous estrogens may induce or exacerbate symptoms of angioedema.",angioedema is an adverse reaction entity
"Some women may encounter amenorrhea or oligomenorrhea after stopping COCs, especially when such a condition was pre-existent.",amenorrhea is an adverse reaction entity
"Some women may encounter amenorrhea or oligomenorrhea after stopping COCs, especially when such a condition was pre-existent.",oligomenorrhea is an adverse reaction entity
"Chloasma may occasionally occur, especially in women with a history of chloasma gravidarum.",Chloasma is an adverse reaction entity
"5.8 Bleeding Irregularities      Breakthrough bleeding and spotting sometimes occur in patients on COCs, especially during the first three months of use.",Breakthrough bleeding is an adverse reaction entity
"5.8 Bleeding Irregularities      Breakthrough bleeding and spotting sometimes occur in patients on COCs, especially during the first three months of use.",spotting is an adverse reaction entity
BOXED WARNING: WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS    WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS      Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives (COC) use.,CARDIOVASCULAR EVENTS is an adverse reaction entity
BOXED WARNING: WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS    WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS      Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives (COC) use.,CARDIOVASCULAR EVENTS is an adverse reaction entity
BOXED WARNING: WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS    WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS      Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives (COC) use.,cardiovascular events is an adverse reaction entity
One (0.2%) patient died as a result of toxic epidermal necrolysis and one additional patient required hospitalization for severe dermatitis.,died is an adverse reaction entity
One (0.2%) patient died as a result of toxic epidermal necrolysis and one additional patient required hospitalization for severe dermatitis.,toxic epidermal necrolysis is an adverse reaction entity
One (0.2%) patient died as a result of toxic epidermal necrolysis and one additional patient required hospitalization for severe dermatitis.,dermatitis is an adverse reaction entity
"Moderate endocrinopathy (requiring hormone replacement or medical intervention; Grade 2) occurred in 12 (2.3%) patients and consisted of hypothyroidism, adrenal insufficiency, hypopituitarism, and 1 case each of hyperthyroidism and Cushing's syndrome.",endocrinopathy is an adverse reaction entity
"Moderate endocrinopathy (requiring hormone replacement or medical intervention; Grade 2) occurred in 12 (2.3%) patients and consisted of hypothyroidism, adrenal insufficiency, hypopituitarism, and 1 case each of hyperthyroidism and Cushing's syndrome.",hypothyroidism is an adverse reaction entity
"Moderate endocrinopathy (requiring hormone replacement or medical intervention; Grade 2) occurred in 12 (2.3%) patients and consisted of hypothyroidism, adrenal insufficiency, hypopituitarism, and 1 case each of hyperthyroidism and Cushing's syndrome.",adrenal insufficiency is an adverse reaction entity
"Moderate endocrinopathy (requiring hormone replacement or medical intervention; Grade 2) occurred in 12 (2.3%) patients and consisted of hypothyroidism, adrenal insufficiency, hypopituitarism, and 1 case each of hyperthyroidism and Cushing's syndrome.",hypopituitarism is an adverse reaction entity
"Moderate endocrinopathy (requiring hormone replacement or medical intervention; Grade 2) occurred in 12 (2.3%) patients and consisted of hypothyroidism, adrenal insufficiency, hypopituitarism, and 1 case each of hyperthyroidism and Cushing's syndrome.",hyperthyroidism is an adverse reaction entity
"Moderate endocrinopathy (requiring hormone replacement or medical intervention; Grade 2) occurred in 12 (2.3%) patients and consisted of hypothyroidism, adrenal insufficiency, hypopituitarism, and 1 case each of hyperthyroidism and Cushing's syndrome.",Cushing's syndrome is an adverse reaction entity
"(5.5)               5.1   Immune-mediated Enterocolitis      In Study 1, severe, life-threatening, or fatal (diarrhea of 7 or more stools above baseline, fever, ileus, peritoneal signs; Grade 3-5) immune-mediated enterocolitis occurred in 34 (7%) YERVOY-treated patients, and moderate (diarrhea with up to 6 stools above baseline, abdominal pain, mucus or blood in stool; Grade 2) enterocolitis occurred in 28 (5%) YERVOY-treated patients.",fatal is an adverse reaction entity
"(5.5)               5.1   Immune-mediated Enterocolitis      In Study 1, severe, life-threatening, or fatal (diarrhea of 7 or more stools above baseline, fever, ileus, peritoneal signs; Grade 3-5) immune-mediated enterocolitis occurred in 34 (7%) YERVOY-treated patients, and moderate (diarrhea with up to 6 stools above baseline, abdominal pain, mucus or blood in stool; Grade 2) enterocolitis occurred in 28 (5%) YERVOY-treated patients.",diarrhea is an adverse reaction entity
"(5.5)               5.1   Immune-mediated Enterocolitis      In Study 1, severe, life-threatening, or fatal (diarrhea of 7 or more stools above baseline, fever, ileus, peritoneal signs; Grade 3-5) immune-mediated enterocolitis occurred in 34 (7%) YERVOY-treated patients, and moderate (diarrhea with up to 6 stools above baseline, abdominal pain, mucus or blood in stool; Grade 2) enterocolitis occurred in 28 (5%) YERVOY-treated patients.",fever is an adverse reaction entity
"(5.5)               5.1   Immune-mediated Enterocolitis      In Study 1, severe, life-threatening, or fatal (diarrhea of 7 or more stools above baseline, fever, ileus, peritoneal signs; Grade 3-5) immune-mediated enterocolitis occurred in 34 (7%) YERVOY-treated patients, and moderate (diarrhea with up to 6 stools above baseline, abdominal pain, mucus or blood in stool; Grade 2) enterocolitis occurred in 28 (5%) YERVOY-treated patients.",ileus is an adverse reaction entity
"(5.5)               5.1   Immune-mediated Enterocolitis      In Study 1, severe, life-threatening, or fatal (diarrhea of 7 or more stools above baseline, fever, ileus, peritoneal signs; Grade 3-5) immune-mediated enterocolitis occurred in 34 (7%) YERVOY-treated patients, and moderate (diarrhea with up to 6 stools above baseline, abdominal pain, mucus or blood in stool; Grade 2) enterocolitis occurred in 28 (5%) YERVOY-treated patients.",peritoneal signs is an adverse reaction entity
"(5.5)               5.1   Immune-mediated Enterocolitis      In Study 1, severe, life-threatening, or fatal (diarrhea of 7 or more stools above baseline, fever, ileus, peritoneal signs; Grade 3-5) immune-mediated enterocolitis occurred in 34 (7%) YERVOY-treated patients, and moderate (diarrhea with up to 6 stools above baseline, abdominal pain, mucus or blood in stool; Grade 2) enterocolitis occurred in 28 (5%) YERVOY-treated patients.",immune-mediated enterocolitis is an adverse reaction entity
"(5.5)               5.1   Immune-mediated Enterocolitis      In Study 1, severe, life-threatening, or fatal (diarrhea of 7 or more stools above baseline, fever, ileus, peritoneal signs; Grade 3-5) immune-mediated enterocolitis occurred in 34 (7%) YERVOY-treated patients, and moderate (diarrhea with up to 6 stools above baseline, abdominal pain, mucus or blood in stool; Grade 2) enterocolitis occurred in 28 (5%) YERVOY-treated patients.",diarrhea is an adverse reaction entity
"(5.5)               5.1   Immune-mediated Enterocolitis      In Study 1, severe, life-threatening, or fatal (diarrhea of 7 or more stools above baseline, fever, ileus, peritoneal signs; Grade 3-5) immune-mediated enterocolitis occurred in 34 (7%) YERVOY-treated patients, and moderate (diarrhea with up to 6 stools above baseline, abdominal pain, mucus or blood in stool; Grade 2) enterocolitis occurred in 28 (5%) YERVOY-treated patients.",abdominal pain is an adverse reaction entity
"(5.5)               5.1   Immune-mediated Enterocolitis      In Study 1, severe, life-threatening, or fatal (diarrhea of 7 or more stools above baseline, fever, ileus, peritoneal signs; Grade 3-5) immune-mediated enterocolitis occurred in 34 (7%) YERVOY-treated patients, and moderate (diarrhea with up to 6 stools above baseline, abdominal pain, mucus or blood in stool; Grade 2) enterocolitis occurred in 28 (5%) YERVOY-treated patients.",mucus in stool is an adverse reaction entity
"(5.5)               5.1   Immune-mediated Enterocolitis      In Study 1, severe, life-threatening, or fatal (diarrhea of 7 or more stools above baseline, fever, ileus, peritoneal signs; Grade 3-5) immune-mediated enterocolitis occurred in 34 (7%) YERVOY-treated patients, and moderate (diarrhea with up to 6 stools above baseline, abdominal pain, mucus or blood in stool; Grade 2) enterocolitis occurred in 28 (5%) YERVOY-treated patients.",blood in stool is an adverse reaction entity
"(5.5)               5.1   Immune-mediated Enterocolitis      In Study 1, severe, life-threatening, or fatal (diarrhea of 7 or more stools above baseline, fever, ileus, peritoneal signs; Grade 3-5) immune-mediated enterocolitis occurred in 34 (7%) YERVOY-treated patients, and moderate (diarrhea with up to 6 stools above baseline, abdominal pain, mucus or blood in stool; Grade 2) enterocolitis occurred in 28 (5%) YERVOY-treated patients.",enterocolitis is an adverse reaction entity
"5.3   Immune-mediated Dermatitis      In Study 1, severe, life-threatening, or fatal immune-mediated dermatitis (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis, or rash complicated by full thickness dermal ulceration, or necrotic, bullous, or hemorrhagic manifestations; Grade 3-5) occurred in 13 (2.5%) YERVOY-treated patients.",fatal is an adverse reaction entity
"5.3   Immune-mediated Dermatitis      In Study 1, severe, life-threatening, or fatal immune-mediated dermatitis (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis, or rash complicated by full thickness dermal ulceration, or necrotic, bullous, or hemorrhagic manifestations; Grade 3-5) occurred in 13 (2.5%) YERVOY-treated patients.",immune-mediated dermatitis is an adverse reaction entity
"5.3   Immune-mediated Dermatitis      In Study 1, severe, life-threatening, or fatal immune-mediated dermatitis (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis, or rash complicated by full thickness dermal ulceration, or necrotic, bullous, or hemorrhagic manifestations; Grade 3-5) occurred in 13 (2.5%) YERVOY-treated patients.",Stevens-Johnson syndrome is an adverse reaction entity
"5.3   Immune-mediated Dermatitis      In Study 1, severe, life-threatening, or fatal immune-mediated dermatitis (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis, or rash complicated by full thickness dermal ulceration, or necrotic, bullous, or hemorrhagic manifestations; Grade 3-5) occurred in 13 (2.5%) YERVOY-treated patients.",toxic epidermal necrolysis is an adverse reaction entity
"5.3   Immune-mediated Dermatitis      In Study 1, severe, life-threatening, or fatal immune-mediated dermatitis (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis, or rash complicated by full thickness dermal ulceration, or necrotic, bullous, or hemorrhagic manifestations; Grade 3-5) occurred in 13 (2.5%) YERVOY-treated patients.",rash is an adverse reaction entity
"5.3   Immune-mediated Dermatitis      In Study 1, severe, life-threatening, or fatal immune-mediated dermatitis (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis, or rash complicated by full thickness dermal ulceration, or necrotic, bullous, or hemorrhagic manifestations; Grade 3-5) occurred in 13 (2.5%) YERVOY-treated patients.",dermal ulceration is an adverse reaction entity
"5.3   Immune-mediated Dermatitis      In Study 1, severe, life-threatening, or fatal immune-mediated dermatitis (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis, or rash complicated by full thickness dermal ulceration, or necrotic, bullous, or hemorrhagic manifestations; Grade 3-5) occurred in 13 (2.5%) YERVOY-treated patients.",dermal necrotic manifestations is an adverse reaction entity
"5.3   Immune-mediated Dermatitis      In Study 1, severe, life-threatening, or fatal immune-mediated dermatitis (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis, or rash complicated by full thickness dermal ulceration, or necrotic, bullous, or hemorrhagic manifestations; Grade 3-5) occurred in 13 (2.5%) YERVOY-treated patients.",dermal bullous manifestations is an adverse reaction entity
"5.3   Immune-mediated Dermatitis      In Study 1, severe, life-threatening, or fatal immune-mediated dermatitis (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis, or rash complicated by full thickness dermal ulceration, or necrotic, bullous, or hemorrhagic manifestations; Grade 3-5) occurred in 13 (2.5%) YERVOY-treated patients.",dermal hemorrhagic manifestations is an adverse reaction entity
"Twenty-nine patients (85%) with Grade 3-5 enterocolitis were treated with high-dose (>=40 mg prednisone equivalent per day) corticosteroids, with a median dose of 80 mg/day of prednisone or equivalent; the median duration of treatment was 2.3 weeks (ranging up to 13.9 weeks) followed by corticosteroid taper.",enterocolitis is an adverse reaction entity
"Concurrent Administration with Vemurafenib      In a dose-finding trial, Grade 3 increases in transaminases with or without concomitant increases in total bilirubin occurred in 6 of 10 patients who received concurrent YERVOY (3 mg/kg) and vemurafenib (960 mg BID or 720 mg BID).",increases in transaminases is an adverse reaction entity
"Concurrent Administration with Vemurafenib      In a dose-finding trial, Grade 3 increases in transaminases with or without concomitant increases in total bilirubin occurred in 6 of 10 patients who received concurrent YERVOY (3 mg/kg) and vemurafenib (960 mg BID or 720 mg BID).",increases in total bilirubin is an adverse reaction entity
"Across all YERVOY-treated patients (n=511), 5 (1%) patients developed intestinal perforation, 4 (0.8%) patients died as a result of complications, and 26 (5%) patients were hospitalized for severe enterocolitis.",intestinal perforation is an adverse reaction entity
"Across all YERVOY-treated patients (n=511), 5 (1%) patients developed intestinal perforation, 4 (0.8%) patients died as a result of complications, and 26 (5%) patients were hospitalized for severe enterocolitis.",died is an adverse reaction entity
"Across all YERVOY-treated patients (n=511), 5 (1%) patients developed intestinal perforation, 4 (0.8%) patients died as a result of complications, and 26 (5%) patients were hospitalized for severe enterocolitis.",enterocolitis is an adverse reaction entity
"Of the 21 patients with moderate to life-threatening endocrinopathy, 17 patients required long-term hormone replacement therapy including, most commonly, adrenal hormones (n=10) and thyroid hormones (n=13).",endocrinopathy is an adverse reaction entity
The median time to onset of moderate to severe immune-mediated endocrinopathy was 11 weeks and ranged up to 19.3 weeks after the initiation of YERVOY.,immune-mediated endocrinopathy is an adverse reaction entity
Table 2:     Severe to Fatal Immune-mediated Adverse Reactions in Study 1     a     Including fatal outcome.,Fatal is an adverse reaction entity
Table 2:     Severe to Fatal Immune-mediated Adverse Reactions in Study 1     a     Including fatal outcome.,Immune-mediated Adverse Reactions is an adverse reaction entity
Table 2:     Severe to Fatal Immune-mediated Adverse Reactions in Study 1     a     Including fatal outcome.,fatal is an adverse reaction entity
"BOXED WARNING: WARNING: RETINAL ABNORMALITIES AND POTENTIAL VISION LOSS    WARNING: RETINAL ABNORMALITIES AND POTENTIAL VISION LOSS      POTIGA can cause retinal abnormalities with funduscopic features similar to those seen in retinal pigment dystrophies, which are known to result in damage to the photoreceptors and vision loss.",RETINAL ABNORMALITIES is an adverse reaction entity
"BOXED WARNING: WARNING: RETINAL ABNORMALITIES AND POTENTIAL VISION LOSS    WARNING: RETINAL ABNORMALITIES AND POTENTIAL VISION LOSS      POTIGA can cause retinal abnormalities with funduscopic features similar to those seen in retinal pigment dystrophies, which are known to result in damage to the photoreceptors and vision loss.",VISION LOSS is an adverse reaction entity
"BOXED WARNING: WARNING: RETINAL ABNORMALITIES AND POTENTIAL VISION LOSS    WARNING: RETINAL ABNORMALITIES AND POTENTIAL VISION LOSS      POTIGA can cause retinal abnormalities with funduscopic features similar to those seen in retinal pigment dystrophies, which are known to result in damage to the photoreceptors and vision loss.",RETINAL ABNORMALITIES is an adverse reaction entity
"BOXED WARNING: WARNING: RETINAL ABNORMALITIES AND POTENTIAL VISION LOSS    WARNING: RETINAL ABNORMALITIES AND POTENTIAL VISION LOSS      POTIGA can cause retinal abnormalities with funduscopic features similar to those seen in retinal pigment dystrophies, which are known to result in damage to the photoreceptors and vision loss.",VISION LOSS is an adverse reaction entity
"BOXED WARNING: WARNING: RETINAL ABNORMALITIES AND POTENTIAL VISION LOSS    WARNING: RETINAL ABNORMALITIES AND POTENTIAL VISION LOSS      POTIGA can cause retinal abnormalities with funduscopic features similar to those seen in retinal pigment dystrophies, which are known to result in damage to the photoreceptors and vision loss.",retinal abnormalities is an adverse reaction entity
"BOXED WARNING: WARNING: RETINAL ABNORMALITIES AND POTENTIAL VISION LOSS    WARNING: RETINAL ABNORMALITIES AND POTENTIAL VISION LOSS      POTIGA can cause retinal abnormalities with funduscopic features similar to those seen in retinal pigment dystrophies, which are known to result in damage to the photoreceptors and vision loss.",retinal abnormalities similar to retinal pigment dystrophies is an adverse reaction entity
"BOXED WARNING: WARNING: RETINAL ABNORMALITIES AND POTENTIAL VISION LOSS    WARNING: RETINAL ABNORMALITIES AND POTENTIAL VISION LOSS      POTIGA can cause retinal abnormalities with funduscopic features similar to those seen in retinal pigment dystrophies, which are known to result in damage to the photoreceptors and vision loss.",damage to the photoreceptors is an adverse reaction entity
"BOXED WARNING: WARNING: RETINAL ABNORMALITIES AND POTENTIAL VISION LOSS    WARNING: RETINAL ABNORMALITIES AND POTENTIAL VISION LOSS      POTIGA can cause retinal abnormalities with funduscopic features similar to those seen in retinal pigment dystrophies, which are known to result in damage to the photoreceptors and vision loss.",vision loss is an adverse reaction entity
"Although some of the patients with retinal abnormalities have been found to have abnormal visual acuity, it is not possible to assess whether POTIGA caused their decreased visual acuity, as baseline assessments are not available for these patients.",retinal abnormalities is an adverse reaction entity
"Although some of the patients with retinal abnormalities have been found to have abnormal visual acuity, it is not possible to assess whether POTIGA caused their decreased visual acuity, as baseline assessments are not available for these patients.",abnormal visual acuity is an adverse reaction entity
"Although some of the patients with retinal abnormalities have been found to have abnormal visual acuity, it is not possible to assess whether POTIGA caused their decreased visual acuity, as baseline assessments are not available for these patients.",decreased visual acuity is an adverse reaction entity
"5.4 Neuropsychiatric Symptoms      Confusional state, psychotic symptoms, and hallucinations were reported more frequently as adverse reactions in patients treated with POTIGA than in those treated with placebo in placebo-controlled epilepsy trials (see Table 2).",Confusional state is an adverse reaction entity
"5.4 Neuropsychiatric Symptoms      Confusional state, psychotic symptoms, and hallucinations were reported more frequently as adverse reactions in patients treated with POTIGA than in those treated with placebo in placebo-controlled epilepsy trials (see Table 2).",psychotic symptoms is an adverse reaction entity
"5.4 Neuropsychiatric Symptoms      Confusional state, psychotic symptoms, and hallucinations were reported more frequently as adverse reactions in patients treated with POTIGA than in those treated with placebo in placebo-controlled epilepsy trials (see Table 2).",hallucinations is an adverse reaction entity
"Hydronephrosis occurred in 2 patients, one of whom had associated renal function impairment that resolved upon discontinuation of POTIGA.",Hydronephrosis is an adverse reaction entity
"Hydronephrosis occurred in 2 patients, one of whom had associated renal function impairment that resolved upon discontinuation of POTIGA.",renal function impairment is an adverse reaction entity
Somnolence was reported in 22% of patients treated with POTIGA and 12% of patients treated with placebo.,Somnolence is an adverse reaction entity
"Approximately 10% of patients in long-term clinical trials developed skin discoloration, generally after 2 or more years of treatment and at higher doses (900 mg or greater) of POTIGA.",skin discoloration is an adverse reaction entity
"Urinary retention was generally reported within the first 6 months of treatment, but was also observed later.",Urinary retention is an adverse reaction entity
"(  5.3  )   *    Neuropsychiatric symptoms: Monitor for confusional state, psychotic symptoms, and hallucinations.",Neuropsychiatric symptoms is an adverse reaction entity
"Common Adverse Reactions in All Controlled Clinical Studies       Overall, the most frequently reported adverse reactions in patients receiving POTIGA (>=4% and occurring approximately twice the placebo rate) were dizziness (23%), somnolence (22%), fatigue (15%), confusional state (9%), vertigo (8%), tremor (8%), abnormal coordination (7%), diplopia (7%), disturbance in attention (6%), memory impairment (6%), asthenia (5%), blurred vision (5%), gait disturbance (4%), aphasia (4%), dysarthria (4%), and balance disorder (4%) (see Table 4).",dizziness is an adverse reaction entity
"Common Adverse Reactions in All Controlled Clinical Studies       Overall, the most frequently reported adverse reactions in patients receiving POTIGA (>=4% and occurring approximately twice the placebo rate) were dizziness (23%), somnolence (22%), fatigue (15%), confusional state (9%), vertigo (8%), tremor (8%), abnormal coordination (7%), diplopia (7%), disturbance in attention (6%), memory impairment (6%), asthenia (5%), blurred vision (5%), gait disturbance (4%), aphasia (4%), dysarthria (4%), and balance disorder (4%) (see Table 4).",somnolence is an adverse reaction entity
"Common Adverse Reactions in All Controlled Clinical Studies       Overall, the most frequently reported adverse reactions in patients receiving POTIGA (>=4% and occurring approximately twice the placebo rate) were dizziness (23%), somnolence (22%), fatigue (15%), confusional state (9%), vertigo (8%), tremor (8%), abnormal coordination (7%), diplopia (7%), disturbance in attention (6%), memory impairment (6%), asthenia (5%), blurred vision (5%), gait disturbance (4%), aphasia (4%), dysarthria (4%), and balance disorder (4%) (see Table 4).",fatigue is an adverse reaction entity
"Common Adverse Reactions in All Controlled Clinical Studies       Overall, the most frequently reported adverse reactions in patients receiving POTIGA (>=4% and occurring approximately twice the placebo rate) were dizziness (23%), somnolence (22%), fatigue (15%), confusional state (9%), vertigo (8%), tremor (8%), abnormal coordination (7%), diplopia (7%), disturbance in attention (6%), memory impairment (6%), asthenia (5%), blurred vision (5%), gait disturbance (4%), aphasia (4%), dysarthria (4%), and balance disorder (4%) (see Table 4).",confusional state is an adverse reaction entity
"Common Adverse Reactions in All Controlled Clinical Studies       Overall, the most frequently reported adverse reactions in patients receiving POTIGA (>=4% and occurring approximately twice the placebo rate) were dizziness (23%), somnolence (22%), fatigue (15%), confusional state (9%), vertigo (8%), tremor (8%), abnormal coordination (7%), diplopia (7%), disturbance in attention (6%), memory impairment (6%), asthenia (5%), blurred vision (5%), gait disturbance (4%), aphasia (4%), dysarthria (4%), and balance disorder (4%) (see Table 4).",vertigo is an adverse reaction entity
"Common Adverse Reactions in All Controlled Clinical Studies       Overall, the most frequently reported adverse reactions in patients receiving POTIGA (>=4% and occurring approximately twice the placebo rate) were dizziness (23%), somnolence (22%), fatigue (15%), confusional state (9%), vertigo (8%), tremor (8%), abnormal coordination (7%), diplopia (7%), disturbance in attention (6%), memory impairment (6%), asthenia (5%), blurred vision (5%), gait disturbance (4%), aphasia (4%), dysarthria (4%), and balance disorder (4%) (see Table 4).",tremor is an adverse reaction entity
"Common Adverse Reactions in All Controlled Clinical Studies       Overall, the most frequently reported adverse reactions in patients receiving POTIGA (>=4% and occurring approximately twice the placebo rate) were dizziness (23%), somnolence (22%), fatigue (15%), confusional state (9%), vertigo (8%), tremor (8%), abnormal coordination (7%), diplopia (7%), disturbance in attention (6%), memory impairment (6%), asthenia (5%), blurred vision (5%), gait disturbance (4%), aphasia (4%), dysarthria (4%), and balance disorder (4%) (see Table 4).",abnormal coordination is an adverse reaction entity
"Common Adverse Reactions in All Controlled Clinical Studies       Overall, the most frequently reported adverse reactions in patients receiving POTIGA (>=4% and occurring approximately twice the placebo rate) were dizziness (23%), somnolence (22%), fatigue (15%), confusional state (9%), vertigo (8%), tremor (8%), abnormal coordination (7%), diplopia (7%), disturbance in attention (6%), memory impairment (6%), asthenia (5%), blurred vision (5%), gait disturbance (4%), aphasia (4%), dysarthria (4%), and balance disorder (4%) (see Table 4).",diplopia is an adverse reaction entity
"Common Adverse Reactions in All Controlled Clinical Studies       Overall, the most frequently reported adverse reactions in patients receiving POTIGA (>=4% and occurring approximately twice the placebo rate) were dizziness (23%), somnolence (22%), fatigue (15%), confusional state (9%), vertigo (8%), tremor (8%), abnormal coordination (7%), diplopia (7%), disturbance in attention (6%), memory impairment (6%), asthenia (5%), blurred vision (5%), gait disturbance (4%), aphasia (4%), dysarthria (4%), and balance disorder (4%) (see Table 4).",disturbance in attention is an adverse reaction entity
"Common Adverse Reactions in All Controlled Clinical Studies       Overall, the most frequently reported adverse reactions in patients receiving POTIGA (>=4% and occurring approximately twice the placebo rate) were dizziness (23%), somnolence (22%), fatigue (15%), confusional state (9%), vertigo (8%), tremor (8%), abnormal coordination (7%), diplopia (7%), disturbance in attention (6%), memory impairment (6%), asthenia (5%), blurred vision (5%), gait disturbance (4%), aphasia (4%), dysarthria (4%), and balance disorder (4%) (see Table 4).",memory impairment is an adverse reaction entity
"Common Adverse Reactions in All Controlled Clinical Studies       Overall, the most frequently reported adverse reactions in patients receiving POTIGA (>=4% and occurring approximately twice the placebo rate) were dizziness (23%), somnolence (22%), fatigue (15%), confusional state (9%), vertigo (8%), tremor (8%), abnormal coordination (7%), diplopia (7%), disturbance in attention (6%), memory impairment (6%), asthenia (5%), blurred vision (5%), gait disturbance (4%), aphasia (4%), dysarthria (4%), and balance disorder (4%) (see Table 4).",asthenia is an adverse reaction entity
"Common Adverse Reactions in All Controlled Clinical Studies       Overall, the most frequently reported adverse reactions in patients receiving POTIGA (>=4% and occurring approximately twice the placebo rate) were dizziness (23%), somnolence (22%), fatigue (15%), confusional state (9%), vertigo (8%), tremor (8%), abnormal coordination (7%), diplopia (7%), disturbance in attention (6%), memory impairment (6%), asthenia (5%), blurred vision (5%), gait disturbance (4%), aphasia (4%), dysarthria (4%), and balance disorder (4%) (see Table 4).",blurred vision is an adverse reaction entity
"Common Adverse Reactions in All Controlled Clinical Studies       Overall, the most frequently reported adverse reactions in patients receiving POTIGA (>=4% and occurring approximately twice the placebo rate) were dizziness (23%), somnolence (22%), fatigue (15%), confusional state (9%), vertigo (8%), tremor (8%), abnormal coordination (7%), diplopia (7%), disturbance in attention (6%), memory impairment (6%), asthenia (5%), blurred vision (5%), gait disturbance (4%), aphasia (4%), dysarthria (4%), and balance disorder (4%) (see Table 4).",gait disturbance is an adverse reaction entity
"Common Adverse Reactions in All Controlled Clinical Studies       Overall, the most frequently reported adverse reactions in patients receiving POTIGA (>=4% and occurring approximately twice the placebo rate) were dizziness (23%), somnolence (22%), fatigue (15%), confusional state (9%), vertigo (8%), tremor (8%), abnormal coordination (7%), diplopia (7%), disturbance in attention (6%), memory impairment (6%), asthenia (5%), blurred vision (5%), gait disturbance (4%), aphasia (4%), dysarthria (4%), and balance disorder (4%) (see Table 4).",aphasia is an adverse reaction entity
"Common Adverse Reactions in All Controlled Clinical Studies       Overall, the most frequently reported adverse reactions in patients receiving POTIGA (>=4% and occurring approximately twice the placebo rate) were dizziness (23%), somnolence (22%), fatigue (15%), confusional state (9%), vertigo (8%), tremor (8%), abnormal coordination (7%), diplopia (7%), disturbance in attention (6%), memory impairment (6%), asthenia (5%), blurred vision (5%), gait disturbance (4%), aphasia (4%), dysarthria (4%), and balance disorder (4%) (see Table 4).",dysarthria is an adverse reaction entity
"Common Adverse Reactions in All Controlled Clinical Studies       Overall, the most frequently reported adverse reactions in patients receiving POTIGA (>=4% and occurring approximately twice the placebo rate) were dizziness (23%), somnolence (22%), fatigue (15%), confusional state (9%), vertigo (8%), tremor (8%), abnormal coordination (7%), diplopia (7%), disturbance in attention (6%), memory impairment (6%), asthenia (5%), blurred vision (5%), gait disturbance (4%), aphasia (4%), dysarthria (4%), and balance disorder (4%) (see Table 4).",balance disorder is an adverse reaction entity
The psychiatric symptoms in the vast majority of patients in both controlled and open-label trials resolved within 7 days of discontinuation of POTIGA.,psychiatric symptoms is an adverse reaction entity
"For those patients continued on POTIGA, dizziness and somnolence appeared to diminish with continued use.",dizziness is an adverse reaction entity
"For those patients continued on POTIGA, dizziness and somnolence appeared to diminish with continued use.",somnolence is an adverse reaction entity
Approximately one third of the patients who had eye examinations performed after approximately 4 years of treatment were found to have retinal pigmentary abnormalities.,retinal pigmentary abnormalities is an adverse reaction entity
"Infections and Infestations:  Cellulitis, folliculitis, paronychia, rash pustular.",Cellulitis is an adverse reaction entity
"Infections and Infestations:  Cellulitis, folliculitis, paronychia, rash pustular.",folliculitis is an adverse reaction entity
"Infections and Infestations:  Cellulitis, folliculitis, paronychia, rash pustular.",paronychia is an adverse reaction entity
"Infections and Infestations:  Cellulitis, folliculitis, paronychia, rash pustular.",rash pustular is an adverse reaction entity
The most common adverse reaction resulting in permanent discontinuation was pyrexia (4%).,pyrexia is an adverse reaction entity
"In patients treated with TAFINLAR in combination with trametinib, the median time to initial onset of fever was 30 days compared with 19 days in patients treated with TAFINLAR as a single agent; the median duration of fever was 6 days with the combination compared with 4 days with TAFINLAR as a single agent.",fever is an adverse reaction entity
"In patients treated with TAFINLAR in combination with trametinib, the median time to initial onset of fever was 30 days compared with 19 days in patients treated with TAFINLAR as a single agent; the median duration of fever was 6 days with the combination compared with 4 days with TAFINLAR as a single agent.",fever is an adverse reaction entity
"In Trial 2, the incidence of basal cell carcinoma was increased in patients receiving TAFINLAR in combination with trametinib: 9% (5/55) of patients receiving TAFINLAR in combination with trametinib compared with 2% (1/53) of patients receiving TAFINLAR as a single agent.",basal cell carcinoma is an adverse reaction entity
e  Cases of cutaneous squamous cell carcinoma were required to be reported as Grade 3 per protocol.,cutaneous squamous cell carcinoma is an adverse reaction entity
"Across clinical trials of TAFINLAR in combination with trametinib (N = 202), severe skin toxicity and secondary infections of the skin requiring hospitalization occurred in 2.5% (5/202) of patients treated with TAFINLAR in combination with trametinib.",skin toxicity is an adverse reaction entity
"Across clinical trials of TAFINLAR in combination with trametinib (N = 202), severe skin toxicity and secondary infections of the skin requiring hospitalization occurred in 2.5% (5/202) of patients treated with TAFINLAR in combination with trametinib.",secondary infections of the skin is an adverse reaction entity
"Pyrexia, chills, and nausea were the most common reasons cited for dose reductions and pyrexia, chills, and decreased ejection fraction were the most common reasons cited for dose interruptions of TAFINLAR and trametinib when used in combination.",Pyrexia is an adverse reaction entity
"Pyrexia, chills, and nausea were the most common reasons cited for dose reductions and pyrexia, chills, and decreased ejection fraction were the most common reasons cited for dose interruptions of TAFINLAR and trametinib when used in combination.",chills is an adverse reaction entity
"Pyrexia, chills, and nausea were the most common reasons cited for dose reductions and pyrexia, chills, and decreased ejection fraction were the most common reasons cited for dose interruptions of TAFINLAR and trametinib when used in combination.",nausea is an adverse reaction entity
"Pyrexia, chills, and nausea were the most common reasons cited for dose reductions and pyrexia, chills, and decreased ejection fraction were the most common reasons cited for dose interruptions of TAFINLAR and trametinib when used in combination.",pyrexia is an adverse reaction entity
"Pyrexia, chills, and nausea were the most common reasons cited for dose reductions and pyrexia, chills, and decreased ejection fraction were the most common reasons cited for dose interruptions of TAFINLAR and trametinib when used in combination.",chills is an adverse reaction entity
"Pyrexia, chills, and nausea were the most common reasons cited for dose reductions and pyrexia, chills, and decreased ejection fraction were the most common reasons cited for dose interruptions of TAFINLAR and trametinib when used in combination.",decreased ejection fraction is an adverse reaction entity
"(  5.5  ,  2.3  )   *    Ocular Toxicities: Perform ophthalmologic evaluation for any visual disturbances.",Ocular Toxicities is an adverse reaction entity
"QT Prolongation:  In Trial 2, QTcF prolongation to >500 msec occurred in 4% (2/55) of patients treated with TAFINLAR in combination with trametinib and in 2% (1/53) of patients treated with TAFINLAR as a single agent.",QTcF prolongation is an adverse reaction entity
"Across clinical trials of TAFINLAR administered in combination with trametinib (N = 202), the incidence of pyrexia was 57% (116/202).",pyrexia is an adverse reaction entity
(  5.9  )   *    Glucose-6-Phosphate Dehydrogenase Deficiency: Closely monitor for hemolytic anemia.,Glucose-6-Phosphate Dehydrogenase Deficiency is an adverse reaction entity
"5.11 Embryofetal Toxicity      Based on its mechanism of action, TAFINLAR can cause fetal harm when administered to a pregnant woman.",fetal harm is an adverse reaction entity
"(  5.4  ,  2.3  )   *    Cardiomyopathy: Assess LVEF before treatment with TAFINLAR in combination with trametinib, after one month of treatment, then every 2 to 3 months thereafter.",Cardiomyopathy is an adverse reaction entity
"In Trial 2, cardiomyopathy occurred in 9% (5/55) of patients treated with TAFINLAR in combination with trametinib and in none of patients treated with TAFINLAR as a single agent.",cardiomyopathy is an adverse reaction entity
"Cutaneous squamous cell carcinoma (SCC), including keratoacanthoma, occurred in 7% of patients receiving TAFINLAR in combination with trametinib and 19% of patients receiving TAFINLAR as a single agent.",Cutaneous squamous cell carcinoma is an adverse reaction entity
"Cutaneous squamous cell carcinoma (SCC), including keratoacanthoma, occurred in 7% of patients receiving TAFINLAR in combination with trametinib and 19% of patients receiving TAFINLAR as a single agent.",SCC is an adverse reaction entity
"Cutaneous squamous cell carcinoma (SCC), including keratoacanthoma, occurred in 7% of patients receiving TAFINLAR in combination with trametinib and 19% of patients receiving TAFINLAR as a single agent.",keratoacanthoma is an adverse reaction entity
The incidence of Grade 3 hyperglycemia based on laboratory values was 6% (12/187) in patients treated with TAFINLAR compared with none of the dacarbazine-treated patients.,hyperglycemia is an adverse reaction entity
"c  Includes the following terms: rash, rash generalized, rash pruritic, rash erythematous, rash papular, rash vesicular, rash macular, and rash maculo-papular.",rash is an adverse reaction entity
"c  Includes the following terms: rash, rash generalized, rash pruritic, rash erythematous, rash papular, rash vesicular, rash macular, and rash maculo-papular.",rash generalized is an adverse reaction entity
"c  Includes the following terms: rash, rash generalized, rash pruritic, rash erythematous, rash papular, rash vesicular, rash macular, and rash maculo-papular.",rash pruritic is an adverse reaction entity
"c  Includes the following terms: rash, rash generalized, rash pruritic, rash erythematous, rash papular, rash vesicular, rash macular, and rash maculo-papular.",rash erythematous is an adverse reaction entity
"c  Includes the following terms: rash, rash generalized, rash pruritic, rash erythematous, rash papular, rash vesicular, rash macular, and rash maculo-papular.",rash papular is an adverse reaction entity
"c  Includes the following terms: rash, rash generalized, rash pruritic, rash erythematous, rash papular, rash vesicular, rash macular, and rash maculo-papular.",rash vesicular is an adverse reaction entity
"c  Includes the following terms: rash, rash generalized, rash pruritic, rash erythematous, rash papular, rash vesicular, rash macular, and rash maculo-papular.",rash macular is an adverse reaction entity
"c  Includes the following terms: rash, rash generalized, rash pruritic, rash erythematous, rash papular, rash vesicular, rash macular, and rash maculo-papular.",rash maculo-papular is an adverse reaction entity
"In patients treated with TAFINLAR, the median time to initial onset of fever (any severity) was 11 days (range: 1 to 202 days) and the median duration of fever was 3 days (range: 1 to 129 days).",fever is an adverse reaction entity
"In patients treated with TAFINLAR, the median time to initial onset of fever (any severity) was 11 days (range: 1 to 202 days) and the median duration of fever was 3 days (range: 1 to 129 days).",fever is an adverse reaction entity
Pain increases occurring during patch application usually began to resolve after patch removal.,Pain increases is an adverse reaction entity
"Controlled Clinical Studies           Common Adverse Reactions       Adverse reactions occurring in >= 5% of patients in the Qutenza group and at an incidence greater than in the control group were application site erythema, application site pain, application site pruritus and application site papules.",application site erythema is an adverse reaction entity
"Controlled Clinical Studies           Common Adverse Reactions       Adverse reactions occurring in >= 5% of patients in the Qutenza group and at an incidence greater than in the control group were application site erythema, application site pain, application site pruritus and application site papules.",application site pain is an adverse reaction entity
"Controlled Clinical Studies           Common Adverse Reactions       Adverse reactions occurring in >= 5% of patients in the Qutenza group and at an incidence greater than in the control group were application site erythema, application site pain, application site pruritus and application site papules.",application site pruritus is an adverse reaction entity
"Controlled Clinical Studies           Common Adverse Reactions       Adverse reactions occurring in >= 5% of patients in the Qutenza group and at an incidence greater than in the control group were application site erythema, application site pain, application site pruritus and application site papules.",application site papules is an adverse reaction entity
"EXCERPT:   The most common adverse reactions in >=13% of patients are: Infections, vomiting, abdominal pain, pyrexia, tonsilitis, anemia, ear infection, diarrhea, nasopharyngitis, and headache.",Infections is an adverse reaction entity
"EXCERPT:   The most common adverse reactions in >=13% of patients are: Infections, vomiting, abdominal pain, pyrexia, tonsilitis, anemia, ear infection, diarrhea, nasopharyngitis, and headache.",vomiting is an adverse reaction entity
"EXCERPT:   The most common adverse reactions in >=13% of patients are: Infections, vomiting, abdominal pain, pyrexia, tonsilitis, anemia, ear infection, diarrhea, nasopharyngitis, and headache.",abdominal pain is an adverse reaction entity
"EXCERPT:   The most common adverse reactions in >=13% of patients are: Infections, vomiting, abdominal pain, pyrexia, tonsilitis, anemia, ear infection, diarrhea, nasopharyngitis, and headache.",pyrexia is an adverse reaction entity
"EXCERPT:   The most common adverse reactions in >=13% of patients are: Infections, vomiting, abdominal pain, pyrexia, tonsilitis, anemia, ear infection, diarrhea, nasopharyngitis, and headache.",tonsilitis is an adverse reaction entity
"EXCERPT:   The most common adverse reactions in >=13% of patients are: Infections, vomiting, abdominal pain, pyrexia, tonsilitis, anemia, ear infection, diarrhea, nasopharyngitis, and headache.",anemia is an adverse reaction entity
"EXCERPT:   The most common adverse reactions in >=13% of patients are: Infections, vomiting, abdominal pain, pyrexia, tonsilitis, anemia, ear infection, diarrhea, nasopharyngitis, and headache.",ear infection is an adverse reaction entity
"EXCERPT:   The most common adverse reactions in >=13% of patients are: Infections, vomiting, abdominal pain, pyrexia, tonsilitis, anemia, ear infection, diarrhea, nasopharyngitis, and headache.",diarrhea is an adverse reaction entity
"EXCERPT:   The most common adverse reactions in >=13% of patients are: Infections, vomiting, abdominal pain, pyrexia, tonsilitis, anemia, ear infection, diarrhea, nasopharyngitis, and headache.",nasopharyngitis is an adverse reaction entity
"EXCERPT:   The most common adverse reactions in >=13% of patients are: Infections, vomiting, abdominal pain, pyrexia, tonsilitis, anemia, ear infection, diarrhea, nasopharyngitis, and headache.",headache is an adverse reaction entity
"In Study 1, CTCAE Grade 3-4 hyperglycemia, based on laboratory values, occurred in 13% of 255 patients.",hyperglycemia is an adverse reaction entity
"In animal studies, administration of ceritinib to rats and rabbits during organogenesis at maternal plasma exposures below the recommended human dose of 750 mg daily caused increases in skeletal anomalies in rats and rabbits.",increases in skeletal anomalies is an adverse reaction entity
"5.8     Embryofetal Toxicity      Based on its mechanism of action, ZYKADIA may cause fetal harm when administered to a pregnant woman.",fetal harm is an adverse reaction entity
"5.4     QT Interval Prolongation       QTc interval prolongation, which may lead to an increased risk for ventricular tachyarrhythmias (e.g., Torsade de pointes) or sudden death, occurred in patients treated with ZYKADIA in clinical trials.",QTc interval prolongation is an adverse reaction entity
"5.4     QT Interval Prolongation       QTc interval prolongation, which may lead to an increased risk for ventricular tachyarrhythmias (e.g., Torsade de pointes) or sudden death, occurred in patients treated with ZYKADIA in clinical trials.",ventricular tachyarrhythmias is an adverse reaction entity
"5.4     QT Interval Prolongation       QTc interval prolongation, which may lead to an increased risk for ventricular tachyarrhythmias (e.g., Torsade de pointes) or sudden death, occurred in patients treated with ZYKADIA in clinical trials.",Torsade de pointes is an adverse reaction entity
"5.4     QT Interval Prolongation       QTc interval prolongation, which may lead to an increased risk for ventricular tachyarrhythmias (e.g., Torsade de pointes) or sudden death, occurred in patients treated with ZYKADIA in clinical trials.",sudden death is an adverse reaction entity
"One patient (0.4%) required permanent discontinuation due to elevated transaminases, and jaundice.",elevated transaminases is an adverse reaction entity
"One patient (0.4%) required permanent discontinuation due to elevated transaminases, and jaundice.",jaundice is an adverse reaction entity
A pharmacokinetic analysis suggested that ZYKADIA causes concentration-dependent increases in the QTc interval.,increases in the QTc interval is an adverse reaction entity
"In Study 1, pneumonitis was reported in 4% of 255 patients treated with ZYKADIA.",pneumonitis is an adverse reaction entity
Transaminase elevations generally occurred within the first 2 months of treatment.,Transaminase elevations is an adverse reaction entity
Seventeen patients (1.0%) required permanent discontinuation due to elevated transaminases.,elevated transaminases is an adverse reaction entity
"(  5.6  ,  8.1  ,  8.3  )             5.1 Hepatotoxicity       Drug-induced hepatotoxicity with fatal outcome occurred in 2 (0.1%) of the 1669 patients treated with XALKORI across clinical trials in patients with NSCLC.",hepatotoxicity is an adverse reaction entity
"(  5.6  ,  8.1  ,  8.3  )             5.1 Hepatotoxicity       Drug-induced hepatotoxicity with fatal outcome occurred in 2 (0.1%) of the 1669 patients treated with XALKORI across clinical trials in patients with NSCLC.",fatal is an adverse reaction entity
"The most frequent adverse reactions that led to permanent discontinuation in XALKORI-treated patients were elevated transaminases (1.2%), hepatotoxicity (1.2%), and ILD (1.2%).",elevated transaminases is an adverse reaction entity
"The most frequent adverse reactions that led to permanent discontinuation in XALKORI-treated patients were elevated transaminases (1.2%), hepatotoxicity (1.2%), and ILD (1.2%).",hepatotoxicity is an adverse reaction entity
"The most frequent adverse reactions that led to permanent discontinuation in XALKORI-treated patients were elevated transaminases (1.2%), hepatotoxicity (1.2%), and ILD (1.2%).",ILD is an adverse reaction entity
"Concurrent elevations in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than or equal to three times the upper limit of normal (ULN) and total bilirubin greater than or equal to two times the ULN, with normal alkaline phosphatase, occurred in 10 patients (0.6%) treated with XALKORI.",elevations in alanine aminotransferase is an adverse reaction entity
"Concurrent elevations in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than or equal to three times the upper limit of normal (ULN) and total bilirubin greater than or equal to two times the ULN, with normal alkaline phosphatase, occurred in 10 patients (0.6%) treated with XALKORI.",elevations in ALT is an adverse reaction entity
"Concurrent elevations in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than or equal to three times the upper limit of normal (ULN) and total bilirubin greater than or equal to two times the ULN, with normal alkaline phosphatase, occurred in 10 patients (0.6%) treated with XALKORI.",elevations in aspartate aminotransferase is an adverse reaction entity
"Concurrent elevations in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than or equal to three times the upper limit of normal (ULN) and total bilirubin greater than or equal to two times the ULN, with normal alkaline phosphatase, occurred in 10 patients (0.6%) treated with XALKORI.",elevations in AST is an adverse reaction entity
"Concurrent elevations in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than or equal to three times the upper limit of normal (ULN) and total bilirubin greater than or equal to two times the ULN, with normal alkaline phosphatase, occurred in 10 patients (0.6%) treated with XALKORI.",total bilirubin two times the ULN is an adverse reaction entity
"Neuropathy       Neuropathy, most commonly sensory in nature, occurred in 419 (25%) of 1669 patients.",Neuropathy is an adverse reaction entity
"Neuropathy       Neuropathy, most commonly sensory in nature, occurred in 419 (25%) of 1669 patients.",Neuropathy sensory is an adverse reaction entity
"The most frequent adverse reactions that led to dose reduction in the patients treated with XALKORI were alanine aminotransferase (ALT) elevation (7.6%) including some patients with concurrent aspartate aminotransferase (AST) elevation, QTc prolongation (2.9%), and neutropenia (2.3%).",alanine aminotransferase elevation is an adverse reaction entity
"The most frequent adverse reactions that led to dose reduction in the patients treated with XALKORI were alanine aminotransferase (ALT) elevation (7.6%) including some patients with concurrent aspartate aminotransferase (AST) elevation, QTc prolongation (2.9%), and neutropenia (2.3%).",ALT elevation is an adverse reaction entity
"The most frequent adverse reactions that led to dose reduction in the patients treated with XALKORI were alanine aminotransferase (ALT) elevation (7.6%) including some patients with concurrent aspartate aminotransferase (AST) elevation, QTc prolongation (2.9%), and neutropenia (2.3%).",aspartate aminotransferase elevation is an adverse reaction entity
"The most frequent adverse reactions that led to dose reduction in the patients treated with XALKORI were alanine aminotransferase (ALT) elevation (7.6%) including some patients with concurrent aspartate aminotransferase (AST) elevation, QTc prolongation (2.9%), and neutropenia (2.3%).",AST elevation is an adverse reaction entity
"The most frequent adverse reactions that led to dose reduction in the patients treated with XALKORI were alanine aminotransferase (ALT) elevation (7.6%) including some patients with concurrent aspartate aminotransferase (AST) elevation, QTc prolongation (2.9%), and neutropenia (2.3%).",QTc prolongation is an adverse reaction entity
"The most frequent adverse reactions that led to dose reduction in the patients treated with XALKORI were alanine aminotransferase (ALT) elevation (7.6%) including some patients with concurrent aspartate aminotransferase (AST) elevation, QTc prolongation (2.9%), and neutropenia (2.3%).",neutropenia is an adverse reaction entity
"5.5 Severe Visual Loss       Across all clinical trials, the incidence of Grade 4 visual field defect with vision loss was 0.2% (4/1669).",visual field defect is an adverse reaction entity
"5.5 Severe Visual Loss       Across all clinical trials, the incidence of Grade 4 visual field defect with vision loss was 0.2% (4/1669).",vision loss is an adverse reaction entity
"One patient experienced disturbance in attention, eyelid disorder, feeling abnormal and headache, and one patient experienced dysphagia.",disturbance in attention is an adverse reaction entity
"One patient experienced disturbance in attention, eyelid disorder, feeling abnormal and headache, and one patient experienced dysphagia.",eyelid disorder is an adverse reaction entity
"One patient experienced disturbance in attention, eyelid disorder, feeling abnormal and headache, and one patient experienced dysphagia.",feeling abnormal is an adverse reaction entity
"One patient experienced disturbance in attention, eyelid disorder, feeling abnormal and headache, and one patient experienced dysphagia.",headache is an adverse reaction entity
"One patient experienced disturbance in attention, eyelid disorder, feeling abnormal and headache, and one patient experienced dysphagia.",dysphagia is an adverse reaction entity
"7)]         EXCERPT:     Cervical Dystonia       Most commonly observed adverse reactions (> 5% of patients) are: muscular weakness, dysphagia, dry mouth, injection site discomfort, fatigue, headache, neck pain, musculoskeletal pain, dysphonia, injection site pain, and eye disorders.",muscular weakness is an adverse reaction entity
"7)]         EXCERPT:     Cervical Dystonia       Most commonly observed adverse reactions (> 5% of patients) are: muscular weakness, dysphagia, dry mouth, injection site discomfort, fatigue, headache, neck pain, musculoskeletal pain, dysphonia, injection site pain, and eye disorders.",dysphagia is an adverse reaction entity
"7)]         EXCERPT:     Cervical Dystonia       Most commonly observed adverse reactions (> 5% of patients) are: muscular weakness, dysphagia, dry mouth, injection site discomfort, fatigue, headache, neck pain, musculoskeletal pain, dysphonia, injection site pain, and eye disorders.",dry mouth is an adverse reaction entity
"7)]         EXCERPT:     Cervical Dystonia       Most commonly observed adverse reactions (> 5% of patients) are: muscular weakness, dysphagia, dry mouth, injection site discomfort, fatigue, headache, neck pain, musculoskeletal pain, dysphonia, injection site pain, and eye disorders.",injection site discomfort is an adverse reaction entity
"7)]         EXCERPT:     Cervical Dystonia       Most commonly observed adverse reactions (> 5% of patients) are: muscular weakness, dysphagia, dry mouth, injection site discomfort, fatigue, headache, neck pain, musculoskeletal pain, dysphonia, injection site pain, and eye disorders.",fatigue is an adverse reaction entity
"7)]         EXCERPT:     Cervical Dystonia       Most commonly observed adverse reactions (> 5% of patients) are: muscular weakness, dysphagia, dry mouth, injection site discomfort, fatigue, headache, neck pain, musculoskeletal pain, dysphonia, injection site pain, and eye disorders.",headache is an adverse reaction entity
"7)]         EXCERPT:     Cervical Dystonia       Most commonly observed adverse reactions (> 5% of patients) are: muscular weakness, dysphagia, dry mouth, injection site discomfort, fatigue, headache, neck pain, musculoskeletal pain, dysphonia, injection site pain, and eye disorders.",neck pain is an adverse reaction entity
"7)]         EXCERPT:     Cervical Dystonia       Most commonly observed adverse reactions (> 5% of patients) are: muscular weakness, dysphagia, dry mouth, injection site discomfort, fatigue, headache, neck pain, musculoskeletal pain, dysphonia, injection site pain, and eye disorders.",musculoskeletal pain is an adverse reaction entity
"7)]         EXCERPT:     Cervical Dystonia       Most commonly observed adverse reactions (> 5% of patients) are: muscular weakness, dysphagia, dry mouth, injection site discomfort, fatigue, headache, neck pain, musculoskeletal pain, dysphonia, injection site pain, and eye disorders.",dysphonia is an adverse reaction entity
"7)]         EXCERPT:     Cervical Dystonia       Most commonly observed adverse reactions (> 5% of patients) are: muscular weakness, dysphagia, dry mouth, injection site discomfort, fatigue, headache, neck pain, musculoskeletal pain, dysphonia, injection site pain, and eye disorders.",injection site pain is an adverse reaction entity
"7)]         EXCERPT:     Cervical Dystonia       Most commonly observed adverse reactions (> 5% of patients) are: muscular weakness, dysphagia, dry mouth, injection site discomfort, fatigue, headache, neck pain, musculoskeletal pain, dysphonia, injection site pain, and eye disorders.",eye disorders is an adverse reaction entity
Swallowing and breathing difficulties can be life threatening and there have been reports of death related to spread of toxin effects.,Swallowing difficulties is an adverse reaction entity
Swallowing and breathing difficulties can be life threatening and there have been reports of death related to spread of toxin effects.,breathing difficulties is an adverse reaction entity
Swallowing and breathing difficulties can be life threatening and there have been reports of death related to spread of toxin effects.,death is an adverse reaction entity
Swallowing and breathing difficulties can be life threatening and there have been reports of death related to spread of toxin effects.,spread of toxin effects is an adverse reaction entity
"These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties.",asthenia is an adverse reaction entity
"These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties.",generalized muscle weakness is an adverse reaction entity
"These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties.",diplopia is an adverse reaction entity
"These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties.",blurred vision is an adverse reaction entity
"These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties.",ptosis is an adverse reaction entity
"These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties.",dysphagia is an adverse reaction entity
"These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties.",dysphonia is an adverse reaction entity
"These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties.",dysarthria is an adverse reaction entity
"These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties.",urinary incontinence is an adverse reaction entity
"These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties.",breathing difficulties is an adverse reaction entity
6 ADVERSE REACTIONS    The following serious adverse reactions are discussed below and elsewhere in labeling:     *  Distant Spread of Toxin Effect [seeBoxed Warning]    *  Lack of Interchangeability between Botulinum Toxin Products [seeWarnings and Precautions (5.1)]    *  Spread of Effects from Toxin [ seeWarnings and Precautions (5.2) ]   *  Dysphagia and Breathing Difficulties [seeWarnings and Precautions (5.3)]    *  Facial Anatomy in the Treatment of Glabellar Lines [seeWarnings and Precautions (5.4)]    *  Pre-existing Neuromuscular Disorders [seeWarnings and Precautions (5.5)]    *  Human Albumin [seeWarnings and Precautions (5.6)]    *  Intradermal Immune Reaction [seeWarnings and Precautions (5.,Distant Spread of Toxin Effect is an adverse reaction entity
6 ADVERSE REACTIONS    The following serious adverse reactions are discussed below and elsewhere in labeling:     *  Distant Spread of Toxin Effect [seeBoxed Warning]    *  Lack of Interchangeability between Botulinum Toxin Products [seeWarnings and Precautions (5.1)]    *  Spread of Effects from Toxin [ seeWarnings and Precautions (5.2) ]   *  Dysphagia and Breathing Difficulties [seeWarnings and Precautions (5.3)]    *  Facial Anatomy in the Treatment of Glabellar Lines [seeWarnings and Precautions (5.4)]    *  Pre-existing Neuromuscular Disorders [seeWarnings and Precautions (5.5)]    *  Human Albumin [seeWarnings and Precautions (5.6)]    *  Intradermal Immune Reaction [seeWarnings and Precautions (5.,Spread of Effects from Toxin is an adverse reaction entity
6 ADVERSE REACTIONS    The following serious adverse reactions are discussed below and elsewhere in labeling:     *  Distant Spread of Toxin Effect [seeBoxed Warning]    *  Lack of Interchangeability between Botulinum Toxin Products [seeWarnings and Precautions (5.1)]    *  Spread of Effects from Toxin [ seeWarnings and Precautions (5.2) ]   *  Dysphagia and Breathing Difficulties [seeWarnings and Precautions (5.3)]    *  Facial Anatomy in the Treatment of Glabellar Lines [seeWarnings and Precautions (5.4)]    *  Pre-existing Neuromuscular Disorders [seeWarnings and Precautions (5.5)]    *  Human Albumin [seeWarnings and Precautions (5.6)]    *  Intradermal Immune Reaction [seeWarnings and Precautions (5.,Dysphagia is an adverse reaction entity
6 ADVERSE REACTIONS    The following serious adverse reactions are discussed below and elsewhere in labeling:     *  Distant Spread of Toxin Effect [seeBoxed Warning]    *  Lack of Interchangeability between Botulinum Toxin Products [seeWarnings and Precautions (5.1)]    *  Spread of Effects from Toxin [ seeWarnings and Precautions (5.2) ]   *  Dysphagia and Breathing Difficulties [seeWarnings and Precautions (5.3)]    *  Facial Anatomy in the Treatment of Glabellar Lines [seeWarnings and Precautions (5.4)]    *  Pre-existing Neuromuscular Disorders [seeWarnings and Precautions (5.5)]    *  Human Albumin [seeWarnings and Precautions (5.6)]    *  Intradermal Immune Reaction [seeWarnings and Precautions (5.,Breathing Difficulties is an adverse reaction entity
6 ADVERSE REACTIONS    The following serious adverse reactions are discussed below and elsewhere in labeling:     *  Distant Spread of Toxin Effect [seeBoxed Warning]    *  Lack of Interchangeability between Botulinum Toxin Products [seeWarnings and Precautions (5.1)]    *  Spread of Effects from Toxin [ seeWarnings and Precautions (5.2) ]   *  Dysphagia and Breathing Difficulties [seeWarnings and Precautions (5.3)]    *  Facial Anatomy in the Treatment of Glabellar Lines [seeWarnings and Precautions (5.4)]    *  Pre-existing Neuromuscular Disorders [seeWarnings and Precautions (5.5)]    *  Human Albumin [seeWarnings and Precautions (5.6)]    *  Intradermal Immune Reaction [seeWarnings and Precautions (5.,Intradermal Immune Reaction is an adverse reaction entity
[  see Warnings and Precautions (5.2)  ]         WARNING: DISTANT SPREAD OF TOXIN EFFECT       See full prescribing information for complete boxed warning          The effects of DYSPORT(r) and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects.,DISTANT SPREAD OF TOXIN EFFECT is an adverse reaction entity
[  see Warnings and Precautions (5.2)  ]         WARNING: DISTANT SPREAD OF TOXIN EFFECT       See full prescribing information for complete boxed warning          The effects of DYSPORT(r) and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects.,spread toxin effects is an adverse reaction entity
"There have been post-marketing reports of serious breathing difficulties, including respiratory failure.",breathing difficulties is an adverse reaction entity
"There have been post-marketing reports of serious breathing difficulties, including respiratory failure.",respiratory failure is an adverse reaction entity
5.3 Dysphagia and Breathing Difficulties    Treatment with DYSPORT    (r)    and other botulinum toxin products can result in swallowing or breathing difficulties.,swallowing difficulties is an adverse reaction entity
5.3 Dysphagia and Breathing Difficulties    Treatment with DYSPORT    (r)    and other botulinum toxin products can result in swallowing or breathing difficulties.,breathing difficulties is an adverse reaction entity
"Glabellar Lines       In placebo-controlled clinical trials of DYSPORT    (r)    , the most common adverse reactions(>=2%) following injection of DYSPORT    (r)    were nasopharyngitis, headache, injection site pain, injection site reaction, upper respiratory tract infection, eyelid edema, eyelid ptosis, sinusitis, and nausea.",nasopharyngitis is an adverse reaction entity
"Glabellar Lines       In placebo-controlled clinical trials of DYSPORT    (r)    , the most common adverse reactions(>=2%) following injection of DYSPORT    (r)    were nasopharyngitis, headache, injection site pain, injection site reaction, upper respiratory tract infection, eyelid edema, eyelid ptosis, sinusitis, and nausea.",headache is an adverse reaction entity
"Glabellar Lines       In placebo-controlled clinical trials of DYSPORT    (r)    , the most common adverse reactions(>=2%) following injection of DYSPORT    (r)    were nasopharyngitis, headache, injection site pain, injection site reaction, upper respiratory tract infection, eyelid edema, eyelid ptosis, sinusitis, and nausea.",injection site pain is an adverse reaction entity
"Glabellar Lines       In placebo-controlled clinical trials of DYSPORT    (r)    , the most common adverse reactions(>=2%) following injection of DYSPORT    (r)    were nasopharyngitis, headache, injection site pain, injection site reaction, upper respiratory tract infection, eyelid edema, eyelid ptosis, sinusitis, and nausea.",injection site reaction is an adverse reaction entity
"Glabellar Lines       In placebo-controlled clinical trials of DYSPORT    (r)    , the most common adverse reactions(>=2%) following injection of DYSPORT    (r)    were nasopharyngitis, headache, injection site pain, injection site reaction, upper respiratory tract infection, eyelid edema, eyelid ptosis, sinusitis, and nausea.",upper respiratory tract infection is an adverse reaction entity
"Glabellar Lines       In placebo-controlled clinical trials of DYSPORT    (r)    , the most common adverse reactions(>=2%) following injection of DYSPORT    (r)    were nasopharyngitis, headache, injection site pain, injection site reaction, upper respiratory tract infection, eyelid edema, eyelid ptosis, sinusitis, and nausea.",eyelid edema is an adverse reaction entity
"Glabellar Lines       In placebo-controlled clinical trials of DYSPORT    (r)    , the most common adverse reactions(>=2%) following injection of DYSPORT    (r)    were nasopharyngitis, headache, injection site pain, injection site reaction, upper respiratory tract infection, eyelid edema, eyelid ptosis, sinusitis, and nausea.",eyelid ptosis is an adverse reaction entity
"Glabellar Lines       In placebo-controlled clinical trials of DYSPORT    (r)    , the most common adverse reactions(>=2%) following injection of DYSPORT    (r)    were nasopharyngitis, headache, injection site pain, injection site reaction, upper respiratory tract infection, eyelid edema, eyelid ptosis, sinusitis, and nausea.",sinusitis is an adverse reaction entity
"Glabellar Lines       In placebo-controlled clinical trials of DYSPORT    (r)    , the most common adverse reactions(>=2%) following injection of DYSPORT    (r)    were nasopharyngitis, headache, injection site pain, injection site reaction, upper respiratory tract infection, eyelid edema, eyelid ptosis, sinusitis, and nausea.",nausea is an adverse reaction entity
"In pooled clinical trials, the incidence of agranulocytosis was 1.7% of patients.",agranulocytosis is an adverse reaction entity
"Skin, subcutaneous tissue disorders:  hyperhidrosis, periorbital edema, photosensitivity reaction, pruritis, urticaria, rash, Henoch-Schonlein purpura.",hyperhidrosis is an adverse reaction entity
"Skin, subcutaneous tissue disorders:  hyperhidrosis, periorbital edema, photosensitivity reaction, pruritis, urticaria, rash, Henoch-Schonlein purpura.",periorbital edema is an adverse reaction entity
"Skin, subcutaneous tissue disorders:  hyperhidrosis, periorbital edema, photosensitivity reaction, pruritis, urticaria, rash, Henoch-Schonlein purpura.",photosensitivity reaction is an adverse reaction entity
"Skin, subcutaneous tissue disorders:  hyperhidrosis, periorbital edema, photosensitivity reaction, pruritis, urticaria, rash, Henoch-Schonlein purpura.",pruritis is an adverse reaction entity
"Skin, subcutaneous tissue disorders:  hyperhidrosis, periorbital edema, photosensitivity reaction, pruritis, urticaria, rash, Henoch-Schonlein purpura.",urticaria is an adverse reaction entity
"Skin, subcutaneous tissue disorders:  hyperhidrosis, periorbital edema, photosensitivity reaction, pruritis, urticaria, rash, Henoch-Schonlein purpura.",rash is an adverse reaction entity
"Skin, subcutaneous tissue disorders:  hyperhidrosis, periorbital edema, photosensitivity reaction, pruritis, urticaria, rash, Henoch-Schonlein purpura.",Henoch-Schonlein purpura is an adverse reaction entity
"Musculoskeletal and connective tissue disorders  : myositis, chondropathy, trismus.",myositis is an adverse reaction entity
"Musculoskeletal and connective tissue disorders  : myositis, chondropathy, trismus.",chondropathy is an adverse reaction entity
"Musculoskeletal and connective tissue disorders  : myositis, chondropathy, trismus.",trismus is an adverse reaction entity
Chromaturia (reddish/brown discoloration of the urine) is a result of the excretion of the iron in the urine.,Chromaturia is an adverse reaction entity
[see Warnings and Precautions (5.1)]                 EXCERPT:     WARNING: AGRANULOCYTOSIS    /NEUTROPENIA          See full prescribing information for complete boxed warning.,AGRANULOCYTOSIS is an adverse reaction entity
[see Warnings and Precautions (5.1)]                 EXCERPT:     WARNING: AGRANULOCYTOSIS    /NEUTROPENIA          See full prescribing information for complete boxed warning.,NEUTROPENIA is an adverse reaction entity
"I  nfections and infestations  : cryptococcal cutaneous infection, enteroviral encephalitis, pharyngitis, pneumonia, sepsis, furuncle, infectious hepatitis, rash pustular, subcutaneous abscess.",cryptococcal cutaneous infection is an adverse reaction entity
"I  nfections and infestations  : cryptococcal cutaneous infection, enteroviral encephalitis, pharyngitis, pneumonia, sepsis, furuncle, infectious hepatitis, rash pustular, subcutaneous abscess.",enteroviral encephalitis is an adverse reaction entity
"I  nfections and infestations  : cryptococcal cutaneous infection, enteroviral encephalitis, pharyngitis, pneumonia, sepsis, furuncle, infectious hepatitis, rash pustular, subcutaneous abscess.",pharyngitis is an adverse reaction entity
"I  nfections and infestations  : cryptococcal cutaneous infection, enteroviral encephalitis, pharyngitis, pneumonia, sepsis, furuncle, infectious hepatitis, rash pustular, subcutaneous abscess.",pneumonia is an adverse reaction entity
"I  nfections and infestations  : cryptococcal cutaneous infection, enteroviral encephalitis, pharyngitis, pneumonia, sepsis, furuncle, infectious hepatitis, rash pustular, subcutaneous abscess.",sepsis is an adverse reaction entity
"I  nfections and infestations  : cryptococcal cutaneous infection, enteroviral encephalitis, pharyngitis, pneumonia, sepsis, furuncle, infectious hepatitis, rash pustular, subcutaneous abscess.",furuncle is an adverse reaction entity
"I  nfections and infestations  : cryptococcal cutaneous infection, enteroviral encephalitis, pharyngitis, pneumonia, sepsis, furuncle, infectious hepatitis, rash pustular, subcutaneous abscess.",infectious hepatitis is an adverse reaction entity
"I  nfections and infestations  : cryptococcal cutaneous infection, enteroviral encephalitis, pharyngitis, pneumonia, sepsis, furuncle, infectious hepatitis, rash pustular, subcutaneous abscess.",rash pustular is an adverse reaction entity
"I  nfections and infestations  : cryptococcal cutaneous infection, enteroviral encephalitis, pharyngitis, pneumonia, sepsis, furuncle, infectious hepatitis, rash pustular, subcutaneous abscess.",subcutaneous abscess is an adverse reaction entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  Anaphylaxis and angioedema: Discontinue and do not restart TECFIDERA if these occur.,Anaphylaxis is an adverse reaction entity
5 WARNINGS AND PRECAUTIONS       EXCERPT:    *  Anaphylaxis and angioedema: Discontinue and do not restart TECFIDERA if these occur.,angioedema is an adverse reaction entity
"Alternatively, administration of non-enteric coated aspirin (up to a dose of 325 mg) 30 minutes prior to TECFIDERA dosing may reduce the incidence or severity of flushing [see Dosing and Administration (  2.1  ) and Clinical Pharmacology (  12.3  )]  .",flushing is an adverse reaction entity
Six percent (6%) of TECFIDERA patients and <1% of placebo patients experienced lymphocyte counts <0.5x10  9  /L (lower limit of normal 0.91x10  9  /L).,lymphocyte counts <0.5x10 9 /L is an adverse reaction entity
5.2 Progressive Multifocal Leukoencephalopathy         A fatal case of progressive multifocal leukoencephalopathy (PML) occurred in a patient with MS who received TECFIDERA for 4 years while enrolled in a clinical trial.,fatal is an adverse reaction entity
5.2 Progressive Multifocal Leukoencephalopathy         A fatal case of progressive multifocal leukoencephalopathy (PML) occurred in a patient with MS who received TECFIDERA for 4 years while enrolled in a clinical trial.,progressive multifocal leukoencephalopathy is an adverse reaction entity
5.2 Progressive Multifocal Leukoencephalopathy         A fatal case of progressive multifocal leukoencephalopathy (PML) occurred in a patient with MS who received TECFIDERA for 4 years while enrolled in a clinical trial.,PML is an adverse reaction entity
"In controlled and uncontrolled clinical trials, 2% of patients experienced lymphocyte counts <0.5 x 10  9  /L for at least six months.",lymphocyte counts <0.5 x 10 9 /L is an adverse reaction entity
"Signs and symptoms have included difficulty breathing, urticaria, and swelling of the throat and tongue.",difficulty breathing is an adverse reaction entity
"Signs and symptoms have included difficulty breathing, urticaria, and swelling of the throat and tongue.",urticaria is an adverse reaction entity
"Signs and symptoms have included difficulty breathing, urticaria, and swelling of the throat and tongue.",swelling of the throat is an adverse reaction entity
"Signs and symptoms have included difficulty breathing, urticaria, and swelling of the throat and tongue.",swelling of the tongue is an adverse reaction entity
5.3 Hepatotoxicity      More hepatic-related adverse reactions were reported with the use of SIRTURO plus other drugs used to treat tuberculosis compared to other drugs used to treat tuberculosis without the addition of SIRTURO.,hepatic-related adverse reactions is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed elsewhere in the labeling:     *  Increased mortality [see  Warnings and Precautions (5.1)  ]    *  QT Prolongation [see  Warnings and Precautions (5.2)   and   Clinical Pharmacology (12.2)  ]    *  Hepatotoxicity [see  Warnings and Precautions (5.3)  ]    *  Drug Interactions [see  Warnings and Precautions (5.4)  ]      *  The most common adverse reactions reported in 10% or more of patients treated with SIRTURO were nausea, arthralgia, headache, hemoptysis and chest pain.",Increased mortality is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed elsewhere in the labeling:     *  Increased mortality [see  Warnings and Precautions (5.1)  ]    *  QT Prolongation [see  Warnings and Precautions (5.2)   and   Clinical Pharmacology (12.2)  ]    *  Hepatotoxicity [see  Warnings and Precautions (5.3)  ]    *  Drug Interactions [see  Warnings and Precautions (5.4)  ]      *  The most common adverse reactions reported in 10% or more of patients treated with SIRTURO were nausea, arthralgia, headache, hemoptysis and chest pain.",QT Prolongation is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed elsewhere in the labeling:     *  Increased mortality [see  Warnings and Precautions (5.1)  ]    *  QT Prolongation [see  Warnings and Precautions (5.2)   and   Clinical Pharmacology (12.2)  ]    *  Hepatotoxicity [see  Warnings and Precautions (5.3)  ]    *  Drug Interactions [see  Warnings and Precautions (5.4)  ]      *  The most common adverse reactions reported in 10% or more of patients treated with SIRTURO were nausea, arthralgia, headache, hemoptysis and chest pain.",Hepatotoxicity is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed elsewhere in the labeling:     *  Increased mortality [see  Warnings and Precautions (5.1)  ]    *  QT Prolongation [see  Warnings and Precautions (5.2)   and   Clinical Pharmacology (12.2)  ]    *  Hepatotoxicity [see  Warnings and Precautions (5.3)  ]    *  Drug Interactions [see  Warnings and Precautions (5.4)  ]      *  The most common adverse reactions reported in 10% or more of patients treated with SIRTURO were nausea, arthralgia, headache, hemoptysis and chest pain.",nausea is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed elsewhere in the labeling:     *  Increased mortality [see  Warnings and Precautions (5.1)  ]    *  QT Prolongation [see  Warnings and Precautions (5.2)   and   Clinical Pharmacology (12.2)  ]    *  Hepatotoxicity [see  Warnings and Precautions (5.3)  ]    *  Drug Interactions [see  Warnings and Precautions (5.4)  ]      *  The most common adverse reactions reported in 10% or more of patients treated with SIRTURO were nausea, arthralgia, headache, hemoptysis and chest pain.",arthralgia is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed elsewhere in the labeling:     *  Increased mortality [see  Warnings and Precautions (5.1)  ]    *  QT Prolongation [see  Warnings and Precautions (5.2)   and   Clinical Pharmacology (12.2)  ]    *  Hepatotoxicity [see  Warnings and Precautions (5.3)  ]    *  Drug Interactions [see  Warnings and Precautions (5.4)  ]      *  The most common adverse reactions reported in 10% or more of patients treated with SIRTURO were nausea, arthralgia, headache, hemoptysis and chest pain.",headache is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed elsewhere in the labeling:     *  Increased mortality [see  Warnings and Precautions (5.1)  ]    *  QT Prolongation [see  Warnings and Precautions (5.2)   and   Clinical Pharmacology (12.2)  ]    *  Hepatotoxicity [see  Warnings and Precautions (5.3)  ]    *  Drug Interactions [see  Warnings and Precautions (5.4)  ]      *  The most common adverse reactions reported in 10% or more of patients treated with SIRTURO were nausea, arthralgia, headache, hemoptysis and chest pain.",hemoptysis is an adverse reaction entity
"6 ADVERSE REACTIONS    The following serious adverse reactions are discussed elsewhere in the labeling:     *  Increased mortality [see  Warnings and Precautions (5.1)  ]    *  QT Prolongation [see  Warnings and Precautions (5.2)   and   Clinical Pharmacology (12.2)  ]    *  Hepatotoxicity [see  Warnings and Precautions (5.3)  ]    *  Drug Interactions [see  Warnings and Precautions (5.4)  ]      *  The most common adverse reactions reported in 10% or more of patients treated with SIRTURO were nausea, arthralgia, headache, hemoptysis and chest pain.",chest pain is an adverse reaction entity
The median time to death for the remaining eight subjects in the SIRTURO treatment group was 329 days after last intake of SIRTURO.,death is an adverse reaction entity
"(  5.3  )             5.1 Increased Mortality      An increased risk of death was seen in the SIRTURO treatment group (9/79, 11.4%) compared to the placebo treatment group (2/81, 2.5%) in one placebo-controlled trial (based on the 120-week visit window).",death is an adverse reaction entity
Dizziness was reported in 13% of patients receiving 600 mg of HORIZANT per day compared with 4% of patients receiving placebo.,Dizziness is an adverse reaction entity
"Adverse reactions reported in these three 12 week studies in <2% of patients treated with 600 mg of HORIZANT and numerically greater than placebo were balance disorder, blurred vision, disorientation, feeling drunk, lethargy, and vertigo.",balance disorder is an adverse reaction entity
"Adverse reactions reported in these three 12 week studies in <2% of patients treated with 600 mg of HORIZANT and numerically greater than placebo were balance disorder, blurred vision, disorientation, feeling drunk, lethargy, and vertigo.",blurred vision is an adverse reaction entity
"Adverse reactions reported in these three 12 week studies in <2% of patients treated with 600 mg of HORIZANT and numerically greater than placebo were balance disorder, blurred vision, disorientation, feeling drunk, lethargy, and vertigo.",disorientation is an adverse reaction entity
"Adverse reactions reported in these three 12 week studies in <2% of patients treated with 600 mg of HORIZANT and numerically greater than placebo were balance disorder, blurred vision, disorientation, feeling drunk, lethargy, and vertigo.",feeling drunk is an adverse reaction entity
"Adverse reactions reported in these three 12 week studies in <2% of patients treated with 600 mg of HORIZANT and numerically greater than placebo were balance disorder, blurred vision, disorientation, feeling drunk, lethargy, and vertigo.",lethargy is an adverse reaction entity
"Adverse reactions reported in these three 12 week studies in <2% of patients treated with 600 mg of HORIZANT and numerically greater than placebo were balance disorder, blurred vision, disorientation, feeling drunk, lethargy, and vertigo.",vertigo is an adverse reaction entity
The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed.,suicidal thoughts is an adverse reaction entity
The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed.,suicidal behavior is an adverse reaction entity
"It is important to note that early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident.",hypersensitivity is an adverse reaction entity
"It is important to note that early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident.",fever is an adverse reaction entity
"It is important to note that early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident.",lymphadenopathy is an adverse reaction entity
"It is important to note that early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident.",rash is an adverse reaction entity
6 ADVERSE REACTIONS    The following adverse reactions are described in more detail in the  Warnings and Precautions  section of the label:     *   Somnolence/sedation and dizziness [see Warnings and Precautions (  5.2  )]       *   RLS: Most common adverse reactions (>=10% and at least 2 times the rate of placebo) were somnolence/sedation and dizziness.,Somnolence is an adverse reaction entity
6 ADVERSE REACTIONS    The following adverse reactions are described in more detail in the  Warnings and Precautions  section of the label:     *   Somnolence/sedation and dizziness [see Warnings and Precautions (  5.2  )]       *   RLS: Most common adverse reactions (>=10% and at least 2 times the rate of placebo) were somnolence/sedation and dizziness.,sedation is an adverse reaction entity
6 ADVERSE REACTIONS    The following adverse reactions are described in more detail in the  Warnings and Precautions  section of the label:     *   Somnolence/sedation and dizziness [see Warnings and Precautions (  5.2  )]       *   RLS: Most common adverse reactions (>=10% and at least 2 times the rate of placebo) were somnolence/sedation and dizziness.,dizziness is an adverse reaction entity
6 ADVERSE REACTIONS    The following adverse reactions are described in more detail in the  Warnings and Precautions  section of the label:     *   Somnolence/sedation and dizziness [see Warnings and Precautions (  5.2  )]       *   RLS: Most common adverse reactions (>=10% and at least 2 times the rate of placebo) were somnolence/sedation and dizziness.,somnolence is an adverse reaction entity
6 ADVERSE REACTIONS    The following adverse reactions are described in more detail in the  Warnings and Precautions  section of the label:     *   Somnolence/sedation and dizziness [see Warnings and Precautions (  5.2  )]       *   RLS: Most common adverse reactions (>=10% and at least 2 times the rate of placebo) were somnolence/sedation and dizziness.,sedation is an adverse reaction entity
6 ADVERSE REACTIONS    The following adverse reactions are described in more detail in the  Warnings and Precautions  section of the label:     *   Somnolence/sedation and dizziness [see Warnings and Precautions (  5.2  )]       *   RLS: Most common adverse reactions (>=10% and at least 2 times the rate of placebo) were somnolence/sedation and dizziness.,dizziness is an adverse reaction entity
"DRESS typically, although not exclusively, presents with fever, rash, and/or lymphadenopathy, in association with other organ system involvement, such as hepatitis, nephritis, hematological abnormalities, myocarditis, or myositis sometimes resembling an acute viral infection.",DRESS is an adverse reaction entity
"DRESS typically, although not exclusively, presents with fever, rash, and/or lymphadenopathy, in association with other organ system involvement, such as hepatitis, nephritis, hematological abnormalities, myocarditis, or myositis sometimes resembling an acute viral infection.",fever is an adverse reaction entity
"DRESS typically, although not exclusively, presents with fever, rash, and/or lymphadenopathy, in association with other organ system involvement, such as hepatitis, nephritis, hematological abnormalities, myocarditis, or myositis sometimes resembling an acute viral infection.",rash is an adverse reaction entity
"DRESS typically, although not exclusively, presents with fever, rash, and/or lymphadenopathy, in association with other organ system involvement, such as hepatitis, nephritis, hematological abnormalities, myocarditis, or myositis sometimes resembling an acute viral infection.",lymphadenopathy is an adverse reaction entity
"DRESS typically, although not exclusively, presents with fever, rash, and/or lymphadenopathy, in association with other organ system involvement, such as hepatitis, nephritis, hematological abnormalities, myocarditis, or myositis sometimes resembling an acute viral infection.",hepatitis is an adverse reaction entity
"DRESS typically, although not exclusively, presents with fever, rash, and/or lymphadenopathy, in association with other organ system involvement, such as hepatitis, nephritis, hematological abnormalities, myocarditis, or myositis sometimes resembling an acute viral infection.",nephritis is an adverse reaction entity
"DRESS typically, although not exclusively, presents with fever, rash, and/or lymphadenopathy, in association with other organ system involvement, such as hepatitis, nephritis, hematological abnormalities, myocarditis, or myositis sometimes resembling an acute viral infection.",hematological abnormalities is an adverse reaction entity
"DRESS typically, although not exclusively, presents with fever, rash, and/or lymphadenopathy, in association with other organ system involvement, such as hepatitis, nephritis, hematological abnormalities, myocarditis, or myositis sometimes resembling an acute viral infection.",myocarditis is an adverse reaction entity
"DRESS typically, although not exclusively, presents with fever, rash, and/or lymphadenopathy, in association with other organ system involvement, such as hepatitis, nephritis, hematological abnormalities, myocarditis, or myositis sometimes resembling an acute viral infection.",myositis is an adverse reaction entity
"Fatigue/asthenia was reported in 6% of patients treated with 1,200 mg of HORIZANT per day compared with 1% of patients receiving placebo.",Fatigue is an adverse reaction entity
"Fatigue/asthenia was reported in 6% of patients treated with 1,200 mg of HORIZANT per day compared with 1% of patients receiving placebo.",asthenia is an adverse reaction entity
5 WARNINGS AND PRECAUTIONS         EXCERPT:    *   Driving impairment: Warn patients not to drive until they have gained sufficient experience with HORIZANT to assess whether it will impair their ability to drive.,Driving impairment is an adverse reaction entity
AEDs increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication.,suicidal thoughts is an adverse reaction entity
AEDs increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication.,suicidal behavior is an adverse reaction entity
Hypersensitivity reactions have uncommonly been reported during the postmarketing use of AdreView [  see  Warnings and Precautions (5.1)    ].,Hypersensitivity reactions is an adverse reaction entity
6 ADVERSE REACTIONS    EXCERPT:   Serious hypersensitivity reactions have been reported following AdreView administration.,hypersensitivity reactions is an adverse reaction entity
Female patients who developed genital mycotic infections on INVOKANA were more likely to experience recurrence and require treatment with oral or topical antifungal agents and anti-microbial agents.,Female genital mycotic infections is an adverse reaction entity
"Additionally, placebo-adjusted BMD declines were 0.1% at the femoral neck for both INVOKANA doses and 0.4% at the distal forearm for patients randomized to INVOKANA 300 mg.",BMD declines at the femoral neck is an adverse reaction entity
"Additionally, placebo-adjusted BMD declines were 0.1% at the femoral neck for both INVOKANA doses and 0.4% at the distal forearm for patients randomized to INVOKANA 300 mg.",BMD declines at the distal forearm is an adverse reaction entity
"Increases in Low-Density Lipoprotein Cholesterol (LDL-C) and non-High-Density Lipoprotein Cholesterol (non-HDL-C)       In the pool of four placebo-controlled trials, dose-related increases in LDL-C with INVOKANA were observed.",increases in LDL-C is an adverse reaction entity
"In the pool of eight clinical trials, the incidence rate of pancreatitis (acute or chronic) was 0.9, 2.7, and 0.9 per 1000 patient-years of exposure to comparator, INVOKANA 100 mg, and INVOKANA 300 mg, respectively.",pancreatitis acute is an adverse reaction entity
"In the pool of eight clinical trials, the incidence rate of pancreatitis (acute or chronic) was 0.9, 2.7, and 0.9 per 1000 patient-years of exposure to comparator, INVOKANA 100 mg, and INVOKANA 300 mg, respectively.",pancreatitis chronic is an adverse reaction entity
Renal function abnormalities can occur after initiating INVOKANA [see  Adverse Reactions (6.1)  ]  .,Renal function abnormalities is an adverse reaction entity
"5.7 Bone Fracture       An increased risk of bone fracture, occurring as early as 12 weeks after treatment initiation, was observed in patients using INVOKANA.",bone fracture is an adverse reaction entity
"In this pool, INVOKANA was also associated with the adverse reactions of fatigue (1.7% with comparator, 2.2% with INVOKANA 100 mg, and 2.0% with INVOKANA 300 mg) and loss of strength or energy (i.e., asthenia) (0.6% with comparator, 0.7% with INVOKANA 100 mg, and 1.1% with INVOKANA 300 mg).",fatigue is an adverse reaction entity
"In this pool, INVOKANA was also associated with the adverse reactions of fatigue (1.7% with comparator, 2.2% with INVOKANA 100 mg, and 2.0% with INVOKANA 300 mg) and loss of strength or energy (i.e., asthenia) (0.6% with comparator, 0.7% with INVOKANA 100 mg, and 1.1% with INVOKANA 300 mg).",loss of strength is an adverse reaction entity
"In this pool, INVOKANA was also associated with the adverse reactions of fatigue (1.7% with comparator, 2.2% with INVOKANA 100 mg, and 2.0% with INVOKANA 300 mg) and loss of strength or energy (i.e., asthenia) (0.6% with comparator, 0.7% with INVOKANA 100 mg, and 1.1% with INVOKANA 300 mg).",loss of energy is an adverse reaction entity
"In this pool, INVOKANA was also associated with the adverse reactions of fatigue (1.7% with comparator, 2.2% with INVOKANA 100 mg, and 2.0% with INVOKANA 300 mg) and loss of strength or energy (i.e., asthenia) (0.6% with comparator, 0.7% with INVOKANA 100 mg, and 1.1% with INVOKANA 300 mg).",asthenia is an adverse reaction entity
"In the pooled analysis of patients with moderate renal impairment, the incidence of renal-related adverse reactions was 3.7% with placebo, 8.9% with INVOKANA 100 mg, and 9.3% with INVOKANA 300 mg. Discontinuations due to renal-related adverse events occurred in 1.0% with placebo, 1.2% with INVOKANA 100 mg, and 1.6% with INVOKANA 300 mg  [see  Warnings and Precautions (5.2)  ]  .",renal-related adverse reactions is an adverse reaction entity
"In the pooled analysis of patients with moderate renal impairment, the incidence of renal-related adverse reactions was 3.7% with placebo, 8.9% with INVOKANA 100 mg, and 9.3% with INVOKANA 300 mg. Discontinuations due to renal-related adverse events occurred in 1.0% with placebo, 1.2% with INVOKANA 100 mg, and 1.6% with INVOKANA 300 mg  [see  Warnings and Precautions (5.2)  ]  .",renal-related adverse events is an adverse reaction entity
"In individual clinical trials  [see  Clinical Studies (14)  ]  , episodes of hypoglycemia occurred at a higher rate when INVOKANA was co-administered with insulin or sulfonylureas (Table 4)  [see  Warnings and Precautions (5.4)  ]  .",hypoglycemia is an adverse reaction entity
5.5 Genital Mycotic Infections      INVOKANA increases the risk of genital mycotic infections.,genital mycotic infections is an adverse reaction entity
INVOKANA can increase the risk of hypoglycemia when combined with insulin or an insulin secretagogue [see  Adverse Reactions (6.1)  ]  .,hypoglycemia is an adverse reaction entity
5.8 Increases in Low-Density Lipoprotein (LDL-C)      Dose-related increases in LDL-C occur with INVOKANA [see  Adverse Reactions (6.1)  ]  .,increases in LDL-C is an adverse reaction entity
"b Includes the terms injection site haemorrhage, injection site irritation, and injection site pain.",injection site haemorrhage is an adverse reaction entity
"b Includes the terms injection site haemorrhage, injection site irritation, and injection site pain.",injection site irritation is an adverse reaction entity
"b Includes the terms injection site haemorrhage, injection site irritation, and injection site pain.",injection site pain is an adverse reaction entity
"Serious adverse reactions reported with alglucosidase alfa included anaphylaxis, which presented as angioedema, throat tightness and chest pain/discomfort.",anaphylaxis is an adverse reaction entity
"Serious adverse reactions reported with alglucosidase alfa included anaphylaxis, which presented as angioedema, throat tightness and chest pain/discomfort.",angioedema is an adverse reaction entity
"Serious adverse reactions reported with alglucosidase alfa included anaphylaxis, which presented as angioedema, throat tightness and chest pain/discomfort.",throat tightness is an adverse reaction entity
"Serious adverse reactions reported with alglucosidase alfa included anaphylaxis, which presented as angioedema, throat tightness and chest pain/discomfort.",chest pain is an adverse reaction entity
"Serious adverse reactions reported with alglucosidase alfa included anaphylaxis, which presented as angioedema, throat tightness and chest pain/discomfort.",chest discomfort is an adverse reaction entity
"Immune-mediated reactions presenting as proteinuria, nephrotic syndrome, and necrotizing skin lesions have occurred in some patients following alglucosidase alfa treatment.",Immune-mediated reactions is an adverse reaction entity
"Immune-mediated reactions presenting as proteinuria, nephrotic syndrome, and necrotizing skin lesions have occurred in some patients following alglucosidase alfa treatment.",proteinuria is an adverse reaction entity
"Immune-mediated reactions presenting as proteinuria, nephrotic syndrome, and necrotizing skin lesions have occurred in some patients following alglucosidase alfa treatment.",nephrotic syndrome is an adverse reaction entity
"Immune-mediated reactions presenting as proteinuria, nephrotic syndrome, and necrotizing skin lesions have occurred in some patients following alglucosidase alfa treatment.",necrotizing skin lesions is an adverse reaction entity
"*  Infantile-onset Pompe disease patients with compromised cardiac or respiratory function may be at risk of serious acute exacerbation of their cardiac or respiratory compromise due to fluid overload, and require additional monitoring (5.3).",acute exacerbation of respiratory compromise is an adverse reaction entity
"*  Infantile-onset Pompe disease patients with compromised cardiac or respiratory function may be at risk of serious acute exacerbation of their cardiac or respiratory compromise due to fluid overload, and require additional monitoring (5.3).",acute exacerbation of cardiac compromise is an adverse reaction entity
"*  Infantile-onset Pompe disease patients with compromised cardiac or respiratory function may be at risk of serious acute exacerbation of their cardiac or respiratory compromise due to fluid overload, and require additional monitoring (5.3).",fluid overload is an adverse reaction entity
Some patients who tested positive for alglucosidase alfa-specific IgE antibodies and experienced hypersensitivity reactions were able to be rechallenged with alglucosidase alfa using a slower infusion rate at lower starting doses and have continued to receive treatment under close clinical supervision  [seeWarnings and Precautions (5.1)]  .,hypersensitivity reactions is an adverse reaction entity
"Furthermore, CRIM-negative infants have shown reduced clinical effect in the presence of high sustained IgG antibody titers with inhibitory activity.",IgG antibody titers with inhibitory activity is an adverse reaction entity
The most serious adverse reactions reported with alglucosidase alfa treatment included anaphylaxis and acute cardiorespiratory failure.,anaphylaxis is an adverse reaction entity
The most serious adverse reactions reported with alglucosidase alfa treatment included anaphylaxis and acute cardiorespiratory failure.,acute cardiorespiratory failure is an adverse reaction entity
"Testing was performed in patients who experienced moderate to severe or recurrent hypersensitivity reactions, for which mast-cell activation was suspected.",recurrent hypersensitivity reactions is an adverse reaction entity
"Testing was performed in patients who experienced moderate to severe or recurrent hypersensitivity reactions, for which mast-cell activation was suspected.",hypersensitivity reactions is an adverse reaction entity
"BOXED WARNING: WARNING:  RISK OF ANAPHYLAXIS, HYPERSENSITIVITY AND IMMUNE-MEDIATED REACTIONS, AND RISK OF CARDIORESPIRATORY FAILURE      WARNING:  RISK OF ANAPHYLAXIS, HYPERSENSITIVITY AND IMMUNE-MEDIATED REACTIONS, AND RISK OF CARDIORESPIRATORY FAILURE          Life-threatening anaphylactic reactions and severe hypersensitivity reactions, presenting as respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria, have occurred in some patients during and after alglucosidase alfa infusions.",ANAPHYLAXIS is an adverse reaction entity
"BOXED WARNING: WARNING:  RISK OF ANAPHYLAXIS, HYPERSENSITIVITY AND IMMUNE-MEDIATED REACTIONS, AND RISK OF CARDIORESPIRATORY FAILURE      WARNING:  RISK OF ANAPHYLAXIS, HYPERSENSITIVITY AND IMMUNE-MEDIATED REACTIONS, AND RISK OF CARDIORESPIRATORY FAILURE          Life-threatening anaphylactic reactions and severe hypersensitivity reactions, presenting as respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria, have occurred in some patients during and after alglucosidase alfa infusions.",HYPERSENSITIVITY is an adverse reaction entity
"BOXED WARNING: WARNING:  RISK OF ANAPHYLAXIS, HYPERSENSITIVITY AND IMMUNE-MEDIATED REACTIONS, AND RISK OF CARDIORESPIRATORY FAILURE      WARNING:  RISK OF ANAPHYLAXIS, HYPERSENSITIVITY AND IMMUNE-MEDIATED REACTIONS, AND RISK OF CARDIORESPIRATORY FAILURE          Life-threatening anaphylactic reactions and severe hypersensitivity reactions, presenting as respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria, have occurred in some patients during and after alglucosidase alfa infusions.",IMMUNE-MEDIATED REACTIONS is an adverse reaction entity
"BOXED WARNING: WARNING:  RISK OF ANAPHYLAXIS, HYPERSENSITIVITY AND IMMUNE-MEDIATED REACTIONS, AND RISK OF CARDIORESPIRATORY FAILURE      WARNING:  RISK OF ANAPHYLAXIS, HYPERSENSITIVITY AND IMMUNE-MEDIATED REACTIONS, AND RISK OF CARDIORESPIRATORY FAILURE          Life-threatening anaphylactic reactions and severe hypersensitivity reactions, presenting as respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria, have occurred in some patients during and after alglucosidase alfa infusions.",CARDIORESPIRATORY FAILURE is an adverse reaction entity
"BOXED WARNING: WARNING:  RISK OF ANAPHYLAXIS, HYPERSENSITIVITY AND IMMUNE-MEDIATED REACTIONS, AND RISK OF CARDIORESPIRATORY FAILURE      WARNING:  RISK OF ANAPHYLAXIS, HYPERSENSITIVITY AND IMMUNE-MEDIATED REACTIONS, AND RISK OF CARDIORESPIRATORY FAILURE          Life-threatening anaphylactic reactions and severe hypersensitivity reactions, presenting as respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria, have occurred in some patients during and after alglucosidase alfa infusions.",ANAPHYLAXIS is an adverse reaction entity
"BOXED WARNING: WARNING:  RISK OF ANAPHYLAXIS, HYPERSENSITIVITY AND IMMUNE-MEDIATED REACTIONS, AND RISK OF CARDIORESPIRATORY FAILURE      WARNING:  RISK OF ANAPHYLAXIS, HYPERSENSITIVITY AND IMMUNE-MEDIATED REACTIONS, AND RISK OF CARDIORESPIRATORY FAILURE          Life-threatening anaphylactic reactions and severe hypersensitivity reactions, presenting as respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria, have occurred in some patients during and after alglucosidase alfa infusions.",HYPERSENSITIVITY is an adverse reaction entity
"BOXED WARNING: WARNING:  RISK OF ANAPHYLAXIS, HYPERSENSITIVITY AND IMMUNE-MEDIATED REACTIONS, AND RISK OF CARDIORESPIRATORY FAILURE      WARNING:  RISK OF ANAPHYLAXIS, HYPERSENSITIVITY AND IMMUNE-MEDIATED REACTIONS, AND RISK OF CARDIORESPIRATORY FAILURE          Life-threatening anaphylactic reactions and severe hypersensitivity reactions, presenting as respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria, have occurred in some patients during and after alglucosidase alfa infusions.",IMMUNE-MEDIATED REACTIONS is an adverse reaction entity
"BOXED WARNING: WARNING:  RISK OF ANAPHYLAXIS, HYPERSENSITIVITY AND IMMUNE-MEDIATED REACTIONS, AND RISK OF CARDIORESPIRATORY FAILURE      WARNING:  RISK OF ANAPHYLAXIS, HYPERSENSITIVITY AND IMMUNE-MEDIATED REACTIONS, AND RISK OF CARDIORESPIRATORY FAILURE          Life-threatening anaphylactic reactions and severe hypersensitivity reactions, presenting as respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria, have occurred in some patients during and after alglucosidase alfa infusions.",CARDIORESPIRATORY FAILURE is an adverse reaction entity
"BOXED WARNING: WARNING:  RISK OF ANAPHYLAXIS, HYPERSENSITIVITY AND IMMUNE-MEDIATED REACTIONS, AND RISK OF CARDIORESPIRATORY FAILURE      WARNING:  RISK OF ANAPHYLAXIS, HYPERSENSITIVITY AND IMMUNE-MEDIATED REACTIONS, AND RISK OF CARDIORESPIRATORY FAILURE          Life-threatening anaphylactic reactions and severe hypersensitivity reactions, presenting as respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria, have occurred in some patients during and after alglucosidase alfa infusions.",anaphylactic reactions is an adverse reaction entity
"BOXED WARNING: WARNING:  RISK OF ANAPHYLAXIS, HYPERSENSITIVITY AND IMMUNE-MEDIATED REACTIONS, AND RISK OF CARDIORESPIRATORY FAILURE      WARNING:  RISK OF ANAPHYLAXIS, HYPERSENSITIVITY AND IMMUNE-MEDIATED REACTIONS, AND RISK OF CARDIORESPIRATORY FAILURE          Life-threatening anaphylactic reactions and severe hypersensitivity reactions, presenting as respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria, have occurred in some patients during and after alglucosidase alfa infusions.",hypersensitivity reactions is an adverse reaction entity
"BOXED WARNING: WARNING:  RISK OF ANAPHYLAXIS, HYPERSENSITIVITY AND IMMUNE-MEDIATED REACTIONS, AND RISK OF CARDIORESPIRATORY FAILURE      WARNING:  RISK OF ANAPHYLAXIS, HYPERSENSITIVITY AND IMMUNE-MEDIATED REACTIONS, AND RISK OF CARDIORESPIRATORY FAILURE          Life-threatening anaphylactic reactions and severe hypersensitivity reactions, presenting as respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria, have occurred in some patients during and after alglucosidase alfa infusions.",respiratory distress is an adverse reaction entity
"BOXED WARNING: WARNING:  RISK OF ANAPHYLAXIS, HYPERSENSITIVITY AND IMMUNE-MEDIATED REACTIONS, AND RISK OF CARDIORESPIRATORY FAILURE      WARNING:  RISK OF ANAPHYLAXIS, HYPERSENSITIVITY AND IMMUNE-MEDIATED REACTIONS, AND RISK OF CARDIORESPIRATORY FAILURE          Life-threatening anaphylactic reactions and severe hypersensitivity reactions, presenting as respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria, have occurred in some patients during and after alglucosidase alfa infusions.",hypoxia is an adverse reaction entity
"BOXED WARNING: WARNING:  RISK OF ANAPHYLAXIS, HYPERSENSITIVITY AND IMMUNE-MEDIATED REACTIONS, AND RISK OF CARDIORESPIRATORY FAILURE      WARNING:  RISK OF ANAPHYLAXIS, HYPERSENSITIVITY AND IMMUNE-MEDIATED REACTIONS, AND RISK OF CARDIORESPIRATORY FAILURE          Life-threatening anaphylactic reactions and severe hypersensitivity reactions, presenting as respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria, have occurred in some patients during and after alglucosidase alfa infusions.",apnea is an adverse reaction entity
"BOXED WARNING: WARNING:  RISK OF ANAPHYLAXIS, HYPERSENSITIVITY AND IMMUNE-MEDIATED REACTIONS, AND RISK OF CARDIORESPIRATORY FAILURE      WARNING:  RISK OF ANAPHYLAXIS, HYPERSENSITIVITY AND IMMUNE-MEDIATED REACTIONS, AND RISK OF CARDIORESPIRATORY FAILURE          Life-threatening anaphylactic reactions and severe hypersensitivity reactions, presenting as respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria, have occurred in some patients during and after alglucosidase alfa infusions.",dyspnea is an adverse reaction entity
"BOXED WARNING: WARNING:  RISK OF ANAPHYLAXIS, HYPERSENSITIVITY AND IMMUNE-MEDIATED REACTIONS, AND RISK OF CARDIORESPIRATORY FAILURE      WARNING:  RISK OF ANAPHYLAXIS, HYPERSENSITIVITY AND IMMUNE-MEDIATED REACTIONS, AND RISK OF CARDIORESPIRATORY FAILURE          Life-threatening anaphylactic reactions and severe hypersensitivity reactions, presenting as respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria, have occurred in some patients during and after alglucosidase alfa infusions.",bradycardia is an adverse reaction entity
"BOXED WARNING: WARNING:  RISK OF ANAPHYLAXIS, HYPERSENSITIVITY AND IMMUNE-MEDIATED REACTIONS, AND RISK OF CARDIORESPIRATORY FAILURE      WARNING:  RISK OF ANAPHYLAXIS, HYPERSENSITIVITY AND IMMUNE-MEDIATED REACTIONS, AND RISK OF CARDIORESPIRATORY FAILURE          Life-threatening anaphylactic reactions and severe hypersensitivity reactions, presenting as respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria, have occurred in some patients during and after alglucosidase alfa infusions.",tachycardia is an adverse reaction entity
"BOXED WARNING: WARNING:  RISK OF ANAPHYLAXIS, HYPERSENSITIVITY AND IMMUNE-MEDIATED REACTIONS, AND RISK OF CARDIORESPIRATORY FAILURE      WARNING:  RISK OF ANAPHYLAXIS, HYPERSENSITIVITY AND IMMUNE-MEDIATED REACTIONS, AND RISK OF CARDIORESPIRATORY FAILURE          Life-threatening anaphylactic reactions and severe hypersensitivity reactions, presenting as respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria, have occurred in some patients during and after alglucosidase alfa infusions.",bronchospasm is an adverse reaction entity
"BOXED WARNING: WARNING:  RISK OF ANAPHYLAXIS, HYPERSENSITIVITY AND IMMUNE-MEDIATED REACTIONS, AND RISK OF CARDIORESPIRATORY FAILURE      WARNING:  RISK OF ANAPHYLAXIS, HYPERSENSITIVITY AND IMMUNE-MEDIATED REACTIONS, AND RISK OF CARDIORESPIRATORY FAILURE          Life-threatening anaphylactic reactions and severe hypersensitivity reactions, presenting as respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria, have occurred in some patients during and after alglucosidase alfa infusions.",throat tightness is an adverse reaction entity
"BOXED WARNING: WARNING:  RISK OF ANAPHYLAXIS, HYPERSENSITIVITY AND IMMUNE-MEDIATED REACTIONS, AND RISK OF CARDIORESPIRATORY FAILURE      WARNING:  RISK OF ANAPHYLAXIS, HYPERSENSITIVITY AND IMMUNE-MEDIATED REACTIONS, AND RISK OF CARDIORESPIRATORY FAILURE          Life-threatening anaphylactic reactions and severe hypersensitivity reactions, presenting as respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria, have occurred in some patients during and after alglucosidase alfa infusions.",hypotension is an adverse reaction entity
"BOXED WARNING: WARNING:  RISK OF ANAPHYLAXIS, HYPERSENSITIVITY AND IMMUNE-MEDIATED REACTIONS, AND RISK OF CARDIORESPIRATORY FAILURE      WARNING:  RISK OF ANAPHYLAXIS, HYPERSENSITIVITY AND IMMUNE-MEDIATED REACTIONS, AND RISK OF CARDIORESPIRATORY FAILURE          Life-threatening anaphylactic reactions and severe hypersensitivity reactions, presenting as respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria, have occurred in some patients during and after alglucosidase alfa infusions.",angioedema is an adverse reaction entity
"BOXED WARNING: WARNING:  RISK OF ANAPHYLAXIS, HYPERSENSITIVITY AND IMMUNE-MEDIATED REACTIONS, AND RISK OF CARDIORESPIRATORY FAILURE      WARNING:  RISK OF ANAPHYLAXIS, HYPERSENSITIVITY AND IMMUNE-MEDIATED REACTIONS, AND RISK OF CARDIORESPIRATORY FAILURE          Life-threatening anaphylactic reactions and severe hypersensitivity reactions, presenting as respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria, have occurred in some patients during and after alglucosidase alfa infusions.",tongue swelling is an adverse reaction entity
"BOXED WARNING: WARNING:  RISK OF ANAPHYLAXIS, HYPERSENSITIVITY AND IMMUNE-MEDIATED REACTIONS, AND RISK OF CARDIORESPIRATORY FAILURE      WARNING:  RISK OF ANAPHYLAXIS, HYPERSENSITIVITY AND IMMUNE-MEDIATED REACTIONS, AND RISK OF CARDIORESPIRATORY FAILURE          Life-threatening anaphylactic reactions and severe hypersensitivity reactions, presenting as respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria, have occurred in some patients during and after alglucosidase alfa infusions.",lip swelling is an adverse reaction entity
"BOXED WARNING: WARNING:  RISK OF ANAPHYLAXIS, HYPERSENSITIVITY AND IMMUNE-MEDIATED REACTIONS, AND RISK OF CARDIORESPIRATORY FAILURE      WARNING:  RISK OF ANAPHYLAXIS, HYPERSENSITIVITY AND IMMUNE-MEDIATED REACTIONS, AND RISK OF CARDIORESPIRATORY FAILURE          Life-threatening anaphylactic reactions and severe hypersensitivity reactions, presenting as respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria, have occurred in some patients during and after alglucosidase alfa infusions.",periorbital edema is an adverse reaction entity
"BOXED WARNING: WARNING:  RISK OF ANAPHYLAXIS, HYPERSENSITIVITY AND IMMUNE-MEDIATED REACTIONS, AND RISK OF CARDIORESPIRATORY FAILURE      WARNING:  RISK OF ANAPHYLAXIS, HYPERSENSITIVITY AND IMMUNE-MEDIATED REACTIONS, AND RISK OF CARDIORESPIRATORY FAILURE          Life-threatening anaphylactic reactions and severe hypersensitivity reactions, presenting as respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria, have occurred in some patients during and after alglucosidase alfa infusions.",face edema is an adverse reaction entity
"BOXED WARNING: WARNING:  RISK OF ANAPHYLAXIS, HYPERSENSITIVITY AND IMMUNE-MEDIATED REACTIONS, AND RISK OF CARDIORESPIRATORY FAILURE      WARNING:  RISK OF ANAPHYLAXIS, HYPERSENSITIVITY AND IMMUNE-MEDIATED REACTIONS, AND RISK OF CARDIORESPIRATORY FAILURE          Life-threatening anaphylactic reactions and severe hypersensitivity reactions, presenting as respiratory distress, hypoxia, apnea, dyspnea, bradycardia, tachycardia, bronchospasm, throat tightness, hypotension, angioedema (including tongue or lip swelling, periorbital edema, and face edema), and urticaria, have occurred in some patients during and after alglucosidase alfa infusions.",urticaria is an adverse reaction entity
*   Risk of Cardiac Arrhythmia and Sudden Cardiac Death during General Anesthesia for Central Venous Catheter Placement: Caution should be used when administering general anesthesia for the placement of a central venous catheter intended for alglucosidase alfa infusion (5.4).,Cardiac Arrhythmia is an adverse reaction entity
*   Risk of Cardiac Arrhythmia and Sudden Cardiac Death during General Anesthesia for Central Venous Catheter Placement: Caution should be used when administering general anesthesia for the placement of a central venous catheter intended for alglucosidase alfa infusion (5.4).,Sudden Cardiac Death is an adverse reaction entity
"In addition to the hypersensitivity reactions reported in clinical trials  [seeAdverse Reactions (6.1)]  , the following hypersensitivity reactions have been reported in at least 2 patients and included: anaphylactic shock, respiratory failure, respiratory arrest, cardiac arrest, hypoxia, dyspnea, wheezing, convulsions, peripheral coldness, restlessness, nervousness, back pain, stridor, pharyngeal edema, abdominal pain, apnea, muscle spasm, and conjunctivitis.",hypersensitivity reactions is an adverse reaction entity
"In addition to the hypersensitivity reactions reported in clinical trials  [seeAdverse Reactions (6.1)]  , the following hypersensitivity reactions have been reported in at least 2 patients and included: anaphylactic shock, respiratory failure, respiratory arrest, cardiac arrest, hypoxia, dyspnea, wheezing, convulsions, peripheral coldness, restlessness, nervousness, back pain, stridor, pharyngeal edema, abdominal pain, apnea, muscle spasm, and conjunctivitis.",hypersensitivity reactions is an adverse reaction entity
"In addition to the hypersensitivity reactions reported in clinical trials  [seeAdverse Reactions (6.1)]  , the following hypersensitivity reactions have been reported in at least 2 patients and included: anaphylactic shock, respiratory failure, respiratory arrest, cardiac arrest, hypoxia, dyspnea, wheezing, convulsions, peripheral coldness, restlessness, nervousness, back pain, stridor, pharyngeal edema, abdominal pain, apnea, muscle spasm, and conjunctivitis.",anaphylactic shock is an adverse reaction entity
"In addition to the hypersensitivity reactions reported in clinical trials  [seeAdverse Reactions (6.1)]  , the following hypersensitivity reactions have been reported in at least 2 patients and included: anaphylactic shock, respiratory failure, respiratory arrest, cardiac arrest, hypoxia, dyspnea, wheezing, convulsions, peripheral coldness, restlessness, nervousness, back pain, stridor, pharyngeal edema, abdominal pain, apnea, muscle spasm, and conjunctivitis.",respiratory failure is an adverse reaction entity
"In addition to the hypersensitivity reactions reported in clinical trials  [seeAdverse Reactions (6.1)]  , the following hypersensitivity reactions have been reported in at least 2 patients and included: anaphylactic shock, respiratory failure, respiratory arrest, cardiac arrest, hypoxia, dyspnea, wheezing, convulsions, peripheral coldness, restlessness, nervousness, back pain, stridor, pharyngeal edema, abdominal pain, apnea, muscle spasm, and conjunctivitis.",respiratory arrest is an adverse reaction entity
"In addition to the hypersensitivity reactions reported in clinical trials  [seeAdverse Reactions (6.1)]  , the following hypersensitivity reactions have been reported in at least 2 patients and included: anaphylactic shock, respiratory failure, respiratory arrest, cardiac arrest, hypoxia, dyspnea, wheezing, convulsions, peripheral coldness, restlessness, nervousness, back pain, stridor, pharyngeal edema, abdominal pain, apnea, muscle spasm, and conjunctivitis.",cardiac arrest is an adverse reaction entity
"In addition to the hypersensitivity reactions reported in clinical trials  [seeAdverse Reactions (6.1)]  , the following hypersensitivity reactions have been reported in at least 2 patients and included: anaphylactic shock, respiratory failure, respiratory arrest, cardiac arrest, hypoxia, dyspnea, wheezing, convulsions, peripheral coldness, restlessness, nervousness, back pain, stridor, pharyngeal edema, abdominal pain, apnea, muscle spasm, and conjunctivitis.",hypoxia is an adverse reaction entity
"In addition to the hypersensitivity reactions reported in clinical trials  [seeAdverse Reactions (6.1)]  , the following hypersensitivity reactions have been reported in at least 2 patients and included: anaphylactic shock, respiratory failure, respiratory arrest, cardiac arrest, hypoxia, dyspnea, wheezing, convulsions, peripheral coldness, restlessness, nervousness, back pain, stridor, pharyngeal edema, abdominal pain, apnea, muscle spasm, and conjunctivitis.",dyspnea is an adverse reaction entity
"In addition to the hypersensitivity reactions reported in clinical trials  [seeAdverse Reactions (6.1)]  , the following hypersensitivity reactions have been reported in at least 2 patients and included: anaphylactic shock, respiratory failure, respiratory arrest, cardiac arrest, hypoxia, dyspnea, wheezing, convulsions, peripheral coldness, restlessness, nervousness, back pain, stridor, pharyngeal edema, abdominal pain, apnea, muscle spasm, and conjunctivitis.",wheezing is an adverse reaction entity
"In addition to the hypersensitivity reactions reported in clinical trials  [seeAdverse Reactions (6.1)]  , the following hypersensitivity reactions have been reported in at least 2 patients and included: anaphylactic shock, respiratory failure, respiratory arrest, cardiac arrest, hypoxia, dyspnea, wheezing, convulsions, peripheral coldness, restlessness, nervousness, back pain, stridor, pharyngeal edema, abdominal pain, apnea, muscle spasm, and conjunctivitis.",convulsions is an adverse reaction entity
"In addition to the hypersensitivity reactions reported in clinical trials  [seeAdverse Reactions (6.1)]  , the following hypersensitivity reactions have been reported in at least 2 patients and included: anaphylactic shock, respiratory failure, respiratory arrest, cardiac arrest, hypoxia, dyspnea, wheezing, convulsions, peripheral coldness, restlessness, nervousness, back pain, stridor, pharyngeal edema, abdominal pain, apnea, muscle spasm, and conjunctivitis.",peripheral coldness is an adverse reaction entity
"In addition to the hypersensitivity reactions reported in clinical trials  [seeAdverse Reactions (6.1)]  , the following hypersensitivity reactions have been reported in at least 2 patients and included: anaphylactic shock, respiratory failure, respiratory arrest, cardiac arrest, hypoxia, dyspnea, wheezing, convulsions, peripheral coldness, restlessness, nervousness, back pain, stridor, pharyngeal edema, abdominal pain, apnea, muscle spasm, and conjunctivitis.",restlessness is an adverse reaction entity
"In addition to the hypersensitivity reactions reported in clinical trials  [seeAdverse Reactions (6.1)]  , the following hypersensitivity reactions have been reported in at least 2 patients and included: anaphylactic shock, respiratory failure, respiratory arrest, cardiac arrest, hypoxia, dyspnea, wheezing, convulsions, peripheral coldness, restlessness, nervousness, back pain, stridor, pharyngeal edema, abdominal pain, apnea, muscle spasm, and conjunctivitis.",nervousness is an adverse reaction entity
"In addition to the hypersensitivity reactions reported in clinical trials  [seeAdverse Reactions (6.1)]  , the following hypersensitivity reactions have been reported in at least 2 patients and included: anaphylactic shock, respiratory failure, respiratory arrest, cardiac arrest, hypoxia, dyspnea, wheezing, convulsions, peripheral coldness, restlessness, nervousness, back pain, stridor, pharyngeal edema, abdominal pain, apnea, muscle spasm, and conjunctivitis.",back pain is an adverse reaction entity
"In addition to the hypersensitivity reactions reported in clinical trials  [seeAdverse Reactions (6.1)]  , the following hypersensitivity reactions have been reported in at least 2 patients and included: anaphylactic shock, respiratory failure, respiratory arrest, cardiac arrest, hypoxia, dyspnea, wheezing, convulsions, peripheral coldness, restlessness, nervousness, back pain, stridor, pharyngeal edema, abdominal pain, apnea, muscle spasm, and conjunctivitis.",stridor is an adverse reaction entity
"In addition to the hypersensitivity reactions reported in clinical trials  [seeAdverse Reactions (6.1)]  , the following hypersensitivity reactions have been reported in at least 2 patients and included: anaphylactic shock, respiratory failure, respiratory arrest, cardiac arrest, hypoxia, dyspnea, wheezing, convulsions, peripheral coldness, restlessness, nervousness, back pain, stridor, pharyngeal edema, abdominal pain, apnea, muscle spasm, and conjunctivitis.",pharyngeal edema is an adverse reaction entity
"In addition to the hypersensitivity reactions reported in clinical trials  [seeAdverse Reactions (6.1)]  , the following hypersensitivity reactions have been reported in at least 2 patients and included: anaphylactic shock, respiratory failure, respiratory arrest, cardiac arrest, hypoxia, dyspnea, wheezing, convulsions, peripheral coldness, restlessness, nervousness, back pain, stridor, pharyngeal edema, abdominal pain, apnea, muscle spasm, and conjunctivitis.",abdominal pain is an adverse reaction entity
"In addition to the hypersensitivity reactions reported in clinical trials  [seeAdverse Reactions (6.1)]  , the following hypersensitivity reactions have been reported in at least 2 patients and included: anaphylactic shock, respiratory failure, respiratory arrest, cardiac arrest, hypoxia, dyspnea, wheezing, convulsions, peripheral coldness, restlessness, nervousness, back pain, stridor, pharyngeal edema, abdominal pain, apnea, muscle spasm, and conjunctivitis.",apnea is an adverse reaction entity
"In addition to the hypersensitivity reactions reported in clinical trials  [seeAdverse Reactions (6.1)]  , the following hypersensitivity reactions have been reported in at least 2 patients and included: anaphylactic shock, respiratory failure, respiratory arrest, cardiac arrest, hypoxia, dyspnea, wheezing, convulsions, peripheral coldness, restlessness, nervousness, back pain, stridor, pharyngeal edema, abdominal pain, apnea, muscle spasm, and conjunctivitis.",muscle spasm is an adverse reaction entity
"In addition to the hypersensitivity reactions reported in clinical trials  [seeAdverse Reactions (6.1)]  , the following hypersensitivity reactions have been reported in at least 2 patients and included: anaphylactic shock, respiratory failure, respiratory arrest, cardiac arrest, hypoxia, dyspnea, wheezing, convulsions, peripheral coldness, restlessness, nervousness, back pain, stridor, pharyngeal edema, abdominal pain, apnea, muscle spasm, and conjunctivitis.",conjunctivitis is an adverse reaction entity
"Table 1: Per Patient Incidence of Grade 1 and 2 Adverse Reactions Assessed as Possibly, Probably, or Definitely Related to VORAXAZE Excluding Hematologic, Hepatic, or Renal Adverse Reactions     1  This incidence includes the following terms: flushing, feeling hot, burning sensation.",flushing is an adverse reaction entity
"Table 1: Per Patient Incidence of Grade 1 and 2 Adverse Reactions Assessed as Possibly, Probably, or Definitely Related to VORAXAZE Excluding Hematologic, Hepatic, or Renal Adverse Reactions     1  This incidence includes the following terms: flushing, feeling hot, burning sensation.",feeling hot is an adverse reaction entity
"Table 1: Per Patient Incidence of Grade 1 and 2 Adverse Reactions Assessed as Possibly, Probably, or Definitely Related to VORAXAZE Excluding Hematologic, Hepatic, or Renal Adverse Reactions     1  This incidence includes the following terms: flushing, feeling hot, burning sensation.",burning sensation is an adverse reaction entity
"The most common related adverse reactions that were not hematologic, hepatic or renal events were paresthesia, flushing, and nausea and/or vomiting, which each occurred in 2% of patients (Table 1).",paresthesia is an adverse reaction entity
"The most common related adverse reactions that were not hematologic, hepatic or renal events were paresthesia, flushing, and nausea and/or vomiting, which each occurred in 2% of patients (Table 1).",flushing is an adverse reaction entity
"The most common related adverse reactions that were not hematologic, hepatic or renal events were paresthesia, flushing, and nausea and/or vomiting, which each occurred in 2% of patients (Table 1).",nausea is an adverse reaction entity
"The most common related adverse reactions that were not hematologic, hepatic or renal events were paresthesia, flushing, and nausea and/or vomiting, which each occurred in 2% of patients (Table 1).",vomiting is an adverse reaction entity
"JARDIANCE may increase the risk of hypotension in patients at risk for volume contraction  [see Warnings and Precautions (  5.1  ) and Use in Specific Populations (  8.5  ,  8.6  )].",hypotension is an adverse reaction entity
5.5 Urinary Tract Infections      JARDIANCE increases the risk for urinary tract infections [see Adverse Reactions (  6.1  )]  .,urinary tract infections is an adverse reaction entity
The incidence of hypoglycemia increased when JARDIANCE was administered with insulin or sulfonylurea  [see Warnings and Precautions (  5.3  )]  .,hypoglycemia is an adverse reaction entity
5.6 Increased Low-Density Lipoprotein Cholesterol (LDL-C)      Increases in LDL-C can occur with JARDIANCE [see Adverse Reactions (  6.1  )]  .,Increases in LDL-C is an adverse reaction entity
More frequent monitoring is recommended in patients with eGFR below 60 mL/min/1.73 m  2  (  5.2  )   *   Hypoglycemia: Consider lowering the dose of insulin secretagogue or insulin to reduce the risk of hypoglycemia when initiating JARDIANCE (  5.3  )   *   Genital mycotic infections: Monitor and treat as appropriate (  5.4  )   *   Urinary tract infections: Monitor and treat as appropriate (  5.5  )   *   Increased LDL-C: Monitor and treat as appropriate (  5.6  )   *   Macrovascular outcomes: There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with JARDIANCE (  5.7  )             5.1 Hypotension      JARDIANCE causes intravascular volume contraction.,Hypoglycemia is an adverse reaction entity
More frequent monitoring is recommended in patients with eGFR below 60 mL/min/1.73 m  2  (  5.2  )   *   Hypoglycemia: Consider lowering the dose of insulin secretagogue or insulin to reduce the risk of hypoglycemia when initiating JARDIANCE (  5.3  )   *   Genital mycotic infections: Monitor and treat as appropriate (  5.4  )   *   Urinary tract infections: Monitor and treat as appropriate (  5.5  )   *   Increased LDL-C: Monitor and treat as appropriate (  5.6  )   *   Macrovascular outcomes: There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with JARDIANCE (  5.7  )             5.1 Hypotension      JARDIANCE causes intravascular volume contraction.,Genital mycotic infections is an adverse reaction entity
More frequent monitoring is recommended in patients with eGFR below 60 mL/min/1.73 m  2  (  5.2  )   *   Hypoglycemia: Consider lowering the dose of insulin secretagogue or insulin to reduce the risk of hypoglycemia when initiating JARDIANCE (  5.3  )   *   Genital mycotic infections: Monitor and treat as appropriate (  5.4  )   *   Urinary tract infections: Monitor and treat as appropriate (  5.5  )   *   Increased LDL-C: Monitor and treat as appropriate (  5.6  )   *   Macrovascular outcomes: There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with JARDIANCE (  5.7  )             5.1 Hypotension      JARDIANCE causes intravascular volume contraction.,Urinary tract infections is an adverse reaction entity
More frequent monitoring is recommended in patients with eGFR below 60 mL/min/1.73 m  2  (  5.2  )   *   Hypoglycemia: Consider lowering the dose of insulin secretagogue or insulin to reduce the risk of hypoglycemia when initiating JARDIANCE (  5.3  )   *   Genital mycotic infections: Monitor and treat as appropriate (  5.4  )   *   Urinary tract infections: Monitor and treat as appropriate (  5.5  )   *   Increased LDL-C: Monitor and treat as appropriate (  5.6  )   *   Macrovascular outcomes: There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with JARDIANCE (  5.7  )             5.1 Hypotension      JARDIANCE causes intravascular volume contraction.,Increased LDL-C is an adverse reaction entity
More frequent monitoring is recommended in patients with eGFR below 60 mL/min/1.73 m  2  (  5.2  )   *   Hypoglycemia: Consider lowering the dose of insulin secretagogue or insulin to reduce the risk of hypoglycemia when initiating JARDIANCE (  5.3  )   *   Genital mycotic infections: Monitor and treat as appropriate (  5.4  )   *   Urinary tract infections: Monitor and treat as appropriate (  5.5  )   *   Increased LDL-C: Monitor and treat as appropriate (  5.6  )   *   Macrovascular outcomes: There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with JARDIANCE (  5.7  )             5.1 Hypotension      JARDIANCE causes intravascular volume contraction.,intravascular volume contraction is an adverse reaction entity
"Volume Depletion  JARDIANCE causes an osmotic diuresis, which may lead to intravascular volume contraction and adverse reactions related to volume depletion.",osmotic diuresis is an adverse reaction entity
"Volume Depletion  JARDIANCE causes an osmotic diuresis, which may lead to intravascular volume contraction and adverse reactions related to volume depletion.",intravascular volume contraction is an adverse reaction entity
"Volume Depletion  JARDIANCE causes an osmotic diuresis, which may lead to intravascular volume contraction and adverse reactions related to volume depletion.",volume depletion is an adverse reaction entity
"5  WARNINGS AND PRECAUTIONS       EXCERPT:    *   Hypotension: Before initiating JARDIANCE assess and correct volume status in patients with renal impairment, the elderly, in patients with low systolic blood pressure, and in patients on diuretics.",Hypotension is an adverse reaction entity
"(5.1)   *    Hypersensitivity: There have been postmarketing reports of serious hypersensitivity reactions in patients treated with NESINA such as anaphylaxis, angioedema and severe cutaneous adverse reactions.",Hypersensitivity is an adverse reaction entity
"(5.1)   *    Hypersensitivity: There have been postmarketing reports of serious hypersensitivity reactions in patients treated with NESINA such as anaphylaxis, angioedema and severe cutaneous adverse reactions.",hypersensitivity reactions is an adverse reaction entity
"(5.1)   *    Hypersensitivity: There have been postmarketing reports of serious hypersensitivity reactions in patients treated with NESINA such as anaphylaxis, angioedema and severe cutaneous adverse reactions.",anaphylaxis is an adverse reaction entity
"(5.1)   *    Hypersensitivity: There have been postmarketing reports of serious hypersensitivity reactions in patients treated with NESINA such as anaphylaxis, angioedema and severe cutaneous adverse reactions.",angioedema is an adverse reaction entity
"(5.1)   *    Hypersensitivity: There have been postmarketing reports of serious hypersensitivity reactions in patients treated with NESINA such as anaphylaxis, angioedema and severe cutaneous adverse reactions.",cutaneous adverse reactions is an adverse reaction entity
5.5 Severe and Disabling Arthralgia        There have been postmarketing reports of severe and disabling arthralgia in patients taking DPP-4 inhibitors.,arthralgia is an adverse reaction entity
"(5.2)   *    Hepatic effects: Postmarketing reports of hepatic failure, sometimes fatal.",Hepatic effects is an adverse reaction entity
"(5.2)   *    Hepatic effects: Postmarketing reports of hepatic failure, sometimes fatal.",hepatic failure is an adverse reaction entity
"(5.2)   *    Hepatic effects: Postmarketing reports of hepatic failure, sometimes fatal.",fatal is an adverse reaction entity
Incidence and Rate of HypoglycemiaAdverse reactions of hypoglycemia were based on all reports of symptomatic and asymptomatic hypoglycemia; a concurrent glucose measurement was not required; intent-to-treat population.,Hypoglycemia is an adverse reaction entity
Incidence and Rate of HypoglycemiaAdverse reactions of hypoglycemia were based on all reports of symptomatic and asymptomatic hypoglycemia; a concurrent glucose measurement was not required; intent-to-treat population.,hypoglycemia is an adverse reaction entity
Incidence and Rate of HypoglycemiaAdverse reactions of hypoglycemia were based on all reports of symptomatic and asymptomatic hypoglycemia; a concurrent glucose measurement was not required; intent-to-treat population.,hypoglycemia is an adverse reaction entity
5.2 Severe Diarrhea or Colitis      Severe diarrhea or colitis (Grade 3 or higher) occurred in 14% of Zydelig-treated patients across clinical trials [see  Adverse Reactions (6.1)  ].,diarrhea is an adverse reaction entity
5.2 Severe Diarrhea or Colitis      Severe diarrhea or colitis (Grade 3 or higher) occurred in 14% of Zydelig-treated patients across clinical trials [see  Adverse Reactions (6.1)  ].,colitis is an adverse reaction entity
"Other severe or life-threatening (Grade >=3) cutaneous reactions, including dermatitis exfoliative, rash, rash erythematous, rash generalized, rash macular, rash maculo-papular, rash papular, rash pruritic, exfoliative rash, and skin disorder, have been reported in Zydelig-treated patients.",cutaneous reactions is an adverse reaction entity
"Other severe or life-threatening (Grade >=3) cutaneous reactions, including dermatitis exfoliative, rash, rash erythematous, rash generalized, rash macular, rash maculo-papular, rash papular, rash pruritic, exfoliative rash, and skin disorder, have been reported in Zydelig-treated patients.",dermatitis exfoliative is an adverse reaction entity
"Other severe or life-threatening (Grade >=3) cutaneous reactions, including dermatitis exfoliative, rash, rash erythematous, rash generalized, rash macular, rash maculo-papular, rash papular, rash pruritic, exfoliative rash, and skin disorder, have been reported in Zydelig-treated patients.",rash is an adverse reaction entity
"Other severe or life-threatening (Grade >=3) cutaneous reactions, including dermatitis exfoliative, rash, rash erythematous, rash generalized, rash macular, rash maculo-papular, rash papular, rash pruritic, exfoliative rash, and skin disorder, have been reported in Zydelig-treated patients.",rash erythematous is an adverse reaction entity
"Other severe or life-threatening (Grade >=3) cutaneous reactions, including dermatitis exfoliative, rash, rash erythematous, rash generalized, rash macular, rash maculo-papular, rash papular, rash pruritic, exfoliative rash, and skin disorder, have been reported in Zydelig-treated patients.",rash generalized is an adverse reaction entity
"Other severe or life-threatening (Grade >=3) cutaneous reactions, including dermatitis exfoliative, rash, rash erythematous, rash generalized, rash macular, rash maculo-papular, rash papular, rash pruritic, exfoliative rash, and skin disorder, have been reported in Zydelig-treated patients.",rash macular is an adverse reaction entity
"Other severe or life-threatening (Grade >=3) cutaneous reactions, including dermatitis exfoliative, rash, rash erythematous, rash generalized, rash macular, rash maculo-papular, rash papular, rash pruritic, exfoliative rash, and skin disorder, have been reported in Zydelig-treated patients.",rash maculo-papular is an adverse reaction entity
"Other severe or life-threatening (Grade >=3) cutaneous reactions, including dermatitis exfoliative, rash, rash erythematous, rash generalized, rash macular, rash maculo-papular, rash papular, rash pruritic, exfoliative rash, and skin disorder, have been reported in Zydelig-treated patients.",rash papular is an adverse reaction entity
"Other severe or life-threatening (Grade >=3) cutaneous reactions, including dermatitis exfoliative, rash, rash erythematous, rash generalized, rash macular, rash maculo-papular, rash papular, rash pruritic, exfoliative rash, and skin disorder, have been reported in Zydelig-treated patients.",rash pruritic is an adverse reaction entity
"Other severe or life-threatening (Grade >=3) cutaneous reactions, including dermatitis exfoliative, rash, rash erythematous, rash generalized, rash macular, rash maculo-papular, rash papular, rash pruritic, exfoliative rash, and skin disorder, have been reported in Zydelig-treated patients.",exfoliative rash is an adverse reaction entity
"Other severe or life-threatening (Grade >=3) cutaneous reactions, including dermatitis exfoliative, rash, rash erythematous, rash generalized, rash macular, rash maculo-papular, rash papular, rash pruritic, exfoliative rash, and skin disorder, have been reported in Zydelig-treated patients.",skin disorder is an adverse reaction entity
"The most common reasons for dose reductions were elevated transaminases, diarrhea or colitis, and rash.",elevated transaminases is an adverse reaction entity
"The most common reasons for dose reductions were elevated transaminases, diarrhea or colitis, and rash.",diarrhea is an adverse reaction entity
"The most common reasons for dose reductions were elevated transaminases, diarrhea or colitis, and rash.",colitis is an adverse reaction entity
"The most common reasons for dose reductions were elevated transaminases, diarrhea or colitis, and rash.",rash is an adverse reaction entity
*  Fatal and/or serious and severe diarrhea or colitis occurred in 14% of Zydelig-treated patients.,Fatal is an adverse reaction entity
*  Fatal and/or serious and severe diarrhea or colitis occurred in 14% of Zydelig-treated patients.,diarrhea is an adverse reaction entity
*  Fatal and/or serious and severe diarrhea or colitis occurred in 14% of Zydelig-treated patients.,colitis is an adverse reaction entity
(  5.5  )   *  Anaphylaxis: Monitor patients for anaphylaxis and discontinue Zydelig.,Anaphylaxis is an adverse reaction entity
"EXCERPT:   WARNING: FATAL AND SERIOUS TOXICITIES: HEPATIC, SEVERE DIARRHEA, COLITIS, PNEUMONITIS, and INTESTINAL PERFORATION         See full prescribing information for complete boxed warning.",FATAL is an adverse reaction entity
"EXCERPT:   WARNING: FATAL AND SERIOUS TOXICITIES: HEPATIC, SEVERE DIARRHEA, COLITIS, PNEUMONITIS, and INTESTINAL PERFORATION         See full prescribing information for complete boxed warning.",TOXICITIES is an adverse reaction entity
"EXCERPT:   WARNING: FATAL AND SERIOUS TOXICITIES: HEPATIC, SEVERE DIARRHEA, COLITIS, PNEUMONITIS, and INTESTINAL PERFORATION         See full prescribing information for complete boxed warning.",TOXICITIES HEPATIC is an adverse reaction entity
"EXCERPT:   WARNING: FATAL AND SERIOUS TOXICITIES: HEPATIC, SEVERE DIARRHEA, COLITIS, PNEUMONITIS, and INTESTINAL PERFORATION         See full prescribing information for complete boxed warning.",DIARRHEA is an adverse reaction entity
"EXCERPT:   WARNING: FATAL AND SERIOUS TOXICITIES: HEPATIC, SEVERE DIARRHEA, COLITIS, PNEUMONITIS, and INTESTINAL PERFORATION         See full prescribing information for complete boxed warning.",COLITIS is an adverse reaction entity
"EXCERPT:   WARNING: FATAL AND SERIOUS TOXICITIES: HEPATIC, SEVERE DIARRHEA, COLITIS, PNEUMONITIS, and INTESTINAL PERFORATION         See full prescribing information for complete boxed warning.",PNEUMONITIS is an adverse reaction entity
"EXCERPT:   WARNING: FATAL AND SERIOUS TOXICITIES: HEPATIC, SEVERE DIARRHEA, COLITIS, PNEUMONITIS, and INTESTINAL PERFORATION         See full prescribing information for complete boxed warning.",INTESTINAL PERFORATION is an adverse reaction entity
"BOXED WARNING: WARNING: FATAL AND SERIOUS TOXICITIES: HEPATIC, SEVERE DIARRHEA, COLITIS, PNEUMONITIS, and  INTESTINAL PERFORATION    WARNING: FATAL AND SERIOUS TOXICITIES: HEPATIC, SEVERE DIARRHEA, COLITIS, PNEUMONITIS, and  INTESTINAL PERFORATION      *  Fatal and/or serious hepatotoxicity occurred in 14% of Zydelig-treated patients.",FATAL is an adverse reaction entity
"BOXED WARNING: WARNING: FATAL AND SERIOUS TOXICITIES: HEPATIC, SEVERE DIARRHEA, COLITIS, PNEUMONITIS, and  INTESTINAL PERFORATION    WARNING: FATAL AND SERIOUS TOXICITIES: HEPATIC, SEVERE DIARRHEA, COLITIS, PNEUMONITIS, and  INTESTINAL PERFORATION      *  Fatal and/or serious hepatotoxicity occurred in 14% of Zydelig-treated patients.",TOXICITIES is an adverse reaction entity
"BOXED WARNING: WARNING: FATAL AND SERIOUS TOXICITIES: HEPATIC, SEVERE DIARRHEA, COLITIS, PNEUMONITIS, and  INTESTINAL PERFORATION    WARNING: FATAL AND SERIOUS TOXICITIES: HEPATIC, SEVERE DIARRHEA, COLITIS, PNEUMONITIS, and  INTESTINAL PERFORATION      *  Fatal and/or serious hepatotoxicity occurred in 14% of Zydelig-treated patients.",TOXICITIES HEPATIC is an adverse reaction entity
"BOXED WARNING: WARNING: FATAL AND SERIOUS TOXICITIES: HEPATIC, SEVERE DIARRHEA, COLITIS, PNEUMONITIS, and  INTESTINAL PERFORATION    WARNING: FATAL AND SERIOUS TOXICITIES: HEPATIC, SEVERE DIARRHEA, COLITIS, PNEUMONITIS, and  INTESTINAL PERFORATION      *  Fatal and/or serious hepatotoxicity occurred in 14% of Zydelig-treated patients.",DIARRHEA is an adverse reaction entity
"BOXED WARNING: WARNING: FATAL AND SERIOUS TOXICITIES: HEPATIC, SEVERE DIARRHEA, COLITIS, PNEUMONITIS, and  INTESTINAL PERFORATION    WARNING: FATAL AND SERIOUS TOXICITIES: HEPATIC, SEVERE DIARRHEA, COLITIS, PNEUMONITIS, and  INTESTINAL PERFORATION      *  Fatal and/or serious hepatotoxicity occurred in 14% of Zydelig-treated patients.",COLITIS is an adverse reaction entity
"BOXED WARNING: WARNING: FATAL AND SERIOUS TOXICITIES: HEPATIC, SEVERE DIARRHEA, COLITIS, PNEUMONITIS, and  INTESTINAL PERFORATION    WARNING: FATAL AND SERIOUS TOXICITIES: HEPATIC, SEVERE DIARRHEA, COLITIS, PNEUMONITIS, and  INTESTINAL PERFORATION      *  Fatal and/or serious hepatotoxicity occurred in 14% of Zydelig-treated patients.",PNEUMONITIS is an adverse reaction entity
"BOXED WARNING: WARNING: FATAL AND SERIOUS TOXICITIES: HEPATIC, SEVERE DIARRHEA, COLITIS, PNEUMONITIS, and  INTESTINAL PERFORATION    WARNING: FATAL AND SERIOUS TOXICITIES: HEPATIC, SEVERE DIARRHEA, COLITIS, PNEUMONITIS, and  INTESTINAL PERFORATION      *  Fatal and/or serious hepatotoxicity occurred in 14% of Zydelig-treated patients.",INTESTINAL PERFORATION is an adverse reaction entity
"BOXED WARNING: WARNING: FATAL AND SERIOUS TOXICITIES: HEPATIC, SEVERE DIARRHEA, COLITIS, PNEUMONITIS, and  INTESTINAL PERFORATION    WARNING: FATAL AND SERIOUS TOXICITIES: HEPATIC, SEVERE DIARRHEA, COLITIS, PNEUMONITIS, and  INTESTINAL PERFORATION      *  Fatal and/or serious hepatotoxicity occurred in 14% of Zydelig-treated patients.",FATAL is an adverse reaction entity
"BOXED WARNING: WARNING: FATAL AND SERIOUS TOXICITIES: HEPATIC, SEVERE DIARRHEA, COLITIS, PNEUMONITIS, and  INTESTINAL PERFORATION    WARNING: FATAL AND SERIOUS TOXICITIES: HEPATIC, SEVERE DIARRHEA, COLITIS, PNEUMONITIS, and  INTESTINAL PERFORATION      *  Fatal and/or serious hepatotoxicity occurred in 14% of Zydelig-treated patients.",TOXICITIES is an adverse reaction entity
"BOXED WARNING: WARNING: FATAL AND SERIOUS TOXICITIES: HEPATIC, SEVERE DIARRHEA, COLITIS, PNEUMONITIS, and  INTESTINAL PERFORATION    WARNING: FATAL AND SERIOUS TOXICITIES: HEPATIC, SEVERE DIARRHEA, COLITIS, PNEUMONITIS, and  INTESTINAL PERFORATION      *  Fatal and/or serious hepatotoxicity occurred in 14% of Zydelig-treated patients.",TOXICITIES HEPATIC is an adverse reaction entity
"BOXED WARNING: WARNING: FATAL AND SERIOUS TOXICITIES: HEPATIC, SEVERE DIARRHEA, COLITIS, PNEUMONITIS, and  INTESTINAL PERFORATION    WARNING: FATAL AND SERIOUS TOXICITIES: HEPATIC, SEVERE DIARRHEA, COLITIS, PNEUMONITIS, and  INTESTINAL PERFORATION      *  Fatal and/or serious hepatotoxicity occurred in 14% of Zydelig-treated patients.",DIARRHEA is an adverse reaction entity
"BOXED WARNING: WARNING: FATAL AND SERIOUS TOXICITIES: HEPATIC, SEVERE DIARRHEA, COLITIS, PNEUMONITIS, and  INTESTINAL PERFORATION    WARNING: FATAL AND SERIOUS TOXICITIES: HEPATIC, SEVERE DIARRHEA, COLITIS, PNEUMONITIS, and  INTESTINAL PERFORATION      *  Fatal and/or serious hepatotoxicity occurred in 14% of Zydelig-treated patients.",COLITIS is an adverse reaction entity
"BOXED WARNING: WARNING: FATAL AND SERIOUS TOXICITIES: HEPATIC, SEVERE DIARRHEA, COLITIS, PNEUMONITIS, and  INTESTINAL PERFORATION    WARNING: FATAL AND SERIOUS TOXICITIES: HEPATIC, SEVERE DIARRHEA, COLITIS, PNEUMONITIS, and  INTESTINAL PERFORATION      *  Fatal and/or serious hepatotoxicity occurred in 14% of Zydelig-treated patients.",PNEUMONITIS is an adverse reaction entity
"BOXED WARNING: WARNING: FATAL AND SERIOUS TOXICITIES: HEPATIC, SEVERE DIARRHEA, COLITIS, PNEUMONITIS, and  INTESTINAL PERFORATION    WARNING: FATAL AND SERIOUS TOXICITIES: HEPATIC, SEVERE DIARRHEA, COLITIS, PNEUMONITIS, and  INTESTINAL PERFORATION      *  Fatal and/or serious hepatotoxicity occurred in 14% of Zydelig-treated patients.",INTESTINAL PERFORATION is an adverse reaction entity
"BOXED WARNING: WARNING: FATAL AND SERIOUS TOXICITIES: HEPATIC, SEVERE DIARRHEA, COLITIS, PNEUMONITIS, and  INTESTINAL PERFORATION    WARNING: FATAL AND SERIOUS TOXICITIES: HEPATIC, SEVERE DIARRHEA, COLITIS, PNEUMONITIS, and  INTESTINAL PERFORATION      *  Fatal and/or serious hepatotoxicity occurred in 14% of Zydelig-treated patients.",Fatal is an adverse reaction entity
"BOXED WARNING: WARNING: FATAL AND SERIOUS TOXICITIES: HEPATIC, SEVERE DIARRHEA, COLITIS, PNEUMONITIS, and  INTESTINAL PERFORATION    WARNING: FATAL AND SERIOUS TOXICITIES: HEPATIC, SEVERE DIARRHEA, COLITIS, PNEUMONITIS, and  INTESTINAL PERFORATION      *  Fatal and/or serious hepatotoxicity occurred in 14% of Zydelig-treated patients.",hepatotoxicity is an adverse reaction entity
"In the relapsed classical HL and sALCL clinical trials, 54% of patients experienced any grade of neuropathy.",neuropathy is an adverse reaction entity
"In Study 3, infusion-related reactions were reported in 25 patients (15%) in the ADCETRIS-treated arm and 3 patients (2%) in the placebo arm.",infusion-related reactions is an adverse reaction entity
"*   Serious infections and opportunistic infections : Closely monitor patients for the emergence of bacterial, fungal or viral infections  (5.4)  .",infections is an adverse reaction entity
"*   Serious infections and opportunistic infections : Closely monitor patients for the emergence of bacterial, fungal or viral infections  (5.4)  .",opportunistic infections is an adverse reaction entity
"The most common adverse reactions (>=20%), regardless of causality, were neutropenia, peripheral sensory neuropathy, fatigue, upper respiratory tract infection, nausea, diarrhea, anemia, pyrexia, thrombocytopenia, rash, abdominal pain, cough, and vomiting.",neutropenia is an adverse reaction entity
"The most common adverse reactions (>=20%), regardless of causality, were neutropenia, peripheral sensory neuropathy, fatigue, upper respiratory tract infection, nausea, diarrhea, anemia, pyrexia, thrombocytopenia, rash, abdominal pain, cough, and vomiting.",peripheral sensory neuropathy is an adverse reaction entity
"The most common adverse reactions (>=20%), regardless of causality, were neutropenia, peripheral sensory neuropathy, fatigue, upper respiratory tract infection, nausea, diarrhea, anemia, pyrexia, thrombocytopenia, rash, abdominal pain, cough, and vomiting.",fatigue is an adverse reaction entity
"The most common adverse reactions (>=20%), regardless of causality, were neutropenia, peripheral sensory neuropathy, fatigue, upper respiratory tract infection, nausea, diarrhea, anemia, pyrexia, thrombocytopenia, rash, abdominal pain, cough, and vomiting.",upper respiratory tract infection is an adverse reaction entity
"The most common adverse reactions (>=20%), regardless of causality, were neutropenia, peripheral sensory neuropathy, fatigue, upper respiratory tract infection, nausea, diarrhea, anemia, pyrexia, thrombocytopenia, rash, abdominal pain, cough, and vomiting.",nausea is an adverse reaction entity
"The most common adverse reactions (>=20%), regardless of causality, were neutropenia, peripheral sensory neuropathy, fatigue, upper respiratory tract infection, nausea, diarrhea, anemia, pyrexia, thrombocytopenia, rash, abdominal pain, cough, and vomiting.",diarrhea is an adverse reaction entity
"The most common adverse reactions (>=20%), regardless of causality, were neutropenia, peripheral sensory neuropathy, fatigue, upper respiratory tract infection, nausea, diarrhea, anemia, pyrexia, thrombocytopenia, rash, abdominal pain, cough, and vomiting.",anemia is an adverse reaction entity
"The most common adverse reactions (>=20%), regardless of causality, were neutropenia, peripheral sensory neuropathy, fatigue, upper respiratory tract infection, nausea, diarrhea, anemia, pyrexia, thrombocytopenia, rash, abdominal pain, cough, and vomiting.",pyrexia is an adverse reaction entity
"The most common adverse reactions (>=20%), regardless of causality, were neutropenia, peripheral sensory neuropathy, fatigue, upper respiratory tract infection, nausea, diarrhea, anemia, pyrexia, thrombocytopenia, rash, abdominal pain, cough, and vomiting.",thrombocytopenia is an adverse reaction entity
"The most common adverse reactions (>=20%), regardless of causality, were neutropenia, peripheral sensory neuropathy, fatigue, upper respiratory tract infection, nausea, diarrhea, anemia, pyrexia, thrombocytopenia, rash, abdominal pain, cough, and vomiting.",rash is an adverse reaction entity
"The most common adverse reactions (>=20%), regardless of causality, were neutropenia, peripheral sensory neuropathy, fatigue, upper respiratory tract infection, nausea, diarrhea, anemia, pyrexia, thrombocytopenia, rash, abdominal pain, cough, and vomiting.",abdominal pain is an adverse reaction entity
"The most common adverse reactions (>=20%), regardless of causality, were neutropenia, peripheral sensory neuropathy, fatigue, upper respiratory tract infection, nausea, diarrhea, anemia, pyrexia, thrombocytopenia, rash, abdominal pain, cough, and vomiting.",cough is an adverse reaction entity
"The most common adverse reactions (>=20%), regardless of causality, were neutropenia, peripheral sensory neuropathy, fatigue, upper respiratory tract infection, nausea, diarrhea, anemia, pyrexia, thrombocytopenia, rash, abdominal pain, cough, and vomiting.",vomiting is an adverse reaction entity
"In Study 3, the most common adverse reactions (>=20%) in the ADCETRIS-treatment arm, regardless of causality, were neutropenia, peripheral sensory neuropathy, thrombocytopenia, anemia, upper respiratory tract infection, fatigue, peripheral motor neuropathy, nausea, cough, and diarrhea.",neutropenia is an adverse reaction entity
"In Study 3, the most common adverse reactions (>=20%) in the ADCETRIS-treatment arm, regardless of causality, were neutropenia, peripheral sensory neuropathy, thrombocytopenia, anemia, upper respiratory tract infection, fatigue, peripheral motor neuropathy, nausea, cough, and diarrhea.",peripheral sensory neuropathy is an adverse reaction entity
"In Study 3, the most common adverse reactions (>=20%) in the ADCETRIS-treatment arm, regardless of causality, were neutropenia, peripheral sensory neuropathy, thrombocytopenia, anemia, upper respiratory tract infection, fatigue, peripheral motor neuropathy, nausea, cough, and diarrhea.",thrombocytopenia is an adverse reaction entity
"In Study 3, the most common adverse reactions (>=20%) in the ADCETRIS-treatment arm, regardless of causality, were neutropenia, peripheral sensory neuropathy, thrombocytopenia, anemia, upper respiratory tract infection, fatigue, peripheral motor neuropathy, nausea, cough, and diarrhea.",anemia is an adverse reaction entity
"In Study 3, the most common adverse reactions (>=20%) in the ADCETRIS-treatment arm, regardless of causality, were neutropenia, peripheral sensory neuropathy, thrombocytopenia, anemia, upper respiratory tract infection, fatigue, peripheral motor neuropathy, nausea, cough, and diarrhea.",upper respiratory tract infection is an adverse reaction entity
"In Study 3, the most common adverse reactions (>=20%) in the ADCETRIS-treatment arm, regardless of causality, were neutropenia, peripheral sensory neuropathy, thrombocytopenia, anemia, upper respiratory tract infection, fatigue, peripheral motor neuropathy, nausea, cough, and diarrhea.",fatigue is an adverse reaction entity
"In Study 3, the most common adverse reactions (>=20%) in the ADCETRIS-treatment arm, regardless of causality, were neutropenia, peripheral sensory neuropathy, thrombocytopenia, anemia, upper respiratory tract infection, fatigue, peripheral motor neuropathy, nausea, cough, and diarrhea.",peripheral motor neuropathy is an adverse reaction entity
"In Study 3, the most common adverse reactions (>=20%) in the ADCETRIS-treatment arm, regardless of causality, were neutropenia, peripheral sensory neuropathy, thrombocytopenia, anemia, upper respiratory tract infection, fatigue, peripheral motor neuropathy, nausea, cough, and diarrhea.",nausea is an adverse reaction entity
"In Study 3, the most common adverse reactions (>=20%) in the ADCETRIS-treatment arm, regardless of causality, were neutropenia, peripheral sensory neuropathy, thrombocytopenia, anemia, upper respiratory tract infection, fatigue, peripheral motor neuropathy, nausea, cough, and diarrhea.",cough is an adverse reaction entity
"In Study 3, the most common adverse reactions (>=20%) in the ADCETRIS-treatment arm, regardless of causality, were neutropenia, peripheral sensory neuropathy, thrombocytopenia, anemia, upper respiratory tract infection, fatigue, peripheral motor neuropathy, nausea, cough, and diarrhea.",diarrhea is an adverse reaction entity
Two of the patients (1%) with persistently positive antibodies experienced adverse reactions consistent with infusion reactions that led to discontinuation of treatment.,infusion reactions is an adverse reaction entity
"Of the patients who reported neuropathy, 51% had residual neuropathy at the time of their last evaluation.",neuropathy is an adverse reaction entity
"Of the patients who reported neuropathy, 51% had residual neuropathy at the time of their last evaluation.",residual neuropathy is an adverse reaction entity
"BOXED WARNING: WARNING: PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML)      WARNING: PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML)        JC virus infection resulting in PML and death can occur in patients receiving ADCETRIS   [see   Warnings and Precautions (      5.9      )    ,     Adverse Reactions (    6.1    )    ]             EXCERPT:     WARNING: PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML)           See Full Prescribing Information for complete boxed warning.",PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY is an adverse reaction entity
"BOXED WARNING: WARNING: PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML)      WARNING: PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML)        JC virus infection resulting in PML and death can occur in patients receiving ADCETRIS   [see   Warnings and Precautions (      5.9      )    ,     Adverse Reactions (    6.1    )    ]             EXCERPT:     WARNING: PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML)           See Full Prescribing Information for complete boxed warning.",PML is an adverse reaction entity
"BOXED WARNING: WARNING: PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML)      WARNING: PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML)        JC virus infection resulting in PML and death can occur in patients receiving ADCETRIS   [see   Warnings and Precautions (      5.9      )    ,     Adverse Reactions (    6.1    )    ]             EXCERPT:     WARNING: PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML)           See Full Prescribing Information for complete boxed warning.",PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY is an adverse reaction entity
"BOXED WARNING: WARNING: PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML)      WARNING: PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML)        JC virus infection resulting in PML and death can occur in patients receiving ADCETRIS   [see   Warnings and Precautions (      5.9      )    ,     Adverse Reactions (    6.1    )    ]             EXCERPT:     WARNING: PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML)           See Full Prescribing Information for complete boxed warning.",PML is an adverse reaction entity
"BOXED WARNING: WARNING: PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML)      WARNING: PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML)        JC virus infection resulting in PML and death can occur in patients receiving ADCETRIS   [see   Warnings and Precautions (      5.9      )    ,     Adverse Reactions (    6.1    )    ]             EXCERPT:     WARNING: PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML)           See Full Prescribing Information for complete boxed warning.",JC virus infection is an adverse reaction entity
"BOXED WARNING: WARNING: PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML)      WARNING: PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML)        JC virus infection resulting in PML and death can occur in patients receiving ADCETRIS   [see   Warnings and Precautions (      5.9      )    ,     Adverse Reactions (    6.1    )    ]             EXCERPT:     WARNING: PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML)           See Full Prescribing Information for complete boxed warning.",PML is an adverse reaction entity
"BOXED WARNING: WARNING: PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML)      WARNING: PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML)        JC virus infection resulting in PML and death can occur in patients receiving ADCETRIS   [see   Warnings and Precautions (      5.9      )    ,     Adverse Reactions (    6.1    )    ]             EXCERPT:     WARNING: PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML)           See Full Prescribing Information for complete boxed warning.",death is an adverse reaction entity
"BOXED WARNING: WARNING: PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML)      WARNING: PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML)        JC virus infection resulting in PML and death can occur in patients receiving ADCETRIS   [see   Warnings and Precautions (      5.9      )    ,     Adverse Reactions (    6.1    )    ]             EXCERPT:     WARNING: PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML)           See Full Prescribing Information for complete boxed warning.",PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY is an adverse reaction entity
"BOXED WARNING: WARNING: PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML)      WARNING: PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML)        JC virus infection resulting in PML and death can occur in patients receiving ADCETRIS   [see   Warnings and Precautions (      5.9      )    ,     Adverse Reactions (    6.1    )    ]             EXCERPT:     WARNING: PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML)           See Full Prescribing Information for complete boxed warning.",PML is an adverse reaction entity
Blood and lymphatic system disorders  : febrile neutropenia  [see  Warnings and Precautions (        5.3        )  ]  .,febrile neutropenia is an adverse reaction entity
"5.11 Serious Dermatologic Reactions         Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), including fatal outcomes, have been reported with ADCETRIS.",Stevens-Johnson syndrome is an adverse reaction entity
"5.11 Serious Dermatologic Reactions         Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), including fatal outcomes, have been reported with ADCETRIS.",SJS is an adverse reaction entity
"5.11 Serious Dermatologic Reactions         Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), including fatal outcomes, have been reported with ADCETRIS.",toxic epidermal necrolysis is an adverse reaction entity
"5.11 Serious Dermatologic Reactions         Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), including fatal outcomes, have been reported with ADCETRIS.",TEN is an adverse reaction entity
"5.11 Serious Dermatologic Reactions         Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), including fatal outcomes, have been reported with ADCETRIS.",fatal is an adverse reaction entity
"5.10 Pulmonary Toxicity         Events of noninfectious pulmonary toxicity including pneumonitis, interstitial lung disease, and acute respiratory distress syndrome (ARDS), some with fatal outcomes, have been reported.",noninfectious pulmonary toxicity is an adverse reaction entity
"5.10 Pulmonary Toxicity         Events of noninfectious pulmonary toxicity including pneumonitis, interstitial lung disease, and acute respiratory distress syndrome (ARDS), some with fatal outcomes, have been reported.",pneumonitis is an adverse reaction entity
"5.10 Pulmonary Toxicity         Events of noninfectious pulmonary toxicity including pneumonitis, interstitial lung disease, and acute respiratory distress syndrome (ARDS), some with fatal outcomes, have been reported.",interstitial lung disease is an adverse reaction entity
"5.10 Pulmonary Toxicity         Events of noninfectious pulmonary toxicity including pneumonitis, interstitial lung disease, and acute respiratory distress syndrome (ARDS), some with fatal outcomes, have been reported.",acute respiratory distress syndrome is an adverse reaction entity
"5.10 Pulmonary Toxicity         Events of noninfectious pulmonary toxicity including pneumonitis, interstitial lung disease, and acute respiratory distress syndrome (ARDS), some with fatal outcomes, have been reported.",ARDS is an adverse reaction entity
"5.10 Pulmonary Toxicity         Events of noninfectious pulmonary toxicity including pneumonitis, interstitial lung disease, and acute respiratory distress syndrome (ARDS), some with fatal outcomes, have been reported.",fatal is an adverse reaction entity
"The most common serious adverse reactions were pneumonia (4%), pyrexia (4%), vomiting (3%), nausea (2%), hepatotoxicity (2%) and peripheral sensory neuropathy (2%).",pneumonia is an adverse reaction entity
"The most common serious adverse reactions were pneumonia (4%), pyrexia (4%), vomiting (3%), nausea (2%), hepatotoxicity (2%) and peripheral sensory neuropathy (2%).",pyrexia is an adverse reaction entity
"The most common serious adverse reactions were pneumonia (4%), pyrexia (4%), vomiting (3%), nausea (2%), hepatotoxicity (2%) and peripheral sensory neuropathy (2%).",vomiting is an adverse reaction entity
"The most common serious adverse reactions were pneumonia (4%), pyrexia (4%), vomiting (3%), nausea (2%), hepatotoxicity (2%) and peripheral sensory neuropathy (2%).",nausea is an adverse reaction entity
"The most common serious adverse reactions were pneumonia (4%), pyrexia (4%), vomiting (3%), nausea (2%), hepatotoxicity (2%) and peripheral sensory neuropathy (2%).",hepatotoxicity is an adverse reaction entity
"The most common serious adverse reactions were pneumonia (4%), pyrexia (4%), vomiting (3%), nausea (2%), hepatotoxicity (2%) and peripheral sensory neuropathy (2%).",peripheral sensory neuropathy is an adverse reaction entity
"Cases were consistent with hepatocellular injury, including elevations of transaminases and/or bilirubin.",hepatocellular injury is an adverse reaction entity
"Cases were consistent with hepatocellular injury, including elevations of transaminases and/or bilirubin.",elevations of transaminases is an adverse reaction entity
"Cases were consistent with hepatocellular injury, including elevations of transaminases and/or bilirubin.",elevations of bilirubin is an adverse reaction entity
5.7     Liver Injury      Elevations of liver enzymes may occur in patients receiving GILENYA.,Elevations of liver enzymes is an adverse reaction entity
Routine ophthalmological examination detected macular edema in some patients with no visual symptoms.,macular edema is an adverse reaction entity
Routine ophthalmological examination detected macular edema in some patients with no visual symptoms.,visual symptoms is an adverse reaction entity
(  5.2  )   *  Progressive multifocal leukoencephalopathy (PML); Withhold GILENYA at the first sign or symptom suggestive of PML.,Progressive multifocal leukoencephalopathy is an adverse reaction entity
(  5.2  )   *  Progressive multifocal leukoencephalopathy (PML); Withhold GILENYA at the first sign or symptom suggestive of PML.,PML is an adverse reaction entity
There is insufficient information to determine the reversibility of the decrease of DLCO after drug discontinuation.,decrease of DLCO is an adverse reaction entity
"The patients had no other identified systemic medical conditions resulting in compromised immune system function and had not previously been treated with natalizumab, which has a known association with PML.",compromised immune system is an adverse reaction entity
"The patients had no other identified systemic medical conditions resulting in compromised immune system function and had not previously been treated with natalizumab, which has a known association with PML.",PML is an adverse reaction entity
A dose-dependent increase in the risk of macular edema occurred in the GILENYA clinical development program.,macular edema is an adverse reaction entity
"However, bronchitis, herpes zoster, influenza, sinusitis, and pneumonia were more common in GILENYA-treated patients.",bronchitis is an adverse reaction entity
"However, bronchitis, herpes zoster, influenza, sinusitis, and pneumonia were more common in GILENYA-treated patients.",herpes zoster is an adverse reaction entity
"However, bronchitis, herpes zoster, influenza, sinusitis, and pneumonia were more common in GILENYA-treated patients.",influenza is an adverse reaction entity
"However, bronchitis, herpes zoster, influenza, sinusitis, and pneumonia were more common in GILENYA-treated patients.",sinusitis is an adverse reaction entity
"However, bronchitis, herpes zoster, influenza, sinusitis, and pneumonia were more common in GILENYA-treated patients.",pneumonia is an adverse reaction entity
"Postmarketing Experience       In the postmarketing setting, third-degree AV block and AV block with junctional escape have been observed during the first-dose 6-hour observation period with GILENYA.",third-degree AV block is an adverse reaction entity
"Postmarketing Experience       In the postmarketing setting, third-degree AV block and AV block with junctional escape have been observed during the first-dose 6-hour observation period with GILENYA.",AV block is an adverse reaction entity
"Postmarketing Experience       In the postmarketing setting, third-degree AV block and AV block with junctional escape have been observed during the first-dose 6-hour observation period with GILENYA.",junctional escape is an adverse reaction entity
"In the combined clinical trial experience with all doses of fingolimod, the rate of macular edema was approximately 20% in MS patients with a history of uveitis versus 0.6% in those without a history of uveitis.",macular edema is an adverse reaction entity
"In MS placebo-controlled trials, the overall rate of infections (72%) with GILENYA was similar to placebo.",infections is an adverse reaction entity
"In some patients, heart rate decrease during the second period is more pronounced than the decrease observed in the first 6 hours.",heart rate decrease is an adverse reaction entity
5.2     Infections       Risk of Infections       GILENYA causes a dose-dependent reduction in peripheral lymphocyte count to 20%-30% of baseline values because of reversible sequestration of lymphocytes in lymphoid tissues.,reduction in peripheral lymphocyte count is an adverse reaction entity
5.2     Infections       Risk of Infections       GILENYA causes a dose-dependent reduction in peripheral lymphocyte count to 20%-30% of baseline values because of reversible sequestration of lymphocytes in lymphoid tissues.,sequestration of lymphocytes in lymphoid tissues is an adverse reaction entity
Patients with preexisting liver disease may be at increased risk of developing elevated liver enzymes when taking GILENYA.,elevated liver enzymes is an adverse reaction entity
Macular edema generally partially or completely resolved with or without treatment after drug discontinuation.,Macular edema is an adverse reaction entity
Continuation of GILENYA in patients who develop macular edema has not been evaluated.,macular edema is an adverse reaction entity
"5.2 Growth of Resistant Organisms with Prolonged Use      As with other anti-infectives, prolonged use of Besivance (besifloxacin ophthalmic suspension) 0.6% may result in overgrowth of non-susceptible organisms, including fungi.",overgrowth of non-susceptible organisms is an adverse reaction entity
"5.2 Growth of Resistant Organisms with Prolonged Use      As with other anti-infectives, prolonged use of Besivance (besifloxacin ophthalmic suspension) 0.6% may result in overgrowth of non-susceptible organisms, including fungi.",overgrowth of fungi is an adverse reaction entity
Extravasation into tissues during Gadavist administration may result in moderate irritation [see Nonclinical Toxicology (  13.2  )]  .,administration irritation is an adverse reaction entity
"5.2 Hypersensitivity Reactions      Anaphylactic and other hypersensitivity reactions with cardiovascular, respiratory or cutaneous manifestations, ranging from mild to severe, including death, have uncommonly occurred following Gadavist administration [see Adverse Reactions (  6  )]  .",Anaphylactic reactions is an adverse reaction entity
"5.2 Hypersensitivity Reactions      Anaphylactic and other hypersensitivity reactions with cardiovascular, respiratory or cutaneous manifestations, ranging from mild to severe, including death, have uncommonly occurred following Gadavist administration [see Adverse Reactions (  6  )]  .",hypersensitivity reactions is an adverse reaction entity
"5.2 Hypersensitivity Reactions      Anaphylactic and other hypersensitivity reactions with cardiovascular, respiratory or cutaneous manifestations, ranging from mild to severe, including death, have uncommonly occurred following Gadavist administration [see Adverse Reactions (  6  )]  .",death is an adverse reaction entity
"*    Cardiac arrest   *    Nephrogenic Systemic Fibrosis (NSF)   *    Hypersensitivity reactions (anaphylactic shock, circulatory collapse, respiratory arrest, pulmonary edema, bronchospasm, cyanosis, oropharyngeal swelling, laryngeal edema, blood pressure increased, chest pain, angioedema, conjunctivitis, hyperhidrosis, cough, sneezing, burning sensation, and pallor) [see Warnings and Precautions (  5.2  )]",Cardiac arrest is an adverse reaction entity
"*    Cardiac arrest   *    Nephrogenic Systemic Fibrosis (NSF)   *    Hypersensitivity reactions (anaphylactic shock, circulatory collapse, respiratory arrest, pulmonary edema, bronchospasm, cyanosis, oropharyngeal swelling, laryngeal edema, blood pressure increased, chest pain, angioedema, conjunctivitis, hyperhidrosis, cough, sneezing, burning sensation, and pallor) [see Warnings and Precautions (  5.2  )]",Nephrogenic Systemic Fibrosis is an adverse reaction entity
"*    Cardiac arrest   *    Nephrogenic Systemic Fibrosis (NSF)   *    Hypersensitivity reactions (anaphylactic shock, circulatory collapse, respiratory arrest, pulmonary edema, bronchospasm, cyanosis, oropharyngeal swelling, laryngeal edema, blood pressure increased, chest pain, angioedema, conjunctivitis, hyperhidrosis, cough, sneezing, burning sensation, and pallor) [see Warnings and Precautions (  5.2  )]",NSF is an adverse reaction entity
"*    Cardiac arrest   *    Nephrogenic Systemic Fibrosis (NSF)   *    Hypersensitivity reactions (anaphylactic shock, circulatory collapse, respiratory arrest, pulmonary edema, bronchospasm, cyanosis, oropharyngeal swelling, laryngeal edema, blood pressure increased, chest pain, angioedema, conjunctivitis, hyperhidrosis, cough, sneezing, burning sensation, and pallor) [see Warnings and Precautions (  5.2  )]",Hypersensitivity reactions is an adverse reaction entity
"*    Cardiac arrest   *    Nephrogenic Systemic Fibrosis (NSF)   *    Hypersensitivity reactions (anaphylactic shock, circulatory collapse, respiratory arrest, pulmonary edema, bronchospasm, cyanosis, oropharyngeal swelling, laryngeal edema, blood pressure increased, chest pain, angioedema, conjunctivitis, hyperhidrosis, cough, sneezing, burning sensation, and pallor) [see Warnings and Precautions (  5.2  )]",anaphylactic shock is an adverse reaction entity
"*    Cardiac arrest   *    Nephrogenic Systemic Fibrosis (NSF)   *    Hypersensitivity reactions (anaphylactic shock, circulatory collapse, respiratory arrest, pulmonary edema, bronchospasm, cyanosis, oropharyngeal swelling, laryngeal edema, blood pressure increased, chest pain, angioedema, conjunctivitis, hyperhidrosis, cough, sneezing, burning sensation, and pallor) [see Warnings and Precautions (  5.2  )]",circulatory collapse is an adverse reaction entity
"*    Cardiac arrest   *    Nephrogenic Systemic Fibrosis (NSF)   *    Hypersensitivity reactions (anaphylactic shock, circulatory collapse, respiratory arrest, pulmonary edema, bronchospasm, cyanosis, oropharyngeal swelling, laryngeal edema, blood pressure increased, chest pain, angioedema, conjunctivitis, hyperhidrosis, cough, sneezing, burning sensation, and pallor) [see Warnings and Precautions (  5.2  )]",respiratory arrest is an adverse reaction entity
"*    Cardiac arrest   *    Nephrogenic Systemic Fibrosis (NSF)   *    Hypersensitivity reactions (anaphylactic shock, circulatory collapse, respiratory arrest, pulmonary edema, bronchospasm, cyanosis, oropharyngeal swelling, laryngeal edema, blood pressure increased, chest pain, angioedema, conjunctivitis, hyperhidrosis, cough, sneezing, burning sensation, and pallor) [see Warnings and Precautions (  5.2  )]",pulmonary edema is an adverse reaction entity
"*    Cardiac arrest   *    Nephrogenic Systemic Fibrosis (NSF)   *    Hypersensitivity reactions (anaphylactic shock, circulatory collapse, respiratory arrest, pulmonary edema, bronchospasm, cyanosis, oropharyngeal swelling, laryngeal edema, blood pressure increased, chest pain, angioedema, conjunctivitis, hyperhidrosis, cough, sneezing, burning sensation, and pallor) [see Warnings and Precautions (  5.2  )]",bronchospasm is an adverse reaction entity
"*    Cardiac arrest   *    Nephrogenic Systemic Fibrosis (NSF)   *    Hypersensitivity reactions (anaphylactic shock, circulatory collapse, respiratory arrest, pulmonary edema, bronchospasm, cyanosis, oropharyngeal swelling, laryngeal edema, blood pressure increased, chest pain, angioedema, conjunctivitis, hyperhidrosis, cough, sneezing, burning sensation, and pallor) [see Warnings and Precautions (  5.2  )]",cyanosis is an adverse reaction entity
"*    Cardiac arrest   *    Nephrogenic Systemic Fibrosis (NSF)   *    Hypersensitivity reactions (anaphylactic shock, circulatory collapse, respiratory arrest, pulmonary edema, bronchospasm, cyanosis, oropharyngeal swelling, laryngeal edema, blood pressure increased, chest pain, angioedema, conjunctivitis, hyperhidrosis, cough, sneezing, burning sensation, and pallor) [see Warnings and Precautions (  5.2  )]",oropharyngeal swelling is an adverse reaction entity
"*    Cardiac arrest   *    Nephrogenic Systemic Fibrosis (NSF)   *    Hypersensitivity reactions (anaphylactic shock, circulatory collapse, respiratory arrest, pulmonary edema, bronchospasm, cyanosis, oropharyngeal swelling, laryngeal edema, blood pressure increased, chest pain, angioedema, conjunctivitis, hyperhidrosis, cough, sneezing, burning sensation, and pallor) [see Warnings and Precautions (  5.2  )]",laryngeal edema is an adverse reaction entity
"*    Cardiac arrest   *    Nephrogenic Systemic Fibrosis (NSF)   *    Hypersensitivity reactions (anaphylactic shock, circulatory collapse, respiratory arrest, pulmonary edema, bronchospasm, cyanosis, oropharyngeal swelling, laryngeal edema, blood pressure increased, chest pain, angioedema, conjunctivitis, hyperhidrosis, cough, sneezing, burning sensation, and pallor) [see Warnings and Precautions (  5.2  )]",blood pressure increased is an adverse reaction entity
"*    Cardiac arrest   *    Nephrogenic Systemic Fibrosis (NSF)   *    Hypersensitivity reactions (anaphylactic shock, circulatory collapse, respiratory arrest, pulmonary edema, bronchospasm, cyanosis, oropharyngeal swelling, laryngeal edema, blood pressure increased, chest pain, angioedema, conjunctivitis, hyperhidrosis, cough, sneezing, burning sensation, and pallor) [see Warnings and Precautions (  5.2  )]",chest pain is an adverse reaction entity
"*    Cardiac arrest   *    Nephrogenic Systemic Fibrosis (NSF)   *    Hypersensitivity reactions (anaphylactic shock, circulatory collapse, respiratory arrest, pulmonary edema, bronchospasm, cyanosis, oropharyngeal swelling, laryngeal edema, blood pressure increased, chest pain, angioedema, conjunctivitis, hyperhidrosis, cough, sneezing, burning sensation, and pallor) [see Warnings and Precautions (  5.2  )]",angioedema is an adverse reaction entity
"*    Cardiac arrest   *    Nephrogenic Systemic Fibrosis (NSF)   *    Hypersensitivity reactions (anaphylactic shock, circulatory collapse, respiratory arrest, pulmonary edema, bronchospasm, cyanosis, oropharyngeal swelling, laryngeal edema, blood pressure increased, chest pain, angioedema, conjunctivitis, hyperhidrosis, cough, sneezing, burning sensation, and pallor) [see Warnings and Precautions (  5.2  )]",conjunctivitis is an adverse reaction entity
"*    Cardiac arrest   *    Nephrogenic Systemic Fibrosis (NSF)   *    Hypersensitivity reactions (anaphylactic shock, circulatory collapse, respiratory arrest, pulmonary edema, bronchospasm, cyanosis, oropharyngeal swelling, laryngeal edema, blood pressure increased, chest pain, angioedema, conjunctivitis, hyperhidrosis, cough, sneezing, burning sensation, and pallor) [see Warnings and Precautions (  5.2  )]",hyperhidrosis is an adverse reaction entity
"*    Cardiac arrest   *    Nephrogenic Systemic Fibrosis (NSF)   *    Hypersensitivity reactions (anaphylactic shock, circulatory collapse, respiratory arrest, pulmonary edema, bronchospasm, cyanosis, oropharyngeal swelling, laryngeal edema, blood pressure increased, chest pain, angioedema, conjunctivitis, hyperhidrosis, cough, sneezing, burning sensation, and pallor) [see Warnings and Precautions (  5.2  )]",cough is an adverse reaction entity
"*    Cardiac arrest   *    Nephrogenic Systemic Fibrosis (NSF)   *    Hypersensitivity reactions (anaphylactic shock, circulatory collapse, respiratory arrest, pulmonary edema, bronchospasm, cyanosis, oropharyngeal swelling, laryngeal edema, blood pressure increased, chest pain, angioedema, conjunctivitis, hyperhidrosis, cough, sneezing, burning sensation, and pallor) [see Warnings and Precautions (  5.2  )]",sneezing is an adverse reaction entity
"*    Cardiac arrest   *    Nephrogenic Systemic Fibrosis (NSF)   *    Hypersensitivity reactions (anaphylactic shock, circulatory collapse, respiratory arrest, pulmonary edema, bronchospasm, cyanosis, oropharyngeal swelling, laryngeal edema, blood pressure increased, chest pain, angioedema, conjunctivitis, hyperhidrosis, cough, sneezing, burning sensation, and pallor) [see Warnings and Precautions (  5.2  )]",burning sensation is an adverse reaction entity
"*    Cardiac arrest   *    Nephrogenic Systemic Fibrosis (NSF)   *    Hypersensitivity reactions (anaphylactic shock, circulatory collapse, respiratory arrest, pulmonary edema, bronchospasm, cyanosis, oropharyngeal swelling, laryngeal edema, blood pressure increased, chest pain, angioedema, conjunctivitis, hyperhidrosis, cough, sneezing, burning sensation, and pallor) [see Warnings and Precautions (  5.2  )]",pallor is an adverse reaction entity
Hypersensitivity reactions  [see Contraindications (4) and Warnings and Precautions (  5.2  )].,Hypersensitivity reactions is an adverse reaction entity
6.2 Post Marketing Experience    Hypersensitivity reactions have been reported rarely during the post-marketing use of BEPREVE.,Hypersensitivity reactions is an adverse reaction entity
"The most frequent adverse reactions in XEOMIN treated subjects were: headache 29 (5.4%), facial paresis 4 (0.7%), injection site hematoma 3 (0.6%) and eyelid edema 2 (0.4%).",headache is an adverse reaction entity
"The most frequent adverse reactions in XEOMIN treated subjects were: headache 29 (5.4%), facial paresis 4 (0.7%), injection site hematoma 3 (0.6%) and eyelid edema 2 (0.4%).",facial paresis is an adverse reaction entity
"The most frequent adverse reactions in XEOMIN treated subjects were: headache 29 (5.4%), facial paresis 4 (0.7%), injection site hematoma 3 (0.6%) and eyelid edema 2 (0.4%).",injection site hematoma is an adverse reaction entity
"The most frequent adverse reactions in XEOMIN treated subjects were: headache 29 (5.4%), facial paresis 4 (0.7%), injection site hematoma 3 (0.6%) and eyelid edema 2 (0.4%).",eyelid edema is an adverse reaction entity
"Common adverse events (>=5% in any XEOMIN treatment group) observed in patients who received XEOMIN (120 Units or 240 Units) included dysphagia, neck pain, muscle weakness, injection site pain, and musculoskeletal pain.",dysphagia is an adverse reaction entity
"Common adverse events (>=5% in any XEOMIN treatment group) observed in patients who received XEOMIN (120 Units or 240 Units) included dysphagia, neck pain, muscle weakness, injection site pain, and musculoskeletal pain.",neck pain is an adverse reaction entity
"Common adverse events (>=5% in any XEOMIN treatment group) observed in patients who received XEOMIN (120 Units or 240 Units) included dysphagia, neck pain, muscle weakness, injection site pain, and musculoskeletal pain.",muscle weakness is an adverse reaction entity
"Common adverse events (>=5% in any XEOMIN treatment group) observed in patients who received XEOMIN (120 Units or 240 Units) included dysphagia, neck pain, muscle weakness, injection site pain, and musculoskeletal pain.",injection site pain is an adverse reaction entity
"Common adverse events (>=5% in any XEOMIN treatment group) observed in patients who received XEOMIN (120 Units or 240 Units) included dysphagia, neck pain, muscle weakness, injection site pain, and musculoskeletal pain.",musculoskeletal pain is an adverse reaction entity
This may result in critical loss of breathing capacity in patients with respiratory disorders who may have become dependent upon these accessory muscles.,loss of breathing capacity is an adverse reaction entity
Swallowing and breathing difficulties can be life threatening and there have been reports of death.,Swallowing difficulties is an adverse reaction entity
Swallowing and breathing difficulties can be life threatening and there have been reports of death.,Swallowing difficulties is an adverse reaction entity
Swallowing and breathing difficulties can be life threatening and there have been reports of death.,breathing difficulties is an adverse reaction entity
Swallowing and breathing difficulties can be life threatening and there have been reports of death.,breathing difficulties is an adverse reaction entity
Swallowing and breathing difficulties can be life threatening and there have been reports of death.,death is an adverse reaction entity
"There have been post-marketing reports of serious breathing difficulties, including respiratory failure, in patients with cervical dystonia treated with botulinum toxin products.",breathing difficulties is an adverse reaction entity
"There have been post-marketing reports of serious breathing difficulties, including respiratory failure, in patients with cervical dystonia treated with botulinum toxin products.",respiratory failure is an adverse reaction entity
No serious adverse events occurred in patients who received XEOMIN; one placebo-treated patient experienced a serious adverse event (dyspnea).,dyspnea is an adverse reaction entity
"Dysphagia may persist for several months, and require use of a feeding tube to maintain adequate nutrition and hydration.",Dysphagia is an adverse reaction entity
Treatment of cervical dystonia with botulinum toxins may weaken neck muscles that serve as accessory muscles of ventilation.,weaken neck muscles is an adverse reaction entity
